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THE IMPORTANCE OF DNA REPAIR CAPACITY TO (AND A MODEL
TO PREDICT) CELL RADIOSENSITIVITY TO IONS

Abstract
David Bruce Flint, BSc.

Advisory Professor: Gabriel Sawakuchi, Ph.D.

Radiation therapy with ions has a number of advantages over conventional radiation
therapy with photons, including favorable depth-dose distributions, greater relative biological
effectiveness (RBE) and a lesser dependence on a number of biological factors known to affect
radiosensitivity to photons, including DNA repair capacity. Thus, it is expected that an
additional benefit of using ions is that they mitigate the great heterogeneities in treatment
responses commonly observed in photon therapies.
However, by analyzing the cell survival of human cancer cell lines exposed to clinically
relevant photon, proton, and carbon ion beams, we show there is not significantly less relative
variability in intrinsic radiosensitivity between radiation qualities. These data imply that
predicting intrinsic radiosensitivity – for which some research is underway for photon therapies
– can provide similar benefits in the case of ion therapies in helping to mitigate heterogeneities
in treatment response.
We also showed that there is no less variability in radiosensitivity between radiation
qualities if the cells’ DNA repair pathways are inhibited pharmacologically, which implies that
DNA repair capacity remains relevant to determining intrinsic radiosensitivity, even for ions. We
confirmed this fact by characterizing the survival of cell lines with differential DNA repair
capacity exposed to photons, protons, helium and carbon ions, and by quantifying DNA repair
by imaging immunohistochemically stained DNA repair proteins. We also showed that while
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non-homologous end joining repair is the more important DNA repair pathway, its importance
relative to homologous recombination repair decreases with increasing ion linear energy
transfer.
Finally, we created an empirical model to predict cellular radiosensitivity to ions on the
basis of that cell’s radiosensitivity to photons, and showed that this model can predict the
response of cells with differing DNA repair capacity, whether naturally occurring, or induced by
gene modification of pharmacological inhibition.
This work may be directly useful in the context of novel radiation therapies combined
with DNA repair inhibition, as our work suggests that similar relative sensitization to ions as to
photons can be achieved through DNA repair inhibition, and we present a model that can be
used to predict ion radiosensitivity or RBEs in spite of this modulation.
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Chapter 1 – Introduction to Radiotherapy with Ions
I.

The Advantages of Ion Radiotherapy
Radiation therapy is one of the primary modalities used to treat cancer, accounting for

some portion of the treatment regimen in roughly 50% of cancer cases treated worldwide3,4.
Radiation kills cancer cells primarily by inducing damage to the cells’ DNA, which, if left
unrepaired, can lead to cell death5. As cancer cells are generally less proficient at maintaining
their genomic integrity than normal cells6-8, they are generally less capable of repairing these
types of lesions. This is due in part to frequent mutations of genes such as p539 which help
facilitate DNA repair by arresting the cell cycle while the damage is being repaired6,9, but also
due to frequent mutations to genes directly responsible for the detection, repair signaling, or
repair of these types of lesions3,4,6,8,10, such as BRCA211 . Generally, these characteristics
render cancer cells more sensitive to radiation than normal cells10-13, which can be leveraged in
the context of radiation therapy to preferentially kill cancer cells without inducing as much
toxicity in the surrounding normal tissues.
But this is not to say that radiation is not deleterious to normal tissues3-5,10,14, and so
much work has been done towards improving therapeutic ratios in cancer treatments by
improving how the radiation dose – the local energy deposited by the radiation per unit mass –
conforms to the tumor volume15. Increasing the dose conformality both reduces normal tissue
toxicities by reducing the doses delivered to the surrounding normal tissues, while also
potentially improving tumor control by allowing for the possibility of dose escalation to the tumor
without significantly increasing normal tissue toxicities15. To achieve these highly conformal
dose distributions, the standard of care for many patients receiving radiation therapy involves
intensity modulated radiation therapy (IMRT) with x-ray photons16,17, where photon beams of
varying intensities and cross-sections are delivered from many positions in an arc around the
patient such that the resulting dose distribution is highly conformal to the tumor15,18-20. Such
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therapies have significantly improved
therapeutic ratios when treating tumors
where this dose conformality is
important due to considerations with
regards to toxicities in the surrounding
normal tissues, such as in pancreatic
cancers21,22, prostate cancers23, head
and neck cancers24,25 and
gynecological cancers26.
But more recently, radiation

Figure 1: 290 MeV/u Carbon ions have inherently favorable depthdose profiles (black) compared to 6 MV x-rays (red) since tumors
typically at some depth in the patient. 290 MeV/u Carbon ions
also have favorable depth-linear energy transfer profiles (blue).

therapies using charged particles (protons and carbon ions) instead of photons have emerged
with the promise of achieving these highly conformal dose distributions due the physics that
govern their interactions within the patient27. The primary advantage of using ions such as
protons or carbon (C) ions over photons in radiation therapy is their inherently superior depth
dose profile, known as a Bragg Peak, where a relatively large dose is deposited deep within the
patient, while the dose upstream and downstream of this peak are relatively minimal (Figure 1).
This is in contrast to the x-ray depth-dose distributions where the maximal dose is deposited at
a relatively shallow depth and there is only a gradual falloff of the dose downstream of the
depth of maximal dose (Figure 1). This is favorable in the case of ions because tumors
generally lie at a modest depth within the patient, and thus by carefully selecting the incident
energy of the ions used, the beam can be tailored to impart most of its dose into the tumor, with
little dose delivered to the tissues upstream of the tumor and little to no dose delivered
downstream27. Clinically, such plans are achieved by creating a spread out Bragg Peak
(SOBP), where a number of incident energies are selected to create a dose distribution that
results in a relatively homogenous dose delivered across the whole tumor volume, but very little
dose deposited beyond the range of the beam (Figure 2). This latter point is extremely useful in
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planning treatments near critical structures such as the spinal cord28,29 where it is of paramount
importance to limit dose to the nearby healthy tissues.
These differing depth dose
profiles arise due to the different
physics governing the interactions
between different types of radiation
and the materials through which they
pass. Photons with energies in the
therapeutic range rarely interact with
matter, but when they do, they typically
impart large amounts of energy via
Compton scattering . Thus the falloff
30

in dose distal to the depth of maximal

Figure 2: Depth-dose profile for unmodulated 100 MeV protons
(black) and 1 cm SOBP for protons of the same nominal energy
(red). The unmodulated beam was simulated as described in
Appendix II, while the SOBP was measured in the same way as
the pristine beams described in Appendix II.

dose loosely follows an exponential decay function, but with a small decay constant (Figure 1)
since it arises from the attenuation of primary photons via interactions upstream which are
rare30. By contrast, ions are charged, and thus continually interact coulombically as they pass
through a material, depositing relatively small amounts of energy continually along their path,
which slows them down until they eventually stop30. But as the particles’ energies decrease, the
energy they impart per unit distance travelled increases, and this increase is particularly
pronounced at lower energies, resulting in the particles depositing the bulk of their energy at
the end of their range30.
These differences in the physics governing how photons and ions deposit energy as
they pass through a material confer an important secondary benefit to ions, in the form of a
favorable depth-linear energy transfer profile (Figure 1). Linear energy transfer (LET) describes
the rate at which particles deposit energy per unit distance travelled as they pass through a
material, which is closely related to the amount of energy deposited into the material locally30.
Thus, as particles pass deeper into a medium and their LETs increase (Figure 1), the density of
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the energy they impart increases, and in turn, so too does the complexity of the DNA lesions
they produce5. Consequently, higher LET particles will induce more complex DNA lesions per
unit dose than lower LET particles31, and since complex lesions are more difficult to repair, they
will thus be more effective at inducing cell death5.
And so higher LET ions (or ions at the end of their range) tend to be more biologically
effective than lower LET ions, which is to say that for the same dose of radiation, higher LET
ions will induce more cell killing. And because the effective LET associated with photon beams
(the LET spectrum of the secondary electron spectrum the photon beam produces) are
relatively low (~0.2 keV/µm for MeV electrons30), ions generally tend to be more biologically
effective than photons32,33. This is often quantified in terms of the relative biological
effectiveness (RBE) of the ions compared to some reference photon radiation source,
calculated as the ratio of the doses, D, required to achieve the same biological endpoint, which
are typically greater than 1 for ions32-34:

𝑅𝑅𝑅𝑅𝑅𝑅𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =

𝐷𝐷𝑝𝑝ℎ𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜,𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
𝐷𝐷𝑖𝑖𝑖𝑖𝑖𝑖,𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

Since the LETs near the end of the particles’ range, which correspond to the tumor, are
much higher than at the entrance, which corresponds to normal tissues, the RBE in the tumor
tends to be higher than the RBE in normal tissues32. This provides an additional benefit to ion
therapies beyond any additional conformality of the dose, which is that the absorbed doses
delivered to the tumor are more effective at killing cells than the absorbed doses delivered to
the healthy normal tissues. Accordingly, recent clinical trials using carbon ions have shown
promising results in treating some conventionally non-responding or surgically inoperable
cancers, including head and neck cancers35-37, hepatocellular carcinoma35,37, rectal cancer35,37,
and in particular pancreatic cancers, where clinical trials have shown the median survival for
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selected patients treated with carbon ions to be nearly twice that of those treated with
photons35,37.
But beyond the inherent physical benefits afforded by ions with their favorable depthdose and depth-LET profiles, ions also have been noted to be less dependent on a number of
factors that are known to contribute to variability in the response to photon therapies, including
tumor oxygenation status1, tumor heterogeneity38, cell cycle phase39, DNA repair capacity40,
genetic background41 and inherent radioresistance42. Thus, ion therapies offer promising new
treatment options to patients and clinicians to potentially improve treatment outcomes across a
wide range of cancer disease sites where it is desirable to mitigate these heterogeneities in
treatment response.
But as detailed below, towards maximizing the use of ions in clinical radiation therapy,
much work remains to be done towards understanding the biological factors that modulate
radiation response, and how their importance differs for ions compared to photon radiation. We
believe that ultimately, the optimal use of ions in clinical setting will rely not only in optimizing
the physical delivery of the dose to the patient, but also in incorporating a greater amount of
biological information derived from the patient and their tumor into the decision-making
workflow, allowing for more informed decisions to be made about which modality to use, and
how to best use it, based upon the individual patient’s expected response.

II.

Accounting for the Improved Biological Effectiveness of Ions
Towards optimizing the physical dose distributions in ion therapies, a major

consideration is how the differing biological effect of ions should be accounted for. For protons,
this has been achieved simply by assuming the RBE to have a value of 1.1 across the
treatment field33. This assumption is based upon analyses of in vitro and in vivo data across a
wide range of conditions, for which the average RBE was found to be 1.1 for protons43.
However more recently, observations of RBEs much larger than 1.1 in the distal falloff region of
clinical SOBPs has called into question the validity of this assumption33, since it may result in
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significantly larger biologically equivalent doses being delivered to tissues distal to the tumor
where critical structures commonly lie44. While methods that use intensity modulated proton
therapy (IMPT) planning in order to minimize the high LET component of the treatment field
occurring adjacent to the critical structures have been proposed45, there is still no widely
accepted and robust method of incorporating the LET information directly into clinical proton
treatment plans. This is in part due to relatively large uncertainties with regards to: the values of
the RBE at the end of the proton’s range, the RBE’s dose and biological endpoint dependence,
as well as the values of RBE for normal tissues46.
But for carbon ions, incorporating the LET information of the beam into the treatment
planning is of paramount importance because the RBEs for carbon ions are well known to have
values significantly larger than 1 and that vary substantially across the treatment field47, but
also that can be modeled in terms of the LET32. But the value of LET to use to characterize a
beam is not straightforward because as the beam slows down, its energy spectrum broadens,
and thus so too does its LET spectrum. Thus, an averaged quantity for LET must be employed,
the two common ways of doing so being the fluence-weighted, LETΦ32,48-50:

𝐿𝐿𝐿𝐿𝐿𝐿𝛷𝛷 =

∞

𝑖𝑖
(𝐸𝐸)𝛷𝛷𝑖𝑖 (𝐸𝐸,𝑧𝑧)d𝐸𝐸
∑𝑖𝑖 ∫0 𝑆𝑆el
∞

∑𝑖𝑖 ∫0 𝛷𝛷 𝑖𝑖 (𝐸𝐸,𝑧𝑧)d𝐸𝐸

,

and the dose-weighted, LETd32,48-50:

𝐿𝐿𝐿𝐿𝐿𝐿d =

∞

𝑖𝑖
(𝐸𝐸) 𝐷𝐷𝑖𝑖 (𝐸𝐸,𝑧𝑧)d𝐸𝐸
∑𝑖𝑖 ∫0 𝑆𝑆el
∞

∑𝑖𝑖 ∫0 𝐷𝐷 𝑖𝑖 (𝐸𝐸,𝑧𝑧)d𝐸𝐸

,

with Siel(E) denoting the electronic stopping power of the ion species i, with energy E; Φi(E,z)
denoting the fluence of the ion species, i, at the location, z; and Di(E,z) denoting the dose
deposited by a given ion species. Note that this formalism includes contributions from different
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ion species which is an important consideration for heavier ions like carbon, where a
substantial amount of nuclear fragmentation occurs at depths where the SOBP typically
resides51.
Towards this, there are two main models that are employed clinically to predict the RBE
for a given ion treatment in terms of the ion’s LET, the local effect model (LEM) 40,52,53 and the
microdosimetric kinetic model (MKM) 54,55 which are described below.

II.1

The Local Effect Model (LEM)

The local effect model has been used extensively for carbon ion therapy clinical
treatment planning in Europe, at the Gesellschaft fur Schwerionenforschung (GSI), in
Darmstadt, Germany; the Heidelberg Ion-Beam Therapy Center (HIT) in Heidelberg, Germany,
and at the Centro Nazionale di Adroterapia Oncologica (CNAO) in Pavia, Italy56. This model is
based upon a track-structure model previously developed by Scholtz and Kraft 57,58 that
predicted the inactivation of cells by ions based upon how the ions deposit dose on microscopic
scales. The LEM employs this track structure approach, considering the cell nucleus to be the
relevant target of radiation damage that results in cell death. In the LEM formalism, it is
assumed that because the doses deposited by photons are relatively homogenous, the
probability of a cell surviving, SFγ, a given dose of radiation, D, depends on the Poissondistributed number of lethal lesions, N 40,52,53,59:

�������
�������
SF𝛾𝛾 (D) = 𝑒𝑒 −𝑁𝑁(𝐷𝐷) 𝑜𝑜𝑜𝑜 − ln �𝑆𝑆𝑆𝑆𝛾𝛾 (𝐷𝐷)� = 𝑁𝑁(𝐷𝐷)

For an infinitesimal volume of the nucleus, dV, the lethal lesions induced in that volume,
dN are given by the density of lethal lesions that would be induced by a homogeneously
distributed doses the same magnitude:
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������� =
𝑑𝑑 𝑁𝑁(𝐷𝐷)

�������
𝑁𝑁(𝐷𝐷)
𝑑𝑑𝑑𝑑
𝑉𝑉

In the case of ions, then, the only difference is that the dose is not homogenously
distributed, and rather is dictated by the track structure of the ions. In particular, we can
describe the dose at a given position in the nucleus, D(x,y,z), as the sum over all dose
contributions from ions traversing the nucleus according to their track structures. Then, if we
assume that in an infinitesimal volume, the density of lesions produced is the same for photons
and ions for the same dose57,58, we can use the cell’s known photon response, SFγ(D), and the
ion local dose distribution, D(x,y,z), to describe the expected number lethal events at any
position in the nucleus:

�����������������
𝑑𝑑 𝑁𝑁(𝐷𝐷(𝑥𝑥,
𝑦𝑦, 𝑧𝑧)) = −

ln �𝑆𝑆𝑆𝑆𝛾𝛾 �𝐷𝐷(𝑥𝑥, 𝑦𝑦, 𝑧𝑧)��
𝑉𝑉

𝑑𝑑𝑑𝑑

Integrating this expression over the volume of the nucleus, we get the expected number
of lethal lesions in the whole nucleus:

������� = − �
𝑁𝑁(𝐷𝐷)
𝑉𝑉

ln �𝑆𝑆𝑆𝑆�𝐷𝐷(𝑥𝑥, 𝑦𝑦, 𝑧𝑧)��
𝑉𝑉

𝑑𝑑𝑑𝑑

Which in turn gives the probability of inducing cell death by the ion57-59:

ln(𝑆𝑆𝑆𝑆𝑖𝑖𝑖𝑖𝑖𝑖 ) = �
𝑉𝑉

ln �𝑆𝑆𝑆𝑆�𝐷𝐷(𝑥𝑥, 𝑦𝑦, 𝑧𝑧)��
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𝑉𝑉

𝑑𝑑𝑑𝑑

Since its initial formulation57,58, LEM has undergone a number of modifications to
improve the accuracy of its predictions59, most recently (LEM IV) to account for the spatial
distribution of the DNA damage induced by the radiation, rather than relying simply on the local
dose distribution56,60. Although in its most recent version, LEM IV has been shown to more
accurately predict the response of in vitro data than the original model (LEM I)60,61, currently the
clinical implementation of LEM remains LEM I62, in part, because LEM I conservatively
overestimates the dose to normal tissues while underestimating the dose to the tumor59, but
also because the discrepancies between the different version of the model are fairly small, and
thus it is unclear the extent to which the different versions of the model may result in
differences in clinical outcomes62.
But a major challenge with using LEM is that it is extremely computationally expensive
to perform the calculations necessary to predict the response of a single cell line53, and thus in
a clinical setting it is not feasible to calculate predictions of individual patients tumor32 unless
approximations are made to hasten the calculation63. Thus, in clinical settings, it is often the
case that the biological input parameters for LEM come from pre-calculated tables for a small
subset of cells lines corresponding to different histological categories32,64, and thus LEM
incorporates very little patient-specific biological information in its predictions besides the tumor
histology. However, as we show in Chapter 2 of this work (which is based on a preprint article
we recently published65), we show that even for higher LET carbon ions, there is a large
amount of variability in the radiosensitivities of different cell lines of the same histological
category, and so without accounting for biological factors besides histology, such models may
result in some patients receiving treatments with insufficient (or unnecessarily high) doses,
resulting in poorer tumor control (or unnecessary normal tissue toxicities), and ultimately
suboptimal therapeutic ratios.
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II.2

The Microdosimetric Kinetic Model (MKM)

The microdosimetric kinetic model (MKM) 54,55,66 has been used extensively in clinical
treatment planning for carbon ion therapy in Japan at the National Institute of Radiological
Sciences (NIRS) in Chiba35,67. Also based on track structure models, the MKM model explains
cell killing in terms of how the microdosimetic characteristics of the ion tracks increase the
likelihood of inducing lethal DNA lesions, thereby increasing the likelihood of cell killing for a
given dose 54,55,66. Their statistical approach considers how energy is imparted by radiation into
sub-nuclear regions, called domains, assuming the survival, S, of a domain without having a
lethal lesion induced by the radiation is related to the dose deposited into the domain via a
linear quadratic relationship54,55,66:

𝑆𝑆 = 𝑒𝑒 −𝐴𝐴 𝐷𝐷−𝐵𝐵 𝐷𝐷

2

Note that this is analogous to the linear quadratic cell survival model (LQM), which
describes the survival, SF, of cells subjected to a dose of radiation, D, in terms of two
parameters, α and β:

𝑆𝑆𝑆𝑆(𝐷𝐷) = 𝑒𝑒 −𝛼𝛼𝛼𝛼−𝛽𝛽𝐷𝐷

2

Under the linear quadratic assumption and considering the energy imparted into these
subdomains by the radiation, the expected fraction of domains receiving j energy deposition
events, but having zero lethal lesions is given by54,55,66:

𝐴𝐴ℎ
𝐵𝐵𝜎𝜎 2
𝐵𝐵ℎ 2 𝑗𝑗 2
�����������
ln�𝑆𝑆(𝚥𝚥)� = − � + 𝑚𝑚2 � 𝑗𝑗 − 𝑚𝑚2 ,
𝑚𝑚
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where the overbar denotes the expectation value, m denotes the mass of the domain, and h
and σ2 are the mean and variance of the energy imparted into the domain per event, j. Then,
under the assumption that the energy deposition events follow a Poisson distribution, taking the
expectation value of the above quantity across all domains relates the expected fraction of
�������, to the dose delivered, D54,55,66:
domains not receiving a lethal lesion, ln(𝑆𝑆)
𝜎𝜎 2
𝐵𝐵
����������� = �������
ln�𝑆𝑆(𝚥𝚥)�
ln(𝑆𝑆) , = − �𝐴𝐴 + � + ℎ� � 𝐷𝐷 − 𝐵𝐵𝐷𝐷 2
ℎ
𝑚𝑚
Then, finally, taking the expectation value of this expression over the different doses received
by the different subdomains, the resulting expression, which describes the probability of
survival of the cell, can be shown to be54,55,66:

2

𝑆𝑆𝑆𝑆(𝐷𝐷) = 𝑒𝑒 −(𝛼𝛼+𝛾𝛾𝛾𝛾)𝐷𝐷−𝛽𝛽𝐷𝐷 ,
where γ is the microdosimetric quantity known as the dose-mean specific energy, which is the
average energy deposited by a single energy deposition event54,55,66 and α and β are the linear
quadratic survival curve parameters. In this way, the MKM model is able to use microdosimetric
quantities that quantify how different types of radiation deposit energy differently on
microscopic scales to explain how different types of radiation are more or less likely to induce
lethal DNA lesions, and in turn, relate this to overall cell survival.
While the MKM has been shown to faithfully predict the response of a number of human
cell lines66, it is limited in that the microdosimetric parameters required as its input are not
readily available. Sophisticated Monte Carlo calculations or tedious physical measurements
must be made in order to compute the saturation corrected dose-mean specific energy of the
beam, which requires complete knowledge of the energy and particle spectrum of the
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beam54,55. Further, in the MKM model, β is invariant across radiation qualities54,55, which differs
from a number of experimental observations that both α and β can vary with LET68,69, and thus
MKM may be incapable of predicting the value of β for cell lines where it varies substantially
with LET. But also, as with LEM, while the MKM model uses the photon survival curve
parameters as inputs, in clinical practice, these values for the patient’s tumor are not available,
and thus the use of the model generally requires the use of tabulated biological input
parameters that from a small number of cell lines of varying histologies67. But as mentioned
before, in Chapter 2 of this work, we show that the assumption that the response of cells of the
same histology will not vary substantially for higher LET carbon ions is not well founded.

III.

The Importance of Ion Radiobiology
While much of the success in ion therapies can be attributed to their favorable physical

characteristics, our current understanding of how ion RBE depends on the high ionization
densities produced are still largely based on physical arguments related to patterns of energy
deposition, namely that higher LETs lead to higher local doses, which are in turn more likely to
induce cell death70. A limitation of our current models is that they incorporate little biological
information into their predictions besides the photon survival curve parameters for a given
histological type, despite the fact that the response of a number of cell lines have been
characterized over a large range of LETs1,71,72 and much variation can be seen between the
response of different cell lines, suggesting that much remains unknown about the underlying
biology governing this dependence.
From a radiobiological standpoint, the primary mechanism by which radiation
inactivates cells is by inducing DNA damage, particularly DNA double strand breaks (DSBs).
DNA DSBs are particularly deleterious lesions that occur when damage occurs to the DNA
molecule’s sugar-phosphate backbone on opposite sides of the double helix, and occurs
sufficiently close together that the molecule is cleaved in two (Figure 3). Failure to repair such a
lesion whether by misrepair, or by being left unrepaired, is very likely to lead to cell death5,35,73.
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Thus, the capacity of cells to repair DNA DSBs is an important factor that governs cells’
intrinsic radiosensitivity74-76, with cells having deficiencies in one of the two main DNA DSB
repair pathways being rendered extremely radiosensitive74,75.
The two primary pathways used to repair DNA double strand breaks are nonhomologous end-joining repair (NHEJ) and homologous recombination (HR). NHEJ is a
relatively simple pathway that acts by fusing the cleaved ends of the genome back together77,78.
During NHEJ repair, the protein Ku70/80 helps to recruit the protein DNA-PKcs to the damage
site. At the damage site, DNA-PKcs forms a scaffolding around the two broken ends of the
DNA molecule from which a number of other proteins, including Artemis, DNA Ligase IV,
XRCC4 and XLF1 can then carry out the repair by fusing the two ends of the DNA molecule
back together77,78. While this process is relatively fast, it can be error-prone because it does not
possess the machinery to rebuild any damage besides the break itself, and so when this
process is undertaken, complete genomic integrity is only maintained in the case of a simple
DSB where no additional damage is induced in the vicinity of the broken ends77,78.
Nevertheless, NHEJ is the most used pathway to repair DSBs in human cells, accounting for
about 90% of all DSB repair79.
By contrast, HR is a much more sophisticated DNA repair pathway that acts by
gathering the homologous strand of DNA (the second copy of the DNA molecule after it has
been synthesized during S phase) and using it as a template to rebuild the broken region80,81.
This is accomplished first by resecting the ends of the broken strands which allows for a
number of proteins including DNA helicases, Rad51 and Rad5480-82 to facilitate the invasion of
the homologous strand in the vicinity of the resected region (Figure 3). Then, the resected
region can be synthesized using the sister chromatid as a template which results in an errorfree reconstruction of the damaged region80,81. Consequently, HR is a much more faithful DSB
repair pathway than NHEJ83 since it is capable of rebuilding damaged sections using the
homologous strand as a template, but it is limited by the fact that homologous strand needs to
have been synthesized in order to perform this type of repair and so HR is only available during
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the G2, or sometimes S phases of the cell cycle80,81. As a result, despite being a less errorprone repair pathway than NHEJ, HR is only used to repair roughly 10% of all DSBs79

Figure 3: Diagram of DNA damage induction by ions, the repair of the lesions, and the resulting outcomes. Low LET
particles induce relatively simple DNA lesions, including DNA double strand breaks that can be repaired relatively
easily via non-homologous end-joining (NHEJ) repair. High LET particles create more complex DNA lesions which
may require the more sophisticated homologous recombination (HR) repair pathway to repair effectively, since
resection and/or reconstruction of the damaged region may be needed for a successful repair. Cells that
successfully repair the damage resume their procession through the cell cycle, while cells that fail to do so die.
*Used with permission from Dr. Scott J. Bright

But beyond simply being a more faithful repair mechanism, because HR can rebuild
damaged sections of the DSBs, it is believed that HR may be more suitable to repair complex
DNA lesions84-86. This is of importance in the context of ion therapies because higher LET ions
produce more complex and clustered DNA lesions than lower LET ions87,88 due their increased
ionization densities, suggesting that HR may play an important role in dictating cell
radiosensitivity to high LET radiation. Data in this work (Chapter 3) as well as few cell survival
studies show that deficiency in HR repair sensitizes cells to high LET radiation89,90, but so too
does deficiency in NHEJ repair40,89,90, and seemingly to a greater extent89,90. So, while NHEJ is
likely to be more important in an absolute sense, since it repairs such a large fraction of all
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DSBs, the relative importance of the two pathways in dictating cell radiosensitivity likely varies
with LET due to NHEJ’s inability to resolve complex lesions.
However, while it is generally believed that dependence of cell radiosensitivity on DNA
repair capacity is a less important consideration at higher LETs due to the increased lethality of
the radiation27,28, as we show in Chapter 2, there is still a considerable amount of variability in
the response of cells with differing DNA repair capacities, even for higher LET carbon ions, and
this variability does not significant decrease with increasing LET. Thus, towards personalizing
ion radiotherapies, we believe that not only does DNA repair capacity have implications with
respect to selecting which modality to use, e.g. photons versus carbon ions, but also how the
biological effectiveness of ions is accounted for at different depths in the treatment field since a
tumor’s DNA repair status may differentially impact the RBE for different radiation qualities.
These considerations are discussed further in Chapters 2 and 3.

IV.

Towards Personalizing Radiotherapy with Ions
In current clinical practice in radiation therapy, the prescription of radiation dose follows

a “one size fits all” approach, where patients whose disease falls under a given histological
category are prescribed the standard dose-fractionation regimen for tumors of that category,
with a few considerations made with regards to their disease staging, patient performance
status and other prognostic factors. While this standardization is useful with regards to
assessing the efficacy of different treatments in clinical trials, it only ensures that the treatments
are effective for the average patient, which can be problematic when there is a great amount of
heterogeneity in patient response.
And for radiation therapy, this heterogeneity in response is ubiquitous. It is well known
that tumors of the same histological category often present large variations in their intrinsic
radiosensitivity to photons91-96, which may in part explain the heterogeneous response of
tumors to radiation therapy97-100. In turn, this means that for an individual patient prescribed
radiation therapy, it is possible that their treatment delivers unnecessarily high doses (and thus
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unnecessarily high normal tissue toxicities) if their tumor is radiosensitive, or fails to deliver
enough dose to control the tumor in cases where their tumor is radioresistant.
Thus, knowledge of a patient’s individual radiosensitivity could help clinicians and
patients make more informed treatment decisions, in particular with regards to the use of ion
therapies. This is because ion therapies are significantly costlier than x-ray therapies, and there
are comparably few facilities that are even capable of offering them. It is important, therefore, to
have a rational way to decide which patients are prescribed the costlier, less accessible ion
therapies, in favor of the less costly, and more readily available photon therapies, and we
believe that the rationale behind these decisions should be based upon which patients stand to
benefit the most from the use of heavy ions. Patients whose treatments are greatly constrained
by normal tissue toxicities and whose tumors are known to be radioresistant will likely derive
more benefit from heavy ions than patients whose tumors are radiosensitive. Thus, having a
way to predict which patients’ tumors are more radiosensitive or radioresistant within a
particular histological category are critical towards making such decisions.
But predicting the radiosensitivity of patients’ tumors ultimately depends on
understanding the underlying radiobiology governing intrinsic radiosensitivity, and in the context
of ions, this is a two-fold problem. First, we need to understand the factors that govern intrinsic
radiosensitivity in the general sense, and second, we must understand how their relative
importance may vary between radiation qualities. Nevertheless, much work has been done
towards identifying factors that contribute to intrinsic radiosensitivity, and these factors include
DNA repair capacity74-76 , the prevalence of anti-apoptotic signaling pathways101,102, tumor
microenvironment factors103, other biological factors related to gene expression104, mutations to
tumor suppressor genes such as p5312,13,101 or KRAS101,105,106 or to genes that contribute to a
cell’s DNA repair capacity such as BRCA111 or BRCA2107, as well as other genotypic
factors108,109.
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In fact, a large number of potential mutations have been identified that are indicators of
intrinsic radiosensitivity or radioresistance 101, which hold promise for use as potential
biomarkers for personalized radiosensitivity due to increased prevalence of tumor genotyping.
But, while the identification of these genetic factors is an important step towards personalized
radiosensitivity, there is increasing evidence that a number of epigenetic factors also mediate
intrinsic radiosensitivity101,110,111. Thus, while genotyping may identify some highly responsive or
resistant tumors, genotyping alone may not be sufficient to accurately predict tumor response
across a broad range of patients. Instead, promising results relating genomic profiles104,112,113 to
intrinsic radiosensitivity seem to alleviate this issue, and may ultimately be the manner by
which intrinsic radiosensitivity is assessed in the clinic. Towards this, in a preliminary study
discussed in Chapter 5, we show that this approach can be used for genes associated with
DNA repair to develop predictive functions of cell intrinsic radiosensitivity.
Although currently the majority of the effort in personalizing radiotherapy has been
focused on personalizing the response to photon radiation, with the emerging prevalence of ion
therapies, and their inherent physical benefits in treating certain tumors, any successful
implementation of personalized radiotherapy to photons will underscore the need for the
translation of this knowledge into our approach to prescribing ions. However, there are a
number of challenges with regards to personalizing intrinsic radiosensitivity in ion therapies.
The primary challenge is with regards to accounting for differences in radiation quality. Unlike
photons, ion therapies have extremely large differences in their biological effectiveness across
a given treatment field as described in CH1§II. Consequently, if a treatment is to be
personalized to a patient’s tumor, not only would we have to account for the intrinsic
radiosensitivity of that patient’s tumor, but we would also need to account for how its intrinsic
radiosensitivity varies across a wide range of radiation qualities. Calibrating a predictive
function capable of achieving this directly would require an inordinate amount of a calibration
data across a huge number of radiation qualities, and thus is unfeasible. But, if a cell’s photon
response can be predicted accurately using a genomic signature, and its ion response can be
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predicted accurately from its photon response, then predicting the ion response directly may be
unnecessary.
Thus, in this work, we present a number of analyses that lay the groundwork towards
alleviating these issues and which highlight the need for the personalization of ion therapy.
First, we show that it is not sufficient to rely on the assumed lesser variability in cellular
response to higher LET radiation by showing directly that the variability in intrinsic
radiosensitivity is not significantly different between photons, protons and even carbon ions
(Chapter 2). Results from these analyses also imply that knowledge of the RBE ultimately be
less important than knowledge of a cell’s intrinsic radiosensitivity when optimizing ion
treatments, suggesting that modeling efforts might better be focused at predicting cell’s
absolute radiosensitivity rather than their sensitivity relative to photons.
We then show that some of this variability can be attributed to biological and genetic
factors related to DNA repair capacity, which we show are not significantly less important in
governing the heterogeneity in cell response to ions than it is to photons (Chapter 2). In
particular, we show that DNA repair capacity, which greatly influences cell radiosensitivity to
photons, remains an important predictor of cell radiosensitivity even for carbon ions, and that
the absence (or attenuation of) DNA repair causes greater changes in cellular radiosensitivity
to ions than the changes induced by increasing ion LET (Chapter 3). This implies that biological
factors such as DNA repair capacity may be absolutely more important than physical factors
such as the ion’s LET in dictating cell radiosensitivity to ions.
And in spite of this, in Chapter 4 we present a model (called PORTAL) that can predict
a cell’s ion radiosensitivity on the basis of its photon radiosensitivity and the dose-weighted
LET of the ions, which we show predicts the response of cells with greatly differing DNA repair
capacities, whether naturally occurring, or induced by pharmocological inhibition or genetic
modification. Thus, with the use of this model, it may be possible to predict a cell’s ion
radiosensitivity indirectly from genomic markers, first by using a genomic function to predict the
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cell’s photon response, and then using its photon response to predict its ion response using our
model.
Then finally, since we showed that DNA repair capacity greatly influences
radiosensitivity across radiation qualities, as a proof of concept we show that it is, in principle,
possible to predict a cell’s intrinsic photon radiosensitivity on the basis of a number of genomic
markers related to DNA repair capacity (Chapter 5). And since, when using PORTAL, we
showed that differences in DNA repair capacity do not perturb its predictions, we believe that
once this genomic function can predict the photon radiosensitivity with sufficient accuracy, the
two models can be combined to predict a cell’s intrinsic radiosensitivity to both photons and
ions.
Thus, in this work, we lay the groundwork for the personalization of ion therapy – a
method to predict a cell’s intrinsic radiosensitivity to photons on the basis of a set of genomic
markers, and then predicting the cell’s response to ions based on their response to photons.
But also, this work may be directly applicable in the context of novel therapies that combine
DNA repair inhibitors with radiation therapy, as the data we present in Chapter 2 suggest that
cells treated with DNA repair inhibitors have comparable variability in radiosensitivity between
radiation qualities which suggest that properly accounting for intrinsic radiosensitivity remains
an important consideration for future personalized ion radiotherapy, even if drugs are used to
radiosensitize the tumors. And since we show that PORTAL’s predictions are compatible with
cells treated with DNA repair inhibitors, but it is not known whether other models can account
for any differences induced by the drugs, the model we present here may be of particular use
for predicting cellular response to ions in therapies where pharmacological inhibition of DNA
repair pathways are combined with the radiation treatment.
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Chapter 2 – The variability in radiosensitivity of cells
exposed to x-rays, protons, and carbon ions

A substantial portion of this chapter is written or based on the following publication in Medical
Physics65 and for which the right to reproduce as part of my dissertation is granted by Wiley:

Flint DB, Bright SJ, McFadden CH, Konishi T, Ohsawa D, Turner B, Lin SH, Grosshans DR,
Chiu HS, Sumazin P, Shaitelman SF, Sawakuchi GO. Cell lines of the same anatomic site and
histologic type show large variability in intrinsic radiosensitivity and relative biological
effectiveness to protons and carbon ions [published online ahead of print 2021/04/11]. Medical
physics. 2021;48(6):3243-3261.

I.

Introduction
Although it is well known that tumors of the same histology present large variations in

intrinsic radiosensitivity for photons91-96, decisions for most tumors regarding the radiotherapy
(RT) type (photons, protons, or carbon ions) and the dose-fractionation regimen are made
independent of factors that are known to modulate a tumor’s intrinsic radiosensitivity, such as a
tumor’s particular biology104 or genotype108,109. This results in a “one-size-fits-all” approach
where treatment decisions are based on histology, patient performance status and disease
stage. This may explain, in part, the heterogeneous response of tumors to RT in any given
cohort of patients.97-100 This is further compounded in the case of heavy ion therapy, where the
relative biological effectiveness (RBE) varies greatly across the treatment volume32 and is
accounted for through the use of models such as the local effect model (LEM)40,52,53, or the
microdosimetric kinetic model (MKM)54,55 which, in clinical practice, predict the RBE for different
histologic types based on the response of a discrete number of cell lines in a small subset of
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histologic types.32,67,114-117. These models are discussed in more detail in CH1§II.1 and
CH1§II.2.
It is generally accepted that these variations in intrinsic radiosensitivity can be mitigated
with heavy ions, which are believed to result in less heterogeneous response between tumors
of the same histologic type.97,118,119 This is in part based on the belief that high-linear energy
transfer (LET) radiation is less dependent on DNA repair capacity35,120, which is known to
greatly affect cellular radiosensitivity75,76. From these assumptions, one might fairly assume that
efforts to predict intrinsic radiosensitivity to ions confers significantly less benefit than predicting
intrinsic radiosensitivity to photons, since across a wide range of factors, the response between
tumors differs substantially less for ions.
But, in this chapter, we show that these assumptions are not well-founded. We show
that cell lines of the same histologic type have remarkable variability in their intrinsic
radiosensitivities to protons and even carbon-ions (C-ions). We further show that the relative
variabilities in intrinsic radiosensitive are not significantly different when comparing photons to
protons and C-ions, and that the variation in intrinsic radiosensitivity are in some cases greater
than the variation in RBE. In addition, our data suggest that relative variations in intrinsic
radiosensitivity of cell lines in which the DNA repair capacity was modulated using several DNA
repair inhibitors is independent of radiation type when comparing photons to protons and Cions. These findings indicate that DNA repair capacity similarly affects the variability in cell
survival for low- and high-LET radiation.

II.

Materials and Methods
II.1

Cell line panel

For the analyses in this chapter, we used a number of human cancer cell lines across
three anatomical sites including lung (n=18), brain (n=10) and pancreas (n=10), obtained from
literature sources including the Particle Irradiation Data Ensemble (PIDE) database2, Liu et al.
2015 121 and Suzuki et al. 2000122 as well as collected by us (Table 1). We classified the tumor
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type of each cell line according to their classification in the Cancer Cell Line Encyclopedia
(CCLE).123 The lung cancer cell lines were all non-small cell lung carcinoma (NSCLC) (n=18),
which were further classified in three histologic subtypes including lung adenocarcinoma
(LUAD) (n=13), lung squamous cell carcinoma (LUSC) (n=4) and large cell lung carcinoma
(LCLC) (n=1). While our cohort of lung cancer cells are not all the same subtype, no distinction
between these subtypes is made in clinical practice to prescribe RT. The NSCLCs were then
further classified according to their molecular subtypes, which were obtained from Yu et al.
2019.124 The brain cancer cell lines were all glioblastoma multiforme (GBM) (n=10) and were
classified by molecular subtype according to their mutation statuses in the genes PTEN and
IDH, which are respectively a tumor suppressor gene commonly mutated in cancers125 , and
commonly mutated gene among gliomas and whose mutation status correlates with
prognosis126 (PTEN-wildtype [n=4] , PTEN-mutant [n=6], IDH-wildtype [n=10], IDH-mutant
[n=0]). The PTEN and IDH mutation statuses were determined from their listing in the
CCLE.123 Furthermore, the GBM cell lines M059K and M059J have differential expression of
the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)127 despite being extracted
from the same tumor128 (M059K has normal DNA-PKcs activity while M059J lacks DNA-PKcs
activity). As DNA-PKcs is essential in repairing DNA double strand breaks (DSBs) via nonhomologous end-joining repair (NHEJ) M059J cells are much more radiosensitive than M059K
cells129. The pancreatic cancer cell lines were all pancreatic adenocarcinoma (PAAD), further
classified in molecular subtypes including basal (n=5) and classical (n=5).124
Additionally, the H1299, H460, Panc 10.05 and PANC-1 cell lines were also treated with
DNA repair inhibitors prior to irradiation to attenuate various DNA repair pathways to differing
degrees. These inhibitors targeted the proteins: ataxia telangiectasia and Rad3 related (ATR),
DNA-PKcs, ataxia telangiectasia mutated (ATM), Poly (ADP-ribose) polymerase (PARP) and
Rad51, which are proteins essential for DNA damage response (DDR)130,131; NHEJ repair132,133,
DDR130,131, DDR and base excision repair (BER)134, and homologous recombination (HR)
repair135, respectively. Details of these drug treatments can be found below in CH2§II.2. These
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cell lines were selected because they represent two anatomic sites and for each anatomic site
one cell line is radiosensitive and the other is radioresistant. For the analyses of variability of
the intrinsic radiosensitivity we included data from cells treated with inhibitors of DNA-PKcs and
ATR to improve the statistical power of our analyses, but to avoid bias in our results, we
included in these analyses only data for which the cells had been treated with the set of DNA
repair inhibitors across all radiation qualities.
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Table 1: List of NSCLC, GBM and PAAD cell lines with their respective histology and respective treatment with DNA
repair inhibitors. “*” , “+”, “‡“ and “#” indicate that radiation response data were obtained from the PIDE database, Liu
et al. 2015121, Suzuki et al. 2000122, or our measurements, respectively (multiple symbols indicates averaged from
multiple sources). Notably, we extracted the data from Suzuki et al. 2000122, which is also in the PIDE database,
directly from their paper because it presented the uncertainties rather than using the Suzuki et al. 2000 data from the
PIDE. NSCLC: Non-small cell lung carcinoma LUAD: Lung adenocarcinoma. LUSC: Lung squamous cell carcinoma.
LCLC: Large cell lung carcinoma. GBM: Glioblastoma multiforme. PAAD: Pancreatic adenocarcinoma. DMSO:
Dimethyl sulfoxide. ATRi: Ataxia telangiectasia and Rad3 related inhibitor. DNA-PKcsi: DNA-dependent protein
kinase, catalytic subunit inhibitor. ATMi: Ataxia telangiectasia mutated inhibitor. [] indicates concentration of inhibitor.

Cell line
LC-1sq‡
H23+
H1563+
H520+
H460*+#
H460-DMSO
H460-DNA-PKcsi [0.1 µM]
H460-ATRi [0.1 µM]
HCC827+
A-549*+‡
SW1573*
NCI-H1915+
Calu-6+
H2126*
H1437*
ABC-1+
H1792+
H1703+
H1869+
H1299*+#
H1299-DMSO
H1299-DNA-PKcsi [0.1 µM]
H1299-ATRi [0.1 µM]
HCC-44+
M059J#
KS-1‡
A-172*‡
LN-229*
SF-126‡
U-87MG*
M059K#
U-251MG*
T98G*#
KNS-60‡
HS766T#
MIA PaCa-2#
HPAC#
AsPC-1#
BxPC-3#
Capan-1#
PK-1#
PANC-1#
PANC-1-DMSO
PANC-1-DNA-PKcsi [0.1 µM]
PANC-1-ATRi [0.1 µM]
Panc 10.05#
Panc 10.05-DMSO
Panc 10.05-DNA-PKcsi [0.1 µM]
Panc 10.05-ATR-i [0.1 µM]
L3.3#

Anatomical
Site

Histologic
Type/Sub-type

Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Lung
Brain
Brain
Brain
Brain
Brain
Brain
Brain
Brain
Brain
Brain
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas

NSCLC/LUSC
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUSC
NSCLC/LCLC
NSCLC/LCLC
NSCLC/LCLC
NSCLC/LCLC
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUSC
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUSC
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUAD
NSCLC/LUAD
GBM
GBM
GBM
GBM
GBM
GBM
GBM
GBM
GBM
GBM
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
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Molecular subtype
Terminal respiratory unit
Terminal respiratory unit
Primitive
Proximal inflammatory
Proximal proliferative
Secretory
Proximal proliferative
Proximal proliferative
Terminal respiratory unit
Proximal inflammatory
Terminal respiratory unit
Basal
Terminal respiratory unit
Terminal respiratory unit
Terminal respiratory unit
Terminal respiratory unit
Proximal inflammatory
PTEN-mutant
PTEN-wildtype
PTEN-wildtype
PTEN-wildtype
PTEN-mutant
PTEN-mutant
PTEN-mutant
PTEN-mutant
PTEN-wildtype
PTEN-mutant
Basal
Classical
Classical
Classical
Basal
Classical
Basal
Classical
Classical
Classical
Classical
Basal
Basal
Basal
Basal
Basal

II.2

Treatment with DNA repair inhibitors

To inhibit ATR, Ceralasertib (AZD6738, Selleckchem) was dissolved in dimethyl
sulfoxide (DMSO) at 10 mM and was used at final concentrations of 0.1 or 2 µM. Alternatively
to inhibit ATR, BAY 1895344, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8(1H-pyrazol-5-yl)-1,7-naphthyridine (Selleckchem) was dissolved in DMSO at 10 mM and was
used at a final concentration of 0.01 µM. To inhibit DNA-PKcs, 8-(4-Dibenzothienyl)-2-(4morpholinyl)-4H-1-benzopyran-4-one (NU7441, Selleckchem) was dissolved in DMSO at 5 mM
and was used at final concentrations ranging from of 0.1 or 0.5 µM. To inhibit ATM, KU55933,
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (S1092, Selleckchem) was dissolved in DMSO
at 10 mM and was used at final concentrations of 0.1 or 10 µM. To inhibit PARP1, Olaparib
(AZD2281, S1060, Selleckchem) was dissolved in DMSO at 10 mM and was used at a final
concentration of 1 µM. To inhibit Rad51, B02 (Cat# S8434, Selleckchem) was dissolved in
DMSO at 10 mM and used at a final concentration of 5 μM. The final concentration of DMSO
was 0.1% in all groups. To combine these treatments with the preparation of samples for the
survival assays, were seeded the cells 24 hours prior to irradiation in 6-well plates or T12.5
flasks. Then, 8 hours prior to irradiation, media was removed and replaced with media
containing the inhibitor or the DMSO vehicle to serve as controls. After 24 hours of incubation
with the inhibitor or vehicle (which corresponded to 16 hours after irradiation), the media
containing the inhibitor (or vehicle) was removed and replaced with fresh media. Cells were not
washed to minimize the disturbance to attached cells. Cell lines and conditions subjected to
treatments with DNA repair inhibitors are listed in Supplemental Table 3.

II.3

Radiation response data

Radiation response data of each cell line were either measured by us (H460, H1299,
BxPC-3, PANC-1, AsPC-1, Panc 10.05, MIA PaCa-2, L3.3, HS766T, PK1, Capan-1, HPAC,
M059K and M059J cell lines) or obtained from the literature. The literature data included data
extracted from the PIDE database2, from Liu et al. 2015121 and from Suzuki et al. 2000122,
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which is also presented in the PIDE. Since the data presented in Suzuki et al. 2000122 paper
contained estimates of the uncertainties, we used the values presented in their paper rather
than those in the PIDE for which no uncertainty is given.
To quantify the intrinsic radiosensitivity of each cell line, the doses at which the
surviving fraction falls to 10% (D10%) and 50% (D50%) on the cell survival curve were calculated
based on the α and β values from the linear quadratic (LQ) model. These values were obtained
from fitting to the clonogenic cell survival data or provided in the literature sources. In cases
where data existed from multiple sources, we used the reported α and β from each source to
estimate the doses at the 10% (D10%), 20%, (D20%), 37% (D37%) and 50% (D50%) survival levels
from each source. We then fitted all the survival estimates across all sources simultaneously
with the LQ model to estimate the final α and β values and their uncertainties for a given
condition used in our analyses.
We quantified the ion RBE relative to photons by taking the ratio of the D10% or D50%
values: RBED10% = D10%,photon/D10%,ion or RBED50% = D50%,photon/D50%,ion.
To quantify the variability of the response within each group, we calculated the range of
D10% or D50% and RBED10% or RBED50% values. To compare between histologic types, LET
values, or treatment with DNA repair inhibitors, we calculated the relative range (range/mean)
and the coefficient of variation (COV) of D10%, D50%, RBED10% and RBED50%. These relative
metrics were chosen for comparisons between groups to highlight the relative variations within
and between groups. This is especially important when comparing between radiation qualities
for which the absolute survival levels are remarkably different such as for low versus high LET
radiation, but for which these differences are accounted for clinically through the use of relative
parameters such as RBE
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II.4

Cell culture

For the analyses in this chapter, data we measured used included the cell lines H460,
H1299, BxPC-3, PANC-1, AsPC-1, Panc 10.05, MIA PaCa-2, L3.3, HS766T, PK1, Capan-1,
HPAC, M059K and M059J which were obtained from the American Type Culture Collection
(ATCC). They were all authenticated using short tandem repeat (STR) DNA profiling at the MD
Anderson Characterized Cell Core Facility (CCLC), and tested negative for mycoplasma
contamination. The cell culture conditions for these cells are given in Appendix 1. All cell lines
were maintained in a humidified atmosphere at 37°C, 5% CO2 in air and were routinely subcultured prior to reaching 100% confluence using 0.25% trypsin.

II.5

Irradiations

For the results presented in this chapter, the cell lines were grown in 6-well plates or T12.5 flasks and exposed to clinical x-ray beams and proton beams at The University of Texas
MD Anderson Cancer Center, and C-ions at the Heavy-Ion Medical Accelerator in Chiba
(HIMAC) (Chiba, Japan). The x-ray irradiations were performed using a 6 MV beam from a
clinical linear accelerator (Truebeam, Varian Medical Systems, Palo Alto, CA) at a water
equivalent depth of 10 cm to simulate a clinical radiation environment. The proton irradiations
were performed using an unmodulated 100 MeV proton beam with slabs of water equivalent
plastic in front of the beam to obtain a dose-weighted LET in water of 9.9 keV/µm, which
corresponds to the end of the proton range. The C-ion irradiations were performed using an
unmodulated 290 MeV/nucleon C-ion beam with dose-weighted LETs in water of 13.5 and 60.5
keV/µm, respectively, which correspond approximately to LET values found at the entrance and
middle of the SOBP for C-ions, respectively. These LET values were obtained using energy
absorbers that are part of the beamline.136 Appendix 2 contains more details about these
irradiation conditions.
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II.6

Clonogenic cell survival assays

To seed the cells for the clonogenic assays, the cells were trypsinized 18-24 hours prior
to irradiation and seeded into 6-well plates or T-12.5 flasks at appropriate numbers for each
dose. After irradiation, cell lines were allowed to form colonies for 7-14 days and then were
fixed and stained with pure ethanol containing 0.5% crystal violet. More details about these
methods can be found in Appendix 2. The plates were then air dried and scanned using a highresolution flatbed scanner (Epson Expression 10000 XL) to produce images to be analyzed
using an ImageJ plugin developed in-house that automatically counts colonies containing more
than 50 cells. Details of these image processing techniques to score colonies can be found in
Appendix 3. Toward these analyses, the clonogenic cell survival assays for x-rays and protons
were independently repeated at least three times each time in triplicate over a period of three
years, while the cell survival assays for most C-ion irradiations were independently repeated at
least two times, at least in duplicate, over a period of three years. However, the cell lines that
were exposed to C-ions and treated with DNA repair inhibitors correspond to a single
experiment performed in duplicate. Each clonogenic cell survival experiment included at least
five doses, and each cell line had a specific range of doses determined according to its
radiosensitivity under the constraint that it contained a dose level that was close to D10%.
Details of how the clonogenic data were analyzed are found in Appendix 2.

II.7

Statistical analyses

The statistical analyses in this chapter were performed in MATLAB 2017 (Mathworks,
Natick, MA) and Graph Pad Prism 7 (Graph Pad, San Diego, CA). The error bars plotted in the
data represent the standard error propagated from the fits of the survival curve parameters (α
and β), including their covariance, to the parameter estimates. To assess the variability
between groups, we performed two-tailed z-tests between the coefficients of variation of each
group.

28

III.

Results
We compared the intrinsic radiosensitivities, defined by D10% (or D50%), within the same

histologic type (NSCLC, GMB and PAAD) and observed a large variability in D10% (or D50%)
values among cell lines exposed to photons, protons, and even C-ions (Figure 1A-C, Figure 5
A-C) varying up to 94±33% (135±44%), 115±11% (147±15%) and 74±6% (99±%19) across
radiation qualities for NSCLC, GBM and PAAD cell lines, respectively, relative to the mean of
each histologic type (Table 2). However, when comparing between radiation qualities, while the
absolute ranges in D10% (or D50%) are much higher for photons than C-ions, when the cell lines’
D10% (or D50%) values for a particular radiation quality are normalized to the mean D10% (or D50%)
in each group, the resulting relative D10% (or D50%) values vary a similar amount across all
radiation qualities (Figure 1D-F, Figure 5D-F, Table 2). Accordingly, when we quantify the
variability in D10% (or D50%) within each group by calculating the COV, no significant differences
can be seen in the variability of D10% (or D50%) between radiation qualities, with p-values
ranging from 0.4579 to 0.8908, 0.6098 to 0.9993 and 0.1492 to 0.9716 for NSCLC, GBM and
PAAD cell lines, respectively (Figure 1G-I, Figure 5D-F, Table 2, Supplemental Table 5). These
data suggest that while the absolute variations in intrinsic radiosensitivity are greater for
photons, when one accounts for the mean survival level for each radiation quality, there is no
difference in the relative variability in cell radiosensitivity between radiation qualities.
Supplemental Note 1 provides tables with the values of D10%, D50%, α and β for the survival
curves used in this work. All the p-values from these comparisons can be found in
Supplemental Note 2. The dataset of cells treated only with radiation, which excluded cells
treated with radiation and DNA repair inhibitors, was also evaluated (Supplemental Note 3).

29

Figure 4: (A-C) Dose for 10% survival fraction to quantify the intrinsic radiosensitivity of the NSCLC, GBM and PAAD
cell lines listed in Table 1. Each data point represents a cell line listed in Table 1. Vertical lines are the standard
deviations. (D-F) Percentage difference of the D10% values from the mean D10% for each radiation quality and
histologic type to quantify the variation in intrinsic radiosensitivity among cell lines of the same histologic type
between different radiation qualities. Vertical lines are the standard deviations. (G-I) Coefficient of variation in D10%
for each radiation quality and histologic type. NSCLC: Non-small cell lung carcinoma. GBM: Glioblastoma
multiforme. PAAD: Pancreatic adenocarcinoma. Supplemental Note 1 contains the values of D10% used in the plots.
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Figure 5: (A-C) Dose for 50% survival fraction to quantify the intrinsic radiosensitivity of several NSCLC, GBM and
PAAD cell lines. Each data point represents a cell line listed in Table 1. Vertical bars are the standard deviations. (DF) Percentage difference of the D50% values from the mean D50% for each radiation quality and histologic type to
quantify the variation in intrinsic radiosensitivity among cell lines of the same histologic type between different
radiation qualities. Vertical bars are the standard deviations. (G-I) Coefficient of variation in D50% for each radiation
quality and histologic type. NSCLC: Non-small cell lung carcinoma. GBM: Glioblastoma multiforme. PAAD:
Pancreatic adenocarcinoma. Supplemental Note 1 contains the values of D50% used in the plots.
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Table 2: Variability in intrinsic radiosensitivity of NSCLC, GBM and PAAD cells listed in Table 1 exposed to 6 MV xrays, 9.9 keV/μm protons, and 13.5 and 60.5 keV/μm C-ions, grouped by histologic type. Relative sensitivity values
are calculated relative to the mean D10% or mean D50% values for each group.
Radiation
Cohort
Cohort
Quality
Size

6 MV
photons
9.9
keV/µm
protons
13.5
keV/µm
C-ions
60.5
keV/µm
C-ions
6 MV
photons
9.9
keV/µm
protons
13.5
keV/µm
C-ions
60.5
keV/µm
C-ions

Most
Sensitive,
D10% or D50%
(Gy)

Most
Sensitivity
Resistant,
Range,
COV in
D10% or D50% D10% or D50% Sensitivity
(Gy)
(Gy)

NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD

24
10
16
8
2
12
10
7
10
8
2
10

3.402±0.002
1.37±0.02
4.26±0.07
2.54±0.05
1.42±0.12
3.18±0.08
3.23±0.01
1.21±0.04
4.5±0.2
2.39±0.09
1.03±0.04

8.91±0.13
6.595±0.006
8.9±0.3
6.75±0.19
4.02±0.05
6.61±0.19
6.67±0.07
5.065±0.009
6.77±0.12
4.25±0.10
3.01±0.14

2.30±0.09

4.07±0.06

NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD

24
10
16
8
2
12
10
7
10
8
2
10

1.04±0.05
0.47±0.02
1.75±0.08
1.02±0.07
0.43±0.04
1.13±0.08
1.206±0.002
0.51±0.07
1.51±0.13
0.92±0.11
0.41±0.07
0.80±0.08

4.49±0.61
3.480±0.004
4.2±0.3
2.81±0.10
1.62±0.06
3.1±0.2
3.5±0.3
2.436±0.005
3.0±0.2
2.10±0.12
0.91±0.10
1.87±0.15

D10%
5.51±0.13
5.22±0.02
4.6±0.3
4.21±0.20
2.60±0.13
3.4±0.2
3.44±0.08
3.85±0.05
2.2±0.3
1.86±0.14
1.98±0.15
1.77±0.11
D50%
3.5±0.6
3.01±0.02
2.4±0.3
1.79±0.12
1.19±0.07
2.0±0.2
2.3±0.3
1.92±0.07
1.5±0.3
1.18±0.16
0.50±0.12
1.08±0.17

Most
Most
Relative RMSPE in
Sensitive Resistant
Sensitivity Sensitivity
Relative to Relative to
Range (%)
(%)
Mean (%) Mean (%)

0.27±0.04
0.37±0.10
0.21±0.04
0.35±0.10
0.7±0.6
0.21±0.05
0.26±0.06
0.42±0.14
0.13±0.03
0.24±0.07
0.7±0.6

-42±12
-70±2
-32±2
-43±2
-48±5
-33±3
-36.1±1.1
-64.6±1.4
-21±6
-29±3
-49±4

52±31
45±11
41±6
51±6
48±7
40±6
32±3
48±2
18±7
26±4
49±13

94±33
115±11
74±6
94±6
95±9
73±6
68±3
112±3
39±9
55±5
98±14

26.9
35.1
20.1
32.4
47.7
19.7
24.3
38.8
12.7
22.5
48.9

0.16±0.04

-34±5

18±9

51±10

15.3

0.34±0.06
0.50±0.14
0.25±0.05
0.36±0.11
0.8±0.8
0.27±0.06
0.31±0.08
0.54±0.19
0.22±0.05
0.33±0.10
0.5±0.5
0.29±0.07

-60±8
-77±2
-34±6
-48±6
-58±5
-43±7
-51±3
-64±5
-35±7
-40±8
-38±15
-42±9

75±43
69±15
57±16
43±14
58±12
56±17
41±14
69±6
27±13
36±12
38±28
36±18

135±44
147±15
91±17
91±15
116±13
99±19
92±14
134±7
62±15
76±14
76±32
78±20

33.6
47.2
24.6
33.7
58.1
26.0
29.7
49.8
20.5
30.4
38.0
27.5

Likewise, we observed large variability in the RBED10% (or RBED50%) values for protons
and C-ions within each of the histologic types investigated (Figure 6A-C, Figure 7A-C), varying
up to 45±7% (63±14%), 33±14% (67±13%) and 56±15% (111±%34) across radiation qualities
for NSCLC, GBM and PAAD cell lines, respectively, relative to the mean of each histologic type
(Table 3). But as with D10% (or D50%), after normalizing the RBED10% (or RBED50%) for each
radiation quality to the mean value in each histologic type, we observe that the RBED10% (or
RBED50%) values span similar relative ranges across radiation qualities (Figure 6D-F, Figure 7
D-F, Table 3). Moreover, the relative variability in RBED10% (or RBED50%), quantified by their
COV, is in some cases significantly higher for C-ions compared to lower LET protons (RBED10%:
P = 0.0095 and P = 0.0274 for NSCLC and PAAD cell lines, respectively, exposed to 13.5
keV/μm C-ions, and P = 0.0175 and P = 0.0020, respectively, exposed to 60.5 keV/μm C-ions;
and with lesser significance seen for RBED50%: P = 0.1297 and P = 0.0081 for PAAD cell lines
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exposed to 13.5 keV/μm and 60.5 keV/μm C-ions, respectively) (Figure 6G-I, Figure 7G-I).
Together, these data suggest that the relative variability in radiosensitivity and RBE are not
smaller for higher LET radiation over the range of LET values investigated in this work. Pvalues for the comparisons between all groups can be found in Supplemental Note 2 and the
results for the RBED10% and RBED50% for the dataset including only untreated cells can be found
in Supplemental Note 3.

Table 3: Variability in RBE of NSCLC, GBM and PAAD cell lines listed in Table 1 exposed to 9.9 keV/μm protons,
and 13.5 and 60.5 keV/μm C-ions, relative to their 6 MV x-ray response, grouped by histologic type. Relative RBE
values are calculated relative to the mean RBED10% or mean RBED50% values for each group.
Radiation
Cohort
Cohort
Quality
Size
9.9
keV/µm
protons
13.5
keV/µm
C-ions
60.5
keV/µm
C-ions

NSCLC
GBM
PAAD

8
2
12

NSCLC
GBM
PAAD

10
7
10

NSCLC

8

GBM
PAAD

9.9
keV/µm
protons
13.5
keV/µm
C-ions
60.5
keV/µm
C-ions

NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD

Lowest
RBE

Highest
RBE

RBE
range

COV in
RBE

RBED10%

Lowest
Highest
Relative
RBE
RBE
RMSPE in
RBE
RBE (%)
Relative to Relative to
range (%)
Mean (%) Mean (%)

1.30±0.05 1.48±0.10
0.96±0.08 1.34±0.04

0.18±0.11 0.044±0.012
0.38±0.09
0.23±0.18

-7±5
-16±10

6±8
16±10

13±10
33±14

4.1
16.5

1.35±0.06 1.55±0.06
0.85±0.02 1.35±0.04
1.13±0.04 1.38±0.02

0.20±0.08 0.039±0.008
0.50±0.04
0.13±0.03
0.25±0.05
0.07±0.02

-4±6
-26±3
-10±4

10±6
17±5
10±3

14±8
43±6
20±5

3.8
12.7
6.9

1.01±0.02 1.37±0.08

0.36±0.08

0.09±0.02

-12±6

19±10

31±12

8.6

2
10

1.34±0.03 2.15±0.04
1.33±0.06 1.80±0.10
1.63±0.04 2.72±0.12

0.81±0.05
0.47±0.12
1.09±0.13

0.14±0.04
0.21±0.16
0.17±0.04

-26±4
-15±7
-16±7

19±6
15±11
40±13

45±7
30±13
56±15

13.2
15.0
16.2

8
2
12
10
7
10
8
2
10

0.91±0.07
1.10±0.11
1.16±0.16
0.73±0.05
0.92±0.13
0.80±0.06
1.23±0.11
1.2±0.2
1.20±0.09

0.89±0.13
0.11±0.15
0.4±0.3
0.71±0.06
0.89±0.13
0.58±0.17
1.1±0.4
1.0±0.4
2.3±0.5

0.19±0.05
0.07±0.05
0.10±0.02
0.23±0.06
0.23±0.07
0.16±0.04
0.22±0.06
0.4±0.3
0.33±0.09

-38±9
-5±16
-17±15
-35±8
-31±10
-33±9
-34±10
-30±19
-43±10

22±17
5±17
13±26
28±12
36±7
16±19
27±26
30±33
69±33

60±19
9±23
30±30
63±14
67±13
49±21
61±27
60±38
111±34

17.5
4.7
9.1
22.0
21.2
15.5
20.5
30.1
31.0

1.80±0.11
1.21±0.11
1.6±0.3
1.44±0.02
1.80±0.03
1.38±0.16
2.4±0.4
2.2±0.3
3.5±0.4

RBED50%
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Figure 6: (A-C) RBE at the dose for 10% (RBED10%) surviving fraction for NSCLC, GBM and PAAD cell lines listed in
Table 1. Each data point represents a cell line (Table 1). Vertical bars are the standard deviations. (D-F) Percent
difference in the RBED10% values relative to the mean RBED10% for each radiation quality and histologic type to
quantify the variation in RBED10% among cell lines of the same histologic type between different radiation qualities.
Vertical bars are the standard deviations. (G-I) Coefficient of variation in RBED10% for each radiation quality and
histologic type. Supplemental Note 1 contains the values of D10% used to calculate the RBED10% values in the plots.
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Figure 7: (A-C) RBE at the dose for 50% (RBED50%) surviving fraction for NSCLC, GBM and PAAD cell lines listed in
Table 1. Each data point represents a cell line (Table 1). Vertical bars are the standard deviations. (D-F) Percent
difference in the RBED50% values relative to the mean RBED50% for each radiation quality and histologic type to
quantify the variation in RBED50% among cell lines of the same histologic type between different radiation qualities.
Vertical bars are the standard deviations. (G-I) Coefficient of variation in RBED50% for each radiation quality and
histologic type. Supplemental Note 1 contains the values of D50% used to calculate the RBED50% values in the plots.
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Among the GBM cell lines we examined, M059K and M059J are a naturally occurring
isogenic pair extracted from the same tumor in which M059K has normal activity of DNA-PKcs
while M059J lacks DNA-PKcs activity127-129, rendering M059K 3.94±0.13 (4.1±0.4) times more
radioresistant than M059J in terms of D10% (D50%). To simulate this phenomenon across other
histologic types, we treated cells with DNA repair inhibitors to reduce their capacity for DNA
repair to varying degrees across different DNA repair pathways, which also modulated their
radiosensitivity (Figure 8A, Figure 9A). This resulted greater variations in D10% (D50%) for the
cells with modulated DNA repair capacity, with values of up to 157%±7% (172%±21%),
141%±8% (171%±24%), 112%±9% (128%±11%), and 108%±8% (129%±19%) for 6 MV x-rays,
9.9 keV/µm, 13.5 keV/µm and 60.5 keV/µm, respectively (Figure 8B, Figure 9B, Table 4).
Consequently, the COVs in the group deficient in DNA repair (treated with DNA repair
inhibitors) are generally larger than those in the group proficient in DNA repair (not treated with
drugs), with significant differences for D10% being seen with 6 MV x-rays (P = 0.0450) and less
significant differences for protons (P = 0.0989), and C-ions (P = 0.2281 at 13.5 keV/μm and P =
0.1166 at 60.5 keV/μm). For the parameter D50%, significant differences were seen for protons
(p = 0.0100) and less significant differences for 6 MV x-rays (p = 0.0874). However, when
comparing across radiation qualities, the COVs show that there are no statistically significant
differences in the variability in D10% or D50% to 6 MV x-rays compared to the variability present
for other radiation qualities, with p-values ranging from 0.4643-0.9723 (Figure 8C, Figure 9C,
Table 4, Supplemental Table 7). The p values for all comparisons can be found in
Supplemental Note 2. Together, these data suggest that while DNA repair capacity is an
important factor affecting the variability in radiosensitivity across all radiation qualities, the
relative importance of DNA repair in governing the variability in radiosensitivity does not
decrease significantly with increasing LET across the radiation qualities used in this work.
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Figure 8: (A) Dose at 10% survival fraction (D10%) for cell lines deficient in DNA repair (treated with DNA repair
inhibitors) (solid symbols) or proficient in DNA repair (not treated with DNA repair inhibitors) (open symbols) exposed
to 6 MV x-rays (black squares), 9.9 keV/µm protons (blue circles), and 13.5 (red triangles) and 60.5 keV/μm C-ions
(magenta diamonds). (B) Percentage difference relative to the mean D10% value for each radiation quality to quantify
the variation in intrinsic radiosensitivity within and between radiation qualities. (C) Coefficient of variation in D10%.
Supplemental Note 1 contains the values of D10% used in the plots.

Figure 9: (A) Dose at 50% survival fraction (D50%) for cell lines deficient in DNA repair (treated with DNA repair
inhibitors) (solid symbols) or proficient in DNA repair (not treated with DNA repair inhibitors) (open symbols) exposed
to 6 MV x-rays (black squares), 9.9 keV/µm protons (blue circles), and 13.5 (red triangles) and 60.5 keV/μm C-ions
(magenta diamonds). (B) Percentage difference relative to the mean D50% value for each radiation quality to quantify
the variation in intrinsic radiosensitivity within and between radiation qualities. (C) Coefficient of variation in D10%.
Supplemental Note 1 contains the values of D50% used in the plots.
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Table 4: Variability in intrinsic radiosensitivity of lung, brain and pancreatic cancer cells exposed to 6 MV x-rays, 9.9
keV/μm protons, and 13.5 and 60.5 keV/μm C-ions. Cells are grouped independent of histology but by whether the
cells have been treated with DNA-repair inhibitors (or have a natural DNA-repair deficiency) versus cells whose DNA
repair was not inhibited. Relative sensitivity values are calculated relative to the mean D10% or mean D50% value for
each group.
Most
Most
Sensitivity
Most
Most
Relative RMSPE in
Cohort Sensitive, Resistant,
Range,
COV in
Sensitive Resistant
Sensitivity Sensitivity
Size D10% or D50% D10% or D50% D10% or D50% Sensitivity Relative to Relative to
Range (%)
(%)
(Gy)
(Gy)
(Gy)
Mean (%) Mean (%)
D10%
6 MV x-rays
37
1.37±0.02 8.71±0.18 7.34±0.18 0.41±0.06 -70.6±1.1
86±7
157±7
61.4
9.9 keV/µm
33
1.42±0.12 6.62±0.17
5.2±0.2
0.36±0.05
-61±3
79±7
141±8
55.7
protons
13.5 keV/µm
9
1.21±0.04 6.67±0.07 5.45±0.09 0.34±0.10 -75.1±1.8
37±9
112±9
48.3
C-ions
60.5 keV/µm
9
1.03±0.04 4.25±0.10 3.22±0.11 0.34±0.09 -65.4±1.7
42±5
108±6
47.7
C-ions
6 MV x-rays
9
4.52±0.08 8.91±0.13 4.39±0.15 0.24±0.06 -33.1±1.9
32±4
65±4
22.6
9.9 keV/µm
9
3.46±0.13 6.75±0.19
3.3±0.2
0.23±0.06
-30±3
36±5
66±6
21.4
protons
13.5 keV/µm
9
3.88±0.13 6.77±0.12 2.89±0.17 0.21±0.06
-32±3
19±3
51±4
19.7
C-ions
60.5 keV/µm
9
2.58±0.12 4.18±0.05 1.61±0.13 0.17±0.05
-28±4
17±3
45±5
16.4
C-ions
D50%
6 MV x-rays
37
0.47±0.02
3.7±0.2
3.3±0.2
0.44±0.06
-75±2
97±21
172±21
65.3
9.9 keV/µm
33
0.43±0.04
3.1±0.2
2.6±0.2
0.45±0.07
-72±4
98±24
171±24
70.7
protons
13.5 keV/µm
9
0.51±0.07 3.38±0.13 2.86±0.15 0.37±0.10
-77±3
51±10
128±11
52.2
C-ions
60.5 keV/µm
9
0.41±0.06 2.10±0.12 1.69±0.13 0.41±0.12
-69±5
59±18
129±19
57.8
C-ions
6 MV x-rays
9
1.95±0.16 4.24±0.19
2.3±0.2
0.27±0.07
-35±7
42±11
77±13
25.7
9.9 keV/µm
9
1.60±0.09 2.75±0.14 1.15±0.17 0.22±0.06
-24±7
30±12
54±14
20.9
protons
13.5 keV/µm
9
1.62±0.15 3.48±0.3
1.9±0.3
0.26±0.07
-36.±7
36±15
72±17
24.1
C-ions
60.5 keV/µm
9
0.91±0.04 2.07±0.09 1.16±0.10 0.30±0.08
-40±5
36±11
77±12
28.6
C-ions
Radiation
Quality

Group

Deficient
DNA repair

Proficient
DNA repair

Deficient
DNA repair

Proficient
DNA repair

The RBED10% (RBED50%) values of the cells deficient in DNA repair are plotted in Figure
10A (Figure 11A) with their corresponding relative variations (Figure 10B, Figure 11B) and
COVs (Figure 10C. Figure 11C) within each radiation quality. Generally, the variability in the
RBED10% (RBED50%) values is higher in the cells deficient in DNA repair than those proficient in
DNA repair (Figure 10C, Figure 11C, Table 5), with significant differences being seen for 9.9
keV/μm protons (P = 0.0012 for RBED10% and P = 0.0003 for RBED50%), and less significant
differences seen for 60.5 keV/μm C-ions (P = 0.1583 for RBED10%). But when comparing
between radiation qualities for cells deficient in DNA repair, we note that once again the COVs
in the RBED10% (RBED50%) tend to be higher for 60.5 keV/µm C-ions (Figure 10C, Figure 11C,
Table 5) compared to 9.9 keV/µm protons and 13.5 keV/µm C-ions, although with lesser
significance (p=0.1562 and p=0.1114, respectively, for RBED10%). Together, these data
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suggest that modulating a cell’s capacity for DNA repair increases the variability in their intrinsic
radiosensitivity even for higher LET radiation, implying that variations in cellular DNA repair
capacity may still strongly influence intrinsic radiosensitivity even for high LET radiation.

Table 5: Variability in RBE of cancer cell lines exposed to 9.9 keV/μm protons, and 13.5 and 60.5 keV/μm C-ions,
relative to their 6 MV x-ray response. Cell lines are grouped independent of histology but by whether the cells are
deficient (treated with DNA-repair inhibitors) or proficient in DNA repair. Relative RBE values are calculated relative
to the mean RBED10% or mean RBED50% values for each group.
Group

Radiation
Quality

9.9 keV/µm
protons
Deficient
13.5 keV/µm
DNA repair C-ions
60.5 keV/µm
C-ions
9.9 keV/µm
protons
Proficient 13.5 keV/µm
DNA repair C-ions
60.5 keV/µm
C-ions
9.9 keV/µm
protons
Deficient
13.5 keV/µm
DNA repair C-ions
60.5 keV/µm
C-ions
9.9 keV/µm
protons
Proficient 13.5 keV/µm
DNA repair C-ions
60.5 keV/µm
C-ions

Cohort
Size

Lowest
RBE

Highest
RBE

RBE
Range

COV in
RBE

RBED10%
33
9

0.79±0.04

1.54±0.09 0.75±0.10 0.124±0.016

0.944±0.016 1.27±0.09 0.32±0.09

Lowest RBE Highest RBE Relative RMSPE in
Relative to Relative to
RBE
RBE
Mean (%) Mean (%) Range (%)
(%)
-39±4

19±9

58±10

19.4

0.11±0.03

-13±6

16±12

29±13

15.2

0.20±0.05

-25±5

42±11

67±12

28.6

9

1.33±0.06

2.50±0.16 1.18±0.16

9

1.21±0.03

1.46±0.03 0.25±0.04 0.055±0.014

-11±4

8±4

19±5

5.2

9

1.02±0.03

1.35±0.04 0.33±0.04

0.10±0.03

-15±4

13±5

28±6

9.8

9

1.59±0.03

2.15±0.04 0.56±0.05

0.12±0.03

-15±4

15±5

30±6

11.0

RBED50%
33

0.70±0.08

2.0±0.3

1.2±0.3

0.21±0.03

-46±10

49±30

95±32

33.4

9

0.76±0.06

1.3±0.2

0.6±0.2

0.17±0.05

-22±11

36±28

58±30

24.7

9

1.16±0.17

2.7±0.5

1.6±0.5

0.27±0.07

-31±15

62±38

93±41

38.4

9

1.21±0.11

1.62±0.16 0.41±0.19

0.08±0.02

-13±12

16±17

29±21

8.0

9

0.83±0.06

1.56±0.16 0.73±0.17

0.19±0.05

-30±9

32±19

61±21

18.1

9

1.43±0.12

0.23±0.06

-30±10

35±23

65±26

21.5

2.8±0.4

1.3±0.4
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Figure 10: (A) RBE at the dose for 10% survival fraction (RBED10%) for cell lines deficient in DNA repair (treated with
DNA repair inhibitors) (solid symbols) or proficient in DNA repair (not treated with DNA repair inhibitors) (open
symbols) exposed to 9.9 keV/µm protons (blue circles), and 13.5 (red triangles) and 60.5 keV/μm C-ions (magenta
diamonds) relative to their 6 MV x-ray response. (B) Percentage difference relative to the mean RBED10% value for
each radiation quality to quantify the variation in RBED10% within and between radiation qualities. (C) Coefficient of
variation in RBED10%. Supplemental Note 1 contains the values of D10% used to calculate the RBED10% values in the
plots.

Figure 11: (A) RBE at the dose for 50% survival fraction (RBED50%) for cell lines deficient in DNA repair (treated with
DNA repair inhibitors) (solid symbols) or proficient in DNA repair (not treated with DNA repair inhibitors) (open
symbols) exposed to 9.9 keV/µm protons (blue circles), and 13.5 (red triangles) and 60.5 keV/μm C-ions (magenta
diamonds) relative to their 6 MV photon response. (B) Percentage difference relative to the mean RBED50% value for
each radiation quality to quantify the variation in RBED50% within and between radiation qualities. (C) Coefficient of
variation in RBED50%. Supplemental Note 1 contains the values of D50% used to calculate the RBED50% values in the
plots.
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IV.

Discussion
Current practice in RT is to prescribe doses and fractionation schedules based on

anatomic site, histology, patient’s performance status and disease staging, disregarding the
tumor’s particular biology, genotype and the radiosensitization effect of any additional
treatments. In particular, RT prescriptions for NSCLC, GBM and PAAD patients do not consider
tumor subtype classification, molecular subtypes, or the intrinsic radiosensitivity despite the fact
that it is well known that the intrinsic radiosensitivity of cell lines can vary substantially within a
given histologic type for low LET photons.91-96 This suggests that for a given cohort of patients
whose tumors are treated with the same fractionation schedule, current practice likely results in
suboptimal treatments whose biological effects are potentially largely under- or overestimated.
This may in turn contribute to poor outcomes, from either suboptimal tumor control or
subjecting normal tissues to unnecessarily high doses.
However, because of the physical characteristics of protons and C-ions, which result in
more complex and clustered DNA lesions than photons, it is expected that protons and C-ions
are less dependent on DNA repair capacity25,26 among a number of other factors, and therefore
these variations in intrinsic radiosensitivity within a histologic type are expected to be less for
protons and C-ions than for photons. Thus, one might expect that the knowledge of intrinsic
radiosensitivity is of less importance in optimizing ion therapies because cell response is
inherently less dependent on it for higher LETs. But our data show that cancer cell lines within
the same histologic type have remarkable differences in intrinsic radiosensitivity for protons and
even for C-ions and that the relative variability in intrinsic radiosensitivity to higher LET
radiation is not significantly lower than to photons, which directly contradicts this assumption.
A limitation of these analyses is the small number of cell lines within each histologic
type, which makes assessing the variability in intrinsic radiosensitivity challenging. To improve
the statistical power of our analysis, we included data from different literature sources, as well
as cells treated with DNA repair inhibitors in the datasets used to quantify the variability in
radiosensitivity (Table 1) for different radiation qualities. To ensure that these inclusions did not

41

artificially modulate the variabilities measured, when comparing across radiation qualities, we
only included data of cells treated with DNA repair inhibitors for treatments that had been
performed across all radiation qualities, and that induced radiosensitivities within the range of
those established with naturally occurring cell lines. Thus, any small additional variability this
may have added is present across all the conditions we compared and should not confound our
conclusions when comparing between them. Furthermore, even if the inclusion of the cells
treated with DNA repair inhibitors added different amounts of variability in radiosensitivity for
different LET values, our data (Figure 8C) show that, if anything, this should have added more
variability to the 6 MV dataset than the proton and C-ion datasets, since the differences
between the deficient versus proficient DNA repair cohorts were most significant for x-rays. But
if this were the case, it would have led us towards concluding that there is more variability in
photon dataset than in the proton and C-ion datasets, while our data support the opposite
conclusion: that the proton and C-ion data are no less variable than the photon data.
Our comparisons of the variability in intrinsic radiosensitivity of cells deficient (or
proficient) in DNA repair, corroborate previous findings that the variability in intrinsic
radiosensitivity to photons strongly depend on DNA repair protein expression31,32, in our case
through the inhibition of ATR, DNA-PKcs, ATM, PARP and Rad51,137,138 and also by comparing
isogenic cell lines with variable DNA-PKcs activity. But we also showed that the relative
variability in intrinsic radiosensitivity to protons or C-ions is the same as the relative variability in
intrinsic radiosensitivity to photons (Figure 1 and Figure 5), even if their DNA repair capacity
had been modulated by inhibiting ATR, DNA-PKcs, ATM, PARP and Rad51, or when
comparing isogenic cell lines with variable DNA-PKcs activity (Figure 8 and Figure 9). But if
DNA repair capacity were relatively less important in determining intrinsic radiosensitivity for
higher LET radiation, we would expect there to be less relative variability induced by
modulating the cell’s DNA repair capacity at higher LETs than at lower LETs, while our data
show that there are no statistically significant differences in relative variability in either cohort
across radiation qualities. Thus, our data suggest that besides its importance in influencing the
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intrinsic radiosensitivity to photons, the DNA repair capacity of cell lines (and possibly tumors)
is also an important factor that influences intrinsic radiosensitivity to higher LET radiation,
including protons and C-ions. This is an important result given the current belief that DNA
repair capacity is of lesser importance in influencing radiosensitivity to higher LET radiation25,26.
This result – that cells’ relative variability in intrinsic radiosensitivity between radiation
qualities is the same, whether or not their DNA repair capacity has been modulated – might
also be understood in light of the observations by Suzuki et al., that D10% for ions is linearly
correlated with D10% for x-rays122, which in Chapter 4, we show hold for a wide range of
radiosensitivity parameters besides D10%, and across a wide range of ion LETs. This correlation
implies that regardless of how these variations manifest themselves in a particular cell line’s
intrinsic photon radiosensitivity, they might simply map linearly to a cell’s ion response.
Accordingly, if a particular cell line is radiosensitive to photons (or made radiosensitive by DNA
repair inhibition), this linear correlation would predict it to be relatively radiosensitive to ions,
and by the same relative amount compared to the other cell lines in its group. Accordingly, the
COVs across radiation qualities would remain unchanged since the standard deviations and
means within each radiation quality would be scaled by the linear relationship observed by
Suzuki et al.122.
Another significant result that these analyses show is that even for 60.5 keV/μm C-ions,
cell lines within the same histologic type can have comparable RBE values despite having
remarkably different intrinsic radiosensitivities. As illustrative examples, the NSCLC cancer cell
lines H1299 and H460 have RBE values of 1.98±0.13 and 1.87±0.11, respectively, while D10%,Cions

of H460 is 60% lower than that of H1299; the GBM cell lines M059K and M059J have RBE

values of 1.80±0.10 and 1.33±0.06, respectively, while D10%,C-ions of M059J is 190% lower than
that of M059K; and the PAAD cell lines PANC-1 and AsPC-1 have RBE values of 1.70±0.05
and 1.64±0.08, respectively, while D10%,C-ions of ASPC-1 is 20% lower than that of PANC-1
(Supplemental Table 1). Thus, while RBE is an important parameter in proton and C-ion
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therapy, in the context of tumor-to-tumor variability in intrinsic radiosensitivity, we argue that
RBE itself cannot best be used without knowledge of the intrinsic radiosensitivity of individual
tumors. This is because, as our data shows, the relative differences in intrinsic radiosensitivity
are likely to be much larger than the relative differences in intrinsic RBE (e.g. the COVs of in
D10% and RBED10% for PAAD cells exposed to 9.9 keV/μm protons (n=12) were 20.5±4.6% and
3.9±0.8% respectively), and thus failing to account or the different intrinsic radiosensitivities of
tumors induces more variability than failing to account for the different RBEs of tumors within
the same histological category. Thus, we believe that ultimately RBE should be used in
combination with intrinsic radiosensitivity to allow for proper dose prescriptions for individual
tumors.
While we believe that towards personalized RT, the consideration of genomic and
tumor-microenvironment features has the potential to remarkably improve RT outcomes,
ideally, these should be used in combination to inform clinicians on the intrinsic radiosensitivity
of individual tumors so that optimal fractionation schedules and choice of radiation type can be
determined. Moreover, as protons and C-ions are expensive and not available for all patients, it
is important to select patients with radioresistant tumors who will most benefit from these
radiation types. Personalized RT will depend on developing methods to predict tumor response
to radiation prospectively and progress has been made in identifying genomic markers that
may predict clinical response to photons.139-145 However, genomic models to predict tumor
responses to protons and C-ions are not yet available. For optimal and rational use of the right
technology – photons, protons or C-ions – for a given tumor, we believe that work should be
focused on developing models able to predict tumor intrinsic radiosensitivity not only to photons
but also to protons and C-ions. In particular, the data presented in this chapter may be further
analyzed to determine if molecular subtypes of each particular histologic type are better
associated with intrinsic radiosensitivity. These data could therefore also be used to further
develop predictive models, including models based on DNA repair and DDR gene expression
profiles, copy number variations or mutations.
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However, as we discuss in Chapters 4, models to predict ion response directly may be
unnecessary if the photon response can be predicted, and can then in turn be used to predict
the ion response based upon its dependence on the photon response.

V.

Conclusions
Our data suggest that cell lines of the same histologic type have remarkable variability

in their intrinsic radiosensitivities to protons and C-ions. Further, our data indicate that the
relative variabilities in intrinsic radiosensitivity are not significantly different when comparing
photons to protons and C-ions and that the variation in intrinsic radiosensitivity are often higher
than the variation in RBE. These are novel findings suggesting that research in modeling ion
therapy response, which has mainly been focused on the development of RBE models, should
also be focused on the development of models that can predict the intrinsic radiosensitivity to
ions. Our findings have important implications in treatment planning because they suggest that
knowledge of the intrinsic radiosensitivity to protons and C-ions is as important as RBE for
treatment planning. This is because our data indicate that cell lines within the same histologic
type can have similar RBE values but very different intrinsic radiosensitivities. Thus, using a
single dose fractionation to treat the same histologic type, might result in failure to control some
tumors because of intrinsic radioresistance. Additionally, it is believed that high-LET radiation is
less dependent on DNA repair capacity, however, our data suggest that relative variations in
intrinsic radiosensitivity of cell lines in which DNA repair capacity was modulated using several
DNA repair inhibitors is greater than in unmodulated cells, even for high-LET radiation, and the
relative variations in intrinsic radiosensitivity when comparing C-ions to protons or photons are
not significantly different, whether or not the cells’ DNA repair capacity was modulated. This
finding questions the classical belief in radiobiology that cell response to high-LET is less
dependent on the DNA repair capacity. We therefore conclude that it is important to develop
predictive models of radiation response that incorporate the genomic variability observed
among tumors, especially to allow proper selection of patients for ion therapy.
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VI.

Supplemental Notes and Data
The data tabulated in this section are the data used for the analyses in this chapter.

Supplemental Note 1: D10%, D50%, α and β values for all data used in this chapter
Supplemental Table 1: D10% and D50% for NSCLC, GBM and PAAD cell lines in order of radiosensitivity to photons.
“*” , “+”, “‡“ and “#” indicate data from the PIDE database, Liu et al. 2015121, Suzuki et al. 2000122, or our
measurements, respectively (multiple symbols indicates averaged from multiple sources). D10% and D50% were
calculated from the corresponding α and β values of each cell line (Supplemental Table 2). For data in which
uncertainties were not reported, we assumed their uncertainty as the average percent uncertainty across all cell
lines whose uncertainties were reported. These data were used to plot (Figure 4 and Figure 5).
D10% (Gy)
D50% (Gy)
C-ions
C-ions
protons
C-ions
C-ions
Histologic
protons
Cell line
13.5
60.5
9.9
13.5
60.5
Type
6 MV x-rays
6 MV x-rays
9.9 keV/µm
keV/µm
keV/µm
keV/µm
keV/µm
keV/µm
LC-1sq‡

NSCLC

H23+
NSCLC
H1563+
NSCLC
H520+
NSCLC
H460*+#
NSCLC
HCC827+ NSCLC
A-549*+‡ NSCLC
SW1573* NSCLC
H1915+
NSCLC
Calu-6+
NSCLC
H2126*
NSCLC
H1437*
NSCLC
ABC-1+
NSCLC
H1792+
NSCLC
H1703+
NSCLC
H1869+
NSCLC
H1299*+# NSCLC
HCC-44+ NSCLC
M059J#
GBM
KS-1‡
GBM
A-172*‡
GBM
LN-229* GBM
SF-126‡ GBM
U-87MG* GBM
M059K# GBM
U-251MG* GBM
T98G*#
GBM
KNS-60‡ GBM
HS766T# PAAD
MIA PaCaPAAD
2#
#
HPAC
PAAD
AsPC-1# PAAD
BxPC-3# PAAD
Capan-1# PAAD
PK-1#
PAAD
PANC-1# PAAD
Panc
PAAD
10.05#
#
L3.3
PAAD

3.402±0.002
3.45±0.16
4.2±0.5
4.20±0.06
4.82±0.17
5.0±0.7
6.34±0.08
5.6±0.4
5.4±0.22
5.8±1.4
5.7±1.0
6.9±0.5
6.6±0.3
6.6±1.5
6.7±0.8
6.7±2.1
8.3±0.5
7.9±4.6
1.37±0.02
2.74±0.04
3.55±0.05
4.37±0.32
4.57±0.02
4.4±0.8
5.41±0.16
6.2±0.4
6.43±0.15
6.595±0.006
4.26±0.07

3.228±0.006

3.46±0.13

3.88±0.13

2.58±0.12

5.57±0.09

6.44±0.10

4.18±0.05

1.42±0.12

1.21±0.04 1.03±0.04
2.39±0.02
2.565±0.016
3.693±0.019

4.02±0.05

4.07±0.11

3.01±0.14

5.065±0.009
5.014±0.019

4.55±0.11
4.81±0.14
5.38±0.08
5.80±0.12
5.84±0.12
6.4±0.2
6.85±0.17

3.18±0.08

8.56±0.19
8.9±0.3

3.9±0.2
4.07±0.15

4.78±0.05
5.0±0.3

3.28±0.17
3.1±0.7

4.87±0.02

6.03±0.19

4.04±0.08

6.33±0.11
6.61±0.19

6.77±0.12

4.07±0.06
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1.5635±0.001
2
1.206±0.002
1.04±0.05
1.57±0.19
1.45±0.02
2.2±0.2
1.7±0.2
1.62±0.15 0.92±0.11
1.9±0.3
3.16±0.05
2.2±0.19
2.16±0.09
2.6±0.6
2.2±0.4
3.5±0.3
3.12±0.13
3.0±0.7
3.0±0.4
3.1±1.0
4.49±0.6
2.72±0.14 3.35±0.14 2.07±0.09
3.2±1.9
0.47±0.02 0.43±0.04 0.51±0.07 0.41±0.07
0.893±0.007
0.755±0.004
1.45±0.020
0.803±0.003
2.00±0.2
2.032±0.009
1.427±0.010
1.7±0.4
1.95±0.16 1.62±0.06 1.87±0.10 0.91±0.10
3.3±0.3
3.28±0.09
2.436±0.005
3.480±0.004
2.263±0.009
1.75±0.08
1.75±0.17
2.14±0.23
2.54±0.12
2.04±0.12
3.2±0.2
2.7±0.3
3.1±0.2

1.13±0.08

3.80±0.19
4.2±0.3

1.6±0.3
1.34±0.11

2.28±0.10
1.51±0.13

0.99±0.05
0.9±0.2

2.13±0.03

2.4±0.3

1.87±0.15

2.75±0.14
3.1±0.2

3.0±0.2

1.51±0.09

Supplemental Table 2: α and β values for NSCLC, GBM and PAAD cell lines in order of radiosensitivity to photons.
“*” , “+”, “‡“ and “#” indicate data from the PIDE database, Liu et al. 2015121, Suzuki et al. 2000122, or our
measurements, respectively (multiple symbols indicates averaged from multiple sources). Uncertainties omitted
when not reported.
α (Gy-1)
β (Gy-2)
Histologic
C-ions
C-ions
C-ions
C-ions
Cell line
protons
protons
6 MV x6 MV xType
13.5
60.5
13.5
60.5
rays
rays
9.9 keV/µm
9.9 keV/µm
keV/µm
keV/µm
keV/µm
keV/µm
0.2446±
0.0004
0.67
0.37
0.44
0.19±0.09
0.30
0.26

LC-1sq‡

NSCLC

H23+
H1563+
H520+
H460*+#
HCC827+
A-549*+‡

NSCLC
NSCLC
NSCLC
NSCLC
NSCLC
NSCLC

SW1573*

NSCLC

H1915+
Calu-6+
H2126*
H1437*
ABC-1+
H1792+
H1703+
H1869+

NSCLC
NSCLC
NSCLC
NSCLC
NSCLC
NSCLC
NSCLC
NSCLC

H1299*+#

NSCLC

HCC-44+
M059J#

NSCLC
GBM

KS-1‡

GBM

A-172*‡

GBM

LN-229*

GBM

SF-126‡

GBM

0.08±0.02
0.25
0.15
0.26
0.05
0.11
0.14
0.14
0.13
0.0065±
0.1095
0.17
1.36±0.11
0.745±
0.005
0.362±
0.018
0.19
0.2113±
0.0015

U-87MG*

GBM

0.34±0.21

M059K#

GBM

U-251MG*

GBM

T98G*#

GBM

KNS-60‡

GBM

0.06±0.03
0.0316±
0.0002

HS766T#

PAAD

0.29±0.03

PaCa-2# PAAD

0.33±0.07

MIA

0.31±0.06
0.031

0.4919±
0.0008

0.15±0.15

0.31±0.10
0.21810±
0.00023

0.1271±
0.0002
0.000
0.044
0.025
0.68±0.17 0.060±0.022 0.15±0.04
0.032
0.028

0.10±0.04

0.05±0.03

0.12±0.05

1.62±0.14

0.94±0.39
0.897±
0.004
0.848±
0.003

1.4±0.4

0.399±
0.004

0.33±0.03

0.21±0.06

0.77±0.04

0.1268±
0.0007
0.1805±
0.0014

0.56±0.07

HPAC#

PAAD

0.20±0.07

AsPC-1#

PAAD

0.13±0.04

0.33±0.15

0.14±0.04

0.70±0.04

BxPC-3#

PAAD

0.31±0.03

0.50±0.05

0.46±0.06

0.74±0.16

Capan-1#

PAAD

0.00±0.04

PK-1#

PAAD

0.19±0.06

PANC-1#

PAAD

0.14±0.04

0.209±
0.009

0.23±0.07

0.20±0.07

Panc 10.05# PAAD

0.11±0.02

0.17±0.03

0.15±0.04

0.40±0.05

L3.3#

0.08±0.03

0.12±0.04

PAAD
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0.0686±
0.0005

0.07±0.03 0.085±0.080

0.045±0.004
0.044±0.000
0.034
0.044
0.025
0.041
0.037
0.031
0.030
0.032
0.033±
0.056±
0.048±
0.102±
0.016
0.006
0.005
0.012
0.016
0.23±0.07 0.000±0.001 0.78±0.33 0.84±0.43
0.035±
0.029±
0.004
0.004
0.081±
0.019±
0.008
0.002
0.076
0.0638±
0.0609±
0.0007
0.0003
0.045±
0.074
0.021±
0.059±
0.089±
0.000±
0.012
0.005
0.019
0.028
0.055
0.047±
0.0647±
0.007
0.0002
0.04816±
0.0556±
0.00009
0.0005
0.058±
0.006
0.039±
0.052±
0.014
0.017
0.058±
0.013
0.055±
0.067±
0.071±
0.000±
0.007
0.032
0.007
0.003
0.015±
0.017±
0.000±
0.000±
0.004
0.008
0.017
0.081
0.068±
0.006
0.027±
0.006
0.029±
0.0542±
0.026±
0.092±
0.007
0.0019
0.012
0.016
0.018±
0.031±
0.028±
0.042±
0.003
0.005
0.006
0.011
0.020±
0.035±
0.004
0.008

Supplemental Table 3. D10% and D50% for NSCLC (H1299 and H460) and PAAD (PANC-1 and Panc 10.05) cell lines
treated with varying concentrations of DNA repair inhibitors to modulate their radiosensitivity. D10% and D50% were
calculated from the corresponding α and β values of each cell line (Supplemental Table 4). DNA-PKcsi: DNA-PKcs
inhibitor Nu7441. ATMi: ATM inhibitor KU55933. ATRi: ATR inhibitor AZD6738. ATRi-BAY: ATR inhibitor BAY
1895344. PARP1i: PARP1 inhibitor Olaparib (AZD2281). RAD51i: Rad51 inhibitor B02. DMSO: DMSO vehicle as
control. [ ] indicates concentration of inhibitor. These data were used to plot Figure 8 and Figure 9.
D10% (Gy)
D50% (Gy)
C-ions
C-ions
protons
C-ions
C-ions
protons
Cell line
6 MV x6 MV x13.5
60.5
9.9
13.5
60.5
rays 9.9 keV/µm
rays
keV/µm keV/µm
keV/µm keV/µm keV/µm
H460+DNA-PKcsi [0.1 µM] 3.98±0.06 2.75±0.08 4.22±0.02 2.69±0.03 1.94±0.12 1.14±0.12 2.26±0.02 1.22±0.04
H460+DNA-PKcsi [0.5µ]
2.70±0.09 2.58±0.05
0.95±0.07 0.93±0.05
H460+DNA-PKcsi [1µ]
2.34±0.05
1.10±0.08
H460+PARP1i [1 µM]
3.15±0.07 2.65±0.04
1.38±0.10 1.18±0.07
H460+RAD51i [5 µM]
4.52±0.04 3.42±0.04
2.34±0.08 1.58±0.08
H460+ATRi-Bay [0.01 µM] 3.53±0.07 2.38±0.18
1.48±0.10
0.9±0.2
H460+ATRi [0.1 µM]
3.69±0.06 2.54±0.05 3.87±0.08 2.39±0.09 1.63±0.09 1.02±0.07 1.97±0.08 0.94±0.14
H460+ATRi [0.5 µM]
2.7±0.2
0.91±0.18
H460+ATMi [0.1µ]
3.97±0.09 2.910±0.018
1.91±0.15 1.17±0.03
H460+ATMi [10µ]
2.38±0.07 2.10±0.06
0.91±0.07 0.85±0.07
H460+DMSO
4.52±0.08 3.75±0.07 4.45±0.08 2.84±0.03 2.03±0.14 1.60±0.09 2.44±0.07 1.35±0.04
H1299+DNA-PKcsi [0.1µ]
7.25±0.13 5.11±0.17 6.02±0.04 3.84±0.05 3.06±0.15
2.1±0.2
2.82±0.06 1.73±0.08
H1299+DNA-PKcsi [0.5 µM] 2.91±0.10 3.69±0.11
0.92±0.07 1.31±0.12
H1299+DNA-PKcsi [1µ]
2.2±0.2
0.65±0.07
H1299+PARP1i [1 µM]
6.19±0.10 4.59±0.12
2.95±0.14 1.86±0.17
H1299+RAD51i [5 µM]
8.71±0.18 6.62±0.17
3.7±0.2
3.1±0.2
H1299+ATRi-Bay [0.01 µM] 6.12±0.11 5.04±0.14
2.49±0.13
2.2±0.2
H1299+ATRi [0.1 µM]
7.9±0.3
5.76±0.07 6.67±0.07 4.25±0.10 2.57±0.19 2.81±0.10 3.38±0.13 2.10±0.12
H1299+ATRi [0.5µ]
6.7±0.4
2.4±0.2
H1299+ATMi [0.1 µM]
8.2±0.2
6.22±0.11
3.01±0.17 3.05±0.16
H1299+ATMi [10 µM]
2.76±0.10 2.54±0.06
1.05±0.12 1.00±0.06
H1299+DMSO
8.91±0.13 6.75±0.19 6.60±0.15 4.14±0.04 4.24±0.19 2.62±0.22 3.48±0.29 2.03±0.07
PANC-1+DNA-PKcsi
[0.1 µM]
5.79±0.11 4.33±0.11 5.77±0.03 3.72±0.03 2.62±0.18 1.85±0.17 2.73±0.05 1.81±0.05
PANC-1+DNA-PKcsi
[0.5 µM]
3.59±0.08 2.33±0.13
1.47±0.10 0.75±0.10
PANC-1+PARP1i [1 µM]
4.29±0.13
1.48±0.12 1.25±0.08
PANC-1+RAD51i [5 µM]
5.87±0.10
2.52±0.17 1.82±0.10
PANC 1+ATRi [0.1 µM]
6.24±0.11 4.32±0.10 6.16±0.10 3.69±0.05 2.83±0.19 1.97±0.16 2.66±0.09 1.54±0.08
PANC-1+ATRi [2 µM]
5.17±0.15 3.75±0.09
2.06±0.17 1.51±0.11
PANC-1+ATMi [0.1 µM]
6.10±0.10 4.56±0.10
2.79±0.16 1.83±0.14
PANC-1+ATMi [10 µM]
2.83±0.12 2.06±0.09
1.04±0.11 0.76±0.09
PANC-1+DMSO
6.26±0.12 4.79±0.08 6.11±0.06 3.90±0.05 2.66±0.18 1.87±0.11 2.89±0.09 1.86±0.10
Panc 10.05+DNA-PKcsi
[0.1 µM]
6.04±0.15 4.45±0.16
5.4±0.8 2.94±0.16 2.18±0.16
1.9±0.2
1.6±0.2
1.3±0.3
Panc 10.05+DNA-PKcsi
[0.5 µM]
2.98±0.15 2.89±0.11
0.91±0.10 0.89±0.09
Panc 10.05+PARP1i [1 µM] 5.58±0.10
2.42±0.12
1.9±0.3
Panc 10.05+RAD51i [5 µM] 6.24±0.13
2.52±0.18 1.81±0.17
Panc 10.05+ATRi [0.1 µM]
5.8±0.3
4.54±0.09
4.5±0.3 2.30±0.09
2.2±0.3
2.04±0.14 2.19±0.15 0.80±0.08
Panc 10.05+ATRi [2 µM]
3.54±0.18 2.57±0.12
1.3±0.2
0.78±0.08
Panc 10.05+ATMi [0.1 µM] 6.52±0.19 5.02±0.13
2.7±0.3
2.5±0.2
Panc 10.05+ATMi [10 µM] 3.01±0.08 2.19±0.07
1.23±0.10 0.83±0.08
Panc 10.05+DMSO
7.4±0.2
5.22±0.15 6.67±0.14 3.51±0.15 2.77±0.31 2.04±0.22 2.01±0.04 1.16±0.14
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Supplemental Table 4: α and β of cell lines treated if inhibitors of DNA repair. DNA-PKcsi: DNA-PKcs inhibitor
Nu7441. ATMi: ATM inhibitor KU55933. ATRi: ATR inhibitor AZD6738. ATRi-BAY: ATR inhibitor BAY 1895344.
PARP1i: PARP1 inhibitor Olaparib (AZD2281). RAD51i: Rad51 inhibitor B02. DMSO: DMSO vehicle as control. [ ]
indicates concentration of inhibitor.
α (Gy-1)
β (Gy-2)
protons C-ions
C-ions
C-ions
C-ions
Cell line
protons
6 MV x9.9
13.5
60.5
13.5
60.5
6 MV x-rays
rays
9.9 keV/µm
keV/µm keV/µm keV/µm
keV/µm
keV/µm
H460+DNA-PKcsi [0.1 uM]
H460+DNA-PKcsi [0.5 uM]
H460+DNA-PKcsi [1 uM]
H460+PARP1i [1 µM]
H460+RAD51i [5 µM]
H460+ATRi-Bay [0.01 µM]

0.15±0.06
0.66±0.08
0.32±0.10
0.32±0.07
0.07±0.03
0.34±0.06

H460+ATRi [0.1 uM]
H460+ATRi [0.5 uM]
H460+ATMi [0.1 uM]
H460+ATMi [10 uM]

0.27±0.05 0.53±0.08 0.10±0.06 0.60±0.21 0.096±0.013 0.15±0.03
0.71±0.20
0.060±0.050
0.16±0.08 0.46±0.02
0.106±0.019 0.113±0.007
0.64±0.09 0.63±0.12
0.14±0.03
0.22±0.04

H460+DMSO

0.21±0.05 0.30±0.06 0.00±0.04 0.25±0.04 0.067±0.012 0.084±0.018

H1299+DNA-PKcsi [0.1 uM]
H1299+DNA-PKcsi [0.5 uM]
H1299+DNA-PKcsi [1 uM]
H1299+PARP1i [1 µM]
H1299+RAD51i [5 µM]
H1299+ATRi-Bay [0.01 µM]

0.16±0.03
0.73±0.07
1.07±0.12
0.11±0.03
0.13±0.03
0.21±0.03

0.44±0.13 0.03±0.01 0.33±0.05 0.108±0.015 0.14±0.04
0.66±0.06
0.071±0.018 0.091±0.019
0.29±0.04
0.37±0.07
0.129±0.018 0.19±0.02
0.24±0.06
0.098±0.006 0.128±0.018
0.70±0.29
0.088±0.014 0.11±0.09

H1299+ATRi [0.1 uM]
H1299+ATRi [0.5 uM]

0.26±0.06 0.13±0.02 0.24±0.05 0.022±0.004 0.037±0.012
0.48±0.08
0.021±0.015 0.040±0.017
0.00±0.00
0.000±0.012
0.29±0.06
0.042±0.005 0.047±0.012
0.12±0.05
0.016±0.004 0.034±0.008
0.19±0.07
0.027±0.005 0.052±0.014
0.0040±
0.26±0.03 0.10±0.03 0.06±0.03 0.12±0.07
0.0051
0.052±0.005
0.26±0.05 0.00±0.00
0.012±0.008

H1299+ATMi [0.1 uM]
H1299+ATMi [10 uM]

0.20±0.02 0.09±0.04
0.55±0.13 0.55±0.07

H1299+DMSO
PANC-1+DNA-PKcsi
[0.1 uM]
PANC-1+DNA-PKcsi
[0.5 uM]
PANC-1+PARP1i [1 µM]
PANC-1+RAD51i [5 µM]

0.08±0.02 0.22±0.05 0.03±0.06 0.13±0.03 0.020±0.003 0.018±0.008
0.124±
0.15±0.04 0.26±0.07
0.015
0.16±0.03 0.042±0.006 0.064±0.016

PANC-1+ATRi [0.1 uM]
PANC-1+ATRi [2 uM]
PANC-1+ATMi [0.1 uM]
PANC-1+ATMi [10 uM]

0.14±0.04
0.26±0.05
0.14±0.03
0.58±0.11

PANC-1+DMSO
Panc 10.05+DNA-PKcsi
[0.1 uM]
Panc 10.05+DNA-PKcsi
[0.5 uM]
Panc 10.05+PARP1i [1 µM]
Panc 10.05+RAD51i [5 µM]

0.18±0.04 0.30±0.04 0.12±0.02 0.17±0.05 0.030±0.006 0.037±0.008

Panc 10.05+ATRi [0.1 uM]

0.27±0.07 0.20±0.05 0.14±0.09 0.80±0.13 0.023±0.010 0.067±0.010
0.0048±0.036
0.47±0.13 0.89±0.12
0.052±0.033
9
0.20±0.05 0.08±0.07
0.024±0.006 0.075±0.013
0.42±0.08 0.71±0.12
0.11±0.02
0.16±0.04
0.345±
0.21±0.05 0.27±0.06
0.007
0.57±0.10 0.013±0.007 0.032±0.011

Panc 10.05+ATRi [2 uM]
Panc 10.05+ATMi [0.1 uM]
Panc 10.05+ATMi [10 uM]
Panc 10.05+DMSO

0.24±0.05 0.009±0.004 0.045±0.007
0.10±0.04
0.14±0.02

0.36±0.06 0.89±0.17
0.43±0.06 0.45±0.06
0.19±0.04 0.28±0.04

0.080±0.016 0.041±0.056
0.024±0.015 0.079±0.015
0.035±0.006 0.053±0.009

0.20±0.07 0.17±0.03 0.33±0.05 0.036±0.006 0.077±0.015
0.36±0.07
0.035±0.010 0.069±0.018
0.30±0.06
0.039±0.005 0.046±0.012
0.79±0.17
0.083±0.033 0.16±0.06

0.28±0.03 0.26±0.08 0.42±0.06 0.30±0.24 0.016±0.004 0.058±0.015
0.76±0.11 0.76±0.11
0.19±0.03 0.23±0.10
0.21±0.04 0.30±0.06

0.005±0.027 0.012±0.033
0.040±0.006 0.069±0.020
0.025±0.005 0.045±0.012
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0.122±
0.004

0.19±0.02

0.127±
0.019

0.15±0.10

0.117±
0.012
0.043±
0.003

0.198±
0.016
0.093±
0.014

0.043±
0.005

0.099±
0.019
0.093±
0.014

0.048±
0.008
0.048±
0.003

0.102±
0.008
0.124±
0.009

0.032±
0.005

0.080±
0.014

0.043±
0.004
0.000±
0.007

0.106±
0.011
0.16±0.06

0.081±
0.029

0.089±
0.038

0.000±
0.000

0.025±
0.023

Supplemental Note 2: Tabulated p values for comparison tests performed between the
COVs of different groups

In this chapter, we performed two-tailed z-test to quantify whether significant differences
could be seen between the COVs in different groups. The values of these tests are
summarized in the tables below.

Supplemental Table 5: P values arising from two-tailed z-tests between the coefficients of variation (COV) in the
response (D10% or D50%) between cells exposed to different radiation qualities (6 MV X-rays, 9.9 keV/µm protons,
and 13.5 keV/µm and 60.5 keV/µm C-ions), for cells of a given histologic type (NSCLC, GBM, PAAD). Redundant
values are omitted from the table.

Cohort
NSCLC
GBM
PAAD

Radiation
Quality
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm

P values when comparing COVD10%
values between different radiation
qualities
9.9
6 MV
keV/µm
13.5 keV/µm
0.5217
0.8112
0.4579
0.6753
0.3932
0.8701
0.6175
0.7724
0.6797
0.6098
0.9851
0.6698
0.9716
0.1492
0.2017
0.4106
0.4685
0.5851

P values when comparing COVD50%
values between different radiation
qualities
9.9
6 MV
keV/µm
13.5 keV/µm
0.8908
0.7639
0.7313
0.8708
0.8096
0.9267
0.6844
0.8680
0.7249
0.9329
0.7545
0.9993
0.8291
0.5938
0.4947
0.6937
0.8531
0.4180

Supplemental Table 6: P values arising from two-tailed z-tests of the coefficients of variation (COV) in the RBED10%
or RBED50% values between cells exposed to different radiation qualities (9.9 keV/µm protons, and 13.5 keV/µm and
60.5 keV/µm C-ions), for cells of a given histologic type (NSCLC, GBM, PAAD). Redundant values are omitted from
the table.

Cohort
NSCLC
GBM
PAAD

Radiation Quality
13.5 keV/µm
60.5 keV/µm
13.5 keV/µm
60.5 keV/µm
13.5 keV/µm
60.5 keV/µm

P values when comparing the
COVRBED10% values between
different radiation qualities
9.9 keV/µm
13.5 keV/µm
0.0095
0.0175
0.8924
0.3837
0.9324
0.4049
0.0274
0.0020
0.0911
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P values when comparing
COVRBED50% values between
different radiation qualities
9.9 keV/µm
13.5 keV/µm
0.5630
0.6892
0.8808
0.0614
0.3052
0.5777
0.1297
0.0081
0.0813

Supplemental Table 7: P values arising from two-tailed z-tests between the coefficients of variation (COV) in the
response (D10% or D50%) of cells exposed to different radiation qualities (6 MV X-rays, 9.9 keV/µm protons, and 13.5
keV/µm and 60.5 keV/µm C-ions) for cells deficient (treated with a DNA repair inhibitor or with a natural DNA repair
defect) and proficient in DNA repair. Redundant values are omitted from the table.

Cohort
Deficient
DNA repair
Proficient
DNA repair

Radiation
Quality
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm

P values when comparing
COVD10% values between
different radiation qualities
9.9
13.5
6 MV
keV/µm
keV/µm
0.4643
0.5375
0.9014
0.5051
0.8656
0.9723
0.8793
0.7175
0.8327
0.4003
0.4847
0.6205

P values when comparing
COVD50% values between
different radiation qualities
9.9
13.5
6 MV
keV/µm
keV/µm
0.8656
0.5816
0.5099
0.8429
0.7597
0.7991
0.5872
0.8676
0.7038
0.7833
0.4218
0.6605

Supplemental Table 8: P values arising from two-tailed z-tests of the coefficients of variation in the RBED10% or
RBED50% values between cells exposed to different radiation qualities (9.9 keV/µm protons, and 13.5 keV/µm and
60.5 keV/µm C-ions) f for cells deficient (treated with a DNA repair inhibitor or with a natural DNA repair defect) and
proficient in DNA repair. Redundant values are omitted from the table.

Cohort
Deficient DNA repair
Proficient DNA repair

Radiation
Quality
13.5 keV/µm
60.5 keV/µm
13.5 keV/µm
60.5 keV/µm

P values when comparing
the COVRBED10% values
between different radiation
qualities
13.5
9.9 keV/µm
keV/µm
0.0095
0.0175
0.8924
0.3837
0.9324
0.4049

P values when comparing
COVRBED50% values
between different radiation
qualities
13.5
9.9 keV/µm
keV/µm
0.5993
0.1562
0.1114
0.4766
0.4518
0.2609

Supplemental Table 9: P values arising from two-tailed z-tests between the coefficients of variation in the response
(D10% or D50%) or RBE (RBED10% or RBED50%) for cells deficient (treated with a DNA repair inhibitor or with a natural
DNA repair defect) and proficient in DNA repair, for a number of radiation qualities (6 MV X-rays, 9.9 keV/µm
protons, and 13.5 keV/µm and 60.5 keV/µm C-ions). Redundant values are omitted from the table.

Parameter
Radiation
Quality
6 MV
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm

P values when
comparing
COVD10% values
between cells
deficient and
proficient in DNA
repair
0.0450
0.0989
0.2281
0.1166

P values when
comparing
COVD50% values
between cells
deficient and
proficient in DNA
repair
0.0874
0.0100
0.3647
0.4629
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P values when
comparing the
COVRBED10% values
cells deficient and
proficient in DNA
repair

P values when
comparing
COVRBED50% values
cells deficient and
proficient in DNA
repair

0.0012
0.9390
0.1583

0.0003
0.8006
0.6478

Supplemental Note 3: Intrinsic radiosensitivity analyses excluding cell lines treated with
DNA inhibitors

Although we argue in CH2§IV that the inclusion of the data for cell lines treated with
DNA repair inhibitors does not confound our conclusions, for completeness, here we show the
same analyses performed without the inclusion of the data for cell lines treated with DNA repair
inhibitors (Supplemental Figure 1-4 and Supplemental Table 10-13). The analyses are
consistent with the analyses presented in CH2§III, however due to the small size of these
cohorts, we cannot make as strong statistical conclusions using these as we can with the
previously presented data.

Supplemental Table 10: Variability in intrinsic radiosensitivity of NSCLC, GBM and PAAD cells listed in Table 1
exposed to 6 MV x-rays, 9.9 keV/μm protons, and 13.5 and 60.5 keV/μm C-ions, grouped by histologic type. Relative
sensitivity values are calculated relative to the mean D10% or mean D50% values for each group. Cells treated with
DNA repair inhibitors were excluded from these analyses.
Radiation Cohort Cohort
Quality
Size

6 MV
photons
9.9
keV/µm
protons
13.5
keV/µm
C-ions
60.5
keV/µm
C-ions
6 MV
photons
9.9
keV/µm
protons
13.5
keV/µm
C-ions
60.5
keV/µm
C-ions

NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD

18
10
10
2
2
6
4
7
4
2
2
4

NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD

18
10
10
2
2
6
4
7
4
2
2
4

Most
Sensitive,
D10% or D50%
(Gy)

Most
Sensitivity
COV in
Most
Most
Relative RMSPE in
Resistant,
Range,
Sensitivity Sensitive Resistant Sensitivity Sensitivity
D10% or D50% D10% or D50%
Relative to Relative to Range
(%)
(Gy)
(Gy)
Mean (%) Mean (%)
(%)
D10%
3.402±0.002
8.3±0.5
4.9±0.5
0.24±0.04
-41± 4
44±36
85±39
23.7
1.37±0.02
6.595±0.006 5.22±0.02 0.37±0.10
-70±2
45±11
115±11
35.1
4.26±0.07
8.9±0.3
4.6±0.3
0.26±0.07
-31±2
45±6
76±7
24.6
3.46±0.13
5.57±0.09
2.1±0.2
0.3±0.3
-23±4
23±5
47±6
23.4
1.42±0.12
4.02±0.05
2.60±0.13
0.7±0.6
-48±5
48±7
95±9
47.7
3.18±0.08
6.61±0.19
3.4±0.2
0.29±0.10
-34±3
37±6
71±6
26.2
3.23±0.01
6.44±0.10
3.2±0.1
0.30±0.14 -31.0±1.4
38±4
69±4
26.4
1.21±0.04
5.065±0.009 3.85±0.05 0.42±0.14 -64.6±1.4
48±2
112±3
38.8
4.78±0.05
6.77±0.12
1.99±0.13 0.16±0.07
-15±3
20±5
35±6
14.1
2.58±0.12
4.18±0.05
1.61±0.13
0.3±0.3
-24±5
24±5
48±7
23.8
1.03±0.04
3.01±0.14
1.98±0.15
0.7±0.6
-49±4
49±13
98±14
48.9
3.1±0.7
4.07±0.06
1.0±0.7
0.14±0.06 -14±21
12±12
26±24
12.0
D50%
1.04±0.05
4.5±0.6
3.5±0.6
0.34±0.07 -59±10
78±49
137±50
33.5
0.47±0.02
3.48±.004
3.01±0.02 0.50±0.14
-77±2
69±15
147±15
47.2
1.75±0.08
4.2±0.3
2.4±0.3
0.31±0.08
-36±6
54±15
89±16
29.3
1.7±0.2
2.72±0.14
1.0±0.3
0.3±0.3
-23±14
23±17
45±22
22.7
0.43±0.04
1.62±0.06
1.19±0.07
0.8±0.8
-58±5
58±12
116±13
58.1
1.13±0.08
3.1±0.2
2.0±0.2
0.39±0.14
-44±7
54±17
97±18
35.9
1.2061±0.0018 3.35±0.14
2.14±0.14
0.4±0.2
-42±3
60±11
102±12
38.4
0.51±0.07
2.436±0.005 1.92±0.07 0.54±0.19
-64±5
69±6
134±7
49.8
1.51±0.13
3.0±0.2
1.5±0.3
0.26±0.12
-34±9
30±16
63±18
22.6
0.92±0.11
2.07±0.09
1.15±0.15
0.5±0.5
-38±10
38±15
77±18
38.5
0.41±0.07
0.91±0.10
0.50±0.12
0.5±0.5
-38±15
38±28
76±32
38.0
0.9±0.2
1.87±0.15
0.9±0.2
0.34±0.15 -29±17
41±20
71±26
29.2
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Supplemental Figure 1: (A-C) Dose for 10% survival fraction to quantify the intrinsic radiosensitivity of the NSCLC,
GBM and PAAD cell lines listed in Table 1. Each data point represents a cell line listed in Table 1. Vertical lines are
the standard deviations. (D-F) Percentage difference of the D10% values from the mean D10% for each radiation
quality and histologic type to quantify the variation in intrinsic radiosensitivity among cell lines of the same histologic
type between different radiation qualities. Vertical lines are the standard deviations. (G-I) Coefficient of variation in
D10% for each radiation quality and histologic type. NSCLC: Non-small cell lung carcinoma. GBM: Glioblastoma
multiforme. PAAD: Pancreatic adenocarcinoma. Supplemental Note 1 contains the values of D10% used in the plots.
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Supplemental Figure 2: (A-C) Dose for 50% survival fraction to quantify the intrinsic radiosensitivity of the NSCLC,
GBM and PAAD cell lines listed in Table 1. Each data point represents a cell line listed in Table 1. Vertical lines are
the standard deviations. (D-F) Percentage difference of the D10% values from the mean D50% for each radiation
quality and histologic type to quantify the variation in intrinsic radiosensitivity among cell lines of the same histologic
type between different radiation qualities. Vertical lines are the standard deviations. (G-I) Coefficient of variation in
D50% for each radiation quality and histologic type. NSCLC: Non-small cell lung carcinoma. GBM: Glioblastoma
multiforme. PAAD: Pancreatic adenocarcinoma. Supplemental Note 1 contains the values of D10% used in the plots.

54

Supplemental Figure 3: RBE at the dose for 10% (RBED10%) surviving fraction for NSCLC, GBM and PAAD cancer
cell lines. Each data point represents a cell line (Table 1). Horizontal lines and vertical bars are the mean and
standard deviation for each histologic type. (D-F) Percent difference in the RBED10% values relative to the mean
RBED10% for each radiation quality and histologic type to quantify the variation in RBED10% among cell lines of the
same histologic type between different radiation qualities. Horizontal lines and vertical bars are the mean and
standard deviation for each histologic type. (G-I) Coefficient of variation in RBED10% for each radiation quality and
histologic type.
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Supplemental Figure 4: RBE at the dose for 50% (RBED50%) surviving fraction for NSCLC, GBM and PAAD cancer
cell lines. Each data point represents a cell line (Table 1). Horizontal lines and vertical bars are the mean and
standard deviation for each histologic type. (D-F) Percent difference in the RBED50% values relative to the mean
RBED50% for each radiation quality and histologic type to quantify the variation in RBED50% among cell lines of the
same histologic type between different radiation qualities. Horizontal lines and vertical bars are the mean and
standard deviation for each histologic type. (G-I) Coefficient of variation in RBED50% for each radiation quality and
histologic type.
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Supplemental Table 11: Variability in RBE of NSCLC, GBM and PAAD cell lines listed in Table 1 exposed to 9.9
keV/μm protons, and 13.5 and 60.5 keV/μm C-ions, relative to their 6 MV x-ray response, grouped by histologic type.
Relative RBE values are calculated relative to the mean RBED10% or mean RBED50% values for each group. Cells
treated with DNA repair inhibitors were excluded from these analyses.
Radiation
Cohort
Quality

Cohort
Size

Lowest
RBE

Highest
RBE

9.9
keV/µm
protons
13.5
keV/µm
C-ions
60.5
keV/µm
C-ions

NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD

2
2
6
4
7
4
2
2
4

1.39±0.07
0.96±0.08
1.35±0.06
1.054±0.002
1.13±0.04
1.13±0.02
1.87±0.11
1.33±0.06
1.64±0.09

1.48±0.10
1.34±0.04
1.43±0.05
1.28±0.08
1.38±0.02
1.26±0.04
1.98±0.13
1.80±0.10
2.10±0.06

9.9
keV/µm
protons
13.5
keV/µm
C-ions
60.5
keV/µm
C-ions

NSCLC
GBM
PAAD
NSCLC
GBM
PAAD
NSCLC
GBM
PAAD

2
2
6
4
7
4
2
2
4

1.3±0.2
1.10±0.11
1.36±0.12
1.296±0.002
0.92±0.13
1.12±0.07
2.2±0.3
1.2±0.2
1.64±0.18

1.6±0.2
1.21±0.11
1.6±0.3
1.44±0.02
1.80±0.03
1.35±0.14
2.4±0.4
2.2±0.3
2.58±0.18

RBE
range

COV in
RBE

RBED10%
0.09±0.12
0.05±0.03
0.38±0.09
0.23±0.18
0.08±0.08 0.026±0.009
0.23±0.08
0.08±0.04
0.25±0.05
0.07±0.02
0.14±0.04
0.05±0.02
0.11±0.17
0.04±0.03
.47±0.12
0.21±0.16
0.46±0.10
0.11±0.05
RBED50%
0.4±0.3
0.19±0.14
0.11±0.15
0.07±0.05
0.2±0.3
0.07±0.02
0.14±0.02 0.043±0.018
0.89±0.13
0.23±0.07
0.23±0.16
0.08±0.03
0.2±0.5
0.06±0.05
1.0±0.4
0.4±0.3
0.9±0.3
0.19±0.08

Lowest
Highest
Relative
RBE
RBE
RBE
Relative to Relative to Range
Mean (%) Mean (%)
(%)

RMSPE
in RBE
(%)

-3±9
-16±10
-3±6
-12±4
-10±4
-4±5
-3±10
-15±7
-10±13

3±11
16±10
3±6
7±9
10±3
8±6
3±11
15±11
15±15

6±15
33±14
6±8
19±10
20±5
12±8
6±15
30±13
25±20

3.2
16.5
2.4
7.3
6.9
4.7
2.8
15.0
9.8

-13±24
-5±16
-8±15
-4±11
-31±10
-11±12
-4±25
-30±19
-26±14

13±30
5±17
8±25
6±12
36±7
7±17
4±28
30±33
16±19

26±38
9±23
16±29
10±16
67±13
19±21
9±37
60±38
42±24

13.1
4.7
5.9
3.7
21.2
6.8
4.3
30.1
16.7

Supplemental Table 12: P values arising from two-tailed z-tests between the coefficients of variation (COV) in the
response (D10% or D50%) between cells exposed to different radiation qualities (6 MV X-rays, 9.9 keV/µm protons,
and 13.5 keV/µm and 60.5 keV/µm C-ions), for cells of a given histologic type (NSCLC, GBM, PAAD), excluding the
cells treated with DNA repair inhibitors. Redundant values are omitted from the table.

Cohort
NSCLC
GBM
PAAD

Radiation
Quality
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm
9.9 keV/µm
13.5 keV/µm
60.5 keV/µm

P values when comparing COVD10%
values between different radiation
qualities
13.5
6 MV
9.9 keV/µm
keV/µm
0.7427
0.6695
0.9308
0.7312
0.9878
0.9166
0.6175
0.7724
0.6797
0.6098
0.9851
0.6698
0.8137
0.3189
0.3076
0.1721
0.1972
0.7869
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P values when comparing COVD50%
values between different radiation
qualities
13.5
6 MV
9.9 keV/µm
keV/µm
0.9272
0.6546
0.7092
0.6684
0.6710
0.8430
0.6844
0.8680
0.7249
0.9329
0.7545
0.9993
0.6055
0.7311
0.4694
0.8718
0.7877
0.6916

Supplemental Table 13: P values arising from two-tailed z-tests of the coefficients of variation (COV) in the RBED10%
or RBED50% values between cells exposed to different radiation qualities (9.9 keV/µm protons, and 13.5 keV/µm and
60.5 keV/µm C-ions), for cells of a given histologic type (NSCLC, GBM, PAAD), excluding the cells treated with DNA
repair inhibitors. Redundant values are omitted from the table.

Cohort
NSCLC
GBM
PAAD

Radiation Quality
13.5 keV/µm
60.5 keV/µm
13.5 keV/µm
60.5 keV/µm
13.5 keV/µm
60.5 keV/µm

P values when comparing the
COVRBED10% values between
different radiation qualities
9.9 keV/µm
13.5 keV/µm
0.4348
0.8944
0.3360
0.3837
0.9324
0.4049
0.2503
0.0760
0.2738
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P values when comparing
COVRBED50% values between
different radiation qualities
9.9 keV/µm
13.5 keV/µm
0.3211
0.4012
0.7301
0.0614
0.3052
0.5777
0.7293
0.1371
0.2031

Chapter 3 – DNA repair capacity is an important factor in
determining ion radiosensitivity up to LETs of 60.5 keV/µm
*Note: a substantial portion of this chapter is written or based on the following
publication146 of which I am an author, and for which the right to reproduce as part of my
dissertation is granted by Elsevier:
Bright, Scott J., David B. Flint, Sharmistha Chakraborty, Conor H. McFadden, David S. Yoon,
Lawrence Bronk, Uwe Titt et al. "Nonhomologous end joining is more important than proton
linear energy transfer in dictating cell death." International Journal of Radiation Oncology*
Biology* Physics 105, no. 5 (2019): 1119-1125.

I.

Introduction
Currently, high energy photon beams are the main form of radiation used

therapeutically, with recent advances being driven by improvements in the conformality of the
dose delivered15,18-20. But interest has also increased in the use of particle beams, including
protons and carbon-ions (C-ions), whose differing physical interaction characteristics30
inherently provide superior dose conformality relative to photons 27,33.
The primary mechanism by which radiation kills cells is by inducing DNA damage120.
This can include inducing lesions on individual bases, or causing breaks in the DNA molecule
in the form of single-stranded (SSBs) or double-strand breaks (DSBs)120. DNA DSBs are
among the most important lesions from a radiobiological perspective because if not
successfully repaired, these types of lesions can often result in cell death5,35,73,120,147. Thus, the
capacity of cells to repair DNA DSBs is an important factor that governs cells’ intrinsic
radiosensitivity74-76.
But beyond their potentially superior dose conformality, particle beams are more
efficient than photons at inducing DSBs because of their increased ionization densities148,149,
which cause the lesions they produce to be more complex87,88 and more clustered 31,149-155 as
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the linear energy transfer (LET) of particles are increased. Complex lesions, which are defined
as DSBs created by several SSBs and/or base damages on opposite sides of the DNA
molecule156, and in particular clustered lesions, which may include SSBs, and/or base damage
in addition to complex DSBs, occurring within 10-20 base pairs of each other, are highly likely
to induce cell death if not repaired157-159. Because of this, particle beams tend to be more
effective at inducing cell death for a given dose than photon beams148,149,160,161.
Cells have a complex system of mechanisms used to repair these different types of
DNA lesions which in turn greatly influence cell survival after radiation exposure159,162. First, the
DNA damage response (DDR) must be activated, whereby a family of proteins including ataxiatelangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), and DNAdependent protein kinase catalytic subunit (DNA-PKcs) are phosphorylated in response to the
presence of DNA damage163. ATM is of particular importance here since it largely regulates the
DDR, particularly the repair of DSBs163,164, by signaling for inhibition of the cell cycle and
promoting DSB repair via one of the two primary DSB repair pathways: non-homologous end
joining (NHEJ) repair or homologous recombination (HR) repair 163,165.
NHEJ is a relatively simple DSB repair pathway which involves bridging the two ends of
a DSB, and processing the DSB ends to allow for ligation77,78. The other primary pathway used
to repair DSBs pathway is HR, in which the homologous strand of DNA is gathered and used
as a template to copy and rebuild the region in the vicinity of the DSB80,81. These DNA repair
pathways are discussed in greater detail in CH1§III.
Since HR results in the extensive resection of DNA from the primary damage site, while
NHEJ performs minimal resection166,167, in the context of repairing complex and clustered DSB
lesions, we might expect that HR repair is advantaged. This is because while HR can resect
and perform error-free repair around the region of the clustered DSBs using the homologous
chromosome as a template, NHEJ is incapable of performing the extensive resection needed to
complete the repair effectively168. Thus, in the context of ion radiobiology, while we might
expect that the relative importance of the two pathways favors HR as the LET of ions is
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increased, relatively little is known about how their relative importance varies with ion LET,
apart from a few studies suggesting that NHEJ is the predominant repair pathway89,169.
The decision about which pathway to choose to repair a DSB is highly regulated to
ensure successful repair170, with proteins such RIF1 helping to promote NHEJ171, and BRCA1
helping to promote the switch from NHEJ to HR166. BRCA1 is of particular interest because it is
commonly mutated in breast and ovarian cancers172, and while it is involved in a number of
processes besides HR, including cell cycle regulation and apoptotic pathways173, it is thought
that BRCA mutations might sensitize cells to radiation because of the roles of BRCA1 and
BRCA2 in DNA repair. However, while some evidence exists to suggest that BRCA mutations
correlate with radiosensitivity11,107,174, this has yet to be proven in a clinical setting172.
In the context of personalized radiotherapy, knowledge of how cell radiosensitivity in
modulated by these two pathways is of critical importance, both towards understanding how the
different types of DNA damage induced by ions and photons interact with biological factors that
ultimately determine radiosensitivity, but also to determine the LET range over which any
differences in these factors might be exploited when optimizing the treatment to a particular
patient’s tumor (or to normal tissues). Since the predominant view is that DNA repair capacity is
a less important factor in determining radiosensitivity for high LET ions27,28, it is important to
establish the range of LETs over which this axiom holds, and characterize any differences in
the region where it does not, so that these factors can be incorporated correctly into any future
personalized radiotherapy regimen. And as our data in Chapter 2 suggest, DNA repair capacity
likely remains an important factor that governs radiosensitivity up to LETs of at least 60.5
keV/µm, which are consistent with those in the middle of clinical C-ion SOBPs.
Thus, in this chapter, we will establish that fact by showing that cells with differential
DNA repair capacity, whether by HR or NHEJ repair, have remarkable changes in
radiosensitivity to photons, protons, He-ions and even C-ions, and that the fraction of DSBs
repaired and the number of DSBs left unrepaired (whether by HR or NHEJ) correlate with cell
survival even for high LET C-ions. These data will also confirm that while NHEJ is the prevalent
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repair pathway in determining radiosensitivity across radiation types, its importance relative to
HR varies with LET, favoring NHEJ less at higher LETs.

II.

Materials and Methods
II.1

Cell Lines

In this chapter, we used a number of cell lines with differing capacities in NHEJ repair or
HR repair to study the relative importance of the two pathways. To study the importance of
NHEJ, we used the M059K and M059J glioblastoma cell lines which are an isogenic pair of cell
lines that were established from the same tumor127,128, but with differential DNA-PKcs activity129
resulting in deficiency in the NHEJ pathway for the M059J cell line.
To study the effect of HR, we used HCC1937 cells which are a triple-negative breast
cancer cell line with a naturally occurring mutation in the BRCA1 gene175 that renders them
deficient in HR. The isogenic HCC1937-BRCA1 cell line (gift from Dr. Shane R, Stecklein from
The University of Kansas Cancer Center), has had the BRCA1 gene restored and thus the cells
are proficient in HR175,176.
Also to study the importance of HR, we also used the lung cancer cell lines H1299 and
H460. The H1299 cells are a p53 mutant, which has been shown to prevent p53-induced
downregulation of RAD51 foci formation177. Since RAD51 is a protein critical to HR repair, we
expect that H1299 has greater HR repair capacity than H460, since H460 is p53 wild-type.
Although it is difficult to compare these cell lines directly since they are not isogenic, trends in
our DNA repair foci data (CH3§III.1) and survival data (CH3§III.4) support the notion that
H1299 cells have a particularly high DNA repair capacity.
To study both HR and NHEJ and to compare their relative importance, we used HT1080
cells that were genetically modified to be deficient in either NHEJ (HT1080-shDNA-PKcs) or to
have a drug-inducible deficiency in HR (HT1080-shRAD51IND). The drug-inducible HR
deficiency was achieved by shRNA silencing of RAD51 via a 1 µg/mL doxyxcycline treatment
for 48 h. This silence was followed by seeding the cells and supplementing them with fresh
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medium without doxycycline, and then by a 24-h recovery period before irradiation 178. The
depletion of RAD51 following this treatment was confirmed via Western blot as described in
Supplemental Note 4. The isogenic HT1080 pair was a gift from Dr. Asaithamby Aroumougame
from The University of Texas Southwestern Medical Center.
As an additional reference cell line for He-ion and C-ion exposures, we used the
pancreatic cancer cell line BxPC3.
The M059K, M059J, HCC1937 (parental), HT1080 (parental), and BxPC3 cell lines
were purchased from the American Type Culture Collection (Manassas, VA, USA). All cell lines
were authenticated using short tandem repeat (STR) DNA profiling at the MD Anderson
Characterized Cell Core Facility (CCLC), and tested negative for mycoplasma contamination.
All cell lines were maintained in a humidified atmosphere at 37°C, 5% CO2 in air and were
routinely sub-cultured prior to reaching 100% confluence using 0.25% trypsin. Further details of
the cell culture conditions for these cells are given in Appendix 1.

II.2

Cell Irradiations

For the results presented in this chapter, the cell lines were grown in 6-well plates or T12.5 flasks and exposed to clinical x-ray beams and proton beams at The University of Texas
MD Anderson Cancer Center, and He-ions and C-ions at the Heavy-Ion Medical Accelerator in
Chiba (HIMAC) (Chiba, Japan). The x-ray irradiations were performed using a 6 MV beam from
a clinical linear accelerator (Truebeam or 2100 series, Varian Medical Systems, Palo Alto, CA)
at a water equivalent depth of 10 cm to simulate a clinical radiation environment. The proton
irradiations were performed using an unmodulated 100 MeV proton beam with slabs of water
equivalent plastic in front of the beam to obtain a dose-weighted LETs in water ranging from
1.2-9.9 keV/µm, which range from the entrance to the end of the proton range. The LETs under
these conditions were calculated by Monte Carlo simulation using a validated model of the
beamline as described in Appendix 2. The He-ion irradiations were performed using an

63

unmodulated 150 MeV/nucleon He-ion beam, with dose-weighted LETs in water ranging from
2.2-14.0 keV/µm, and the C-ion irradiations were performed using an unmodulated 290
MeV/nucleon C-ion beam with dose-weighted LETs in water ranging from 13.5-60.5 keV/µm,
respectively. These LETs range from the approximate LETs at the entrance to the middle of
clinically relevant SOBPs. These LET values were obtained using energy absorbers that are
part of the beamline.136 Appendix 2 contains more details about these irradiation conditions.

II.3

Clonogenic Survival Assays

To measure the cell survival, we performed clonogenic assays by trypsinizing the cells
18-24 hours prior to irradiation and seeded them into 6-well plates or T-12.5. After irradiation,
cell lines were allowed to form colonies for 7-14 days and then were fixed and stained with pure
ethanol containing 0.5% crystal violet. More details about these methods can be found in
Appendix 2. The plates were then air dried and scanned using a high-resolution flatbed
scanner (Epson Expression 10000 XL) to produce images to be analyzed using an ImageJ
plugin developed to automatically count colonies containing more than 50 cells. Details of the
image analysis techniques used to score colonies can be found in Appendix 3. Toward these
analyses, the clonogenic cell survival assays for x-rays and protons were independently
repeated at least three times each time in triplicate over a period of three years, while the cell
survival assays for most C-ion irradiations were independently repeated at least two times, at
least in duplicate, over a period of three years. Each clonogenic cell survival experiment
included at least five doses, and each cell line had a specific range of doses determined
according to its radiosensitivity, under the constraint that it contained a dose level that was
close to D10%. Details of how the clonogenic data were analyzed are found in Appendix 2.
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II.4

Radiation response data

To quantify the radiosensitivity of each cell line, we calculated the dose at which the
surviving fraction falls to 10% on the cell survival curve (D10%), or the surviving fraction after a
dose of 2 Gy (SF2Gy) based on the α and β values from the linear quadratic (LQ) model. The α
and β values were obtained from fitting the clonogenic cell survival data to the LQ model using
variance-weighted least squares minimization in Graph Pad Prism 7 (Graph Pad, San Diego,
CA). We quantified the ion RBE relative to photons by taking the ratio of the D10% values:
RBED10% = D10%,photon/D10%,ion. More details on these analyses can be found in Appendix 2.
To quantify the relative importance of cells of differing DNA repair capacity, we
calculated the sensitization enhancement ratio (SER) for deficiency in a given repair pathway,
P, at each radiation quality, Q as follows:

𝑆𝑆𝑆𝑆𝑆𝑆𝑃𝑃,𝑄𝑄 =

𝐷𝐷10%.𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃,𝑄𝑄
𝐷𝐷10%.,𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝑐𝑐𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖,𝑄𝑄

The SERP,Q quantifies the relative sensitization gained from the absence of a repair
pathway at a given radiation quality, and thus allows us to quantify how the importance of a
particular pathway varies with LET.
We also quantified each cell line’s sensitization relative to the wild-type’s (SRW) photon
response for a given radiation quality Q as follows:

𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙,𝑄𝑄 =

𝐷𝐷10%.,𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤−𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡,6𝑀𝑀𝑀𝑀
𝐷𝐷10%.,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙,𝑄𝑄

This quantity allows us to simultaneously assess the relative differences in sensitization
from the LET effect and differential repair capacity as it does not hide information about the
absolute sensitivities of the cells across LET.

65

All radiation response data are tabulated in CH3§VI (Supplemental Note 5).

II.5

Immunohistochemical (IHC) staining of DNA damage repair response

To assess the amount of DNA damage and quantify the amount of repair, we seeded
cells into 96-well glass-bottom plates 24 hours prior to irradiation, and then exposed them to a
dose of 2 Gy using x-rays, or C-ions with LETs of 13.5 keV/µm or 60.5 keV/µm. 30 min and 24
h after irradiation, the cells were fixed using a 4% PFA solution for 10 min at room temperature,
before being washed 3 times with PBS for 5 min. Later, to permeabilize the cells for antibody
staining, the cells were treated with 0.2% Triton-X for 10 min at room temperature, and then
blocked with 0.2% fish gelatin and 5% goat serum. Then the cells were stained overnight at
4°C with primary antibodies for the proteins: γ-H2AX (JWB301, EMD Millipore, Burlington, MA,
USA), 53BP1 (NB100-394, Novus Biologicals, Centennial, CO, USA), RIF1 (GTX85728,
GeneTex, Irvine, CA, USA) and RAD51 (AB213, ABCAM Inc., Cambridge, UK) in the following
combinations: γ-H2AX & 53BP1, γ-H2AX & RAD51, and 53BP1 & RIF1. After primary antibody
staining was complete, the samples were washed with PBS three times for 10 min before being
incubated for 1 h at room temperature with flurophore-conjugated secondary antibodies. These
fluorophores were Alexa Fluor 488 (#A-11034, Thermo Fisher Scientific, Waltham, MA, USA) to
tag 53BP1 and RAD51, and Alexa Fluor 594 (#A-11005, Thermo Fisher Scientific, Waltham,
MA, USA) to tag γ-H2AX and RIF1. After secondary antibody staining was complete, the cells
were washed three times with PBS for 10 min before being stained with DAPI (4′,6-diamidino-2phenylindole) (5 µg/mL) (#62248, Thermo Fisher Scientific) for 10 min at room temperature,
which stains the whole nucleus.
Thus, the resulting samples were stained with three combinations of fluorescent
markers to identify nuclear DSB repair foci: γH2AX & 53BP1 to identify foci associated with
generic DSB repair, γH2AX & RAD51 to identify foci associated HR repair, and 53BP1 & RIF1
to identify foci associated with for NHEJ repair. An example of the images acquired for these
stain combinations can be seen in Figure 12.

66

*Note: while this author did help to prepare, irradiate and fix the IHC samples used in
this work, the IHC staining was graciously performed by Dr. Sharmistha Chakraborty.

II.6

Analysis of IHC stained cells

The stained plates were imaged on an Olympus FV1200 confocal microscope using a
60X, 1.35 NA objective, with a lateral resolution of 0.19 μm and an axial resolution of 0.86 μm.
Three dimensional (z-stack) images of the cells and their stained DSB repair foci (7–15 µm in
depth, 0.43 µm step size, 0.094 μm lateral pixel size) were created, using a 405 nm laser to
excite the DAPI stain, a 473 nm laser to excite the Alexa Fluor 488 stain, and a 543 nm laser to
excite the Alexa Fluor 594 stain. An example of the resulting images can be seen in Figure 12.

Figure 12: DSB repair foci in M059J cells exposed to 2 Gy of 60.5 keV/µm carbon ions, 24 h after irradiation. The
cell nuclei (blue) are stained with DAPI (blue A,E,I) and the DNA repair proteins (green and red) are tagged with
Alexa Fluor 488 (B,F,J) or Alexa Fluor 594 (C,G,K). Colocalized nuclear 53BP1 and γH2AX (D) indicate generic DSB
repair. Colocalized nuclear 53BP1 and RIF1 (H) indicate NHEJ repair. RAD51 and γH2AX (L) indicate HR repair.
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We then analyzed the three-dimensional images using the Imaris 9.2.1 image
processing suite (Bitplane AG, Zurich, Switzerland) to identify DSB repair foci associated with
each stain and confined within the DAPI-stained nucleus (Figure 13) using the Imaris Cell
module. We quantified the number of foci in each nucleus by scoring the colocalized nuclear
foci in the red and green channels, with colocalization being defined as having a greater than
50% volumetric overlap. We then calculated the average number of foci per nucleus by
averaging the number of colocalized foci across all nuclei scored for that condition, and
calculated the uncertainty by taking the standard error on the mean across all nuclei scored.

Figure 13: γH2AX (green) and 53BP1 (red) DSB repair foci in H460 cells (blue DAPI-stained nucleus) exposed to
6MV x-rays to a dose of 2 Gy, 30 min after irradiation. (A) Maximum intensity projection (MIP) of γH2AX foci
superimposed on cell nucleus. (B) MIP of 53BP1 foci imposed on cell nucleus. (C) MIP of γH2AX and 53BP1 foci
superimposed on cell nucleus. (D-F) The foci contours determined with Imaris superimposed on the MIP of the
nucleus.

We accounted for the background by subtracting the number of foci per nucleus scored in the
unirradiated controls from the number scored in the irradiated samples.
We chose to use this low throughput approach to acquiring the foci data since C-ions
induce more clustered DNA lesions than photons, and so we wished to be able to individual
resolve foci in as close proximity as possible. However, this meant that relatively few nuclei
could be scored per condition. In general, each field we acquired contained 5-10 nuclei
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depending on the cell line, and we scored 10 fields per condition so that we could score at least
50 nuclei per condition. However, in some cases for the γH2AX & 53BP1 stain combination, the
whole well could not be imaged due to geometric constraints of the microscope system, and so
all of the nuclei in the portion of the well that could be imaged were imaged. The number of
nuclei scored per condition are given in Supplemental Note 6.
We quantified the DNA repair capacity of the cells after irradiation using two metrics
related to the number of background subtracted colocalized DNA DSB foci formed after
irradiation. First, we considered the number of persistent foci, which we defined as foci
remaining 24 h after irradiation, and second by calculating the fraction of foci repaired between
30 min and 24 h post irradiation as follows:

𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 =

𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹30 𝑚𝑚𝑚𝑚𝑚𝑚 − 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹24 ℎ
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹30 𝑚𝑚𝑚𝑚𝑚𝑚

Persistent foci quantify DSB repair capacity by quantifying the extent to which a given
cell fails to repair damage following radiation exposure, while the repair fraction quantifies the
extent which a given cell can repair the damage it receives after irradiation.
Finally, it should be noted that these analyses correspond to a single independent
experiment for each condition due to having limited access to C-ion beam irradiations.

II.7

Statistical Analyses

The statistical analyses in this chapter were performed in MATLAB 2017 (Mathworks,
Natick, MA) to quantify the number of colocalized foci per nucleus, and Graph Pad Prism 7 to
estimate the survival curve fit parameters (Graph Pad, San Diego, CA). The error bars shown
in the number of foci per nucleus represent the standard error propagated from the number of
DSBs measured per nucleus into the repair capacity metrics. The error bars plotted in the
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survival data represent the standard error propagated from the fits of the survival curve
parameters (α and β), including their covariance, to the parameter estimates.

III.

Results
III.1

Persistence and repair of

DSB are associated with radiosensitivity
to C-ions, even up to LETs of 60.5 keV/µm
We analyzed the number of generic
DSB foci (colocalized γH2AX & 53BP1) in
cells exposed to x-rays and C-ions, noting
that even for 60.5 keV/µm C-ions, the number
of persistent foci were associated with cell
radiosensitivity (Figure 14A,B), namely that
radiosensitive cells had more persistent foci
than resistant cells. We also noted that the
fraction of foci repaired were associated with
radiosensitivity (Figure 14A,C), namely that
radiosensitive cells repaired a smaller fraction
of their foci than radioresistant cells.
Accordingly, when we compared these two
metrics of DNA repair capacity across the
whole cell line panel, we noted that they
correlate with the survival fraction for a dose
of 2 Gy for both x-rays (R2 = 0.93 and R2 =
0.82 for the number of persistent foci and
repair fraction, respectively) (Figure 15A,B)
and C-ions (R2 = 0.75 and R2 = 0.69 for the

Figure 14: (A) Survival of radioresistant H1299 cells
(blue), NHEJ deficient M059J cells (green) and NHEJ
proficient M059K cells (red) exposed to 60.5 keV/µm Cions. (B) Number of persistent DNA DSB foci (foci
remaining after 24 h) in the same cell lines following
irradiations with X-rays, 13.5 keV/µm C-ions, or 60.5
keV/µm C-ions to a dose of 2 Gy. (C) The fraction of DSB
foci (defined as [Foci30min – Foci24h]/ Foci30min) under the
same conditions. All foci counted were colocalized γH2AX
and 53BP1 after subtracting the background.
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number of persistent foci and repair fraction, respectively) (Figure 15C,D). These data imply
that a cell’s ability to repair its DNA is an important factor in determining its radiosensitivity,
even at high LETs. While the lesser correlations for C-ions than x-rays may indicate that the
importance of DNA repair capacity is slightly less at higher LETs, this trend might also be partly
explained by the smaller absolute range in radiosensitivity values that is expected at higher
LETs since (as discussed in Chapter 2), which in turn lessens the correlations.

Figure 15: Correlations between the surviving fraction for a dose of 2 Gy and the number of persistent foci (foci
remaining 24 h after irradiation) (A,C), or the fraction of DSB foci repaired after 24 h foci (defined as [Foci30min –
Foci24h]/ Foci30min) (B,D) for H460, H1299, BxPC3, M059K and M059J cells exposed to 6 MV X-rays (A,B) or 60.5
keV/µm C-ions (C,D).
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III.2

Non-homologous end-joining repair capacity is an extremely important

factor in determining cell radiosensitivity to photons, protons, helium ions and
carbon ions
We characterized the survival of a pair of cell lines with differential capacity for NHEJ
(M059K and M059J) exposed to 6 MV x-rays, protons (LETd values from 1.2 - 9.9 keV/µm), Heions (LETd values from 2.2 - 14.0 keV/µm), and C-ions (LETd values from 13.5 - 60.5 keV/µm)
(Figure 16A,B). While for both cell lines, as the LET was increased, survival decreased, the
NHEJ deficient M059J cells (Figure 16B) were significantly more radiosensitive than the NHEJ
proficient M059K cells across all LETs (Figure 16A). However, there was little variation in
M059J’s survival between different radiation types and ion LETs (Figure 16B) compared to the
large variations in the response of the NHEJ proficient M059K cells (Figure 16A), with the
D10% values for M059J varying from 1.03±0.04 Gy to 1.58±0.02 Gy across all radiation

Figure 16: Survival of M059K cells (A) and M059J cells (B) exposed to 6 MV x-rays, 2.6 keV/µm protons, 14.0
keV/µm He ions and 60.5 keV/µm C ions (other conditions omitted for clarity). The RBE for the M059K cells (C) and
M059J cells (D) are shown for all conditions measured. The dashed lines in C and D are one phase exponential fits
to these data and serve only to help guide the eye to the trends across all radiation types.
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qualities compared to 3.01±0.20 Gy to 5.41±0.16 Gy for M059K cells. Similarly, relatively large
variations in response across radiation types were observed in the other NHEJ proficient cell
lines we investigated under the same irradiation conditions (Figure 20A,B), with the D10% values
for H1299, H460 and BxPC3 cells varying from 4.18±0.05 Gy to 8.12±0.08 Gy, 2.58±0.12 Gy to
4.81±0.04 Gy, and 3.11±0.45 Gy to 5.80±0.11 Gy across all radiation types, respectively.
Similar trends were observed in the HT1080 isogenic pair (HT1080 and HT1080-shDNA-PKcs
cells) discussed in CH3§III.5 (Figure 22), with the D10% values varying from 2.49±0.04 Gy to
2.85±0.03 Gy for the NHEJ deficient HT1080-shDNA-PKcs cells compared to 4.69±0.06 Gy to
8.02±0.26Gy for the NHEJ proficient HT1080 cells across all x-ray and proton radiation
qualities. See Supplemental Note 5 for all D10% values.
Accordingly, when the LET response of their RBEs were calculated, the NHEJ deficient
(M059J) cells exhibited minimal variations in RBE with increasing LET (varying from 0.95±0.03
to 1.33±0.5 across all ion LETs) compared to the isogenic, but NHEJ proficient, M059K cells
(Figure 16C,D) (varying from 1.06±0.04 to 1.80±0.13 across all ion LETs), or when compared
to the other NHEJ proficient cell lines (Figure 20A,B) (which varied from 1.09±0.02 to
1.94±0.03, 1.03±0.01 to 1.87±0.09 and 0.94±0.02 to 1.86±0.03 for the H1299, H460 and
BxPC3 cells, respectively, across all ion LETs) . Similar trends were observed in the HT1080
isogenic pair (HT1080 and HT1080-shDNA-PKcs cells) discussed in CH3§III.5 (Figure 22), with
the RBEs varying from 1.10±0.02 to 1.19 ±0.02 for the NHEJ deficient HT1080-shDNA-PKcs,
compared to 1.14±0.04 to 1.71±0.06 for the NHEJ proficient HT1080 cells across all proton
radiation qualities. See Supplemental Note 5 for all RBED10% values.
These data suggest that in the absence of NHEJ, there is little difference in the
biological effectiveness of ion radiation of different LETs, and less difference between the
biological effectiveness of ions and x-rays. This implies that NHEJ repair capacity is an
important factor both in determining intrinsic radiosensitivity but also modulating how
radiosensitivity depends on an ion’s LET. As discussed in CH3§III.3, these conclusions are
supported by our foci data considering just DSB foci associated with NHEJ repair (Figure 18),
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which show that across our cell line panel, the persistence of NHEJ foci and the repaired
fraction of NHEJ foci are correlated with survival to both x-rays and 60.5 keV/µm C-ions.

III.3

The relative importance of NHEJ repair capacity decreases with LET

To quantify the relative importance of NHEJ between different radiation qualities, we
calculated the sensitization enhancement ratio (SERNHEJ,Q) for each radiation quality, Q, of the
M059J cells relative to the M059K cells. This quantifies the relative sensitization gained from
the absence of a NHEJ at each radiation quality:

𝑆𝑆𝑆𝑆𝑆𝑆𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁,𝑄𝑄 =

𝐷𝐷10%.,𝑀𝑀059𝐾𝐾,𝑄𝑄
𝐷𝐷10%.,𝑀𝑀059𝐽𝐽,𝑄𝑄

To quantify the relative importance of NHEJ repair capacity without losing scope of the
magnitude of the LET effect in determining cell radiosensitivity, for each radiation quality, Q, we
also calculated the sensitivity of the two cell lines relative to the wild type’s (M059K) x-ray
radiosensitivity (SRW) (note that this is equivalent to RBE for the M059K cells):

𝑆𝑆𝑆𝑆𝑆𝑆𝑀𝑀059𝐾𝐾,𝑄𝑄 =

𝐷𝐷10%.,𝑀𝑀059𝐾𝐾,6𝑀𝑀𝑀𝑀
𝐷𝐷10%.,𝑀𝑀059𝐾𝐾,6𝑀𝑀𝑀𝑀
𝑎𝑎𝑎𝑎𝑎𝑎 𝑆𝑆𝑆𝑆𝑆𝑆𝑀𝑀059𝐽𝐽,𝑄𝑄 =
𝐷𝐷10%.,𝑀𝑀059𝐾𝐾,𝑄𝑄
𝐷𝐷10%.,𝑀𝑀059𝐽𝐽,𝑄𝑄

In general, we noted the SERs were largest for lower LET radiation and decreased with
increasing LET for protons, helium and C-ions (Figure 17A), varying from 3.94±0.13 to
2.87±0.14 across radiation qualities. We observed similar trends in the HT1080 isogenic pair
(HT1080 and HT1080-shDNA-PKcs) discussed in CH3§III.5 (Figure 22D), where the SERs
varied from 2.81±0.10 to 1.97±0.05 between 6MV x-rays and 9.9 keV/µm protons. This
suggests that NHEJ is comparatively more important in determining radiosensitivity at lower
LETs than at higher LETs. But it is important to note that when comparing the SRW’s, NHEJ
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deficiency resulted in considerably greater sensitivity across all radiation qualities (with SRW
values ranging from 3.43±0.12 to 5.23±0.26 for the M059J cells compared to 0.95±0.03 to
1.80±0.10 for the M059K cells) (Figure 17B). In fact, when we compare the amount of
sensitization induced by NHEJ deficiency in terms of the SER to the amount of sensitization
induced by the LET effect in terms of the RBE, we see that NHEJ sensitizes cells more to any
radiation quality than the LET effect does, even for high LET carbon ions (SER of 2.91±0.18 for
the M059J cells compared to an RBE (or SRW) of 1.80±0.10 for the M059K cells at 60.5
keV/µm) (Figure 17A,B). See Supplemental Note 5 for all SER and SWR values.
This result suggests that NHEJ repair capacity is actually a more important factor than
ion LET in determining cell radiosensitivity to ions. So, even though NHEJ’s relative importance
may be lesser for higher LET radiation compared to lower LET radiation, NHEJ repair capacity
still profoundly influences cell radiosensitivity at higher LETs.

Figure 17: (A) Sensitization enhancement ratio of M059J cells relative to M059K cells exposed to x-rays (black),
protons (blue), He ions (red) and C ions (green). (B) Sensitization of M059K and M059J cells relative to the wild
type’s (M059K’s) x-ray response. The dashed lines are one phase exponential fits to these data and serve only to
help guide the eye to the trends across all radiation types.

These conclusions are supported by our DSB repair foci data across the whole cell line
panel, considering only DSBs associated with NHEJ repair (Figure 18). Both the number of foci
left unrepaired after 24 h and the fraction of foci repaired within 24 h after irradiation correlate
strongly with survival for x-rays and C-ions (R2 = 0.85 and 0.70 for the number of persistent foci
and R2 = 0.97 and 0.67 for the repaired fraction, exposed to x-rays and C-ions, respectively)
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(Figure 18). The lesser correlations observed for C-ions are consistent with the notion that
while cell survival is still strongly modulated by NHEJ repair capacity at high LETs, the degree
to which this modulation impacts radiosensitivity may be greater for x-rays.

Figure 18: Correlations between DSB repair foci associated with NHEJ repair and the surviving fraction for a dose of
2 Gy for H460, H1299, BxPC3, M059K and M059J cells exposed to 6 MV X-rays (A,B) or 60.5 keV/µm C-ions (C,D).
The number of persistent foci (foci remaining 24 h after irradiation) (A,C), or the fraction of DSB foci repaired after 24
h foci (defined as [Foci30min – Foci24h]/ Foci30min) (B,D) correlate with the surviving fraction for a dose of 2 Gy.

III.4

Homologous recombination repair capacity greatly affects cell survival to

photons, protons, helium and carbon ions
We characterized the survival of a pair of cell lines with differential capacity for HR
(HCC1937 and HCC1937-BRCA1) exposed to 6 MV x-rays (Figure 19A) and 9.9 keV/µm
protons (Figure 19B). Similar to what we observed for the cells lines with differential NHEJ,
both cell lines’ survival was lower for higher LET radiation (Figure 19A-C) (p < 0.0001 and p =
0.0236 when comparing the D10% values of the HCC1937 and HCC1937-BRCA1 cells,
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respectively). Similar results were observed for the HT1080 isogenic pair (HT1080 and
HT1080-shRAD51IND) discussed in CH3§III.5 (Figure 22A,B), where the D10% values ranged
from 8.02±0.26 Gy to 4.69±0.06 Gy for the HT1080 cells and 4.07±0.09 Gy to 3.22±0.03 Gy for
the HT1080-shRAD51IND cells, respectively. See Supplemental Note 5 for all D10% values.
However, in contrast to the NHEJ deficient pairs, for the HCC1937 cells, the
sensitization gained in the absence of HR was not smaller at higher LETs (Figure 19D) (SER of
1.53±0.18 for 9.9 keV/µm protons compared to 1.29 ± 0.24 for 6 MV x-rays), and for the
HT1080 isogenic pair (HT1080 and HT1080-shRAD51IND) discussed in CH3§III.5, while the
SERs were smaller at higher LETs (1.46±0.03 for 9.9 keV/µm versus 1.97±0.08 for 6 MV xrays), these differences were relatively small compared to the differences seen for NHEJ
deficiency (SERs of 1.97±0.05 and 2.81±0.10 for the HT1080-shDNA-PKcs cells exposed to
9.9 keV/µm protons and 6 MV x-rays, respectively) (Figure 22D). Nevertheless, for both the
HCC1937 and HT1080 isogenic pairs, the HR deficient cells were more radiosensitive than the
HR proficient cells for each radiation quality (Figure 19A-C, Figure 22A,B) (see Supplemental
Note 5 for D10% values), although for the HCC1937 cells, this was less significant for x-rays (p =
0.2163) than for protons (p = 0.0011). These results suggest that HR repair capacity greatly
influences cell radiosensitivity to photons and protons.
Also in contrast to the isogenic pairs with differential NHEJ, there was considerable
variation in the response of cells with HR deficiencies across different radiation types and ion
LETs (Figure 19C, Figure 22A,B), with the HCC1937 cells and the HT1080-shRAD51IND cells
being 2.0±0.2 and 1.26±0.03 more radiosensitive to 9.9 keV/µm protons than to x-rays,
respectively, compared to the M059J cells and the HT1080-shDNA-PKcs cells being 1.00±0.04
and 1.19±0.02 more radiosensitive to 9.9 keV/µm protons than to x-rays, respectively. This
suggests that in the absence of HR, ion LET remains an important factor in determining cell
radiosensitivity.
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Figure 19: Survival of HCC1937 cells (blue) and HCC1937-BRCA1 cells (black) exposed to 6 MV X-rays (A) and 9.9
keV/µm protons (B). Their radiosensititivities (D10%) are shown in (C). The sensitization enhancement ratio (SER)
for the absence of BRCA1 (calculated relative to the knock-in cell line) at the two radiation qualities is given in (D).

To support these data over a wider range of LETs, we characterized the survival of
H1299 and H460 lung cancer cells exposed to 6 MV x-rays, protons (LETd values from 1.2 - 9.9
keV/µm), He-ions (LETd values from 2.2 - 14.0 keV/µm), and C-ions (LETd values from 13.5 60.5 keV/µm). The H1299 cells are a p53 mutant, which has been shown to prevent p53induced downregulation of RAD51 foci formation177. Since RAD51 is a protein critical to HR
repair, we expect that H1299 has greater HR repair capacity than H460, since H460 is p53
wild-type. Across all radiation types, the H1299 cells were significantly more radioresistant
(D10% values ranging from 4.18±0.05 Gy to 8.12±0.08 Gy) than the H460 cells (D10% values
ranging from 2.58±0.12 Gy to 4.81±0.04 Gy) and maintained a prominent shoulder in their
survival curve even up to LETs of 60.5 keV/µm (Figure 20A,B). Although these cells are not
isogenic, and thus other factors might contribute to their differences in survival, these results
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are nevertheless consistent with the notion that HR repair capacity remains relevant in
determining cell survival up to LETs of 60.5 keV/µm.

Figure 20: Survival of H1299 cells (A) and H460 cells (B) exposed to 6 MV x-rays, 2.6 keV/µm protons, 14.0 keV/µm
He ions and 60.5 keV/µm C ions (other conditions omitted for clarity). The RBE for the H1299 cells (C) and H460
cells (D) are shown for all conditions measured. The dashed lines are one phase exponential fits to these data and
serve only to help guide the eye to the trends across all radiation types.

Although the H1299 cells were the most radioresistant at all LETs, their RBE values
(ranging from 1.09±0.02 to 1.94±0.03) seemed to span similar ranges to the H460 cells
(ranging from 1.03±0.01 to 1.87±0.09) (Figure 20A,B). This may suggest that the importance of
HR repair capacity does not vary as much as NHEJ repair capacity in determining
radiosensitivity as a function of LET, modulating radiosensitivity to x-rays and ions similarly,
and consequently not resulting as in large differences in RBEs between cells with differential
repair capacity. This notion is consistent with the comparably little LET variation seen in the
SERs for the HT1080 isogenic pair with differential HR discussed in CH3§III.5 (Figure 22)
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(SERs ranging from 1.97±0.08 to 1.46±0.03 compared to 2.81±0.11 to 1.97±0.05 for the NHEJ
deficient pair).
Our conclusion that HR repair capacity remains an important factor in determining ion
radiosensitivity even up to 60.5 keV/µm is supported by our DSB repair foci data across the
whole cell line panel, considering only DSBs associated with HR repair. The number of HR foci
left unrepaired after 24 h correlates with survival for x-rays (R2 = 0.93) (Figure 21A) and C-ions
(R2 = 0.54) (Figure 21B). As with the NHEJ, these lesser correlations with C-ions are consistent
with the notion that while cell survival is still modulated by HR repair capacity at high LETs, the
degree to which this modulation impacts radiosensitivity may be greater for x-rays.

Figure 21: Correlations between the number of persistent DSB repair foci (foci remaining afte 24 h) associated with
HR repair and the surviving fraction for a dose of 2 Gy for H460, H1299, BxPC3, M059K and M059J cells exposed to
6 MV X-rays (A) or 60.5 keV/µm C-ions (B).

III.5

The relative importance of homologous recombination repair and

nonhomologous end-joining vary with LET
To directly compare the relative importance HR and NHEJ repair capacity in influencing
cell radiosensitivity as a function of ion LET, we characterized the survival of HT1080 cells
which were genetically modified to be deficient in either NHEJ (HT1080-shDNA-PKcs) or HR
(HT1080-shRAD51IND) exposed to 6 MV x-rays, and to protons (LETd values from 1.2 - 9.9
keV/µm) (Figure 22A,B). Both the HR and NHEJ deficient cells were more radiosensitive than
the parental cells across all radiation qualities, but the NHEJ deficient cells were the most
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radiosensitive to all radiation qualities (Figure 22A,B), with the NHEJ and HR deficient cells
being 3.35 ± 0.14 and respectively 2.49 ± 0.09 times more sensitive to 9.9 keV/µm protons
than the parental cells (in terms of the D10% values). This result implies that NHEJ repair
capacity is a more important factor than HR repair capacity in determining radiosensitivity.
When we calculated RBEs for these cell lines, we noted that the RBEs are generally
higher for the parental cells (ranging from 1.14±0.04 to 1.71±0.06) than either deficient cell line
(ranging from 0.97±0.03 to 1.26±0.03 for HT1080-shRAD51IND and 1.10±0.02 to 1.19±0.02 for
HT1080-shDNA-PKcs) (Figure 22C). But when we compared the RBEs of the HR and NHEJ
deficient cells are compared to one another, while the NHEJ deficient cells’ RBE varies little as
a function of LET (ranging from 1.10±0.02 to 1.19±0.02 ) (Figure 22C) which is in line with our
previous observations with the M059K and M059J isogenic pair (Figure 16C,D), the RBE
response of the HR deficient cells, while lesser than that of the parental cells, increases readily
across this range of LETs (ranging from 0.97±0.03 to 1.26±0.03 ) (Figure 22C). This result
implies that the relative importance of HR repair capacity does not decrease with LET to the
extent that NHEJ repair capacity does, in turn suggesting that the relative importance of the two
pathways may depend on ion LET.
Thus, to quantify the relative importance of the two pathways, we calculated the SER of
each deficient cell line relative to the wild type (Figure 22D). First, the SERs show that the
sensitization gained from NHEJ deficiency is greater than that from HR deficiency across all
LETs (Figure 22D) (with SERs ranging from 2.81±0.11 to 1.97±0.05 for the HT1080-shDNAPKcs cell cells compared to 1.97±0.08 to 1.46±0.03 for the HT1080-shRAD51IND ), implying that
NHEJ is more important than HR in determining radiosensitivity across all radiation qualities.
But consistent with our previous observations in the M059K and M059J isogenic pair (Figure
17A), the amount of sensitization induced by NHEJ deficiency decreases with LET (Figure
22D). However, while the same is true for the HR deficient cells, their SERs decrease to a far
lesser extent across this range (1.97±0.08 to 1.46±0.03) than do those for the NHEJ deficient
cells (2.81±0.11 to 1.97±0.05), with the SERs for the HR deficient cells seemingly plateauing at
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higher LETs (Figure 22D). This suggests that the relative importance of HR repair capacity is
much less dependent on LET than NHEJ repair capacity.
Thus, while the absolute importance of DNA repair capacity to determining
radiosensitivity decreases with LET for both pathways, the importance of NHEJ repair capacity
decreases significantly more, and thus the importance of HR repair relative to NHEJ repair
capacity increases with LET.

Figure 22: Survival of HT1080 cells and genetically modified to be deficient in HR repair or NHEJ repair as well as
wild type cells exposed to x-rays and protons with LETs of 1.2, 2.6 and 9.9 keV/µm. (A) Wild type cells (saturated
curves) and NHEJ-deficient cells (desaturated curves). (B) HR deficient cells. (C) The RBEs of the wild type cells
(black), the NHEJ deficient cells (blue) and the HR deficient cells (green). (D) The sensitization enhancement ratios
at each radiation quality for the NHEJ deficient cells (blue) and HR deficient cells (green) relative to the wild type
cells. The dashed lines are one phase exponential fits to these data and serve only to help guide the eye to the
trends across all radiation types.

IV.

Discussions
In this chapter, we demonstrated that clinically relevant protons, He ions and C-ions can

induce significantly different radiosensitivity responses in human cancer cell lines with differing
DNA repair capacity – namely that in the absence of either NHEJ or HR, cells are significantly
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more radiosensitive, regardless of radiation quality (Figure 16A,B; Figure 19A,B; Figure 22A,B).
We also noted that the amount of DSBs a cell can repair, whether by NHEJ (Figure 18), HR
(Figure 21), or any pathway (Figure 15), are correlated with survival, even for high LET C-ions.
These data imply that a cell’s DNA repair capacity is still an important factor in determining its
radiosensitivity, even to high LET ions.
However, we noted that there was a differential response between the two pathways as
a function of ion LET. While NHEJ deficiency induced a greater increase in radiosensitivity
across all radiation qualities (Figure 22D), which suggests that in general NHEJ is the more
important pathway, the importance of HR relative to NHEJ was seen to favor NHEJ less for
increasing ion LETs (Figure 22D). Thus, this implies that the relative importance of HR
increases with increasing ion LET.
An important trend in these data is that survival in NHEJ-deficient cells differ less
between photon and ion radiation than NHEJ-proficient cells, regardless of ion or LET (Figure
16A,B; Figure 22A). This suggests that NHEJ is responsible for repairing most of the lethal
lesions induced, regardless of radiation quality, as in the absence of NHEJ, HR largely cannot
compensate for the loss of NHEJ. This would imply that relatively fewer lesions are needed to
induce cell death in NHEJ-deficient cells, and the complexity of the damage induced is of less
importance than simply the number of DSBs induced when determining their survival. Thus, in
a clinical scenario, if a tumor is known to be NHEJ-deficient, these results imply that the choice
of radiation modality should be chosen primarily based upon dose conformality, without
accounting for the expected RBE-depth profile of whatever ions are available. This is because,
due to the lesser dependence of their survival on ion LET, the RBEs of NHEJ-deficient cells will
be significantly smaller than those for NHEJ-proficient cells (Figure 16C,D; Figure 22C). In turn,
when accounting for the RBE-depth profile of the beam under the current clinical paradigm
(where cells’ RBEs are assumed to follow the same trends as cell lines of the same histological
category), this will result in significant overestimations of the tumor’s RBE, and thus potentially
less biologically effective dose being delivered to the tumor than could be delivered with
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photons while achieving the same normal tissue sparing.
Our data also showed that HR deficiency renders cells more radiosensitive for all LETs,
but that the amount of sensitization depends both on LET (Figure 19; Figure 22A,B) and on
how the pathway is disrupted. This latter consideration stems from the fact that, while HR
deficiency was achieved via RAD51 knockdown in the HT1080 cells, and via BRCA1 mutation
in the HCC1937 cells, the sensitization for HT1080-shRAD51IND cells was smaller for 9.9
keV/µm protons (SER of 1.46±0.03) than for photons (SER of 1.97±0.08) (Figure 22D), while
the sensitization of HCC1937 cells were similar for protons (SER of 1.53±0.18) and photons
(SER of 1.29±0.24) (Figure 19). These observations reinforce the notion that simply using a
single genomic feature as biomarkers for personalizing radiotherapy may not be sufficient in all
cases to predict individual radiosensitivity, as the overall effect of some genomic features may
be highly context dependent.
Towards this, our data allow us to consider the effect of HR deficiency by two
mechanisms, one occurring upstream (BRCA1167) and one occurring downstream (RAD5180) of
DNA end resection. Upstream of DNA end resection, we noted that HR deficiency via BRCA1
mutation causes cells to be more sensitive across radiation types, but that the sensitization was
similar between protons and photons. Thus we postulate that higher-LET protons might create
a significant population of clustered DSB lesions that are not effectively repaired by NHEJ, and
thus the in absence of HR they are particularly deleterious. In the absence of BRCA1, the
switch to HR cannot be made and thus any complex lesions must be repaired via NHEJ. If
higher-LET protons induce these clustered lesions, then the absence of HR will greatly
increase sensitivity, and this increased sensitivity may compensate for the general decrease in
SERs that are generally seen with increasing LETs due to the lesser importance of DNA repair.
However, downstream of DNA end resection, the depletion of RAD51 showed a
radiosensitizing effect across all radiation types but that was smaller for higher LETs. Since
RAD51 helps to facilitate the invasion of the homologous strand as part of HR repair, it
operates after the DSB lesion has been resected, and thus after the choice of using HR has
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been made80. But if a cell commits to HR, resects the damaged region, and then is unable to
complete the repair, this unrepaired lesion may lead to mitotic catastrophe and cell death154,179.
Thus, since HR can be used to repair simple or clustered DSB lesions so long as the cell has
the homologous strand available180-182, a defect in HR that occurs downstream of the end
resection will be deleterious across all radiation types. But in the case of lower LET radiation,
this type of defect will have the unfortunate characteristic that in addition to the cell not being
able to repair any clustered lesions for which HR may be necessary, this defect will result in a
number of unsuccessful attempts to repair lesions that otherwise could have been successfully
repaired by NHEJ. Thus, as we saw, the sensitization at lower LETs was larger for this type of
defect (Figure 22D).
Additionally, it is noteworthy that the for similar deficiencies, but for the different
isogenic cell line pairs (M059K and M059J versus HT1080 and HT1080-shDNA-PKcs)
markedly different SERs were observed for the same radiation qualities, with the sensitization
of M059J relative to M059K being greater for x-rays and protons (ranging from 3.94±0.13 to
2.87±0.14) than for HT1080-shDNA-PKcs relative to HT1080 (ranging from 2.81±0.10 to
1.97±0.05) (Figure 17A, Figure 22D). This once again underscores the importance of how the
context of genetic deficiencies related to DNA repair capacity might affect how they contribute
to individual radiosensitivity alongside the large number of other contributing factors. Thus,
while our data support the fact that DNA repair capacity is an important component that drives
individual radiosensitivity across radiation types, ultimately, it must be considered at the same
time as other biological factors relevant to the cell being considered. Consequently, efforts to
predict personalized radiosensitivity must incorporate a wide range of factors including DNA
repair capacity to accurately predict individual radiosensitivity.

V.

Conclusions
In this chapter, we showed that in human cell lines, DNA repair capacity is an important

driver of radiosensitivity. We showed that cells with differential DNA repair capacity, whether by
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HR or NHEJ repair, have in remarkable differences in their radiosensitivities to photons,
protons, He-ions and even C-ions, and that both that the fraction of DSBs repaired and the
number of DSBs left unrepaired (whether by HR or NHEJ) correlate with cell survival even for
high LET C-ions. We also confirm that while NHEJ is ultimately the more important repair
pathway in determining radiosensitivity up to 60.5 keV/µm, its importance relative to HR varies
with LET, favoring NHEJ less at higher LETs. These results are important as they underscore
the importance of DNA repair capacity in determining individual radiosensitivity even for high
LET ions, where many had considered DNA repair capacity to be less important.
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VI.

Supplemental Notes and Data

Supplemental Note 4: Confirmation of RAD51 depletion in HT1080-shRAD51IND cells by
Western blot
*Note: a substantial portion of this note is written or based on the supplemental
information contained in the following publication146 of which I am an author, and for
which the right to reproduce as part of my dissertation is granted by Elsevier::
Bright, Scott J., David B. Flint, Sharmistha Chakraborty, Conor H. McFadden, David S. Yoon,
Lawrence Bronk, Uwe Titt et al. "Nonhomologous end joining is more important than proton
linear energy transfer in dictating cell death." International Journal of Radiation Oncology*
Biology* Physics 105, no. 5 (2019): 1119-1125.

**Note: these analyses were performed by Dr. Scott J. Bright, and are included here for
completeness

To confirm that our doxycycline treatment for HT1008-RAD51IND cells resulted in the
depletion of RAD51, we prepared whole cell lysates that had been treated with doxycycline for
48 h, with and without a 24-h recovery period, and also over a 72-h treatment. We then used a
western blotting kit (#12957, Cell Signaling Technology, Danvers, MA, USA) to assess the
expression of RAD51 as follows. First, protein was extracted from whole cell lysates and
quantified. Then, 20 µg of protein was heated to 95°C for 5 min before being cooled on ice. The
protein samples were then centrifuged at 3,500 g for 4 min at 4°C to separate the protein from
the supernatant, and then combined with a suitable volume of loading buffer. Each protein
sample was then resolved on a 4%-20% gradient SDS-PAGE gel (#456-1095, Bio-Rad,
Hercules, CA, USA), run at 100 V for 15 min, followed by 1 h at 160 V (PowerPac HC, BioRad). The proteins were then transferred to nitrocellulose membranes with the Trans-Blot
Turbo transfer system (Bio-Rad), and then the membranes were blocked in blocking buffer
before being incubated overnight at 4°C with primary antibodies for RAD51 (Ab88752: 1 μg/mL,
Abcam, Cambridge, UK) and actin (Ab8224, 1 µg/mL, Abcam). The blots were then washed in
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TBST (a mixture of tris-buffered saline and polysorbate 20) before being incubated with species
conjugated with horseradish peroxidase secondary antibody. Then, the blots incubated with a
chemiluminescent substrate (#6883, SignalFire ECL Reagent, Cell Signaling Technology) for 1
min at room temperature before being imaged with a chemiluminescent imaging system
(ChemiDoc XRS+, Bio-Rad).
The resulting Western blots are shown in Supplemental Figure 5 , and show that the for
the 48 h doxycyline treatment, with our without recovery, the expression of RAD51 is depleted.

Supplemental Figure 5: Western blot results for HT1080-shRAD51IND
cells subjected to doxycycline treatments of 48 and 72 h, with or
without at 24 h recovery period

88

Supplemental Note 5: Radiation response data for cell lines used in this chapter
Supplemental Table 14: All survival data for cell lines used in this chapter
Radiation type Cell line
H460
H1299
M059K
M059J
BxPC3
6 MV
Photons
HT1080
HT1080-RAD51IND
HT1080-shDNA-PKcs
HCC1937
HCC1937-BRCA
H460
H1299
M059K
1.2 keV/μm M059J
Protons
BxPC3
HT1080
HT1080-RAD51IND
HT1080-shDNA-PKcs
H460
H1299
M059K
2.6 keV/μm M059J
Protons
BxPC3
HT1080
HT1080-RAD51IND
HT1080-shDNA-PKcs
H460
H1299
M059K
M059J
9.9 keV/μm BxPC3
Protons
HT1080
HT1080-RAD51IND
HT1080-shDNA-PKcs
HCC1937
HCC1937-BRCA1
H460
H1299
2.2 keV/μm
M059K
He-ions
M059J
BxPC3
H460
H1299
7.0 keV/μm
M059K
He-ions
M059J
BxPC3
H460
H1299
14.0 keV/μm
M059K
He-ions
M059J
BxPC3
H460
H1299
13.5 keV/μm
M059K
C-ions
M059J
BxPC3
H460
H1299
27.9 keV/μm
M059K
C-ions
M059J
BxPC3
H460
H1299
60.5 keV/μm
M059K
C-ions
M059J
BxPC3

α (Gy-1)
0.046±0.033
0.089±0.018
0.314±0.055
1.360±0.107
0.308±0.029
0.091 ± 0.032
0.544 ± 0.061
0.47 ± 0.04
0.845 ± 0.069
0.844 ± 0.129
0.02 ± 0.03
0.13 ± 0.02
0.222 ± 0.036
0.7 ± 0.1
0.353 ± 0.018
0.051 ± 0.008
0.446 ± 0.041
0.69 ± 0.05
0.17 ± 0.05
0.08 ± 0.02
0.330±0.035
1.581±0.099
0.337 ± 0.023
0.159 ± 0.029
0.415 ± 0.057
0.74 ± 0.05
0.15 ± 0.15
0.10 ± 0.04
0.361±0.045
1.683±0.070
0.496 ± 0.054
0.076 ± 0.031
0.545 ± 0.018
0.90 ± 0.04
1.583 ± 0.023
1.342 ± 0.322
0.182±0.055
0.230±0.052
0.112±0.018
1.034±0.163
0.319±0.062
0.122±0.048
0.197±0.041
0.364±0.040
1.425±0.301
0.361±0.089
0.089±0.056
0.153±0.030
0.553±0.059
1.326±0.110
0.453±0.073
0.307±0.096
0.045±0.029
0.206±0.061
0.944±0.389
0.458±0.064
0.502±0.048
0.098±0.070
0.649±0.101
1.823±0.198
0.543±0.126
0.676±0.173
0.124±0.048
0.765±0.036
1.365±0.442
0.740±0.157

β (Gy-2)
0.0899±0.0066
0.0240±0.0024
0.0206±0.0117
0.2318±0.0717
0.0154±0.0042
0.024 ± 0.006
0.005 ± 0.014
0.12 ± 0.01
0.000 ± 0.004
0.014 ± 0.042
0.100 ± 0.006
0.024 ± 0.003
0.026 ± 0.007
0.42 ± 0.04
0.003 ± 0.003
0.039 ± 0.002
0.025 ± 0.008
0.08 ± 0.02
0.085 ± 0.010
0.034 ± 0.003
0.0242±0.0066
0.0000±0.0000
0.008 ± 0.004
0.036 ± 0.006
0.048 ± 0.011
0.07 ± 0.02
0.150 ± 0.037
0.056 ± 0.006
0.0573±0.0082
0.0000±0.0000
0.017 ± 0.008
0.089 ± 0.007
0.053 ± 0.004
0.03 ± 0.01
0.135 ± 0.015
0.000 ± 0.088
0.0821±0.0108
0.0105±0.0079
0.0709±0.0036
0.5182±0.1155
0.0090±0.0112
0.1050±0.0123
0.0163±0.0059
0.0242±0.0080
0.2688±0.2121
0.0130±0.0148
0.1328±0.0159
0.0287±0.0048
0.0000±0.0160
0.4942±0.0922
0.0102±0.0141
0.0740±0.0291
0.0485±0.0048
0.0886±0.0194
0.7848±0.3312
0.0002±0.0167
0.0892±0.0174
0.0748±0.0139
0.0000±0.0000
0.2446±0.1673
0.0102±0.0373
0.0845±0.0797
0.1020±0.0124
0.0000±0.0283
0.8363±0.4291
0.0000±0.0812

Norm cov(α,β)
-0.9729
-0.9746
-0.9724
-0.9617
-0.9477
-0.9689
-0.9769
-0.9498
-0.9548
-0.9631
-0.9671
-0.9502
-0.9784
-0.9713
-0.9743
-0.9758
-0.9737
-0.9674
-0.9637
-0.9519
-0.9761
-0.9668
-0.9778
-0.9779
-0.9679
-0.9692
-0.9625
-0.948
-0.9401
-0.8285
-0.954
-0.9252
-0.9452
-0.9509
-0.9508
-0.7431
-0.9653
-0.9689
-0.9569
-0.9674
-0.9681
-0.9708
-0.9721
-0.9591
-0.9739
-0.9667
-0.9734
-0.9483
-0.9535
-0.9702
-0.9365
-0.9723
-0.9412
-0.9691
-0.9652
-0.9699
-0.9773
-0.972
-0.9684
-0.9648
-0.9803
-0.9743
-0.9714
-0.9624
-0.9627
-0.9682
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D10% (Gy)
4.812±0.040
8.119±0.076
5.407±0.162
1.372±0.020
5.797±0.117
8.02 ± 0.26
4.07 ± 0.09
2.85 ± 0.03
2.725 ± 0.224
2.61 ± 0.11
4.69 ± 0.04
7.45 ± 0.12
5.722±0.116
1.578±0.025
6.17 ± 0.09
7.06 ± 0.05
4.19 ± 0.07
2.60 ± 0.04
4.31 ± 0.06
7.19 ± 0.08
5.081±0.068
1.456±0.091
6.01 ± 0.09
6.12 ± 0.08
3.84 ± 0.09
2.49 ± 0.04
3.46 ± 0.13
5.57 ± 0.09
3.930±0.091
1.368±0.057
4.07 ± 0.15
4.69 ± 0.06
3.22 ± 0.03
2.39 ± 0.04
1.31 ± 0.01
1.72 ± 0.29
4.302±0.075
7.479±0.301
4.967±0.032
1.334±0.023
6.153±0.254
4.138±0.052
7.289±0.169
4.799±0.091
1.298±0.043
5.349±0.253
3.842±0.050
6.684±0.126
4.165±0.442
1.200±0.013
4.608±0.218
3.879±0.131
6.445±0.101
4.067±0.109
1.214±0.045
5.020±0.295
2.993±0.033
4.932±0.097
3.548±0.553
1.101±0.024
3.947±0.217
2.576±0.124
4.182±0.054
3.008±0.200
1.033±0.040
3.114±0.454

SF2Gy (Gy)
0.637±0.026
0.761±0.021
0.491±0.032
0.026±0.003
0.508±0.022
0.76 ± 0.03
0.33 ± 0.02
0.24 ± 0.01
0.185 ± 0.023
0.17 ± 0.02
0.64 ± 0.02
0.70 ± 0.02
0.699±0.022
0.533±0.031
0.49 ± 0.01
0.77 ± 0.01
0.37 ± 0.02
0.19 ± 0.01
0.51 ± 0.03
0.75 ± 0.02
0.469±0.021
0.042±0.008
0.49 ± 0.01
0.63 ± 0.02
0.36 ± 0.03
0.17 ± 0.01
0.41 ± 0.07
0.65 ± 0.03
0.386±0.024
0.035±0.005
0.35 ± 0.03
0.60 ± 0.02
0.27 ± 0.01
0.15 ± 0.01
0.02 ± 0.00
0.07 ± 0.03
0.500±0.034
0.606±0.045
0.603±0.014
0.016±0.003
0.510±0.042
0.515±0.025
0.632±0.037
0.439±0.022
0.020±0.006
0.461±0.056
0.492±0.026
0.657±0.028
0.331±0.020
0.010±0.002
0.388±0.037
0.403±0.034
0.753±0.031
0.465±0.023
0.007±0.004
0.400±0.026
0.256±0.008
0.609±0.053
0.273±0.055
0.010±0.003
0.324±0.036
0.184±0.015
0.519±0.026
0.216±0.010
0.002±0.002
0.228±0.019

RBED(10%)
1.000±0.012
1.000±0.013
1.000±0.042
1.000±0.021
1.000±0.029
1.00 ± 0.05
1.00 ± 0.03
1.00 ± 0.01
1.000 ± 0.116
1.00 ± 0.06
1.03 ± 0.01
1.09 ± 0.02
1.089±0.020
0.945±0.034
0.94 ± 0.02
1.14 ± 0.04
0.97 ± 0.03
1.10 ± 0.02
1.12 ± 0.02
1.13 ± 0.02
1.064±0.035
0.942±0.061
0.96 ± 0.02
1.31 ± 0.05
1.06 ± 0.03
1.14 ± 0.02
1.39 ± 0.05
1.46 ± 0.03
1.376±0.052
1.003±0.044
1.43 ± 0.06
1.71 ± 0.06
1.26 ± 0.03
1.19 ± 0.02
2.08 ± 0.17
1.52 ± 0.27
1.119±0.022
1.086±0.045
1.089±0.033
1.028±0.023
0.942±0.043
1.163±0.017
1.114±0.028
1.127±0.040
1.057±0.039
1.084±0.056
1.253±0.019
1.215±0.026
1.298±0.143
1.144±0.021
1.258±0.065
1.240±0.043
1.260±0.023
1.329±0.054
1.130±0.045
1.155±0.072
1.608±0.022
1.646±0.036
1.524±0.242
1.247±0.033
1.469±0.086
1.868±0.091
1.941±0.031
1.797±0.131
1.328±0.055
1.862±0.274

Supplemental Table 15: SER and SRW values calculated across all relevant cell lines in this chapter
Radiation type

6 MV photons

1.2 keV/μm
Protons

2.6 keV/μm
Protons

9.9 keV/μm
Protons

2.2 keV/μm
He-ions
7.0 keV/μm
He-ions
14.0 keV/μm
He-ions
13.5 keV/μm
C-ions
27.9 keV/μm
C-ions
60.5 keV/μm
C-ions

Cell line
M059K
M059J
HT1080
HT1080-RAD51IND
HT1080-shDNA-PKcs
HCC1937
HCC1937-BRCA1
M059K
M059J
HT1080
HT1080-RAD51IND
HT1080-shDNA-PKcs
M059K
M059J
HT1080
HT1080-RAD51IND
HT1080-shDNA-PKcs
M059K
M059J
HT1080
HT1080-RAD51IND
HT1080-shDNA-PKcs
HCC1937
HCC1937-BRCA1
M059K
M059J
M059K
M059J
M059K
M059J
M059K
M059J
M059K
M059J
M059K
M059J

SER
/
3.94 ± 0.13
/
1.97 ± 0.08
2.81 ± 0.11
1.29 ± 0.24
/
/
3.63 ± 0.09
/
1.68 ± 0.03
2.72 ± 0.05
/
3.49 ± 0.22
1.59 ± 0.04
2.45 ± 0.05
/
2.87 ± 0.14
/
1.46 ± 0.03
1.97 ± 0.05
1.53 ± 0.18
/
/
3.72 ± 0.07
/
3.70 ± 0.14
/
3.47 ± 0.37
/
3.35 ± 0.15
/
3.21 ± 0.49
/
2.91 ± 0.18
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SRW
1.00 ± 0.04
3.94 ± 0.13
1.000 ± 0.012
1.62 ± 0.11
2.46 ± 0.07
1.29 ± 0.24
1.00 ± 0.15
0.90 ± 0.03
3.27 ± 0.10
1.082 ± 0.015
1.64 ± 0.06
2.40 ± 0.03
0.95 ± 0.03
3.43 ± 0.12
1.254 ± 0.015
1.91 ± 0.03
2.52 ± 0.04
1.06 ± 0.03
3.71 ± 0.26
1.419 ± 0.049
2.29 ± 0.09
3.03 ± 0.08
2.58 ± 0.43
1.60 ± 0.52
1.09 ± 0.03
4.05 ± 0.14
1.13 ± 0.04
4.17 ± 0.19
1.30 ± 0.14
4.51 ± 0.14
1.33 ± 0.05
4.45 ± 0.21
1.53 ± 0.24
4.91 ± 0.18
1.80 ± 0.10
5.23 ± 0.26

Supplemental Note 6: Foci data collected in this chapter

Supplemental Table 16: Number nuclei scored per condition for the cell lines measured in this work.
γH2AX & 53BP1
53BP1 & RIF1
γH2AX & RAD51
Radiation
Cell line 0 Gy, 0 Gy, 2 Gy, 2 Gy, 0 Gy, 0 Gy, 2 Gy, 2 Gy, 0 Gy, 0 Gy, 2 Gy, 2 Gy,
type
30 min 24 h 30 min 24 h 30 min 24 h 30 min 24 h 30 min 24 h 30 min 24 h
H1299
112
112
124
118
115
130
130
116
126
101
105
105
H460
143
269
138
224
155
233
134
264
144
243
153
243
6 MV
BxPC3
163
168
147
142
174
137
147
120
140
137
163
124
photons
M059K
95
102
94
99
97
154
95
97
111
121
86
100
M059J
111
104
131
102
98
119
107
96
110
101
119
87
H1299
111
65
60
20
86
85
62
120
71
72
63
76
13.5
H460
138
145
89
211
147
161
110
159
151
183
122
166
keV/µm
BxPC3
126
176
203
187
167
207
187
169
176
178
147
200
Carbon
M059K
42
37
57
80
47
80
46
85
93
69
70
59
Ions
M059J
56
57
75
62
58
76
80
74
46
81
64
71
H1299
111
65
51
68
86
85
72
102
71
72
63
94
60.5
H460
138
145
153
135
147
161
125
149
151
183
121
160
keV/µm
BxPC3
126
176
127
188
167
207
169
161
176
178
203
154
Carbon
M059K
42
37
45
52
47
80
43
56
93
69
51
68
Ions
M059J
56
57
55
51
58
76
61
55
46
81
57
33

Supplemental Table 17: Number of persistent foci and fraction of foci repaired across the cell lines measured in this
work. Fraction of HR foci repaired are omitted since the peak recruitment occurs far after our early time point.

Radiation type Cell line

6 MV photons

13.5 keV/µm
Carbon Ions

60.5 keV/µm
Carbon Ions

H1299
H460
BxPC3
M059K
M059J
H1299
H460
BxPC3
M059K
M059J
H1299
H460
BxPC3
M059K
M059J

Generic DSB foci
NHEJ foci
HR foci
Number of
Number of
Fraction of
Number of
Fraction of
persistent
persistent foci
Foci Repaired persistent foci Foci Repaired
/ nucleus
foci /
after 24h
/ nucleus
after 24h
nucleus
-1.2 ± 0.7
1.05 ± 0.03
1.7 ± 0.6
0.962 ± 0.015
-3.2 ± 1.0
-1.9 ± 0.2
1.19 ± 0.03
0.7 ± 0.1
0.975 ± 0.006
-1.5 ± 0.3
-1.3 ± 0.8
1.04 ± 0.03
5.0 ± 1.1
0.86 ± 0.03
3.3 ± 0.9
5.7 ± 1.6
0.89 ± 0.03
11.1 ± 2.2
0.75 ± 0.05
-4.2 ± 1.6
17.4 ± 2.4
0.56 ± 0.07
14.0 ± 1.4
0.50 ± 0.10
25.3 ± 2.9
0.9 ± 0.8
0.97 ± 0.02
3.0 ± 1.0
0.76 ± 0.08
-7.0 ± 1.6
9.3 ± 0.7
0.76 ± 0.02
5.6 ± 0.6
0.856 ± 0.017
8.7 ± 0.6
-5.1 ± 0.6
1.18 ± 0.03
1.3 ± 0.2
0.959 ± 0.007
2.0 ± 0.2
3.1 ± 3.4
0.90 ± 0.10
2.4 ± 2.9
0.93 ± 0.09
10.1 ± 1.4
22.8 ± 2.4
0.59 ± 0.05
17.7 ± 1.6
-1.38 ± 0.34
8.9 ± 2.1
-1.4 ± 0.6 1.048 ± 0.019
3.7 ± 1.0
0.91 ± 0.02
-0.4 ± 1.9
1.7 ± 0.3 0.933 ± 0.014
-1.1 ± 0.5
1.04 ± 0.02
-0.8 ± 0.3
1.4 ± 0.8
0.88 ± 0.07
6.3 ± 0.7
0.64 ± 0.05
1.6 ± 0.3
9.5 ± 4.4
0.66 ± 0.17
2.8 ± 2.7
0.93 ± 0.07
6.2 ± 1.6
19.4 ± 2.7
0.54 ± 0.07
25.1 ± 1.7
0.20 ± 0.07
9.1 ± 2.9
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Chapter 4 – An empirical model to predict a cell’s
radiosensitivity to ions on the basis of its radiosensitivity to
photons: PORTAL

*Note: A substantial portion of this chapter is written or based on the following
publication183, which is currently under review in the Medical Physics and for which a
preprint is available on bioRxiv:

David B. Flint, Scott J. Bright, Conor H. McFadden, Teruaki Konishi, Daisuke Ohsawa,
Alisa Kobayashi, Simona F. Shaitelman, Gabriel O. Sawakuchi. “An empirical model to
predict survival curve and relative biological effectiveness after helium and carbon ion
irradiation based solely on the cell survival after photon irradiation”. bioRxiv. doi:
https://doi.org/10.1101/2020.06.19.161836 (2020).

I.

Introduction
Cancer therapy using carbon (C) ion beams has a number of benefits compared to

conventional photon beams, including inherently superior depth-dose distributions 35,184, less
dependence on tumor oxygenation status 185, and increased biological effectiveness 35,184. But,
while much progress has been made towards understanding how the physical properties of
ions, namely their linear energy transfer (LET), influence these differences in cell response
compared to photons, much remains unclear about how the ion response depends on cell
biology and to what extent the physical and biological mechanisms governing radiosensitivity to
ions interact with one another in determining intrinsic ion radiosensitivity.
Towards understanding the physical components of ion radiosensitivity, several models
have been proposed to explain the widely-characterized variations in relative biological
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effectiveness (RBE) for different radiation qualities. Notably, the microdosimetric kinetic model
(MKM) 54,55 explains the increasing RBE values for increasing LET values in terms of how
microdosimetric differences between radiation qualities modulate the probability of inducing
lethal DNA lesions for a given dose, while the local effect model (LEM) 40,52,53 explains the
variations in RBE in terms of how increasing the LETs affect the heterogeneity of the
microscopic dose distribution, and in turn how those higher local doses are more likely to
induce DNA double strand breaks (DSBs). However currently, these models can only
incorporate biological information indirectly from the cells’ photon survival curve parameters,
despite numerous observations that biological factors including tumor histology 70,109, genotype
, cell cycle phase 70,186-188, and DNA damage repair capacity 70,188,189 greatly affect cellular

70,109

radiosensitivity, and as we show in Chapters 2 and 3 with respect to DNA repair capacity, the
premise that these heterogeneities are less relevant to ion therapies radiosensitivity is not
generally valid. It is perhaps, therefore, unsurprising that the LET response of cell
radiosensitivity has been shown to vary greatly between cell lines190.
Furthermore, given the use of these models to predict the RBE in clinical settings 70,
and with the advent of novel combined drug and radiation therapies using chemotherapy
drugs191,192 or with DNA repair inhibitors193-195, it is not obvious how these models might
incorporate differences in radiosensitivity that are induced by the drug treatment, and in turn
how that might affect the cell’s RBE response. This is of particular importance for combination
therapies involving DNA repair inhibitors, since, as we show in Chapter 2, these greatly affect
cellular radiosensitivity, but it is not generally known how this might impact cells’ LET response.
Thus, the extent to which our current clinical ion RBE models can accurately predict the
response of cells with differing genotypes, histologic subtypes, DNA repair capacities, or
subjected to drug treatments is unknown. However, in agreement with Suzuki et al. 122, in this
chapter we will show that independently of how these biological factors might govern a cell’s
inherent (photon) radiosensitivity, the relationship between a cell’s radiosensitivity to ions,
including protons, helium (He-) and C-ions, and its radiosensitivity to photons is linear. Thus, if
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this linear relationship is known for a particular ion LET, a cell’s radiosensitivity to that ion LET,
and thus its RBE, can be predicted based only on a cell’s photon radiosensitivity.
And as we show in this chapter, since these linear trends varying regularly with LET
(with the slope decreasing exponentially and the intercept increasing linear with LET), the linear
trend for any LET of interest can be easily predicted. This premise forms the basis of the model
we present in this chapter, which represents a simple, easily implementable empirical model
that predicts ion radiosensitivity and RBE while accounting for biological variability and the
effects of drugs within its framework due to their modulation of the model’s input: cell
radiosensitivity to photons. In turn, this alleviates the impact of many uncertainties regarding
estimating ion RBE due to how the different biological factors impacting intrinsic cellular
radiosensitivity affect ion radiosensitivity. In the context of our model, regardless of how these
factors combine to influence a cell’s photon radiosensitivity, photon radiosensitivity can be
mapped linearly to ion radiosensitivity for any LET. We shall refer to this model as PORTAL
due its basis on our observations of the Proportionality Of Radiosensitivities That Attenuates
with LET.
Thus, towards personalized radiotherapy, this suggests that if a cell’s photon
radiosensitivity can be predicted, that is sufficient to predict its ion radiosensitivity using
PORTAL, obviating the impractical tasking of training models to predict intrinsic radiosensitivity
directly across the continuous spectrum of radiation qualities that ions present.

II.

Materials and Methods
II.1

Cell Lines

We chose a cell line panel covering 11 human cancer cell lines of different histologic
subtypes, genotypes, and capacity for DNA repair (H460, H1299, BxPC-3, PANC-1, AsPC-1,
PANC10.05, M059K and M059J, HT1080, HT1080-shRAD51IND, HT1080-shDNA-PKcs, MDAMB-231, MDA-MB-231-XBP1-KO and PANC1-XBP1-KO) to quantify cellular survival after
radiation. These cell lines span wide range of radiosensitivities from D10%,photon = 1.37±0.02 Gy
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for the radiosensitive M059J (glioblastoma) cell line, to D10%,photon = 8.56±0.19 Gy for the
radioresistant PANC 10.05 (pancreatic cancer) cell line. The M059J cell line, which is vastly
more radiosensitive than the M059K (glioblastoma) cell line established from the same
tumor128, is deficient in the protein DNA-PKcs, which renders them deficient in DNA double
strand break (DSB) repair via non-homologous end joining (NHEJ) 129. The HT1080shRAD51IND cell line has a drug-inducible deficiency in RAD51 which renders them deficient in
HR. The HT1080-shDNA-PKcs cell line has a deficiency in DNA-PKcs which renders it deficient
in NHEJ. The H460 (lung cancer) cell line has wild type TP53196 in contrast to the other cell
lines which are TP53 mutants. Apart from the MDA-MB-231, MDA-MB-231-XBP1-KO and
PANC1-XBP1-KO cell lines, further details of these cell lines can be found in Chapter 3. The
MDA-MB-231 cell lines are a triple negative breast cancer cell line, and the MDA-MB-231XPB1-KO are a clone of this cell line that were created by CRISPR-Cas9 transient transfection
using a PX359 vector targeting the XPB1 gene in MDA-MB-231. After the transfection, XBP1
deficient clones (MDA-MB-231-XPB1-KO) were selected and verified by Western blot and
Sanger Sequencing. XBP1 is a transcription factor that is recruited to DNA damage response
(DDR) genes following oxidative stress, and is thus suspected to be involved in the DDR197,
thus likely decreasing the DNA repair capacity of the cells. The PANC1-XBP1-KO were
modified in the same manner. HT1080-shRAD51IND and HT1080-shDNA-PKcs cell lines were a
gift from Dr. Asaithamby Aroumougame from the University of Texas Southwestern Medical
Center while the MDA-MB-231-XBP1-KO and PANC1-XBP1-KO cell lines were a gift from Dr.
Dadi Jiang from The University of Texas MD Anderson Cancer Center. All other cell lines used
in this chapter were purchased from the American Type Culture Collection (Manassas, VA,
USA). All cell lines were authenticated using short tandem repeat (STR) DNA profiling at the
MD Anderson Characterized Cell Core Facility (CCLC), and tested negative for mycoplasma
contamination. The cells were cultured in incubators at 37°C and 5% CO2. Further details of the
cell culture conditions for these cells are given in Appendix 1.
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II.2

Irradiations

We exposed the cell lines to clinical x-ray beams and proton beams at The University of
Texas MD Anderson Cancer Center, and He-ions and C-ions at the Heavy-Ion Medical
Accelerator in Chiba (HIMAC) (Chiba, Japan). The x-ray irradiations were performed using a 6
MV beam from a clinical linear accelerator (Truebeam or 2100 series, Varian Medical Systems,
Palo Alto, CA) at a water equivalent depth of 10 cm to simulate a clinical radiation environment.
The proton irradiations were performed using an unmodulated 100 MeV proton beam with
slabs of water equivalent plastic in front of the beam to obtain dose-weighted LETs in water
ranging from 1.2-9.9 keV/µm, which range from the entrance to the end of the proton range.
The LETs under these conditions were calculated by Monte Carlo simulation using a validated
model of the beamline as described in Appendix 2. The He-ion irradiations were performed
using an unmodulated 150 MeV/nucleon He-ion beam, with dose-weighted LETs in water
ranging from 2.2-14.0 keV/µm, and the C-ion irradiations were performed using an
unmodulated 290 MeV/nucleon C-ion beam with dose-weighted LETs in water ranging from
13.5-60.5 keV/µm, respectively. These LETs range from the approximate LETs at the entrance
to the middle of clinically relevant SOBPs and obtained using energy absorbers that are part of
the beamline.136 Appendix 2 contains more details about these irradiation conditions.

II.3

Clonogenic Assays

We performed clonogenic assays to quantify survival for each cell line at each LET they
were irradiated. We seeded the cells 18-24 hours prior to irradiation into 6-well plates or T-12.5
flasks and after irradiation, the cell lines were allowed to form colonies for 7-14 days before
being fixed and stained with pure ethanol containing 0.5% crystal violet. More details about
these methods can be found in Appendix 2. The stained dishes were then air dried and
scanned using a high spatial resolution flatbed scanner (Epson Expression 10000 XL) to
produce images that were analyzed using ImageJ plugins developed to automatically count
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colonies containing more than 50 cells. Details of the image analysis techniques used to score
colonies can be found in Appendix 3.

II.4

Drug Inhibitor Treatments

H460, H1299, PANC-1 and Panc 10.05 cell lines were also treated with the DNA repair
inhibitors NU7441, which inhibits DNA-PKcs (which is essential in NHEJ repair), and AZD6738
which inhibits ATR (which is essential in DNA damage response). H1299 was additionally
treated with B02 which inhibits RAD51, which is essential in homologous recombination (HR)
repair. Prior to irradiation these inhibitors were administered as follows: cells were seeded 24
hours prior to irradiation in 6 well plates, and 8 hours prior to irradiation, media was removed
and replaced with media containing the inhibitor or DMSO vehicle. After 24 hours of incubation
with the inhibitor or vehicle, the media was removed and replaced with fresh media. Cells were
not washed to minimize disturbance to attached cells. The inhibitors used were Ceralasertib
(AZD6738, ATRi, Selleckchem) which was dissolved in DMSO at 10 mM and was used at a
final concentration of 0.1 µM; 8-(4-Dibenzothienyl)-2-(4-morpholinyl)-4H-1-benzopyran-4-one
(NU7441, DNA-PKcsi, Selleckchem) which was dissolved in DMSO at 5 mM and was used at
0.1 or 1 µM final concentrations; and B02 (Cat# S8434, Rad51i, Selleckchem) was dissolved in
DMSO at 10 mM and used at a 5 μM concentration. The final concentration of DMSO was
0.1% in all drug-treated groups and their controls.

II.5

Radiation Response Data

From the measured cell survival curves, we calculated the dose required to achieve
surviving fractions of 5%, 10%, 20%, 37%, and 50%, as well as the survival fraction at 2 Gy to
quantify cell radiosensitivity after photon or ion irradiations and refer to these radiosensitivity
parameters as RPphoton = [D5%,photon, D10%,photon, D20%,photon, D37%,photon, D50%,photon and SF2Gy,photon ]
and RPion = [D5%,ion, D10%,ion, D20%,ion, D37%,ion, D50%,ion and SF2Gy,ion], respectively. All clonogenic
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cell survival data collected in this chapter were done in duplicate or triplicate and repeated at
least two times, except for the cells XBP1-deficient pairs, which were done a single time in
quadruplicate, and the data collected for the cell lines treated with inhibitors, for which only a
single He- or C-ions experiment was performed in duplicate. However, for the cells treated with
inhibitors, because for a given cell line, three cohorts were used (e.g. DNA-PKcsi, ATRi, DMSO
vehicle), the location of the trends derived from this dataset have similar statistical power to
three independent experiments performed with each untreated cell line. Thus, while this
dataset has greater variance than the cell lines not treated with inhibitors, because it contains
so many individual data points, we used it to confirm whether the trends in the drug-treated cell
lines agree with the untreated cell lines.

II.6

Statistical Analyses

Statistical analyses in this chapter were performed in MATLAB 2017 (Mathworks,
Natick, MA) and Graph Pad Prism 7 (Graph Pad, San Diego, CA). Error bars represent the
standard error propagated from the fitted survival curve parameters (α and β), including their
covariance, to the radiosensitivity parameters estimated from them. The confidence intervals
represent the uncertainty from our fit parameters, including their covariance, propagated into
our predictive function, calculating the 95% confidence intervals as ±1.96 times the standard
error of the prediction.

III.

Results
III.1

Ion radiosensitivity parameters correlate with photon radiosensitivity

parameters for protons, He-ions and C-ions
Suzuki et al. 122 noted that D10%,ion is linearly correlated with D10%,photon for C-ions with
LET values of 13.3 and 77 keV/μm. Our survival data show that this linear relation holds not
only for C-ions, but also for protons and He-ions over the LETd range of 1.2−60.5 keV/μm, and
that in addition, not only does this relationship hold for D10%, but also for a number of other
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parameters that characterize radiosensitivity: D5%, D20%, D37%, D50% and SF2Gy (Figure 23,
Supplemental Results 2), with R2 values ranging from 0.722-0.999 (Supplemental Results 2).
These results imply the linear correlation between ion and photon radiosensitivity is a universal
phenomenon that holds across ion types and LETs.

III.2

The linear relationship between ion and photon radiosensitivity varies

regularly with LET
Although Suzuki et al. 122 previously observed a linear relationship between D10% to ions
and photons, they did not comment on how the slopes and intercepts of these correlations
depend on LET. It is apparent from our data that the slopes decrease with increasing LET and
the intercepts seemingly increase with LET (Figure 23A-C, D-F, G-I).
To confirm the extent to which this holds for all LET values, we analyzed the survival
data in the Particle Irradiation Data Ensemble (PIDE) version 3.2 database2 for cells exposed to
protons, He- and C-ions. We binned these data into LET bins of width 1-10 keV/μm, over LET
values ranging from 1.6-26 keV/μm for protons, 1.8-125 keV/μm for He-ions and 12.16-225
keV/μm for C-ions (Supplemental Method 1) and plotted the RPion versus RPphoton values for
each LET bin, fitting the data with a linear function from which we extracted the slopes and
intercepts. We noted that the slopes and intercepts of RPion vs. RPphoton vary regularly with LET
up to at least 26 keV/μm for protons, 125 keV/μm for He-ions and 225 keV/μm for C-ions
(Figure 24, Supplemental Results 3). A one phase exponential decay (R2 = 0.8981 for D10%,C-ion)
and a linear function (R2 = 0.4578 for D10%,C-ion) provide good fits for the slope and intercept
versus LET, respectively (Supplemental Results 3 contains R2 values across all conditions).
These functions are empirical and do not represent any intended theoretical description.
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Figure 23: (A-I) D10%,ion vs. D10%,photon, (G-R) D37%,ion vs. D37%,photon, and (M-AA) D50%,ion vs. D50%,photon for protons, He- and C-ions in order of increasing LET from 1.2 to
60.5 keV/µm. Black circles represent survival measurements for individual cell lines. Lines represent linear fits to the data of cell lines exposed to radiation alone. The
results for D5%, D20% and SF2Gy are given in Supplemental Results 2. 1: M059J, 2: H460, 3: M059K, 4: AsPC-1, 5: BxPC-3, 6: PANC-1, 7: H1299, 8: Panc 10.05, 9:
HT1080, 10: HT1080-shRAD51IND, 11: HT1080-shDNA-PKcs
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With these functions governing how the slope and intercept of the correlation between
RPion and RPphoton depend on LET, we can create a general formalism of how RPion relates to
RPphoton in terms 5 free parameters, c, d, f, g and h that predict RPion from RPphoton for a given
LET:

𝑹𝑹𝑹𝑹𝒊𝒊𝒊𝒊𝒊𝒊 = �(𝒄𝒄 − 𝒅𝒅) ∙ 𝒆𝒆−𝒇𝒇 ∙𝑳𝑳𝑳𝑳𝑳𝑳 + 𝒅𝒅� ∙ 𝑹𝑹𝑹𝑹𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑 + 𝒈𝒈 ∙ 𝑳𝑳𝑳𝑳𝑳𝑳 + 𝒉𝒉

(1)

In this formalism, at a given LET value, this function scales a cell’s radiosensitivity to
photons linearly to yield its radiosensitivity to ions, allowing the slope (governed by c,d and f)
and intercept (governed by g and h) of this linear scaling to decrease exponentially and
increase linearly, respectively, with LET. Thus, we named this formalism PORTAL, since it is
based on observations of the Proportionality Of Radiosensitivities That Attenuates with LET.
With this form, since PORTAL predicts a cells’ ion radiosensitivity for any given LET, all
of the data in the PIDE database could be used to train it without the need for binning. This is
because after generalizing PORTAL, there is no need for large cohorts of data at any particular
LET value to determine the linear relationship between RPion and RPphoton at that LET; rather
this information is encoded by the values of the free parameters c, d, f, g and h. Thus, to
determine the values of these free parameters, we fit our model to the response of all the cell
lines in the PIDE database for LET values up to 37.8 keV/μm for protons (R2=0.8739 for D10%),
201 keV/μm for He-ions (R2=0.7344 for D10%) and 225 keV/μm for C-ions (R2=0.8461 for D10%)
using an unweighted least-squares minimization technique in MATLAB. The values of these
parameters are given in Supplemental Results 4.
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Figure 24: We used the PIDE database2 to determine the trends in the slope (A-I) and intercept (J-R) of the linear functions that relate photon and ion radiosenstivity
(D10%, D37% and D50% shown here) as a function of ion LET (ranging from 1.6-225 keV/µm) for protons, He-ions and C-ions. The results for D5%, D20% and SF2Gy are given
in Supplemental Results 3.
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III.3

Predicting of the linear relationship between ion and photon

radiosensitivity at a given LET
After training PORTAL on the PIDE database, we used it to predict the relationship
between ion and photon radiosensitivity for 1.2, 2.6 and 9.9 keV/μm protons; 2.2, 7.0 and 14.0
keV/μm He-ions; and 13.5, 27.9 keV/μm and 60.5 keV/μm for C-ions, and compared these
predictions to the measured response of our cell line panel (Figure 25). These LET values and
cell lines were not used to determine the parameters of our model and therefore served as a
validation cohort. Our measured data agreed within a root mean square percentage error
(RMSPE) of 13.7%, 11.9%, and 7.1% for 1.2, 2.6 and 9.9 keV/μm protons, respectively; 9.6%,
5.1%, and 8.9% for 2.2, 7.0 and 14.0 keV/μm He-ions, respectively; and 7.3%, 6.0% and 21.3%
for 13.5, 27.9 and 60.5 keV/μm (C-ions) for D10%, respectively. The RMSPE for D5%, D20%, D37%,
D50% and SF2Gy are shown in in Supplemental Results 5. Across all conditions, the RMSPEs in
D5%, D10%, D20%, D37%, D50% and SF2Gy were 11.2%, 10.6%, 11.8%, 15.7%, 19.6%, and 25.7%,
respectively.
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Figure 25: Predicted trends (with 95% confidence interval) and measured data for the linear relation between D10% (A-I), D37% (J-R) and D50% (S-AA) for ions vs. photons.
Numbers indicate the cell line and are given in the caption of Figure 23. Results for D5%, D20% and SF2Gy are given in Supplemental Results 5.
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III.4

Prediction of ion RBE

RBE is defined as the ratio of the photon dose to the ion dose required to achieve the
same biological endpoint:

𝑹𝑹𝑹𝑹𝑹𝑹𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆 =

𝑹𝑹𝑹𝑹𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑,𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆

(2)

𝑹𝑹𝑹𝑹𝒊𝒊𝒊𝒊𝒊𝒊,𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆

Thus, in the context of our model, we can substitute our expression for RPion into the
expression for RBE to yield the predictive function:

𝑹𝑹𝑹𝑹𝑹𝑹𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆 = ��𝒄𝒄𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆 − 𝒅𝒅𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆 � ∙ 𝒆𝒆

−𝒇𝒇𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆 ∙𝑳𝑳𝑳𝑳𝑳𝑳

+ 𝒅𝒅𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆 +

𝒈𝒈𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆 ∙𝑳𝑳𝑳𝑳𝑳𝑳+𝒉𝒉𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆
𝑹𝑹𝑹𝑹𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑𝒑,𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆𝒆

−𝟏𝟏

� ,

(3)

which gives the RBE in terms of our model parameters and RPphoton. We then used this function
to predict how RBE depends on RPphoton for all of the LETs we measured, which can be seen in
Figure 26 (see Supplemental Results 6 for plots of RBED5% and RBED20%) Our measured
RBED10% values agreed with this function’s predictions within a RMSPE of 11.6%, 10.3% and
8.2% for 1.2, 2.6 and 9.9 keV/μm protons; 5.0%, 5.3%, 8.1% for 2.2, 7.0, 14.0 and 13.5 keV/μm
He-ions; and 6.8%, 5.7% and 17.1% for 13.5, 27.9 and 60.5 keV/μm, respectively (see
Supplemental Results 6 for other RMSPE values). The RMSPE values across all conditions for
the parameters RBED5%, RBED10%, RBED20%, RBED37%, RBED50% were 9.6%, 9.0%, 10.5%,
15.1%, 19.8%.
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Figure 26: Measured RBE values of for individual cell lines exposed to protons, helium ions and carbon ions (black points) and the trends predicted by our model in terms
of the cell line’s D10%,photon (A-I), D37%,photon (J-R) and D50%,photon (S-A) with 95% confidence intervals (shaded gray area)). Numbers indicate the cell line and are given in the
caption of Figure 23. These cell lines and LET values were not used to determine the linear functions and served as a validation of the model. Plots for RBED5% and
RBED20% are in given in Supplemental Results 6.
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III.5

Prediction of ion survival curves

Using the survival curve for photons (the αphoton and βphoton values from the linear
quadratic model), it is straightforward to calculate all the elements of RPphoton. All the elements
of RPion can then easily be predicted for a given LET using our model. Thus, as PORTAL
predicts 6 points on the ion
survival curve (D5%,ion, D10%,ion,
D20%,ion, D37%,ion, D50%,ion and
SF2Gy,ion), its predictions can be fit
to the linear quadratic model (or
in principle other models) to
predict the ion survival curve
(Figure 28, Supplemental Figure
10). To quantify the agreement
between our predicted and
measured survival curves, we
integrated the curves to calculate
the mean inactivation dose, D̅
(Figure 27). Our model generally
predicted the ion survival curves
quite well, predicting D̅ within a
RMSPE of 13.5%, 14.8% and
10.3% for 1.2, 2.6 and 9.9
keV/µm protons; 13.6%, 6.7%,
and 11.8% for 2.2, 7.0, 14.0

Figure 27: Predicted versus measured mean inactivation doses, D̅, of
cells cells exposed to 9.9 keV/µm protons, 14.0 keV/µm He-ions, 13.5
keV/µm C-ions and 60.5 keV/µm C-ions, the survival curves for which
are shown in Figure 28. The numbers indicate the cell line and are given
in the caption of Figure 23.

keV/μm He-ions; and 12.6%, 10.1% and 25.1% for 13.5, 27.9 and 60.5 keV/μm C-ions,
respectively.
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Figure 28: Predicted (orange, with 95% confidence interval) and measured (black, with 95% confidence interval) survival curve for M059K and M059J cells (A-I), H460
and H1299 cells (J-R), and BxPC-3 cells (S-AA) exposed to protons He- and C-ions. Shaded areas are 95% confidence intervals. Predicted survival curves for other cell
lines can be found in Figure 30, Figure 31 and in Supplemental Results 7.
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III.6

Prediction of cell lines treated with ion and DNA repair inhibitors

We compared the response of the cells treated with DNA repair inhibors to the trends
we observed in the untreated cells. Figure 29 shows the response (D10%, D37% and D50%) of the
drug-treated cells superimposed upon the ion versus photon radiosensitivity trends in our data
that were not treated with inhibitors (which are shown in Figure 23). These data demonstrate
that the trends we observed in the DNA-repair inhibited cells agree with trends we observed in
cells not treated with DNA repair inhibitors (trends for other parameters are shown in
Supplemental Results 8). We do not report R2 for these trends since many of these drug
treatments corresponds to a single independent experiment, and so much of the variance in
these data can be attributed to experimental uncertainy. Nevertheless, the agreement of these
trends indicates that within our formalism, it may be possible to predict the response of cell
lines treated with DNA repair inhibitors using our model, as the drug-inhibited data follow the
same linear trend at a given LET as the uninhibited data.
When comparing the responses of the predicted survival curves, we noted that there
was good agreement between the predicted survival curves for protons (Figure 30 and Figure
31) where each measured dataset corresponded to the average over at least four independent
experiments. Accordingly the RMSPE in D̅ (Figure 32) were 16.9%, for 9.9 keV/μm protons,
and 37.4% across all He- and C-ions conditions where there was only one experimental
replicate. Given that the RMSPEs in the predicted D̅ values for the uninhibited cells were fairly
comparable between LETs, these results support the notion that much of the variability in our
drug-treated at higher LETs can likely be attributed to additional experimental uncertainty in the
measured survival curves due to them corresponding to a only a single experimental replicate.
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Figure 29: Measured ion versus photon radiosensitivity for cells treated with DNA repair inhibitors (red)
superimposed on the 95% prediction interval derived from the data not treated with drugs (gray) for the parameters
D10% (A-D), D37% (E-H) and D50% (I-L), for cells exposed to 9.9 keV/µm protons, 14.0 keV/µm He-ions, 13.5 keV/µm
C-ions and 60.5 keV/µm C-ions. Results for D5%, D20% and SF2Gy are given in Supplemental Results 8. Numbers
indicate the cell line and drug combination: 12: H460+ATRi (0.1 μM), 13: H460+DNA-PKcsi (0.1 μM), 14:
H460+DMSO, 15: Panc 10.05+ATRi (0.1 μM), 16: Panc10.05+DNA-PKcsi (0.1 μM), 17: PANC-1+DNA-PKcsi (0.1
μM), 18: PANC-1+DMSO, 19: PANC-1+ATRi (0.1 μM), 20: H1299+DNA-PKcsi (0.1 μM), 21: Panc 10.05+DMSO,
22: H1299+ATRi (0.1 μM), 23: H1299+DMSO, 24: H1299+Rad51i, and 25:H1299+DNA-PKcsi (1 μM)
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Figure 30: Predicted (orange, with 95% confidence interval) and measured (black, with 95% confidence interval)
survival curve for PANC1 and PANC1005 cells exposed to 9.9 keV/µm protons and 13.5 and 60.5 keV/μm C-ions
The cells were treated with the DNA repair inhibitors to inhibit DNA-PKcs (M-R) and ATR (S-X), with just the DMSO
vehicle (G-L), and without any treatment (A-F).
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Figure 31: Predicted (orange, with 95% confidence interval) and measured (black, with 95% confidence interval) survival curve for H460 and H1299 cells exposed to
9.9 keV/µm protons, 14.0 keV/μm He-ions and 13.5 and 60.5 keV/μm C-ions. The cells were treated with the DNA repair inhibitors to inhibit DNA-PKcs (H-N), ATR (OT), and RAD51 (U), with just the DMSO vehicle (A-G). Predicted survival curves without any treatment are given in Figure 28.
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Figure 32: Predicted versus measured mean inactivation doses, D̅, of cells exposed to (A) 9.9 keV/µm protons, (B)
14.0 keV/µm He-ions, (C) 13.5 keV/µm C-ions and (D) 60.5 keV/µm C-ions, and treated with DNA repair inhibitors.
The predicted survival curves for these cells are shown in are shown in Figure 30 and Figure 31. The numbers
indicate the cell line and are given in the caption of Figure 28.

III.7

Prediction of cell lines with DNA repair deficiencies

Among the cohort of cells we investigated were the M059J cells which are naturally
deficient in NHEJ repair. Despite this gene deficiency which greatly modulates their photon
radiosensitivity, their response to protons, He-ions and C-ions, were consistent with those of
the other cell liens we investigated, (Figure 23), and we were able to predict their survival
curves with PORTAL (Figure 28A-I). These results imply that large naturally-occurring
differences in DNA repair capacity do not hamper the effectiveness of our model.
But additionally, as part of the our cohort of cells used to characterize the response to
protons were the HT1080 cells which had been genetically modified to be deficient in either HR
repair (HT1080-shRAD51IND) or NHEJ repair (HT1080-shDNA-PKcs). In spite of these
modifications, their response fell in line with the other cell lines (Figure 23) and we were also
able to predict their survival curves (Figure 33), implying that even engineered deficiencies in
DNA repair capacity do not greatly affect our model’s predictions. To verify this for higher LETs,
we predicted the reponse of the cells that had been genetically modified to be deficient in the
DNA repair protein XBP1 (PANC1-XBP1-KO and MDA-MB-231-XBP1-KO) which were
exposed to C-ions (Figure 33). These predictions were generally good, with D̅ being predicted
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within an RMSPE of 10.4% across all cells with genetically engineered deficiencies in DNA
repair capacity (Figure 33M-R). These results suggest that not only are our model’s predictions
not grealy affected by gene deficiencies that greatly impact a cell’s radiosensitvitiy, but that if
these deficiencies can be induced in some way, our model is capable of accounting for this
modulation within its framework.

Figure 33: Predicted (orange, with 95% confidence interval) and measured (black, with 95% confidence interval)
survival curves for cells with induced genetic deficiencies in DNA repair proteins – HT1080-shDNA-PKcs (A-C),
PANC1-XBP1-KO(D-F), HT1080-shRAD51IND (G-I), MDA-MB-231-XBP1-KO (J-H) – exposed to protons and C-ions.
(M-R) Predicted versus measured mean inactivation doses, D̅, of these survival curves. Numbers indicate the cell
lines: 6: PANC-1, 9: HT1080, 10: HT1080-shRAD51IND, 11: HT1080-shDNA-PKcs, 26: PANC1-XBP1-KO, 27: MDAMB-231, 28: MDA-MB-231-XBP1-KO
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III.8

Comparison against other ion RBE models

While we do not have the infrastructure to perform calculations with the commonly used
clinical RBE models like LEM or MKM to directly compare the accuracy of PORTAL against
them, a recent study198 parameterized the accuracy of LEM and MKM in predicting the survival
curve parameter α for a number of cell lines in terms of χ2:
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where N was the number of experimental data points for a given cell line across the whole
PIDE database. Their data showed that depending on which model was used, LEM (I, II, III, or
IV) or MKM, χ2 values ranged from 0.201-1.887 for HSG cells, between 0.167-0.344 for V79
cells and between 0.047-0.048 for CHO-K1 cells exposed to C-ions of varying LETs198 (Table
6).
Since our model predicts α as well, we can calculate this same statistic across our data
to compare them. However, we do not possess enough LET values for a given cell line to
accurately calculate the χ2 values on an individual cell line basis, but we can instead calculate
them across our whole cell line panel (untreated with drugs) and across all LETs for carbon
ions, resulting in a χ2 value of 0.251 (n=24). This value is comparable to the values seen by
Monini et al. 198 with LEM or MKM.
However, as these analyses are not performed on the same dataset or cell liens, it is
difficult to assess the relative accuracy of the different models. Thus, to better assess the
accuracy of our model compared to LEM and MKM, we retrained PORTAL on the data in the
PIDE database, including our measured data (not including cells treated with DNA repair
inhibitors), and excluding the data for V79, HSG or respectively CHO-K1 cells. This, in turn,
would allow us to predict the response of these cell lines and assess the relative accuracy of
PORTAL compared to LEM and MKM for the same dataset that Monini et al. 198 used in their
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assessment. In retraining our model for this purpose, we included data across all LETs since
the LET response of these cells in the PIDE database were measured up to ~500 keV/µm, and
then predicted the αion values for the V79, HSG and CHO-K1 cells using PORTAL, calculating
the χ2 statistic to quantify the accuracy of the predictions for each cell line. Since these
analyses correspond to the same dataset, we can compare the χ2 values directly to assess the
relative accuracy the different models. In general, our model predicted the response of V79
cells comparably to LEM and MKM (although generally slightly better than LEM) (χ2 = 0.173),
the response of HSG cells considerably better than LEM and MKM (χ2 = 0.061), and the
response of the CHO-K1 cells comparably (although slightly worse) to LEM and MKM (χ2 =
0.057) (Table 6).
Table 6: χ2 values compiled by Monini et al. 198 between the predicted (using the LEM and MKM models) and
measured αion values for the V79, HSG and CHO-K1 cells exposed to carbon ions in the PIDE database alongside
the χ2 for the same datasets calculated using our PORTAL

Model
PORTAL
LEM I
LEM II
LEM III
LEM IV
MKM

Cell line

V79
0.173
0.344
0.287
0.176
/
0.167

χ2 across all C-ion data

HSG

CHO-K1

0.061
1.887
1.060
0.794
0.201
0.209

0.057
0.048
0.038
0.045
/
0.047

However, it is worth noting that an additional strength of our model is that it predicts the
biological endpoints, such as RBE, directly, and is not completely reliant on accurately
predicting αion to do so. This is important because the uncertainty in estimating αion in survival
experiments is relatively large, but because our model predicts αion and βion simultaneously
using the LQM, our model can leverage the fact that the covariances of αion and βion tend to be
negative, which in turn means that our predictions have lesser variance than relying solely on
αion. Thus, for example, when calculating the χ2 values across all RBED10% values for C-ions in
this work (cells not treated with drugs), we find χ2 = 0.012 which is considerably less than the χ2
values we calculated for αion (χ2 = 0.251) (the χ2 values for the other RBE parameters are given
in Table 7). Likewise, when calculating the χ2 values in the RBED10% values for the V79, HSG
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and CHO-K1 cells in the PIDE database, we found χ2 values of 0.127, 0.086, and 0.023,
respectively, which are all considerably smaller than the values reported for αion reported by
Monini et al.198. Thus, in the case of the MKM model, where β is fixed, we expect that our
model may predict RBE more accurately, since estimating the RBE with MKM relies mainly on
how the quantity αion varies with LET. And, since the MKM model generally outperformed the
LEM I-III models and had comparable performance to LEM IV in Monini et al.’s analyses198, we
believe our model may also outperform the LEM. However, a direct comparison of these
models is ideally needed to confirm this.
Table 7: χ2 values between predicted and measured RBE values and αion across all cell lines in this chapter (not
treated with drugs) exposed to C-ions with LETs of 13.5 keV/µm, 27.9 keV/µm and 60.5 keV/µm.
Parameter

RBED5%

RBED10%

Value

0.013

0.012

III.9

χ2 across all C-ion data
RBED20%
RBED37%
0.016

0.025

RBED50%

αion

0.040

0.251

Predictions at higher LETs

Although we did not take measurements to validate our model’s predictions at higher
LETs, it is encouraging to note that for higher LETs, our model predicts the expected overkill
shape, where RBE achieves some maximal value and then begins to decrease (Figure 34).
Interestingly, our model also predicts a number of trends that are consistent with observations
in the literature: larger RBE values for biological endpoints that correspond to higher survival
levels (e.g. RBED50% > RBED37% > RBED10%), smaller RBE values for very radiosensitive
cells32,40,90,199 (e.g. M059J cells) compared to radioresistant cells187,200,201 (e.g. H1299 cells), and
comparable RBE values across cell lines at low LETs 202.

Figure 34: RBE of the H1299 cells (black), Panc1 cells (red), BxPC3 cells (orange), M059K cells (green), H460 cells
(blue) and M059J cells (magenta) predicted using PORTAL as function of C-ion LET for (A) RBED10% (B) RBED37%
(C) RBED50%
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To show how the predicted shape of the RBE trends agree with experimental data, we
compared the response of the V79 cells and HSG cells exposed to C-ions, for the experiment
by Furusawa et al 20001 (as reported in the PIDE database), to the predictions made with
PORTAL when the V79 or HSG cells were omitted from the training data, but data were
included up to 502 keV/µm as described in CH4§III.8 (Figure 35). Despite the considerable
amount of noise in these data, and the fact that we cannot confirm whether the trends we
modeled have the same functional form at LETs higher than 225 keV/µm, we predicted
RBED10% within a RMSPE of 16.8% and 18.8% for HSG and V79 cells, respectively and
RBED50% within a RMSPE of 20.7% and 23.3% for HSG and V79 cells, respectively.

Figure 35: Measured RBED10% (A) and RBED50% (B) response for V79 cells (red points) and HSG cells (blue points)
exposed to C-ions, reported in the PIDE database for the experiment by Furusawa et al 20001.

However, the predictions for RBED10% are systematically low in the higher RBE regions
(Figure 35A) and the predicted distributions too broad for RBED50% (Figure 35B), which may
indicate that the exponential and linear functions used to model the LET response of the linear
correlation’s slope and intercept may be improved upon. However, since these experimental
data (which were excluded in training towards these analyses) represent a considerable portion
of the training data set at higher LETs, it is unclear to what extent any discrepancies between
PORTAL’s predictions and the experimental measurements reflect limitations in the model’s
functional form, limitations in the training data, or both.
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IV.

Discussion
Ion LET is understood to modulate radiosensitivity through differing patterns of energy

deposition: higher LET radiations are more densely ionizing, which results in an increased
DNA-double strand break (DSB) yield and clustered DSB yield per unit dose 31 and,
consequently, increased RBEs. But the LET effect also depends on ion species. For the same
LET, different ions will have differing DNA damage yields due to differing track ionization
densities, e.g., a He-ion will have a higher DSB and clustered DSB yield compared to a C-ion
of the same LET due to its much denser track 31. This generally leads to higher RBE values at
the same LET for an ion of lower charge 31. One approach to reconcile the response of different
ions is to use an ion-independent substitute for beam quality such as the Q factor proposed by
Luhr et al 203. However, in creating our model, as there were sufficient data in the PIDE
database to model each ion’s LET response independently, we decided to simply use doseweighted LET to parameterize the beam quality, fitting the model parameters for each ion
separately to account for the effects of different ions.
The strong linear correlations we observed between ion and photon radiosensitivity
suggest that a simple proportionality relationship governs an ion’s radiosensitivity for a given
dose-weighted LET. This proportionality holds across a wide range of biological differences
between the cell lines in our panel (and training data) that are known to modulate
radiosensitivity—particularly with respect to histological type and genotype 70,109, DNA repair
capacity 70,188,189, anatomical site, tumorigenicity, species of origin–in addition to the
pharmacologic inhibition of a number of DNA repair proteins. This suggests that regardless of
whatever biological factors govern a particular cell’s intrinsic radiosensitivity, the physical
component of that cell’s radiosensitivity to ions (that is dictated by the beam quality) is largely
independent of these biological factors, since the same simple proportionality constant scales
all of these biological perturbations for a given dose-weighted LET.
This proportionality can be understood when we consider how the induction of lethal
DNA lesions relates to, for example, the quantity D10%. Under the framework of the Curtis
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Lethal-Potentially Lethal (LPL) model 204, a given dose of radiation will induce a number of DNA
lesions, some of which are lethal and result in cell death, and some of which are only
potentially lethal if not repaired. But D10% occurs well beyond the repair shoulder (where the
repair of potentially lethal lesions is most relevant), and so cell death in the vicinity of D10% is
dominated by the induction of irreparable, lethal lesions. Consequently, D10% can be
understood as the dose resulting in a 90% probability of inducing at least one lethal lesion.
Because the number of lesions induced by a given radiation dose follows a Poisson
distribution54, D10% occurs when the number of lethal lesions per cell, η, has an expectation
value of ~2.3. But if we assume, as in the LPL model, that in the vicinity D10% the expected
number of lethal lesions induced is proportional to dose 204, then D10%,ion, and D10%,photon are both
proportional to the same quantity, η≈2.3. This is because regardless of the values of the D10%
for either radiation quality, if those doses did not result in the same expected number of lethal
lesions per cell, they would not achieve the same biological endpoint. Thus, since D10%,ion, and
D10%,photon are proportional to the same quantity, η≈2.3, they must be proportional to one
another. Similar arguments can be made for the other radiosensitivity parameters examined.
As for how this proportionality varies with LET, it is helpful to consider the fact that the
linear relationship between ion and photon radiosensitivity represents an isoeffect line, where
radiations of two different qualities produce the same biological endpoint. In our case, this
endpoint, e.g. 10% survival, is proportional to the number of lethal lesions induced. Since the
number of DSBs per unit dose increases with ion LET over the range of LET values we
investigated 31, ions with higher LET values will produce more DSBs, and thus more lethal DNA
lesions per unit dose. Accordingly, for higher LETs, this isoeffect line must be scaled down
along the ion axis to account for the fact that less ion dose is required to induce the same
number of lethal lesions, and accordingly, we see that as the LET is increased, the slope of
RPion versus RPphoton decreases.
The trend of increasing positive intercepts of RPion versus RPphoton with LET can best be
understood when considering the limit where, for instance, D10%,photon approaches zero. In this
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limit, cells are extremely radiosensitive to the approximately homogenous radiation doses
deposited by photons. But to deliver such small doses with ions requires a fluence so low that
many nuclei will not be hit by ions. Consequently, the cells whose nuclei are indeed hit will
receive a nuclear dose much larger than D10%,photon and almost certainly die, whereas the cells
that are not hit will receive no dose, and, disregarding any bystander effects, survive.
Therefore, D10%,ion in this limit is simply the dose that results in 10% of nuclei receiving at least
one hit. This number must be positive because it is a physical dose and must increase with
LET, because as the LET is increased a greater dose is required to achieve the same fluence.
For very low LET values, the trends in our data suggest the intercepts of the RPion
versus RPphoton tend towards small, possibly null values, although their uncertainties are too
large to assert exactly how they trend with great confidence. Nevertheless, for a null intercept,
our formalism suggests that the RBE trend would tend to a value of (slope of RPion versus
RPphoton )-1. This prediction, that at very low LET values, RBE becomes increasingly
independent of radiosensitivity and tends to a constant value, is in line with the observation by
Britten and Murray 202 that RBE is constant for low LET values, even among cells with different
DNA repair proficiencies.
But in terms of the general RBE trends our model predicts, we see a non-linear
relationship between ion RBE and photon radiosensitivity, which follows mathematically from
the linear relationship between radiosensitivity to ions and photons. This relationship predicts
higher RBE values for radioresistant cells, lower RBE values for radiosensitive cells, and subunity RBE values for extremely radiosensitive cells (Figure 26). These predictions are
consistent with observations of near (and sometimes sub-) unity RBE for radiosensitive cells
deficient in DSB repair 32,40,90,199 and comparatively large RBE values for radioresistant cells
.

187,200,201

This nonlinear relationship also predicts RBE values much less than one in the limit
where PRphoton approaches zero. This unintuitive result follows from the fact that for very
radiosensitive cells, the dose required to achieve, for example, 10% survival is substantially

121

higher for ions than for photons. This is because in this limit, only very small photon doses,
which are approximately homogenous, are required to achieve 10% survival, whereas for ions,
a dose large enough to result in at least 90% of the cells being hit at least once is still required,
and thus the RBE values are significantly smaller than one. But in the extremely radiosensitive
limit, in which the homogeneity of photon doses breaks down, D10% is achieved when the
secondary electron fluence produced by the photon beam is equal to the ion fluence required to
achieve 90% hits. The RBE in this case would tend to the ratio of the LET values of the photon
beam’s secondary electron spectrum to the ion’s, which typically has a value much less than
one since the ion’s LETs tend to be much higher.
However, for very low LET protons, the photon source may become relevant, as a very
low energy photon source may create a secondary electron spectrum whose LETs can be
higher than very low LET protons. Given that the RBE values for orthovoltage x-rays relative to
megavoltage x-rays tend to be on the order of 0.8-0.9205, the choice of photons source in the
context of our model is likely important when trying to predict the response of very low LET
protons. This may, in part, explain the lesser accuracy we observed when predicting cell
response to lower LET protons compared to higher LET protons (RMSPEs in D10% of of 13.7%,
11.9%, and 7.1% for 1.2, 2.6 and 9.9 keV/μm protons, respectively).
The near unity of RBE values at low LET values also implies that any small LET effect
at low LET values is dominated by the biological factors governing a cell’s inherent
radiosensitivity. But when the LET is increased, the RBE gains a noticeable dependence on
photon radiosensitivity (Figure 26), which suggests that for higher LET ions, both the biological
factors that govern intrinsic (photon) radiosensitivity and the physical factors that modulate it for
ions contribute to a cell’s radiosensitivity. Thus, we posit that in the absence of changes in
other physical parameters affecting radiosensitivity such as oxic status, the relationship
between the biological and physical factors that govern a cell’s radiosensitivity to ions might
best be understood by a two-step approach. First, biological factors such as genotype or DNA
repair capacity determine a cell’s intrinsic radiosensitivity to low-LET radiation such as photons.
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Second, a linear relationship scales the cell’s ion sensitivity proportionally to its photon
radiosensitivity. This linear scaling, being applied equally to all cell lines, must be biologyindependent, and thus represents a purely physical relationship between photon and ion
radiosensitivity.
Our work therefore suggests a nuanced relationship between the biological factors
governing a cell’s intrinsic radiosensitivity and the physical factors governing the LET effect in
determining a cell’s ion radiosensitivity: biological factors determine a cell’s intrinsic
radiosensitivity; physical factors determine generally how cell radiosensitivity varies with LET;
but biological factors, in determining a particular cell’s intrinsic radiosensitivity, dictate how that
cell’s radiosensitivity will vary with ion LET. Thus, in the context of personalized radiotherapy, if
these biological factors can be accounted for to predict a cell’s photon radiosensitivity, it should
be possible to predict the cell’s ion radiosensitivity based solely on their linear proportionality
using our model.
A great strength of our model is that, in addition to predicting the ion survival curve
parameters from which any number of biological endpoints might be calculated (e.g. α/β, SFXGy,
DX%, D̅, etc), our model can also predict many of these endpoints directly since the linear
correlations upon which its based hold across a wide range of endpoints. Although it is
technically feasible to predict survival at a given dose with LEM 40,52,53 the computations are not
straightforward and are too computationally expensive for a clinical setting 206,207. In the case of
the MKM model, by contrast, βion is constant 54,55, which differs from some experimental
observations2,68,69, and thus only αion can be predicted. Meanwhile, the simplicity of our model
allows for the survival curve parameters, any number of biological endpoints, and the whole ion
survival curves to be predicted in a single spreadsheet.
Further, the LEM and MKM models are limited in that they require sophisticated Monte
Carlo calculations or physical measurements to compute microdosimetric quantities such as
the saturation corrected dose-mean specific energy of the beam (in the case of MKM) 54,55 or
the local dose distribution within the cell nucleus (in the case of LEM). By contrast, our model
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requires only the photon survival curve (also required for LEM and MKM) and dose-weighted
LET, which is much easier to compute than the physical quantities required by the LEM and
MKM models, but also very importantly can be physically measured using a tissue-equivalent
proportional counter208.
But that our model relies only on the dose-weighted LET to parameterize the beam
quality is particularly advantageous in the case of C-ion beams, where nuclear fragmentation
creates heavily mixed fields at any appreciable depth, and thus the definition of LET or any
other parameter that quantifies the radiation quality becomes somewhat arbitrary. But since the
data in the PIDE database contains both monoenergetic beams and mixed fields but reports
the dose-weighted LET values, it seems that at least in the context of our model, the doseweighted LET is sufficient to characterize the beam quality.
Unique to our model is that it can predict the response of cell lines irradiated with ions in
combination with DNA repair inhibitors including DNA-PKcs, ATR and Rad51 inhibitors. This is
an important aspect of our model because of ongoing clinical trials involving DNA-repair
inhibitors combined with radiation [DNA-PKcs (e.g., NCT02516813) 193, ATM (e.g.,
NCT03423628) 194, ATR (e.g., NCT02223923, NCT04052555, NCT02567422, and
NCT03641547) 195, PARP (e.g., NCT02229656, NCT03212742, NCT03109080, and
NCT01589419)]. Because our model incorporates the biological factors governing cells’
intrinsic radiation response through their radiosensitivity to photons, and that our model’s
mapping from photon to ion radiosensitivity seems to account for these perturbations, we
hypothesize that it might also predict the response of cells exposed in combination with other
DNA repair inhibitors or even chemotherapeutic drugs. Our model may also be able to predict
the response of hypoxic cells, however, since hypoxia changes the relationship between
radiation dose and cell death to a different extent for x-rays and ions 185, it may be that the
trends for hypoxic cells must be modeled separately from normoxic cells. But in all these areas,
further investigation is needed to confirm the applicability of our model.
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A significant limitation of our model is that it requires photon survival data as its input.
While this does indirectly incorporate biological factors governing a cell’s inherent
radiosensitivity into the model’s predictions, in a clinical setting, this type of survival data is
rarely available. But at the same time, this limitation is faced when using LEM or MKM, and
given that the linear relationship between RPion and RPphoton is observed in cell lines of various
histologic subtypes, anatomical sites, DNA repair capacities, and genotypes, the universality of
this phenomenon implies that this is likely the only input we need to characterize a cell line’s
biological response.
An additional limitation to this work is that although our model was trained over a large
range of LET values (up to 201 and 225 keV/µm for He- and C-ions, respectively), the LET
range over which we validated our model’s predictions (up to 14 and 60.5 keV/µm for He- and
C-ions, respectively) was limited. Very high LET values for a given ion can only be achieved at
the end of the ion range, where very high dose and LET gradients render survival
measurements difficult to make accurately. Thus, we choose to limit our highest LET values to
minimize these dosimetric uncertainties arising from the experimental setup, thus ensuring the
robustness of our validation dataset. So, while it is worth noting the maximum LET values we
validated are approximately equal to the dose-weighted LET values in the middle of clinically
relevant spread-out Bragg peaks 209, for the portion of the beam at the very end of the range
where the LET values are extremely high, further validation needs to the done. Nevertheless,
that our model predicts the characteristic overkill shape of the RBE dependence (Figure 34 and
Figure 35), and that we could predict the response of V79, HSG and CHO-K1 cells up to 500
keV/µm with comparable (and in some cases better) accuracy to LEM and MKM is extremely
encouraging, especially given that the data in the PIDE is too sparse at such high LETs to
know the extent to which the trends we modeled persist past ~225 keV/µm.
A final limitation of this work in the context of personalized ion therapies is with regards
to its ultimate applicability to predict tumor response to radiation. In vivo, a number of additional
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factors contribute to the tumor’s response to radiation including tumor microenvironment
factors103, tumor oxygenation185, and involvement of the immune system210, none of which
PORTAL makes any attempt to account for. But, as our PORTAL does accounts for the
variability in intrinsic radiosensitivity, for which there is evidence to suggest is the driving factor
in dictating individual tumor response to radiation211, we suspect that our model will largely be
compatible with predicting the response of tumors.

V.

Conclusions
In this chapter, we showed that radiosensitivity to ions is linearly correlated with

radiosensitivity to photons across a wide range of LETs and definitions of radiosensitivity, and
that this fact can be used to predict a cell’s ion radiosensitivity in terms of its photon
radiosensitivity. We developed a model called PORTAL based on these trends to predict ion
radiosensitivity, RBE and the cell survival curve of cell lines exposed to protons, He- and Cions, based on their response to photons. We showed that PORTAL can be used to predict the
proton, He- and C-ions response in cell lines for which the photon response is known, including
in cells with natural or engineered deficiencies in DNA repair, and also cells exposed in
combination with DNA-repair inhibitors of DNA-PKcs, ATR and Rad51, which is unique to our
model. We also showed that PORTAL has comparable (and sometimes better) accuracy than
the LEM and MKM models which are used in clinical treatment planning for C-ion therapy. Our
model also predicted a number of trends that have been previously reported in the literature
including: (i) that the RBE of radiosensitive cells varies little with LET, (ii) that the RBE of
radioresistant cells varies greatly with LET, (iii) that RBE is constant and near unity across cell
lines for low LET values, and (iv) that there is much greater RBE variation between cell lines at
higher LET values. These data suggest that biological factors in addition to physical factors
have important roles in determining how cell radiosensitivity varies with LET, but that if a cell’s
photon radiosensitivity is known, regardless of how these biological factors modulate the cell’s
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photon radiosensitivity, its ion radiosensitivity can be determined by a simple linear
proportionality to its photon radiosensitivity.
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VI.

Supplemental Information

Supplemental Method 1: Analyzing the PIDE Database
Although the PIDE database has data for a hundreds of cell lines over a wide range of
LET values (0.9-500 keV/µm for protons, He- and C-ions), generally there aren’t sufficient data
at any particular LET to calculate the RPion versus RPphoton trends as we are able to do with our
data. To work around this, we binned the data for similar LET values and fit those datasets as if
they were the mean LET for that bin. While this undoubtedly increases the uncertainty in these
analyses, it nevertheless allows us to determine how the data trends for subsequent analyses.
The bins themselves were chosen so as to cover a large range of LET values with the bins
modestly spaced and containing a reasonable number of individual survival points. Details of
the bins chosen are given in Supplemental Table 20.
As a final note, the PIDE database provides two sets of analyses that can be used: the
α and β values of the linear quadratic model reported in the original publication or those
calculated by the authors of the PIDE using the raw data from the publication. For consistency,
we used the values calculated by the PIDE authors except where they were not provided or
could not be used to determine all of the radiosensitivity parameters. A total of 49 LET values
across 42 cell lines were used for He-ions and 113 LET values across 91 cell lines were used
for C-ions.

Supplemental Table 18: Details of bins used to analyze the proton data in the PIDE database.

Bin
Number
1
2
3
4
5
6

Lowest LET
in bin
(keV/µm)
1.60
2.20
2.60
3.70
4.41
5.10

Highest LET
in bin
(keV/µm)
1.90
2.33
3.00
4.02
4.74
5.30

Mean LET in
bin
(keV/µm)
1.78
2.24
2.84
3.97
4.54
5.18
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Standard
Deviation of LETs
in bin (keV/µm)
0.13
0.05
0.15
0.10
0.14
0.11

Number of
data points
in bin
7
14
11
9
4
5

7
8
9
10
11
12
13

7.50
10.20
13.40
15.00
17.00
19.50
23.70

7.90
11.00
14.00
15.60
18.00
20.50
26.00

7.71
10.75
13.70
15.25
17.69
20.02
24.87

0.14
0.35
0.29
0.25
0.34
0.35
1.05

Supplemental Table 19: Details of bins used to analyze the He-ion data in the PIDE database.

Bin
Number
1
2
3
4
5
6
7
8
9

Lowest LET
in bin
(keV/µm)
1.80
6.00
16.20
23.05
40.00
61.00
88.00
101.70
120.00

Highest LET
in bin
(keV/µm)
4.60
9.12
20.48
28.00
50.00
70.00
90.00
110.00
125.00

Mean LET in
bin
(keV/µm)
2.67
7.78
18.62
26.16
44.15
67.80
89.60
108.25
122.64

Standard
Deviation of LETs
in bin (keV/µm)
1.11
1.30
1.61
2.39
4.78
3.90
0.89
2.83
1.68

Supplemental Table 20: Details of bins used to analyze the C-ion data in the PIDE database.

Bin
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Lowest LET
in bin
(keV/µm)
12.16
19.00
29.50
38.00
46.00
55.00
68.00
76.00
78.50
88.00
99.00
105.00
150.00
220.00

Highest LET
in bin
(keV/µm)
13.80
23.00
33.60
40.60
50.30
61.50
70.00
77.10
81.00
94.00
103.00
110.00
153.50
225.00

Mean LET in
bin
(keV/µm)
13.14
20.60
30.83
39.65
49.58
59.26
69.90
76.93
80.25
92.10
100.77
107.17
151.75
221.88

Standard
Deviation of LETs
in bin (keV/µm)
0.39
1.13
1.27
0.69
1.20
2.02
0.45
0.36
0.63
2.60
1.42
2.04
1.63
1.55

13
8
7
4
7
10
9

Number of
data points
in bin
5
4
14
7
13
5
5
11
22

Number of
data points
in bin
41
21
22
29
25
8
20
20
19
10
13
12
12
8

Supplemental Results 1: Summary of measured cell survival curves
Supplemental Table 21 - Supplemental Table 24 show the survival parameters measured

for each cell line at each radiation quality according to the linear quadratic model. The α and β
values were determined in GraphPad7 via variance weighted least squares minimization, along
with the normalized covariance of α and β (NormCov(α,β) = cov(α,β)/σασβ). Then, the
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radiosensitivity metrics D5%, D10%, D20%, D37%, D50% and SF2Gy were calculated, along with their
uncertainties, from the values of α, β and NormCov(α,β).
Supplemental Table 21: Survival parameters measured for our cell line panel exposed to He-ions and Cions: α and β from the linear quadratic model, their normalized covariance, NormCov(α, β), the dose for
5%, 10%, 20%, 37% and 50% survival (D5%, D10%, D20%, D37%, and D50%), the mean inactivation dose, D̅,
the surviving fraction for a dose of 2 Gy, SF2Gy, and the RBE for ions using D10% as the biological
endpoint, RBED10%. For some survival curves the linear quadratic model gave a very small β values. β
was assumed to be 0 in cases where this made uncertainty calculations not feasible.
Radiation
Cell line
type

6 MV
Photons

1.2
keV/μm
Protons

2.6
keV/μm
Protons

9.9
keV/μm
Protons

α (Gy-1)

HT1080
HT1080shRAD51IND
HT1080-sh
DNA-PKcs
H460
H1299
M059K
M059J
BxPC-3
AsPC-1
PANC-1
Panc 10.05
HT1080
HT1080shRAD51IND
HT1080-sh
DNA-PKcs
H460
H1299
M059K
M059J
BxPC-3
HT1080
HT1080shRAD51IND
HT1080-sh
DNA-PKcs
H460
H1299
M059K
M059J
BxPC-3
HT1080
HT1080shRAD51IND
HT1080-sh
DNA-PKcs
H460
H1299
M059K
M059J
BxPC-3
AsPC-1
PANC-1
Panc 10.05

β (Gy-2)

Norm
cov D5% (Gy)
(α,β)

D10% (Gy) D20% (Gy) D37% (Gy) D50% (Gy) SF2Gy (Gy)

D̅ (Gy)

RBED(10%)

0.091±0.032 0.0245±0.0055 -0.9689 9.359±0.386 8.017±0.263 6.461±0.149 4.780±0.130 3.778±0.170 0.756±0.032 4.197±0.107 1.000±0.046
0.544±0.061 0.0055±0.0136 -0.9769 5.234±0.155 4.069±0.093 2.877±0.119 1.796±0.118 1.259±0.099 0.330±0.023 1.778±0.057 1.000±0.032
0.470±0.036 0.1181±0.0126 -0.9498 3.425±0.038 2.853±0.028 2.203±0.029 1.528±0.035 1.145±0.035 0.243±0.007 1.373±0.023 1.000±0.014
0.046±0.033 0.0899±0.0066 -0.9729
0.089±0.018 0.0240±0.0024 -0.9746
0.314±0.055 0.0206±0.0117 -0.9724
1.360±0.107 0.2318±0.0717 -0.9617
0.308±0.029 0.0154±0.0042 -0.9477
0.134±0.037 0.0546±0.0071 -0.9613
0.136±0.045 0.0292±0.0074 -0.9705
0.113±0.024 0.0182±0.0034 -0.9528
0.051±0.008 0.0390±0.0016 -0.9758

5.523±0.047
9.475±0.115
6.639±0.309
1.706±0.028
7.162±0.131
6.282±0.106
8.064±0.260
10.01±0.28
8.138±0.065

4.812±0.040
8.119±0.076
5.407±0.162
1.372±0.020
5.797±0.117
5.383±0.079
6.851±0.167
8.563±0.190
7.061±0.045

3.983±0.050
6.546±0.074
4.046±0.120
1.010±0.023
4.301±0.130
4.341±0.079
5.451±0.135
6.797±0.139
5.807±0.026

3.080±0.072
4.848±0.111
2.689±0.162
0.657±0.025
2.829±0.131
3.215±0.107
3.953±0.192
4.911±0.166
4.441±0.023

2.533±0.087
3.834±0.133
1.954±0.165
0.472±0.022
2.042±0.117
2.543±0.124
3.070±0.227
3.802±0.191
3.616±0.032

0.637±0.026
0.761±0.021
0.491±0.032
0.026±0.003
0.508±0.022
0.615±0.029
0.678±0.041
0.741±0.027
0.773±0.008

2.716±0.185
4.256±0.285
2.488±0.374
0.619±0.043
2.641±0.207
2.822±0.249
3.484±0.495
4.333±0.426
3.906±0.023

1.000±0.012
1.000±0.013
1.000±0.042
1.000±0.021
1.000±0.029
1.000±0.021
1.000±0.034
1.000±0.031
1.135±0.038

0.446±0.041 0.0246±0.0081 -0.9737 5.215±0.072 4.192±0.072 3.083±0.092 2.007±0.094 1.440±0.083 0.371±0.019 1.892±0.057 0.971±0.028
0.687±0.054 0.0767±0.0160 -0.9674 3.211±0.037 2.599±0.041 1.928±0.049 1.268±0.050 0.916±0.044 0.186±0.009 1.184±0.032 1.098±0.020
0.024±0.031 0.0996±0.0063 -0.9671
0.131±0.021 0.0239±0.0032 -0.9502
0.268±0.045 0.0235±0.0086 -0.9769
0.840±0.133 0.3919±0.0775 -0.9706
0.376±0.046 0.0107±0.0076 -0.9545

5.365±0.043
8.791±0.163
6.947±0.213
1.893±0.030
6.694±0.196

4.689±0.038
7.454±0.115
5.722±0.116
1.578±0.025
5.320±0.157

3.901±0.046
5.914±0.098
4.348±0.109
1.221±0.032
3.858±0.173

3.041±0.064
4.269±0.121
2.948±0.154
0.848±0.040
2.471±0.168

2.520±0.077
3.303±0.136
2.173±0.160
0.636±0.041
1.756±0.145

0.640±0.024
0.699±0.022
0.533±0.031
0.039±0.003
0.452±0.029

2.691±0.069
3.768±0.091
2.686±0.087
0.761±0.027
2.368±0.101

1.026±0.012
1.089±0.020
0.945±0.034
0.869±0.019
1.090±0.039

0.159±0.029 0.0355±0.0056 -0.9779 7.212±0.140 6.116±0.084 4.854±0.062 3.505±0.095 2.712±0.116 0.631±0.024 3.093±0.068 1.311±0.047
0.415±0.057 0.0477±0.0112 -0.9679 4.688±0.079 3.845±0.092 2.905±0.112 1.955±0.117 1.433±0.108 0.360±0.026 1.791±0.078 1.058±0.035
0.742±0.051 0.0726±0.0151 -0.9692 3.097±0.034 2.493±0.039 1.838±0.046 1.199±0.044 0.861±0.038 0.169±0.008 1.127±0.029 1.144±0.021
0.167±0.047 0.0851±0.0097 -0.9637
0.078±0.020 0.0337±0.0029 -0.9519
0.330±0.035 0.0242±0.0066 -0.9761
1.581±0.099 0.0000±0.0000 -0.9668
0.324±0.042 0.0116±0.0080 -0.9758

5.031±0.064
8.338±0.105
6.229±0.102
1.895±0.118
7.322±0.300

4.310±0.063
7.186±0.083
5.081±0.068
1.456±0.091
5.869±0.142

3.475±0.079
5.847±0.082
3.810±0.088
1.018±0.064
4.301±0.112

2.573±0.102
4.394±0.106
2.538±0.107
0.629±0.039
2.788±0.147

2.035±0.114
3.522±0.123
1.848±0.103
0.438±0.027
1.995±0.142

0.509±0.030
0.748±0.022
0.469±0.021
0.042±0.008
0.499±0.026

2.259±0.086
3.856±0.094
2.343±0.062
0.633±0.040
2.639±0.068

1.116±0.019
1.130±0.017
1.064±0.035
0.942±0.061
0.988±0.031

0.076±0.031 0.0885±0.0067 -0.9252 5.406±0.074 4.691±0.063 3.858±0.061 2.951±0.072 2.403±0.081 0.603±0.023 2.722±0.018 1.709±0.061
0.545±0.018 0.0526±0.0042 -0.9452 3.973±0.024 3.222±0.025 2.398±0.028 1.582±0.027 1.145±0.023 0.272±0.006 1.422±0.015 1.263±0.030
0.902±0.037 0.0251±0.0087 -0.9509 3.060±0.042 2.393±0.044 1.703±0.041 1.070±0.032 0.753±0.025 0.149±0.006 1.214±0.017 1.192±0.025
0.146±0.150 0.1503±0.0375 -0.9625 4.006±0.122 3.460±0.126 2.824±0.159 2.133±0.207 1.717±0.233 0.410±0.066 1.930±0.027 1.391±0.052
0.102±0.037 0.0559±0.0063 -0.948 6.464±0.102 5.569±0.091 4.529±0.101 3.401±0.128 2.724±0.145 0.652±0.033 2.753±0.019 1.458±0.027
0.361±0.045 0.0573±0.0082 -0.9401 4.739±0.084 3.930±0.091 3.016±0.101 2.073±0.104 1.543±0.097 0.386±0.024 1.825±0.010 1.376±0.052
1.683±0.070 0.0000±0.0000 -0.8285 1.780±0.074 1.368±0.057 0.956±0.040 0.591±0.025 0.412±0.017 0.035±0.005 0.785±0.024 1.003±0.044
0.534±0.059 0.0109±0.0103 -0.9524 5.083±0.146 3.988±0.152 2.849±0.156 1.797±0.132 1.266±0.106 0.329±0.026 1.912±0.011 1.454±0.063
0.325±0.148 0.0675±0.0322 -0.9623 4.677±0.201 3.911±0.199 3.037±0.247 2.123±0.292 1.601±0.293 0.399±0.070 1.992±0.012 1.377±0.073
0.209±0.009 0.0542±0.0019 -0.9604 5.749±0.024 4.866±0.017 3.849±0.017 2.766±0.023 2.133±0.025 0.530±0.006 2.351±0.010 1.408±0.035
0.167±0.031 0.0311±0.0051 -0.9559 7.496±0.152 6.334±0.108 4.998±0.101 3.578±0.129 2.750±0.143 0.633±0.026 2.813±0.024 1.352±0.038

Supplemental Table 22: Survival parameters measured for our cell line panel exposed to He-ions and Cions: α and β from the linear quadratic model, their normalized covariance, NormCov(α, β), the dose for
5%, 10%, 20%, 37% and 50% survival (D5%, D10%, D20%, D37%, and D50%), the mean inactivation dose, D̅,
the surviving fraction for a dose of 2 Gy, SF2Gy, and the RBE for ions using D10% as the biological
endpoint, RBED10%. For some survival curves the linear quadratic model gave a very small β values. β
was assumed to be 0 in cases where this made uncertainty calculations not feasible.
Radiation
Cell line
type
H460

α (Gy-1)

β (Gy-2)

Norm
D5% (Gy)
cov(α,β)

D10% (Gy) D20% (Gy) D37% (Gy) D50% (Gy) SF2Gy (Gy)

D̅ (Gy)

RBED(10%)

0.182±0.055 0.0821±0.0108 -0.9653 5.033±0.072 4.302±0.075 3.455±0.096 2.543±0.123 2.001±0.134 0.500±0.034 2.234±0.223 1.119±0.022
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H1299
2.2
M059K
keV/μm
M059J
He-ions
BxPC3
H460
H1299
7.0
keV/μm M059K
He-ions M059J
BxPC3
H460
H1299
14.0
keV/μm M059K
He-ions M059J
BxPC3
H460
H1299
M059K
13.5
M059J
keV/μm
BxPC3
C-ions
AsPC-1
PANC-1
Panc1005
H460
H1299
M059K
27.9
M059J
keV/μm
BxPC3
C-ions
AsPC-1
PANC-1
Panc1005
H460
H1299
M059K
60.5
M059J
keV/μm
C-ions BxPC3
AsPC-1
PANC-1
Panc1005

0.230±0.052 0.0105±0.0079
0.112±0.018 0.0709±0.0036
1.034±0.163 0.5182±0.1155
0.319±0.062 0.0090±0.0112
0.122±0.048 0.1050±0.0123
0.197±0.041 0.0163±0.0059
0.364±0.040 0.0242±0.0080
1.425±0.301 0.2688±0.2121
0.361±0.089 0.0130±0.0148
0.089±0.056 0.1328±0.0159
0.153±0.030 0.0287±0.0048
0.553±0.059 0.0000±0.0160
1.326±0.110 0.4942±0.0922
0.453±0.073 0.0102±0.0141

-0.9689
-0.9569
-0.9674
-0.9681
-0.9708
-0.9721
-0.9591
-0.9739
-0.9667
-0.9734
-0.9483
-0.9535
-0.9702
-0.9365

9.194±0.561
5.762±0.038
1.605±0.030
7.715±0.510
4.792±0.073
8.798±0.279
5.912±0.130
1.612±0.059
6.689±0.328
4.426±0.071
7.898±0.173
5.419±0.575
1.462±0.020
5.847±0.297

7.479±0.301
4.967±0.032
1.334±0.023
6.153±0.254
4.138±0.052
7.289±0.169
4.799±0.091
1.298±0.043
5.349±0.253
3.842±0.050
6.684±0.126
4.165±0.442
1.200±0.013
4.608±0.218

5.587±0.232
4.043±0.035
1.027±0.028
4.481±0.209
3.377±0.050
5.586±0.172
3.575±0.100
0.957±0.056
3.908±0.305
3.162±0.047
5.286±0.115
2.911±0.309
0.907±0.014
3.309±0.215

3.705±0.300
3.041±0.046
0.709±0.035
2.884±0.250
2.551±0.073
3.832±0.232
2.362±0.112
0.624±0.062
2.524±0.317
2.421±0.069
3.798±0.142
1.799±0.191
0.611±0.018
2.098±0.198

2.690±0.301
2.438±0.053
0.530±0.035
2.055±0.234
2.053±0.089
2.847±0.243
1.711±0.104
0.448±0.056
1.803±0.280
1.973±0.086
2.927±0.156
1.254±0.133
0.448±0.018
1.482±0.166

0.606±0.045
0.603±0.014
0.016±0.003
0.510±0.042
0.515±0.025
0.632±0.037
0.439±0.022
0.020±0.006
0.461±0.056
0.492±0.026
0.657±0.028
0.331±0.020
0.010±0.002
0.388±0.037

0.307±0.096 0.0740±0.0291
0.045±0.029 0.0485±0.0048
0.206±0.061 0.0886±0.0194
0.944±0.389 0.7848±0.3312
0.458±0.064 0.0002±0.0167
0.143±0.036 0.0709±0.0074
0.227±0.066 0.0256±0.0123
0.151±0.041 0.0280±0.0058
0.502±0.048 0.0892±0.0174
0.098±0.070 0.0748±0.0139
0.649±0.101 0.0000±0.0000
1.823±0.198 0.2446±0.1673
0.543±0.126 0.0102±0.0373
0.361±0.107 0.0802±0.0271
0.196±0.033 0.0553±0.0071
0.202±0.065 0.0342±0.0108
0.676±0.173 0.0845±0.0797

-0.9723
-0.9412
-0.9691
-0.9652
-0.9699
-0.9716
-0.978
-0.9749
-0.9773
-0.972
-0.9684
-0.9648
-0.9803
-0.974
-0.9693
-0.9718
-0.9743

4.621±0.218
7.412±0.124
4.768±0.166
1.443±0.065
6.527±0.705
5.570±0.064
7.250±0.346
7.999±0.153
3.627±0.060
5.707±0.120
4.616±0.720
1.386±0.037
5.039±0.538
4.263±0.109
5.801±0.082
6.859±0.191
3.173±0.242

3.879±0.131
6.445±0.101
4.067±0.109
1.214±0.045
5.020±0.295
4.780±0.050
6.029±0.191
6.770±0.116
2.993±0.033
4.932±0.097
3.548±0.553
1.101±0.024
3.947±0.217
3.561±0.098
4.922±0.057
5.766±0.148
2.576±0.124

3.032±0.092
5.318±0.095
3.256±0.065
0.952±0.046
3.512±0.121
3.862±0.059
4.645±0.153
5.356±0.147
2.280±0.031
4.029±0.117
2.480±0.387
0.798±0.028
2.815±0.146
2.763±0.132
3.909±0.060
4.515±0.187
1.920±0.081

2.139±0.132
4.089±0.117
2.384±0.075
0.675±0.062
2.171±0.141
2.870±0.084
3.211±0.231
3.849±0.205
1.551±0.044
3.048±0.167
1.532±0.239
0.510±0.029
1.772±0.192
1.928±0.166
2.825±0.083
3.194±0.248
1.269±0.111

1.624±0.152
3.346±0.136
1.867±0.095
0.514±0.067
1.514±0.131
2.277±0.098
2.399±0.255
2.967±0.226
1.146±0.047
2.458±0.199
1.068±0.167
0.363±0.025
1.247±0.178
1.452±0.170
2.189±0.095
2.431±0.264
0.920±0.114

0.403±0.034
0.753±0.031
0.465±0.023
0.007±0.004
0.400±0.026
0.566±0.025
0.573±0.048
0.662±0.039
0.256±0.008
0.609±0.053
0.273±0.055
0.010±0.003
0.324±0.036
0.352±0.039
0.542±0.022
0.582±0.052
0.184±0.015

3.434±0.675
2.668±0.104
0.639±0.063
2.750±0.552
2.239±0.196
3.464±0.483
2.196±0.201
0.587±0.107
2.398±0.549
2.130±0.205
3.357±0.305
1.809±0.192
0.559±0.035
2.035±0.344
1.905±0.338
3.601±0.298
2.097±0.251
0.600±0.122
2.181±0.458
2.519±0.190
2.889±0.549
3.402±0.416
1.410±0.097
2.676±0.401
1.541±0.261
0.490±0.052
1.734±0.491
1.726±0.292
2.493±0.185
2.840±0.475
1.179±0.269

1.086±0.045
1.089±0.033
1.028±0.023
0.942±0.043
1.163±0.017
1.114±0.028
1.127±0.040
1.057±0.039
1.084±0.056
1.253±0.019
1.215±0.026
1.298±0.143
1.144±0.021
1.258±0.065
1.240±0.043
1.260±0.023
1.329±0.054
1.130±0.045
1.155±0.072
1.126±0.020
1.136±0.045
1.265±0.035
1.608±0.022
1.646±0.036
1.524±0.242
1.247±0.033
1.469±0.086
1.512±0.047
1.392±0.038
1.485±0.050
1.868±0.091

0.124±0.048 0.1020±0.0124 -0.9714 4.846±0.076 4.182±0.054 3.411±0.052 2.573±0.075 2.069±0.092 0.519±0.026 2.258±0.204 1.941±0.031
0.765±0.036 0.0000±0.0283 -0.9624 3.914±0.390 3.008±0.200 2.103±0.072 1.299±0.017 0.906±0.016 0.216±0.010 1.307±0.062 1.797±0.131
1.365±0.442 0.8363±0.4291 -0.9627 1.245±0.058 1.033±0.040 0.793±0.043 0.546±0.054 0.407±0.055 0.002±0.002 0.493±0.095 1.328±0.055
0.740±0.157 0.0000±0.0812 -0.9682 4.051±0.991 3.114±0.454 2.176±0.136 1.344±0.106 0.937±0.109 0.228±0.019 1.352±0.288 1.862±0.274
0.703±0.035 0.0000±0.0030 -0.8257 4.261±0.157 3.275±0.130 2.289±0.098 1.414±0.065 0.986±0.046 0.245±0.015 1.422±0.072 1.644±0.070
0.197±0.072 0.0924±0.0161 -0.9699 4.728±0.082 4.039±0.078 3.242±0.101 2.384±0.135 1.874±0.150 0.466±0.039 2.095±0.262 1.696±0.053
0.396±0.048 0.0415±0.0108 -0.9754 4.971±0.076 4.073±0.062 3.072±0.084 2.063±0.099 1.510±0.095 0.383±0.021 1.893±0.172 2.103±0.057
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Supplemental Table 23: Survival parameters measured for our cell lines treated with DNA repair inhibitors: α and β from the linear quadratic model, their
normalized covariance, NormCov(α, β), the dose for 5%, 10%, 20%, 37% and 50% survival (D5%, D10%, D20%, D37%, and D50%), the mean inactivation
dose, D̅, the surviving fraction for a dose of 2 Gy, SF2Gy, and the RBE for ions using D10% as the biological endpoint, RBED10%. For some survival curves
the linear quadratic model gave a very small β values. β was assumed to be 0 in cases where this made uncertainty calculations not feasible.

Radiation
type

Cell line

H460+DMSO
H460+NU7441 (DNA-PKcsi, 0.1 µM)
H460+AZD6738 (ATRi, 0.1 µM)
H1299+DMSO
H1299+B02 (Rad51i, 0.5 µM)
H1299+NU7441 (DNA-PKcsi, 0.1 µM)
H1299+NU7441 (DNA-PKcsi, 1 µM)
6 MV
Photons H1299+AZD6738 (ATRi, 0.1 µM)
PANC-1+DMSO
Panc1+NU7441 (DNA-PKcsi, 0.1 µM)
Panc1+AZD6738 (ATRi, 0.1 µM)
Panc1005+DMSO
Panc1005+NU7441 (DNA-PKcsi, 0.1 µM)
Panc1005+AZD6738 (ATRi, 0.1 µM)
H460+DMSO
H460+NU7441 (DNA-PKcsi, 0.1 µM)
H460+AZD6738 (ATRi, 0.1 µM)
H1299+DMSO
H1299+NU7441 (DNA-PKcsi, 0.1 µM)
9.9 keVμm H1299+AZD6738 (ATRi, 0.1 µM)
Protons PANC-1+DMSO
Panc1+NU7441 (DNA-PKcsi, 0.1 µM)
Panc1+AZD6738 (ATRi, 0.1 µM)
Panc1005+DMSO
Panc1005+NU7441 (DNA-PKcsi, 0.1 µM)
Panc1005+AZD6738 (ATRi, 0.1 µM)

α (Gy-1)

β (Gy-2)

0.013±0.022
0.237±0.069
0.269±0.053
0.077±0.023
0.127±0.029
0.159±0.025
1.068±0.122
0.259±0.032
0.182±0.038
0.154±0.041
0.143±0.038
0.214±0.050
0.282±0.034
0.269±0.071
0.299±0.060
0.442±0.127
0.526±0.082
0.217±0.046
0.263±0.064
0.100±0.028
0.302±0.039
0.257±0.071
0.201±0.068
0.274±0.065
0.261±0.082
0.202±0.052

0.0790±0.0043
0.1125±0.0160
0.0963±0.0128
0.0204±0.0029
0.0158±0.0037
0.0218±0.0040
0.0000±0.0123
0.0040±0.0051
0.0297±0.0058
0.0421±0.0064
0.0362±0.0058
0.0129±0.0066
0.0164±0.0042
0.0228±0.0095
0.0843±0.0177
0.1433±0.0405
0.1498±0.0254
0.0185±0.0076
0.0367±0.0116
0.0521±0.0052
0.0373±0.0084
0.0636±0.0156
0.0767±0.0153
0.0319±0.0110
0.0578±0.0149
0.0673±0.0099

Norm
cov(α,β)
-0.9723
-0.9586
-0.9602
-0.9754
-0.9694
-0.9549
-0.9296
-0.9547
-0.9636
-0.9582
-0.9629
-0.9645
-0.9594
-0.9561
-0.9725
-0.9612
-0.9645
-0.9701
-0.9447
-0.959
-0.9599
-0.9548
-0.9565
-0.9674
-0.9537
-0.9522

D5% (Gy)

D10% (Gy)

D20% (Gy)

D37% (Gy)

D50% (Gy)

SF2Gy (Gy)

D̅ (Gy)

RBED(10%)

6.076±0.044
4.214±0.070
4.352±0.061
10.383±0.196
10.330±0.278
8.621±0.202
2.805±0.238
10.006±0.646
7.437±0.142
6.798±0.117
7.334±0.128
9.047±0.361
7.421±0.137
6.993±0.248
4.448±0.106
3.284±0.087
3.048±0.046
8.159±0.335
6.137±0.203
6.683±0.095
5.790±0.121
5.134±0.138
5.074±0.121
6.302±0.164
5.288±0.150
5.340±0.095

5.316±0.033
3.592±0.075
3.687±0.058
8.908±0.126
8.707±0.176
7.250±0.134
2.156±0.197
7.914±0.325
6.259±0.115
5.785±0.109
6.242±0.109
7.424±0.241
6.041±0.150
5.754±0.267
3.747±0.065
2.754±0.082
2.540±0.051
6.749±0.193
5.112±0.168
5.757±0.070
4.794±0.082
4.327±0.113
4.322±0.100
5.222±0.148
4.446±0.158
4.540±0.093

4.431±0.034
2.874±0.093
2.922±0.071
7.198±0.101
6.845±0.153
5.681±0.108
1.507±0.148
5.706±0.184
4.909±0.136
4.615±0.132
4.980±0.130
5.612±0.264
4.518±0.174
4.367±0.313
2.944±0.056
2.148±0.101
1.962±0.064
5.161±0.153
3.947±0.182
4.680±0.065
3.671±0.084
3.401±0.126
3.454±0.112
4.003±0.187
3.482±0.190
3.616±0.110

3.465±0.050
2.101±0.113
2.106±0.088
5.348±0.151
4.873±0.215
4.023±0.135
0.931±0.097
3.632±0.199
3.482±0.174
3.360±0.166
3.627±0.170
3.778±0.319
3.000±0.174
2.955±0.329
2.093±0.081
1.511±0.121
1.362±0.072
3.530±0.209
2.737±0.209
3.512±0.086
2.515±0.103
2.420±0.157
2.521±0.144
2.747±0.222
2.464±0.219
2.627±0.135

2.880±0.062
1.644±0.121
1.627±0.094
4.242±0.188
3.727±0.244
3.064±0.149
0.649±0.070
2.572±0.186
2.656±0.185
2.619±0.179
2.827±0.188
2.771±0.313
2.180±0.156
2.175±0.305
1.599±0.092
1.145±0.124
1.021±0.070
2.617±0.223
2.050±0.209
2.811±0.102
1.868±0.105
1.850±0.166
1.969±0.159
2.042±0.218
1.876±0.221
2.043±0.143

0.710±0.019
0.397±0.032
0.397±0.023
0.790±0.027
0.728±0.032
0.666±0.024
0.118±0.023
0.586±0.027
0.617±0.033
0.621±0.036
0.650±0.036
0.619±0.046
0.533±0.028
0.533±0.057
0.393±0.021
0.233±0.025
0.192±0.014
0.602±0.037
0.510±0.044
0.665±0.024
0.471±0.022
0.464±0.039
0.492±0.040
0.508±0.044
0.471±0.051
0.510±0.034

3.071±0.155
1.848±0.195
1.860±0.158
4.694±0.435
4.322±0.506
3.576±0.311
0.936±0.107
3.506±0.508
3.093±0.328
2.959±0.305
3.193±0.335
3.460±0.601
2.777±0.254
2.696±0.483
1.857±0.055
1.347±0.086
1.223±0.050
3.197±0.122
2.459±0.144
3.082±0.076
2.276±0.065
2.146±0.114
2.218±0.113
2.483±0.146
2.191±0.161
2.314±0.106

1.000±0.009
1.000±0.029
1.000±0.022
1.000±0.020
1.000±0.029
1.000±0.026
1.000±0.129
1.000±0.058
1.000±0.026
1.000±0.027
1.000±0.025
1.000±0.046
1.000±0.035
1.000±0.066
1.207±0.030
1.446±0.049
1.452±0.037
1.320±0.042
1.613±0.070
1.375±0.059
1.305±0.033
1.337±0.043
1.444±0.042
1.422±0.061
1.359±0.059
1.267±0.064
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Supplemental Table 24: Survival parameters measured for our cell lines treated with DNA repair inhibitors: α and β from the linear quadratic model, their
normalized covariance, NormCov(α, β), the dose for 5%, 10%, 20%, 37% and 50% survival (D5%, D10%, D20%, D37%, and D50%), the mean inactivation
dose, D̅, the surviving fraction for a dose of 2 Gy, SF2Gy, and the RBE for ions using D10% as the biological endpoint, RBED10%. For some survival curves
the linear quadratic model gave a very small β values. β was assumed to be 0 in cases where this made uncertainty calculations not feasible.

Radiation
type

Cell line

H1299+DMSO
14.0 keV/μm
H1299+B02 (Rad51i, 5 µM)
He-ions
H1299+NU7441 (DNA-PKcsi, 1 µM)
H460+DMSO
H460+NU7441 (DNA-PKcsi, 0.1 µM)
H460+AZD6738 (ATRi, 0.1 µM)
H1299+DMSO
H1299+NU7441 (DNA-PKcsi, 0.1 µM)
13.5 keV/μm H1299+AZD6738 (ATRi, 0.1 µM)
C-ions Panc1+DMSO
Panc1+NU7441 (DNA-PKcsi, 0.1 µM)
Panc1+AZD6738 (ATRi, 0.1 µM)
Panc1005+DMSO
Panc1005+NU7441 (DNA-PKcsi, 0.1 µM)
Panc1005+AZD6738 (ATRi, 0.1 µM)
H460+DMSO
H460+NU7441 (DNA-PKcsi, 0. 1 µM)
H460+AZD6738 (ATRi, 0.1 µM)
H1299+DMSO
H1299+NU7441 (DNA-PKcsi, 0.1 µM)
60.5 keV/μm H1299+AZD6738 (ATRi, 0.1 µM]
C-ions Panc1+DMSO
Panc1+NU7441 (DNA-PKcsi, 0.1 µM)
Panc1+AZD6738 (ATRi, 0.1 µM)
Panc1005+DMSO
Panc1005+NU7441 (DNA-PKcsi, 0.1 µM)
Panc1005+AZD6738 (ATRi, 0.1 µM)

α (Gy-1)

β (Gy-2)

0.196±0.016
0.235±0.026
1.591±0.267
0.000±0.041
0.030±0.014
0.103±0.059
0.033±0.057
0.126±0.016
0.062±0.029
0.117±0.024
0.124±0.015
0.174±0.026
0.345±0.007
0.424±0.064
0.138±0.091
0.248±0.042
0.335±0.052
0.596±0.214
0.134±0.033
0.241±0.047
0.123±0.067
0.175±0.050
0.159±0.032
0.329±0.050
0.567±0.099
0.302±0.238
0.798±0.129

0.0175±0.0022
0.0276±0.0046
0.0000±0.0409
0.1165±0.0120
0.1224±0.0040
0.1268±0.0190
0.0478±0.0083
0.0427±0.0030
0.0425±0.0047
0.0426±0.0045
0.0478±0.0031
0.0324±0.0053
0.0000±0.0000
0.0000±0.0074
0.0809±0.0288
0.1975±0.0163
0.1937±0.0229
0.1535±0.0960
0.1018±0.0078
0.0933±0.0136
0.0986±0.0189
0.1064±0.0113
0.1239±0.0089
0.0798±0.0143
0.0252±0.0232
0.1638±0.0601
0.0889±0.0385

Norm
cov(α,β)
-0.9787
-0.9612
-0.8995
-0.9587
-0.9735
-0.9689
-0.9655
-0.9757
-0.9767
-0.9800
-0.9807
-0.9761
-0.7559
-0.9387
-0.9662
-0.9653
-0.9745
-0.9759
-0.9566
-0.9680
-0.9686
-0.9658
-0.9746
-0.9745
-0.9612
-0.9916
-0.9643

D5% (Gy)

D10% (Gy)

D20% (Gy)

D37% (Gy)

D50% (Gy)

SF2Gy (Gy)

D̅ (Gy)

RBED(10%)

8.623±0.077
6.998±0.115
1.883±0.237
5.071±0.105
4.828±0.026
4.471±0.115
7.574±0.168
7.032±0.067
7.699±0.111
7.127±0.096
6.732±0.056
7.300±0.169
8.674±0.177
7.067±1.066
5.290±0.364
3.317±0.037
3.163±0.050
2.883±0.161
4.807±0.049
4.521±0.082
4.923±0.148
4.549±0.053
4.317±0.037
4.404±0.078
4.419±0.159
3.454±0.101
2.850±0.081

7.157±0.052
5.821±0.078
1.447±0.196
4.446±0.078
4.218±0.018
3.874±0.080
6.599±0.148
6.017±0.042
6.668±0.075
6.108±0.059
5.770±0.035
6.164±0.103
6.667±0.136
5.432±0.819
4.548±0.255
2.844±0.026
2.691±0.031
2.390±0.092
4.144±0.041
3.842±0.054
4.248±0.101
3.903±0.052
3.717±0.026
3.693±0.048
3.515±0.145
2.940±0.155
2.298±0.095

5.499±0.070
4.486±0.078
1.012±0.146
3.717±0.055
3.507±0.013
3.179±0.052
5.464±0.176
4.840±0.032
5.469±0.068
4.927±0.045
4.654±0.025
4.858±0.056
4.660±0.095
3.797±0.573
3.687±0.149
2.295±0.023
2.146±0.022
1.833±0.090
3.373±0.044
3.059±0.047
3.464±0.072
3.154±0.067
3.019±0.027
2.881±0.049
2.551±0.167
2.346±0.219
1.697±0.106

3.785±0.093
3.102±0.099
0.625±0.096
2.921±0.053
2.732±0.016
2.423±0.061
4.225±0.243
3.571±0.047
4.164±0.104
3.651±0.071
3.449±0.040
3.471±0.074
2.879±0.059
2.345±0.354
2.754±0.118
1.702±0.031
1.561±0.032
1.259±0.127
2.536±0.059
2.220±0.066
2.612±0.093
2.345±0.087
2.263±0.040
2.027±0.070
1.636±0.161
1.709±0.271
1.109±0.099

2.820±0.096
2.318±0.103
0.436±0.069
2.439±0.065
2.262±0.021
1.966±0.079
3.475±0.289
2.816±0.059
3.377±0.132
2.889±0.090
2.730±0.051
2.663±0.093
2.007±0.041
1.635±0.247
2.195±0.152
1.348±0.037
1.216±0.039
0.936±0.135
2.034±0.068
1.725±0.077
2.100±0.118
1.861±0.097
1.809±0.048
1.536±0.077
1.163±0.137
1.333±0.287
0.798±0.085

0.629±0.015
0.560±0.019
0.042±0.016
0.628±0.024
0.578±0.007
0.490±0.023
0.773±0.064
0.655±0.013
0.746±0.029
0.668±0.020
0.645±0.012
0.620±0.019
0.501±0.007
0.428±0.043
0.549±0.042
0.276±0.008
0.236±0.006
0.164±0.016
0.509±0.019
0.425±0.019
0.527±0.033
0.461±0.026
0.443±0.013
0.376±0.017
0.291±0.033
0.284±0.068
0.142±0.017

3.415±0.178
2.791±0.197
0.629±0.105
2.596±0.220
2.417±0.065
2.129±0.225
3.727±0.604
3.137±0.137
3.659±0.313
3.205±0.212
3.028±0.122
3.074±0.237
2.896±0.060
2.359±0.356
2.416±0.497
1.494±0.081
1.375±0.090
1.137±0.273
2.226±0.132
1.956±0.163
2.293±0.301
2.058±0.170
1.986±0.103
1.807±0.154
1.566±0.261
1.505±0.435
1.041±0.137

1.245±0.020
1.496±0.036
1.490±0.243
1.196±0.022
0.852±0.018
0.952±0.025
1.350±0.036
1.205±0.024
1.187±0.051
1.025±0.021
1.003±0.020
1.013±0.025
1.113±0.043
1.112±0.170
1.265±0.092
1.869±0.021
1.335±0.032
1.543±0.064
2.150±0.037
1.887±0.044
1.863±0.088
1.603±0.036
1.556±0.031
1.690±0.037
2.112±0.111
2.055±0.120
2.504±0.155
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Supplemental Results 2: The linear correlations between radiosensitivity metrics are
stronger for parameters corresponding to lower survival levels
We calculated the radiosensitivity metrics D5%, D10%, D20%, D37%, D50% and SF2Gy and
saw that independent of the parameter used to characterize radiosensitivity, radiosensitivity to
photons and ions are linearly related, but to differing degrees. Supplemental Figure 6 shows
the correlations for the parameters that are not shown in Figure 23 and Supplemental Table 25
gives the R2 values.

Supplemental Table 25: R2 values determined for the correlations between ion and photon radiosensitivity for the
metrics D5% , D10% , D20%,, D37%,, D50%, and SF2Gy. Abbreviations – LET: linear energy transfer; D5% D10%, … D50%:
dose for 5%, 10%, …, 50% survival; SF2Gy: surviving fraction for a dose of 2 Gy.

LET
(keV/μm)
1.2
Protons 2.6
9.9
2.2
He-ions 7.0
14.0
13.5
C-ions 27.9
60.5
Ion

D5%
0.9791
0.9435
0.9397
0.9665
0.9956
0.9986
0.9489
0.9667
0.9224

D10%
0.9779
0.9462
0.951
0.9732
0.9968
0.9954
0.9737
0.9714
0.9462

R2 value
D20%
D37%
0.9746
0.9681
0.9435
0.9357
0.9589
0.9642
0.9559
0.8722
0.9963
0.9912
0.9886
0.9822
0.9847
0.9638
0.9621
0.9448
0.9261
0.8516
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D50%
0.9616
0.9247
0.9643
0.7621
0.9837
0.981
0.9248
0.9118
0.7824

SF2Gy
0.9705
0.9490
0.9347
0.8464
0.9903
0.9762
0.9031
0.8008
0.7215

Supplemental Figure 6: (A-F) D5%,ion vs. D5%,photon, (G-L) D20%,ion vs. D20%,photon, and (M-R) SF2Gy,ion vs. SF2Gy,photon for He- and C-ions in order of increasing LET from 2.2 to
60.5 keV/µm. Black circles and red squares represent data of cell lines treated with radiation alone and drug in combination of radiation. Lines represent linear fits to the
data of cell lines exposed to radiation alone.
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Supplemental Results 3: Summary PIDE database fits
For the all the radiosensitivity parameters, we noted that the slope and intercept of the correlations varied regularly with LET.
Supplemental Figure 7 shows the trends for the radiosensitivity parameters that were not shown in Figure 24:

Supplemental Figure 7: We used the PIDE database to determine the trends in the slope (A-I) and intercept (J-R) of the linear functions that relate photon and ion
radiosenstivity (D5%, D20% and SF2Gy shown here) as a function of ion LET (ranging from 1.6-225 keV/µm) for protons, He-ions and C-ions. The results for are D10%, D37%
and D50% are shown in Figure 24.
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Supplemental Table 26 shows the goodness of fit parameters for the linear and exponential functions used
to model the variation of the intercept and slope, respectively, as a function of LET:

Supplemental Table 26: R2 values for the fits of the binned PIDE database data

Ion

Parameter

Slope
Intercept
Slope
He-ions
Intercept
Slope
C-ions
Intercept
Protons

R2 value
D5%
D10%
D20%
D37%
0.4814
0.6246
0.7092
0.6987
0.1027
0.1408
0.1477
0.1060
0.8411
0.8663
0.9576
0.9682
0.003186 0.0008205 0.2524
0.1037
0.9182
0.8981
0.8768
0.8580
0.4198
0.4578
0.4622
0.4213
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D50%
0.6729
0.0755
0.9733
0.09708
0.8329
0.337

SF2Gy
0.5507
0.0007
0.9363
0.08689
0.6327
0.1205

Supplemental Results 4: Model Parameters determined from the PIDE database
Our formalism can be generalized into the following function of 5 parameters, c d f g
and h, that predicts RPion from RPphoton for a given LET:

𝑅𝑅𝑅𝑅𝑖𝑖𝑖𝑖𝑖𝑖 = �(𝑐𝑐 − 𝑑𝑑) ∙ 𝑒𝑒 −𝑓𝑓 ∙𝐿𝐿𝐿𝐿𝐿𝐿 + 𝑑𝑑� ∙ 𝑅𝑅𝑅𝑅𝑝𝑝ℎ𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 + 𝑔𝑔 ∙ 𝐿𝐿𝐿𝐿𝐿𝐿 + ℎ
With this form, there is no need to bin the data from the PIDE database to determine the values
of c, d, f, g and h. Instead, we fit the measured response for all of the cell lines in the database
for all LET values to this function. Supplemental Table 28 and Supplemental Table 29 show the
values determined for that fit while Supplemental Table 30 gives the R2 values for these fits.

Supplemental Table 27: Model parameters fit to the proton data in the PIDE database.

Parameter
c
σc
d
σd
f
σf
g
σg
h
σh
σcd
σcf
σcg
σch
σdf
σdg
σdh
σfg
σfh
σgh

D5%

7.83672E-01
3.04623E-02
2.22060E-14
9.26067E-01
2.16495E-02
2.94239E-02
3.03374E-02
3.02458E-02
5.00000E-01
2.75173E-01
1.07628E-03
1.56532E-04
4.22487E-04
-5.11339E-03
2.67209E-02
-1.95673E-02
1.19165E-01
-5.04568E-04
3.17909E-03
-6.23086E-03

D10%

7.65563E-01
2.92493E-02
2.22048E-14
8.77158E-01
2.23293E-02
2.94887E-02
1.76510E-02
2.44542E-02
5.00000E-01
2.23789E-01
9.59357E-04
1.46861E-04
3.18429E-04
-3.93431E-03
2.53849E-02
-1.52857E-02
9.29702E-02
-4.23571E-04
2.66030E-03
-4.09862E-03

D20%

7.40473E-01
2.90890E-02
2.22045E-14
7.81777E-01
2.42297E-02
2.98899E-02
7.91011E-03
1.87512E-02
5.00000E-01
1.75588E-01
1.02189E-03
1.54175E-04
2.31512E-04
-2.99829E-03
2.29201E-02
-1.06069E-02
6.49906E-02
-3.36818E-04
2.13468E-03
-2.45812E-03

138

D37%

7.05665E-01
3.03040E-02
2.22047E-14
6.55788E-01
2.76207E-02
3.09020E-02
2.22045E-14
1.33700E-02
5.00000E-01
1.31227E-01
1.28193E-03
1.87411E-04
1.61471E-04
-2.26421E-03
1.98312E-02
-6.35396E-03
3.97881E-02
-2.47605E-04
1.61575E-03
-1.30075E-03

D50%

6.82283E-01
3.21999E-02
2.22726E-14
4.77703E-01
3.47699E-02
3.07999E-02
2.22047E-14
1.04349E-02
5.00000E-01
1.06593E-01
1.04408E-03
2.13625E-04
1.24190E-04
-1.88384E-03
1.43045E-02
-3.70737E-03
2.35582E-02
-1.96233E-04
1.31991E-03
-8.21453E-04

SF2Gy

1.05665E+00
6.06569E-02
2.23640E-14
2.88303E-01
4.69160E-02
1.81274E-02
2.60703E-03
2.50219E-03
6.46741E-03
3.29539E-02
-2.23313E-03
8.00407E-05
8.79252E-05
-1.60680E-03
4.82449E-03
-5.30922E-04
4.45054E-03
-2.19697E-05
2.21051E-04
-6.13252E-05

Supplemental Table 28: Model parameters fit to the He-ion data in the PIDE database.

Parameter
c
σc
d
σd
f
σf
g
σg
h
σh
σcd
σcf
σcg
σch
σdf
σdg
σdh
σfg
σfh
σgh

D5%

9.78192E-01
7.99093E-02
2.22045E-14
7.10790E-02
2.92885E-02
6.98416E-03
1.24326E-02
5.48098E-03
5.00000E-01
5.65702E-01
-2.09236E-04
-8.39714E-05
2.27249E-04
-3.07760E-02
3.45941E-04
-2.89935E-04
1.30561E-02
-3.05054E-05
2.87071E-03
-2.60152E-03

D10%

9.77361E-01
7.34579E-02
2.22045E-14
6.28453E-02
3.18266E-02
6.99371E-03
8.95089E-03
4.13664E-03
5.00000E-01
4.19007E-01
4.99155E-05
-3.99201E-05
1.39924E-04
-1.92373E-02
2.89490E-04
-1.88558E-04
7.21899E-03
-2.27129E-05
2.09325E-03
-1.42988E-03

D20%

9.85892E-01
6.82252E-02
2.21178E-03
5.57237E-02
3.48315E-02
7.08629E-03
6.00980E-03
2.92939E-03
4.05102E-01
2.90354E-01
1.90243E-04
3.75608E-06
7.87557E-05
-1.09939E-02
2.45543E-04
-1.15466E-04
3.73788E-03
-1.59720E-05
1.44005E-03
-6.91103E-04

D37%

9.95311E-01
6.54317E-02
2.35963E-02
4.81781E-02
4.04781E-02
7.91746E-03
2.98410E-03
1.88474E-03
3.14120E-01
1.84661E-01
3.21494E-04
6.71254E-05
3.67089E-05
-5.41017E-03
2.12718E-04
-6.04875E-05
1.39014E-03
-1.11421E-05
9.94169E-04
-2.77763E-04

D50%

9.99622E-01
6.57619E-02
3.38732E-02
4.44805E-02
4.49821E-02
8.83451E-03
1.61888E-03
1.37419E-03
2.59757E-01
1.34156E-01
3.68805E-04
1.23935E-04
2.09373E-05
-3.25794E-03
2.02815E-04
-3.89420E-05
6.82242E-04
-8.85041E-06
7.90577E-04
-1.46041E-04

Supplemental Table 29: Model parameters fit to the C-ion data in the PIDE database.

Parameter
c
σc
d
σd
f
σf
g
σg
h
σh
σcd
σcf
σcg
σch
σdf
σdg
σdh
σfg
σfh
σgh

D5%

9.81377E-01
3.05133E-02
1.27490E-01
5.21650E-02
1.88337E-02
2.25968E-03
7.44330E-03
2.32143E-03
6.24177E-02
1.84107E-01
-7.23998E-05
4.42500E-06
2.78286E-05
-3.52901E-03
1.05990E-04
-1.06754E-04
5.15777E-03
-4.12412E-06
2.61357E-04
-3.42584E-04

D10%

9.74305E-01
3.02111E-02
1.32391E-01
5.16260E-02
1.88554E-02
2.29477E-03
5.34081E-03
1.91377E-03
2.27503E-14
1.50871E-01
-3.53523E-05
6.89964E-06
2.15972E-05
-2.76583E-03
1.06811E-04
-8.67180E-05
4.19401E-03
-3.42170E-06
2.14379E-04
-2.32121E-04

D20%

9.52298E-01
3.16965E-02
1.36955E-01
5.27049E-02
1.91784E-02
2.53650E-03
3.21779E-03
1.53382E-03
2.22045E-14
1.20588E-01
4.40604E-05
1.31402E-05
1.62294E-05
-2.16580E-03
1.20787E-04
-7.02442E-05
3.38432E-03
-2.98629E-06
1.84539E-04
-1.49011E-04

D37%

9.17992E-01
3.55268E-02
1.27348E-01
5.79653E-02
1.91243E-02
2.93669E-03
1.79803E-03
1.19263E-03
2.22045E-14
9.35565E-02
1.56368E-04
2.44425E-05
1.26206E-05
-1.74955E-03
1.54498E-04
-5.91076E-05
2.86276E-03
-2.61233E-06
1.58603E-04
-9.03178E-05

D50%

8.87838E-01
3.92012E-02
1.10784E-01
6.41201E-02
1.87219E-02
3.25190E-03
1.25471E-03
9.89918E-04
2.22045E-14
7.75941E-02
2.61799E-04
3.55816E-05
1.09591E-05
-1.53778E-03
1.90060E-04
-5.34206E-05
2.60998E-03
-2.32981E-06
1.39431E-04
-6.24330E-05

Supplemental Table 30: R2 values for the fits of the PIDE database data without binning

Ion
Protons
He-ions
C-ions

D5%
0.8714
0.7024
0.8394

D10%
0.8739
0.7344
0.8461

R2 value
D20%
D37%
0.8658
0.8437
0.7597
0.7754
0.8360
0.8010
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D50%
0.8201
0.7779
0.7621

SF2Gy
0.7732
0.7336
0.7036

SF2Gy

1.11952E+00
8.42318E-02
3.36018E-02
6.87765E-02
3.75276E-02
8.55492E-03
5.05559E-04
4.48520E-04
2.22048E-14
4.13718E-02
2.57351E-04
6.51013E-05
1.25074E-05
-1.68301E-03
3.70928E-04
-2.25586E-05
7.27083E-04
-2.90508E-06
2.41131E-04
-1.49325E-05

SF2Gy

9.51203E-01
5.38453E-02
1.16750E-01
9.62528E-02
1.89489E-02
4.40507E-03
2.22045E-14
3.39633E-04
2.22045E-14
2.64963E-02
1.73632E-04
3.74410E-05
5.83268E-06
-7.96143E-04
3.83238E-04
-2.85935E-05
1.34798E-03
-1.16364E-06
7.16635E-05
-7.16324E-06

Since our data agreed with the data in the PIDE database, we subsequently included
our data (not including drug-treated cells) into the database and recalculated the fits with higher
statistical power. Those results are shown Supplemental Table 31, Supplemental Table 32 and
Supplemental Table 33 while Supplemental Table 34 gives the R2 values for these fits.
Supplemental Table 31: Model parameters fit to the proton data in the PIDE database combined with the data
collected in this work.

Parameter
c
σc
d
σd
f
σf
g
σg
h
σh
σcd
σcf
σcg
σch
σdf
σdg
σdh
σfg
σfh
σgh

D5%

7.91948E-01
2.82081E-02
2.22052E-14
7.60990E-01
2.30084E-02
2.54553E-02
3.23196E-02
2.76690E-02
5.00000E-01
2.42619E-01
3.29452E-04
1.15662E-04
3.67369E-04
-4.35740E-03
1.89417E-02
-1.47977E-02
8.63447E-02
-3.95478E-04
2.38174E-03
-5.00069E-03

D10%

7.74552E-01
2.70935E-02
2.22045E-14
7.25226E-01
2.36571E-02
2.55572E-02
1.91652E-02
2.23638E-02
5.00000E-01
1.97166E-01
3.16860E-04
1.09128E-04
2.77042E-04
-3.35042E-03
1.81421E-02
-1.16053E-02
6.76282E-02
-3.32258E-04
1.99516E-03
-3.28437E-03

D20%

7.49870E-01
2.69402E-02
2.22045E-14
6.58252E-01
2.54162E-02
2.60774E-02
8.76730E-03
1.71473E-02
5.00000E-01
1.54516E-01
4.59270E-04
1.16502E-04
2.01662E-04
-2.54987E-03
1.67975E-02
-8.17762E-03
4.79800E-02
-2.65496E-04
1.60815E-03
-1.96566E-03

D37%

7.14475E-01
2.80475E-02
2.22046E-14
5.73999E-01
2.83332E-02
2.73427E-02
2.22045E-14
1.22369E-02
5.00000E-01
1.15339E-01
7.89033E-04
1.46049E-04
1.41115E-04
-1.92272E-03
1.53302E-02
-5.07082E-03
3.03696E-02
-1.97219E-04
1.22815E-03
-1.03831E-03

D50%

6.90142E-01
2.98086E-02
2.22310E-14
4.27245E-01
3.53054E-02
2.75205E-02
2.22046E-14
9.56889E-03
5.00000E-01
9.37109E-02
6.75911E-04
1.68650E-04
1.09120E-04
-1.60137E-03
1.14109E-02
-3.02678E-03
1.83805E-02
-1.58137E-04
1.01451E-03
-6.56321E-04

SF2Gy

1.05001E+00
5.23090E-02
2.22045E-14
2.76445E-01
4.48311E-02
1.61656E-02
2.38852E-03
2.26468E-03
4.67529E-03
2.78150E-02
-1.68725E-03
7.66982E-05
6.73729E-05
-1.17357E-03
4.12902E-03
-4.54512E-04
3.46877E-03
-1.70963E-05
1.53967E-04
-4.58418E-05

Supplemental Table 32: Model parameters fit to the He-ion data in the PIDE database combined with the data
collected in this work.

Parameter
c
σc
d
σd
f
σf
g
σg
h
σh
σcd
σcf
σcg
σch
σdf
σdg
σdh
σfg
σfh
σgh

D5%

1.04780E+00
5.42169E-02
2.22045E-14
6.53046E-02
2.65441E-02
4.24151E-03
1.47517E-02
4.02525E-03
3.87311E-02
3.61239E-01
-2.02008E-05
-8.81988E-06
1.02056E-04
-1.39647E-02
2.04431E-04
-2.09229E-04
6.72822E-03
-1.23590E-05
9.15949E-04
-1.08785E-03

D10%

1.04072E+00
5.09764E-02
7.78489E-03
5.93334E-02
2.82650E-02
4.31749E-03
1.09784E-02
3.15552E-03
7.14691E-02
2.78172E-01
5.40244E-05
1.74189E-06
6.97653E-05
-9.57731E-03
1.83395E-04
-1.47868E-04
4.36331E-03
-9.76021E-06
7.12767E-04
-6.50527E-04

D20%

1.02178E+00
4.90772E-02
2.76345E-02
5.27288E-02
3.15239E-02
4.74185E-03
6.70673E-03
2.30860E-03
1.37130E-01
2.01132E-01
1.52981E-04
1.98449E-05
4.30288E-05
-6.05681E-03
1.68592E-04
-9.37433E-05
2.30969E-03
-7.69027E-06
5.55472E-04
-3.39318E-04
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D37%

9.90923E-01
4.95474E-02
4.24203E-02
4.78505E-02
3.57642E-02
5.56270E-03
3.28864E-03
1.58750E-03
1.76450E-01
1.37450E-01
2.23594E-04
4.90732E-05
2.50679E-05
-3.64044E-03
1.66333E-04
-5.64114E-05
1.11899E-03
-6.01748E-06
4.34717E-04
-1.57972E-04

D50%

9.65001E-01
5.15459E-02
4.84719E-02
4.59050E-02
3.88637E-02
6.39743E-03
1.76961E-03
1.21604E-03
1.78329E-01
1.05327E-01
2.58969E-04
7.90990E-05
1.75488E-05
-2.59697E-03
1.73543E-04
-4.02711E-05
6.95149E-04
-5.16469E-06
3.77101E-04
-9.26442E-05

SF2Gy

1.09046E+00
6.33957E-02
7.86959E-02
6.48099E-02
3.62921E-02
6.88036E-03
2.67036E-04
3.65781E-04
2.24264E-14
3.00307E-02
3.11745E-04
7.33837E-05
7.08048E-06
-1.00487E-03
2.87964E-04
-1.82826E-05
3.84475E-04
-1.76251E-06
1.18887E-04
-7.87203E-06

Supplemental Table 33: Model parameters fit to the C-ion data in the PIDE database combined with the data
collected in this work.

Parameter
c
σc
d
σd
f
σf
g
σg
h
σh
σcd
σcf
σcg
σch
σdf
σdg
σdh
σfg
σfh
σgh

D5%

9.79999E-01
2.71088E-02
1.30387E-01
5.13959E-02
1.87834E-02
2.15123E-03
6.83433E-03
2.25507E-03
1.38841E-01
1.71475E-01
-8.05359E-05
2.40485E-06
2.43720E-05
-2.99119E-03
1.00119E-04
-1.02586E-04
4.74017E-03
-3.84567E-06
2.32039E-04
-3.07186E-04

D10%

9.81562E-01
2.70109E-02
1.32748E-01
5.13087E-02
1.86770E-02
2.14926E-03
5.03179E-03
1.87041E-03
3.99502E-02
1.41871E-01
-6.13477E-05
3.85759E-06
1.96556E-05
-2.41558E-03
1.00104E-04
-8.45741E-05
3.93633E-03
-3.15652E-06
1.89318E-04
-2.11691E-04

D20%

9.74292E-01
2.88434E-02
1.32735E-01
5.36608E-02
1.88170E-02
2.33708E-03
3.25979E-03
1.52901E-03
2.70079E-14
1.16074E-01
-1.11549E-05
7.96358E-06
1.59711E-05
-2.01297E-03
1.14067E-04
-7.16056E-05
3.34649E-03
-2.76151E-06
1.64395E-04
-1.42104E-04

D37%

9.55371E-01
3.33777E-02
1.24134E-01
5.95739E-02
1.90323E-02
2.75347E-03
1.84313E-03
1.21525E-03
2.22292E-14
9.26400E-02
9.95318E-05
1.79436E-05
1.30701E-05
-1.72549E-03
1.49501E-04
-6.20522E-05
2.91246E-03
-2.51204E-06
1.48050E-04
-9.04873E-05

D50%

9.31113E-01
3.80019E-02
1.18378E-01
6.39276E-02
1.94642E-02
3.22089E-03
1.04647E-03
1.01324E-03
2.59148E-02
7.77626E-02
2.61539E-04
3.26373E-05
1.08440E-05
-1.52300E-03
1.87665E-04
-5.44336E-05
2.54944E-03
-2.38077E-06
1.39288E-04
-6.33960E-05

SF2Gy

1.00170E+00
5.05182E-02
1.13124E-01
9.93132E-02
1.86507E-02
4.00716E-03
2.22045E-14
3.44247E-04
2.22045E-14
2.59273E-02
1.32756E-08
2.32099E-05
6.07599E-06
-7.81126E-04
3.61881E-04
-2.99997E-05
1.36691E-03
-1.07676E-06
6.35851E-05
-7.05699E-06

Supplemental Table 34: R2 values for the fits of the unbinned PIDE database data combined with the data collected
in this work

Ion
Protons
He-ions
C-ions

D5%
0.8727
0.8374
0.8542

D10%
0.8754
0.8505
0.8597

R2 value
D20%
D37%
0.8679
0.8471
0.8556
0.8484
0.8453
0.8069

D50%
0.8244
0.8349
0.7640

SF2Gy
0.7917
0.8022
0.6297

As a general note, after incorporating our data into the training data, the uncertainties in
the model parameters are lower, and the R2 values of the fits are higher, implying an improved
performance of the model after incorporating our additional data into the training data.
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Supplemental Results 5: RPion versus RPphoton predictions
We predicted the relationship between ion and photon radiosensitivity for the parameters D10%, D37% and D50% (Figure 25). The predictions
for the parameters D5%, D20% and SF2Gy are given in Supplemental Figure 8.

Supplemental Figure 8 Predicted trends (with 95% confidence interval) and measured data for the linear relation between D5% (A-I), D20% (J-R) and SF2Gy (S-A) for ions
vs. photons. Numbers indicate the cell line and are given in Figure 23’s caption. Results for D10%, D37% and D50% are given in Figure 23.
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Using our model, we were able to predict the RPion versus RPphoton trend for three He-ion LET
values (2.2, 7.0 and 14.0 keV/μm) and three C-ion LET values (13.5, 27.9 and 60.5 keV/μm).
Supplemental Table 35 summarizes the accuracy of those predictions.
Supplemental Table 35: Root mean square percentage error between predicted RPion and RPphoton trend and values
derived from survival data for cells exposed to He-, C-ions and 6 MV x-rays

LET
Parameter
D5%
D10%
D20%
D37%
D50%
SF2Gy
Total
Combined

Root mean square percentage error
Protons
He-ions
1.2
2.6
9.9
2.2
7.0
14.0
13.5
keV/µm keV/µm keV/µm keV/µm keV/µm keV/µm keV/µm
15.0% 12.8%
6.8% 10.7% 6.1%
9.9%
8.6%
13.7% 11.9%
7.1%
9.6% 5.1%
8.9%
7.3%
12.9% 13.2%
9.6% 10.7% 5.6%
9.5%
9.7%
13.9% 17.2% 14.1% 15.1% 7.9% 11.7% 17.3%
15.8% 20.8% 17.8% 19.8% 10.1% 13.8% 24.8%
19.6% 22.8% 10.8% 25.0% 9.4% 28.4% 31.1%
15.3%

17.0%

11.7%

16.2%

7.6%
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15.3%

18.7%

C-ions
27.9
keV/µm
5.3%
6.0%
8.4%
11.7%
16.4%
26.4%

Total
60.5 Combined
keV/µm
11.2%
21.8%
10.6%
21.3%
11.8%
23.4%
15.7%
29.6%
19.6%
35.2%
25.7%
51.1%

14.3%

32.1%

Supplemental Results 6: Accuracy of RBE versus RPphoton predictions
Equation 3 predicts the RBE for a given ion LET for a particular cell line based upon its radiosensitivity. The predictions for RBED10%,
RBED37% and RBED50% are given in Figure 26, while the predictions for RBED5% and RBED20% are given in Supplemental Figure 9.

Supplemental Figure 9: Measured RBE values of for individual cell lines exposed to protons, helium ions and carbon ions (black points) and the trends predicted by our
model in terms of the cell line’s D5%,photon (A-I) and D20%,photon (J-R) with 95% confidence intervals (shaded gray area)). Numbers indicate the cell line and are given in the
caption of Figure 23. These cell lines and LET values were not used to determine the linear functions and served as a validation of the model. Plots for RBED10% ,
RBED20% and RBED50% are in given in Figure 26.
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Using our model, we were able to predict the RBE versus RPphoton trend for three He-ion LET
values (2.2, 7.0 and 14.0 keV/μm) and three C-ion LET values (13.5, 27.9 and 60.5 keV/μm).
Supplemental Table 36 summarizes the accuracy of those predictions.
Supplemental Table 36: Root mean square percentage error between predicted RBE and RPphoton trend and values
derived from survival data for cells exposed to He-, C-ions and 6 MV x-rays.

LET
Parameter
RBE (D5%)
RBE (D10%)
RBE (D20%)
RBE (D37%)
RBE (D50%)
Total
Combined

Root mean square percentage error
Protons
He-ions
1.2
2.6
9.9
2.2
7.0
14.0
13.5
keV/µm keV/µm keV/µm keV/µm keV/µm keV/µm keV/µm
12.6% 10.7%
8.1%
8.1% 6.2%
9.3%
8.4%
11.6% 10.3%
8.1%
5.0% 5.3%
8.1%
6.8%
11.4% 13.5% 11.4% 6.6% 6.2%
8.5%
8.5%
14.0% 22.5% 18.6% 13.4% 9.2% 10.3% 13.9%
17.9% 31.3% 24.7% 18.8% 12.4% 12.0% 18.5%
13.7%

19.4%

15.6%

11.6%

13.6%
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9.7%

12.0%

C-ions
27.9
keV/µm
5.4%
5.7%
8.1%
11.6%
17.9%
10.8%

Total
60.5 Combined
keV/µm
9.6%
17.0%
9.0%
17.1%
10.5%
18.1%
15.1%
20.5%
19.8%
22.9%
19.3%

Supplemental Results 7: Survival curves predicted for PANC-1, AsPC-1 and Panc 10.05
cell lines exposed to C-ion radiation
As we did not expose the AsPC-1 cells to protons or treat them with DNA repair
inhibitors, we did not include their predicted survival curves in Figure 28, Figure 30, or Figure
31. Further, as we did not expose the PANC1 or PANC1005 cells treated with DNA repair
inhibitors to 28 keV/μm C-ions, their predicted survival curves are not shown in Figure 30, or
Figure 31. For completeness, these predicted survival curves are given below:

Supplemental Figure 10: Predicted (orange, with 95% confidence interval) and measured (black, with 95%
confidence interval) survival curve for Panc1 cells exposed to C-ions with LETs ranging from 13.5 to 60.5 keV/μm.
Cells were treated with the DNA repair inhibitors to inhibit DNA-PKcs (E,H), ATR (F,I), with just the DMSO vehicle
(D,G), and without any treatment (A-C).
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Supplemental Results 8: Prediction of cell lines treated with ion and DNA repair
inhibitors
Supplemental Figure 11 shows the response of DNA repair-inhibited cells compared to
the 95% prediction interval based upon the untreated cells for the radiosensitivity parameters
D5%, D20% and SF2Gy. The data for the parameters D10%, D37% and D50% is given in Figure 29.

Supplemental Figure 11: Measured ion versus photon radiosensitivity for cells treated with DNA repair inhibitors
(red) superimposed on the 95% prediction interval derived from the data not treated with drugs (gray) for the
parameters D5% (A-D), D20% (E-H) and SF2Gy (I-L), for cells exposed to 9.9 keV/µm protons, 14.0 keV/µm He-ions,
13.5 keV/µm C-ions and 60.5 keV/µm C-ions. Results for D10%, D37% and D50% are given in Figure 29. Numbers
indicate the cell line and given in the Figure 29‘s caption.
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Chapter 5 – Towards personalized ion radiotherapy
I.

The current state of individualized radiosensitivity
In current clinical practice in radiation therapy, radiation doses are prescribed based on

the histological category of the patient’s tumor, with all patients with the same tumor histology
being prescribed a dose-fractionation regimen tailored to treating tumors of that histological
category, subject to a few additional considerations with regards to their disease staging,
patient performance status and other prognostic factors. But while it is well-known that tumors
within the same histological category can have widely different responses to radiation, there is
currently no robust way to predict individual patient tumor sensitivity and adjust the treatment
accordingly. Thus, in current clinical practice, is it is likely that a substantial number of patients
receive suboptimal treatments – either receiving insufficient doses when their tumors are
radioresistant and failing to achieve complete tumor control, or receiving unnecessarily high
doses when their tumors are radiosensitive and being subjected to unnecessary normal tissue
toxicities.
Towards addressing these inter-patient heterogeneities, a great amount of research is
currently underway that is focused on identifying biomarkers to predict patient response to
radiation, with the ultimate goal of being able to identify the radioresponsive and radioresistant
patients before treatment in order to select the best treatment option for a given patient. While
these efforts have identified a number of factors that are known to greatly influence cell
radiosensitivity, including DNA repair capacity74-76, tumor microenvironment factors103, and
biological factors related to gene expression104, none of these techniques have yet to be
translated into common clinical practice. But as a first step towards the clinic, there is a current
clinical trial underway for medulloblastoma patients (NCT01878617) which aims to stratify
patients based on their molecular subtype. This trial would decrease the radiation doses
delivered to patients with low clinical risk and in the WNT molecular subtype, since the WNT
subtype is typically highly responsive to radiation212, in the hopes that the deleterious effects of
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high doses radiation to the brain and spinal cord can be spared while achieving the same
survival rates. So while there is still much work to be done to make personalized radiation
therapy part of the standard of care, it is clear that tailoring a patient’s radiation therapy
prescription based upon molecular biomarkers is becoming closer to a clinical reality.
But with respect to ion therapies such techniques are still quite far from clinical
implementation, as most of the effort towards personalizing radiation therapy has been
predicated on predicting radiation response to photons. In the absence of methods to predict
ion response directly, we must resort to translating the approaches used to predict photon
response to the domain of ions. But that imposes a secondary hurdle: not only must such a
framework account for the heterogeneity in response between patients, but ideally, it must also
account for the differential tumor response between radiation types, which is not itself fully
understood.

II.

Our work highlight the need for personalized ion therapies
In the context of ion therapy, it has often been thought that these heterogeneities can

be mitigated to some extent by the use of ions instead of photons, due to a number of
observations of lesser dependence of cell response on a number of factors including, DNA
repair capacity40, genetic background41, cell cycle phase39, and inter-and intra-tumor
heterogeneity97,118,119. However, while it is true that there is a larger absolute range in the
radiosensitivity values for cells exposed to photons compared to higher LET ions, as we show
in Chapter 2, when one accounts for the increased sensitivity of cells to ions, and calculates the
relative amount of variability instead of the absolute amount, no significant differences can be
seen between radiation types. This is an extremely important revelation given that tumors are
not prescribed the same physical dose between radiation types, and the absorbed doses
prescribed are scaled down depending on the assumed relative biological effectiveness of the
radiation. Thus, disregarding any improved dose conformality with ions that may allow for
higher biologically equivalent doses being delivered to the tumor, if the absorbed dose of an ion
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treatment is scaled down to account for the ion’s RBE and the tumor is inherently
radioresistant, it will receive comparably insufficient doses across radiation types, and underrespond regardless of the choice of radiation.
This argument tacitly hinges on the assumption that if a cell is radioresistant to photons,
it will also be radioresistant to ions, and in Chapter 2, we could only infer this indirectly from the
fact that the relative variability in cell radiosensitivities did not depend on radiation type.
Notably, if the relative variability in radiosensitivities between radiation types were the same, it
would likely be the case that if a cell were radioresistant to photons, it would likely also be
relatively radioresistant to protons or C-ions by the same amount. But to support this directly, in
Chapter 4, we showed that across 6 parameterizations of radiosensitivity, the dose required to
achieve 5%, 10%, 20%, 37% and 50% survival, (D5%, D10%, D20%, D37%, D50%) as well as the
surviving fraction for a dose of 2 Gy (SF2Gy), ion radiosensitivity is linearly correlated with
photon radiosensitivity. Since the relationship between ion and photon radiosensitivity for a
given LET is governed by a linear function, the hierarchy of radiosensitivities between cell lines
is preserved since this function is monotonic, and, for a small intercept, their relative spacing is
preserved as well, since all radiosensitivities are scaled by the same factor for the same LET.
Thus, as these linear trends can account for the majority of the variance in radiosensistivities
between radiation types (on the order of 95-99% based upon the R2 values of the for D10%,ion
versus for D10%,photon correlations), our data in Chapter 4 establish that as a general matter,
cells that are radiosensitive (or radioresistant) to photons are relatively radiosensitive (or
radioresistant) to ions by the same relative amount. While this may seem like an intuitively
obvious result, it is not a fact that, to our knowledge, has previously been established.
However, for very high LET ions, it may be the case that this axiom no longer holds,
and this is because as our trends in Chapter 4 suggest, as the LET is increased, the slope of
this linear correlation decreases, while its intercept increases. Thus, for high LET values, it may
be that the intercept of the correlation is comparable in magnitude to the slope, and thus the
intercept might perturb the slope’s scaling enough that the relative spread in the data is no
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longer preserved. However, as we did not see any significant differences in the relative
variability of the radiosensitivities of cells exposed to 60.5 keV/µm C-ions which are
comparable to the middle of clinically relevant C-ion SOBPs, if this occurs at all for C-ions, it
likely doesn’t occur until much higher LETs that are of less relevance to C-ion therapies since
they correspond to a relatively small portion of a clinically relevant treatment field.
This is all to say that the data we present in Chapter 2 (and supported by the data we
presented in Chapter 4) clearly establish that the personalization of ion therapies can provide
as much benefit as the personalization of photon therapies, since there is a comparable
amount of heterogeneity in cellular radiation response whether to photons, protons, or C-ions.
However, there is an additional corollary to these data that highlight the importance of
personalizing of ion therapies, which is the apparent shortcomings of using the quantity RBE to
account for differences in radiation quality across clinical ion treatment fields. These
shortcomings are twofold. First, as we showed in Chapter 2, cell lines in the same histological
category can have substantially different RBEs at higher LETs, and as we show in Chapter 3,
the degree to which RBE varies with LET can vary substantially between cell lines, even for cell
lines within the same histological category. For example, the relative range of RBED10% values
we measured in non-small cell lung cancer, pancreatic adenocarcinoma and glioblastoma cell
lines exposed to 60.5 keV/µm C-ions were 45±7%, 30±13% and 56±15%, respectively. Also, as
we noted in Chapter 2, the variations in intrinsic radiosensitivity between cell lines, even when
exposed to C-ions, are of the same order, and often larger than the variations in RBE between
cell lines. For example, the relative range of D10% values we measured in non-small cell lung
cancer, pancreatic adenocarcinoma and glioblastoma cell lines exposed to 60.5 keV/µm C-ions
were 55±5%, 98±14% and 51±10%, respectively. Thus, as current clinical practice in C-ion
therapy estimates the RBE in a treatment field based upon the response of a small subset of
cell lines, the true RBE for a patient’s tumor can vary substantially from what is assumed in
treatment planning, but also, failing to account for a patient’s individual radiosensitivity likely
causes as great, if not greater differences in treatment outcomes than failing to account for
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their individual RBE. Thus, as we recommend in Chapter 2, RBE cannot best be used to
account for differences in the biological effect of radiation without the knowledge of intrinsic
radiosensitivity as well, and thus modelling efforts which seek to predict how RBE varies as a
function of ion LET would be better directed towards predicting cell radiosensitivity to ions.
Ideally, if the patient’s intrinsic radiosensitivity to ions can be incorporated into the treatment
planning optimization, then RBE as a parameter would become redundant, as the treatment
can be optimized according to the patient’s intrinsic radiosensitivity directly to deliver the
appropriate absorbed doses to that patient.

III.

The implications of our work towards future personalized ion therapies
Towards predicting individual ion radiosensitivity in addition to RBE, in Chapter 4 we

presented a model that predicts a cell’s radiosensitivity to ions on the basis of the linear
dependence on its radiosensitivity to photons. Our model, PORTAL, provides a number of
advantages in the context of personalized ion therapy when compared to the currently
implemented clinical models of ion RBE, the local effect model (LEM) and microdosimetric
kinetic model (MKM). With LEM and MKM although it is technically feasible to predict ion
radiosensitivity directly, the MKM model fixes the β value in the linear quadratic model between
radiation qualities, which is contrary to some experimental observations of differing β values for
certain cell lines between differing radiation qualities68,69, while with the LEM, the computation
of a particular cell’s ion survival curve for a given radiation quality is too computationally
expensive to be used in a clinical setting. Additionally, both of these models require
sophisticated Monte Carlo calculations to be performed to determine microdosimetric quantities
used in the model (in the case of MKM) or to determine the local dose distribution in a cell
nucleus (in the case of LEM) which are technically demanding, and for which much expertise is
required. By contrast, PORTAL can easily and rapidly predict a cell’s ion survival curve using
only its photon survival curve (which is also required for LEM and MKM) and the dose-weighted
LET (which is easier to determine and can be measured directly as described by Kanai et al.208
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) as its inputs. PORTAL also appears to have similar (or superior) predictive accuracy to these
models, suggesting that it may be an ideal candidate to use for future personalization of ion
therapies.
But towards truly personalizing ion therapies, the question remains as to which of the
biological factors that are known to govern radiosensitivity to photons can be incorporated into
any approach that predicts response to ion therapies. This is because factors whose impact
varies greatly between radiation qualities may not suitably predict radiation response across
the large range of radiation qualities present in a single ion therapy field. In Chapter 2, we
showed that one particular factor, DNA repair capacity, which is known to be extremely
important in governing photon radiosensitivity, but is often thought to be of less importance in
governing cell radiosensitivity to higher LET radiation40, is in fact not significantly less important
to the relative variability in cellular radiosensitivity between radiation qualities at least up to 60.5
keV/µm, when accounting for the mean radiosensitivity at each radiation quality. Thus, DNA
repair capacity, whose relative importance in governing the heterogeneous response between
cells remains insensitive to changes in radiation quality, is likely a factor around which such an
effort to personalize ion therapies might revolve.
To incorporate information about a cell line’s DNA repair capacity into any personalized
ion therapy regimen it is of utmost importance to understand both how and the extent to which
it influences intrinsic cellular radiosensitivity, but also how its influence might vary across
radiation types. This is because among the DNA repair pathways used to repair the most
deleterious lesions induced by radiation (DNA double strand breaks, DSBs), non-homologous
end-joining (NHEJ) repair and homologous recombination repair (HR), there is an expectation
that HR may be more suitable to repairing the more complex lesions induced by higher LET
radiation. Thus, the importance of a cell’s DNA repair capacity in governing its radiosensitivity
to ions may depend differently on its capacity to repair via NHEJ than via HR, and this
dependence may also change as a function of ion LET.
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Indeed, in Chapter 3, we showed in particular, that deficiencies in DNA repair pathways
result in remarkable differences in radiosensitivity to protons, He-ions and C-ions, and not just
photons, which implies that DNA repair capacity remains an important determining factor in cell
radiosensitivity even for ions. These data were supported by our observations of the repair of
radiation induced DNA DSB foci, which showed that even for 60.5 keV/µm, the fraction of DSBs
repaired or the number left unrepaired are correlated with cell survival. Altogether these data
suggest that the degree to which a cell can repair its DNA remains an important factor in
determining its survival to high LET radiation.
Moreover, we also showed that the relative importance of NHEJ and HR varies with ion
LET, namely that the relative importance of HR increases with ion LET although the relative
importance of NHEJ remains the highest across all LETs. These results stress the importance
of incorporating DNA repair capacity into any future personalized ion therapy regimen, as not
only is a cell’s capacity to repair its DNA of significant importance in determining its
radiosensitivity to ions, but that differences in repair capacity via different pathways (or in the
factors that govern DNA repair pathways choice) may influence how a cell’s radiosensitivity
varies with ion LET. Thus, models that strive to predict individual radiosensitivity to ions must
not only account for DNA repair capacity within their framework, but also must account for how
its relative importance varies between radiation qualities. This presents a special problem for
ion therapies, as it is challenging to train any such model on for a single radiation quality such
as x-rays, let alone for the continuous spectrum of radiation qualities presented by
therapeutically relevant ion beams.
However, in Chapter 4, we presented a model called PORTAL that predicts a cell’s ion
radiosensitivity in terms of its photon radiosensitivity, and our data suggest that this model’s
predictions are insensitive to differences in DNA repair capacity. Because it’s predictions are
not perturbed by differences in DNA repair capacity, whether naturally occurring, induced by
genetic modification, or induced by pharmacological inhibition, it stands to reason that this
model can be combined with any model that predicts a cell’s photon radiosensitivity on the
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basis of its DNA repair capacity to predict that cell’s ion radiosensitivity. It is important to make
the distinction here that while, in principle any model that predicts a cell’s photon
radiosensitivity on any basis can be combined with any model that predicts ion radiosensitivity
on the basis of photon radiosensitivity, we do not know a priori whether the errors inherent to
any such models are correlated, and thus whether the errors on the final prediction will be
amplified by their combination. But since PORTAL is based on the fact that radiosensitivites are
linearly correlated, and since this correlation is independent of DNA repair capacity, we can be
confident that if the photon radiosensitivity is predicted on the basis of the cell’s DNA repair
capacity, errors in predicting the photon response are unlikely to be amplified when passing
them through PORTAL. And since PORTAL’s predictions seem to be independent to a large
number of other factors that determine radiosensitivity, including anatomical site, histological
type and genotype, it is likely that PORTAL can be combined with other models that predicts
ion radiosensitivity without issue.
This is especially important in the context of novel therapies that combine DNA repair
inhibitors with radiation therapy, as it is not known whether other models can account for any
differences induced by the drugs, but have shown directly that PORTAL’s predictions are
compatible with cells treated with DNA repair inhibitors. And since the data we present in
Chapter 2 suggest that cells treated with DNA repair inhibitors have comparable variability in
radiosensitivity between radiation qualities, properly accounting for intrinsic radiosensitivity
remains an important consideration for future personalized ion radiotherapy, even if drugs are
used to radiosensitize the tumors.
However, there are two main limitations to the work presented here which both relate to
the ultimate applicability of these techniques to the clinic. First, all of the work presented here
are in vitro studies which must first be translated into in vivo studies before ultimately being
translated into clinical use. But since a number of factors beyond DNA repair capacity influence
the radiation response of tumors, including tumor microenvironment factors103, tumor
oxygenation185, and involvement of the immune system210, is unclear to what extent PORTAL
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can ultimately be translated into clinical practice. Nevertheless, since intrinsic cellular
radiosensitivity is largely indicative of tumor radiosensitivity 211, we expect that PORTAL might
still be applicable in an in vivo setting. However, future work must be done to verify the extent
to which PORTAL’s predictions can be reproduced in an in vivo setting.
The second main limitation of this work is that the ideal use of PORTAL in the clinic
would depend strongly on our ability to predict an individual patient’s radiosensitivity to photons
to use in conjunction with PORTAL to predict their radiosensitivity to ions. While such a model
does not currently exist, the data presented in this work suggest that as DNA repair capacity
greatly influences cellular radiosensitivity across radiation types, it might be possible to create a
model that predicts photon radiosensitivity based on a genomic signature related to DNA repair
capacity.

IV.

Future directions – predicting photon radiosensitivity as a means to predict
ion radiosensitivity
In Chapters 2-4 we established that DNA repair capacity is an important factor that

influences cell radiosensitivity to photons, protons, He-ions and C-ions, which suggest that a
cell’s DNA repair could be used as the basis for a predictive model of radiosensitivity that would
be applicable to ions. And, although in Chapter 3 we showed that the relative importance of the
NHEJ and HR pathways in determining radiosensitivity vary with ion LET which might
complicate the task of ion radiosensitivity directly on the basis of a cell’s DNA repair capacity, in
Chapter 4 we showed that ion radiosensitivity can be predicted with our model PORTAL in
spite of any differences in DNA repair capacity, whether naturally occurring, or induced by
genetic modification or pharmacological inhibition. Thus, if there were a model that could
predict a cell’s photon radiosensitivity on the basis of its DNA repair capacity, it could be
combined with PORTAL (or potentially other models) to predict a cell’s ion radiosensitivity.
Towards this, in collaboration with our colleagues at Baylor University (in large part
thanks to Dr. Hua-Sheng Chiu, Assistant Professor who performed all of the computational

156

work towards this), we are working towards creating a model that predicts radiosensitivity to
photons based upon a genomic signature of DNA repair genes called DRIVER (DNA Repair to
IndiVidualizE Radiotherapy). Briefly, DRIVER relates gene expression and copy number
variations for a panel of 25 genes associated with DNA repair (see Supplemental Note 7) to a
number of different biological endpoints (D10%, D20%, D37% and D50%) which can then be used to
predict the cell survival curve.
As a proof-of-concept, we trained this function on a panel of cell lines for which we had
measured the x-ray survival or which were included in the PIDE database, and for which there
was genomic information available on the Cancer Cell Line Encyclopedia (CCLE) database213
(see Supplemental Note 8). We then tested DRIVER’s accuracy in predicting the
radiosensitivity of a number of other cell lines that had been reported in the literature, and for
which the genomic information was available on the CCLE 213 (see Supplemental Note 8).

Figure 36: Predictions of photon radiosensitivity using DRIVER for a number of cell lines in the literature. (A) Shows
the predicted and measured radiosensitivity values. Each black point corresponds to the measured and predicted
radiosensitivity measured for a single cell line (see Supplemental Note 8 for details of the cell lines) (B) shows the
distribution of relative deviations between the measured and prediction D10% values.

Figure 36 compares radiosensitivity (D10%) values predicted by DRIVER to the
measured values reported in the literature and shows that DRIVER predicted their
radiosensitivity within a RMSPE of 34.0%. While this variability is on the same order as the
variability in radiosensitivity typically observed between cell lines, it is important to note that
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DRIVER’s predictions are correlated with the measured survival data with a Pearson R value of
0.464 (Figure 36A). While this correlation coefficient may not at first seem impressive, as a
proof-of-concept, the fact that with a relatively limited panel of DNA repair genes and a
relatively limited training data set we were able to explain roughly 21.5% of the variance in the
intrinsic radiosensitivity between cell lines is actually quite remarkable, particularly when one
considers how many different biological factors are known to contribute to a cell’s
radiosensitivity. Although the slightly negative R2 value suggests that the predictions currently
vary less from the mean radiosensitivity predicted than the individual radiosensitivities
predicted, we expect that after incorporating a larger training dataset into DRIVER, which will
allow us to expand our gene panel, we will be able to improve the predictive power of DRIVER
to the point where it can be used, at the very least to stratify tumors as either radioresistant or
radiosensitive, or perhaps to the point where it can be combined with PORTAL to make
clinically useful predictions of ion radiosensitivity.

158

V.

Supplemental Information

Supplemental Note 7: Gene panel used in DRIVER

Supplemental Table 37: Panel of genes used by DRIVER to predict each radiosensitivity parameter (D10%, D20%,
D37% and D50%) in terms of the gene expression or gene copy number, and the importance rank of each gene.

Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Parameter

D10%
CUL4B_CNV
RAD54L_EXP
HUS1B_EXP
CNOT8_CNV
ATF2_CNV
BRSK1_EXP
ZNF385A_EXP
TNP1_CNV
WEE1_CNV
CDKN1A_EXP
TOPORS_EXP
WRN_EXP
EEF1E1_CNV
ERCC6_CNV
DDB2_EXP
CDKN1B_CNV
PPP1R15A_EXP
RBM38_EXP
IGHMBP2_EXP
CDKN1B_EXP
MRE11A_EXP
E2F4_EXP
RFWD3_EXP
PRKDC_EXP
HMBS_CNV

Gene Expression (GENE_EXP) or
Gene Copy Number Variation (GENE_CNV)
D20%
D37%
RAD54L_EXP
CUL4B_CNV
HUS1B_EXP
ATF2_CNV
WEE1_CNV
CDKN1A_EXP
CNOT8_CNV
TNP1_CNV
BRSK1_EXP
WRN_EXP
ZNF385A_EXP
ERCC6_CNV
DDB2_EXP
CDKN1B_EXP
EEF1E1_CNV
HMBS_CNV
TOPORS_EXP
HELB_EXP
POLA1_CNV
IGHMBP2_EXP
MPG_CNV
ING1_EXP
MRE11A_EXP
PRKDC_EXP
CDKN1B_CNV
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HUS1B_EXP
CUL4B_CNV
RAD54L_EXP
MPG_CNV
WEE1_CNV
CDKN1A_EXP
WRN_EXP
CDKN1B_EXP
ATF2_CNV
DDB2_EXP
BRSK1_EXP
TNP1_CNV
ERCC6_CNV
HELB_EXP
HMBS_CNV
EEF1E1_CNV
ZNF385A_EXP
POLA1_CNV
CNOT8_CNV
ING1_EXP
APTX_CNV
TFDP2_CNV
H2AFX_EXP
POLD1_EXP
RFC3_EXP

D50%

HUS1B_EXP
CUL4B_CNV
MPG_CNV
CDKN1A_EXP
CDKN1B_EXP
WRN_EXP
WEE1_CNV
RAD54L_EXP
ATF2_CNV
HELB_EXP
DDB2_EXP
POLD1_EXP
APTX_CNV
RFC3_EXP
BRSK1_EXP
ING1_EXP
POLA1_CNV
EEF1E1_CNV
HMBS_CNV
H2AFX_EXP
RAD54L_CNV
TNP1_CNV
ERCC6_CNV
PLK3_CNV
TFDP2_CNV

Supplemental Note 8: Cell lines used to train and validate DRIVER
To train DRIVER, we used cell survival data we collected, as well as from a number of
literature sources for which the genomic data were available on the CCLE213. In cases where
data existed from multiple sources for the same cell line, the D10%, D20%, D37% and D50% values
were averaged. These data are summarized in Supplemental Table 38. Uncertainties were not
considered in the training data since the data in the PIDE did not contain uncertainty estimates
and thus uncertainties in the training data could not be accounted for when training DRIVER.
To validate DRIVER, we used cell survival data we collected as well as from a number
of sources in the literature where the α and β values were reported and where the genomic
data were available on the CCLE213. We combined data from multiple sources estimating the
D10%, D20%, D37% and D50% values for each experiment from the reported α and β and then fitting
these estimates to the linear quadratic model to determine the average survival curve
parameters from which the expected D10%, D20%, D37% and D50% values were determined along
with their uncertainties.
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Supplemental Table 38: Cell survival data used to train DRIVER. The survival data were data we measured, or were
obtained from the PIDE database2 or from Liu et al. 2015 121 as noted. Data from multiple sources were averaged.
The tumor histologies were those reported on the CCLE

Cell Line
HCT_116
HCC1937
KS-1
MeWo
SCC-25
NCI-H23
H4
A172
HL-60
MDA-MB-436
Hep_G2
LN-229
SF126
Hep_3B2.1-7
NCI-H1563
NCI-H520
HuH-7
COLO-679
NCI-H460
PC-3
HCC827
U-87_MG
ONS-76
M059K
SW_1573
BxPC-3
A549
NCI-H1915
U-251_MG
Calu-6
NCI-H2126
KNS-60
DU_145
PANC-1
T98G
HT-1080
NCI-H1437
ABC-1
NCI-H1792
NCI-H1703
NCI-H1869
Panc_10.05
HCC-44
NCI-H1299

Histology
Colon carcinoma
Breast ductal carcinoma
Glioblastoma
Melanoma
Squamous cell carcinoma tongue
Lung adenocarcinmoa
Astrocytoma
Glioblastoma
Acute Myeloid Leukemia
Invasive ductal carcinoma
Hepatoblastoma
Glioblastoma
Glioblastoma
Pediatric Hepatocellular
carcinoma
Lung Adenocarcinoma
Squamous cell lung
carcinomaa
Adult hepatocellular
carcinmoa
Cutaneous melanoma
Large cell lung carcinmoa
Prostate carcinoma
Lung adenocarcinoma
Glioblastoma
Medduloblastoma
Glioblastoma
Lung adenocarcinmoa
Pancreatic adenocarcinoma
Lung adenocarcinoma
Non-small cell lung
carcinoma
Astrocytoma
Lung adenocarcinoma
Large cell lung carcinoma
Glioblastoma
Prostate carcinoma
Pancreatic ductal
adecarcinoma
Glioblastoma
Fibrosarcoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Squamous cell lung
carcinoma
Squamous cell lung
carcinoma
Pancreatic ductal
adecarcinoma
Lung adenocarcinoma
Large cell lung carcinoma

D10%
(Gy)

D20%
(Gy)

D37%
(Gy)

D50%
(Gy)%

PIDE

4.59

3.39

2.23

1.60

Liu et al
PIDE
PIDE
PIDE
PIDE
PIDE
PIDE
PIDE

4.60
4.66
4.74
4.81
4.93
5.04
5.07
5.10

3.50
3.43
3.64
4.02
3.89
4.20
3.92
3.96

2.38
2.25
2.52
3.17
2.81
3.29
2.73
2.78

1.74
1.61
1.87
2.64
2.17
2.73
2.03
2.09

PIDE

5.21

4.21

3.14

2.49

Liu et al

5.41

4.05

2.70

1.95

Liu et al

5.59

4.29

2.96

2.19

PIDE

5.80

4.30

2.84

2.04

PIDE
PIDE
PIDE
Liu et al
PIDE
PIDE
Our data
Liu et al
Our data
Liu et al, PIDE

5.81
5.93
6.19
6.38
6.38
6.60
6.62
6.67
6.82
6.84

4.58
4.59
5.13
5.11
4.87
5.47
5.15
5.30
5.65
5.32

3.31
3.21
3.99
3.76
3.35
4.24
3.62
3.84
4.39
3.77

2.56
2.40
3.28
2.93
2.47
3.48
2.72
2.96
3.61
2.87

Liu et al

6.91

5.69

4.37

3.55

PIDE
Liu et al
Liu et al
PIDE
PIDE

7.28
7.34
7.46
7.49
8.56

5.88
5.84
5.94
6.00
6.80

4.38
4.25
4.33
4.40
4.93

3.46
3.29
3.35
3.43
3.80

Our data

8.73

6.77

4.74

3.55

Our data, PIDE
Our data, PIDE
Liu et al, PIDE
Liu et al
Liu et al

9.88
4.20
4.25
4.33
4.57

8.01
3.08
3.44
3.39
3.63

6.04
2.01
2.58
2.40
2.63

4.86
1.44
2.05
1.82
2.03

Liu et al

4.59

3.39

2.23

1.60

Liu et al

4.60

3.50

2.38

1.74

Our data

4.66

3.43

2.25

1.61

Liu et al
Our data, PIDE

4.74
4.81

3.64
4.02

2.52
3.17

1.87
2.64

Data Source
PIDE
Our data
PIDE
PIDE
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4.20
4.25
4.33
4.57

3.08
3.44
3.39
3.63

2.01
2.58
2.40
2.63

1.44
2.05
1.82
2.03

Supplemental Table 39: Cell survival data used to validate DRIVER. The survival data were obtained from the
literature across a number of sources as well as data we measured. For cell lines for which multiple sources of data
existed, the data were combined by fitting the D10%, D20%, D37%, and D50% from each experiment to the linear
quadratic model to determine expected survival curves, these radiosensitivity parameters and their uncertainties.

Cell
Line

Histology

Data Source

H358

Lung adenocarcinoma

H522

Lung adenocarcinoma

H322

Lung adenocarcinoma

Carmichael et al. 1989 214
Carmichael et al. 1989 214,
Anakura et al. 2019 215
Carmichael et al. 1989 214,
Warenius et al. 1994 216

COR-L23

Lung adenosquamous
carcinoma
Lung adenosquamous
carcinoma
Lung squamous cell
carcinoma
Lung large cell carcinoma
Lung small cell lung
cancer
Lung small cell lung
cancer
Lung small cell lung
cancer
Lung small cell lung
cancer
Lung small cell lung
cancer
Lung adenocarcinoma
Lung adenocarcinoma
Lung squamous cell
carcinoma
Lung large cell carcinoma

LN-18

Glioblastoma

SW_1783

Astrocytoma

42-MGBA

Glioblastoma

U118_MG

Glioblastoma

RKO

Colon carcinoma

HT-29

Colon carcinoma

SW620

Colon carcinoma

LoVo

Colon adenocarcinoma

SW480

Colon adenocarcinoma

HCT-15
COLO320
SW403
SW948
SW1116
SW48

Colon adenocarcinoma

H596
H647
H226
H661
H69
H209
H82
H526
H841
H1650
H1975
LK-2

D10%
(Gy)

D20%
(Gy)

D37%
(Gy)

D50%
(Gy)%

5.21±0.32

4.04±0.19

2.83±0.22

2.12±0.25

5.19±0.54

3.90±0.32

2.61±0.38

1.90±0.39

Carmichael et al. 1989 214

5.38±0.68

4.27±0.60

3.10±0.50

2.39±0.44

Carmichael et al. 1989 214

5.09±0.89

3.87±0.72

2.64±0.54

1.94±0.43

4.72±0.46

3.67±0.39

2.57±0.32

1.93±0.27

Carmichael et al. 1989 214

5.39±0.75

4.14±0.62

2.87±0.48

2.13±0.39

Carmichael et al. 1989 214
Carmichael et al. 1989 214,
Kehwar et al. 2017 217
Carmichael et al. 1989 214,
Kehwar et al. 2017 217
Carmichael et al. 1989 214,
Kehwar et al. 2017 217

6.32±0.38

5.16±0.35

3.91±0.31

3.14±0.28

3.02±0.11

2.15±0.07

1.36±0.04

0.95±0.03

3.91±0.10

2.95±0.06

1.99±0.07

1.45±0.08

3.95±0.11

3.18±0.07

2.35±0.07

1.85±0.09

Carmichael et al. 1989 214

3.03±0.78

2.40±0.71

1.73±0.61

1.33±0.53

Carmichael et al. 1989 214

5.96±0.23

4.73±0.20

3.44±0.17

2.66±0.15

215

Anakura et al. 2019
Anakura et al. 2019 215

3.57±0.15
5.07±0.19

2.49±0.09
3.71±0.11

1.55±0.10
2.42±0.13

1.07±0.09
1.72±0.13

Anakura et al. 2019 215

6.63±0.22

5.33±0.13

3.94±0.15

3.09±0.19

Warenius et al. 1994 216
Barazzuol et al. 2012 218,
Mayhead 2018 219,
Chew et al. 2019 220
Chautard et al. 2010 221,
Ferrandon et al. 2015 222

3.61±0.21

2.69±0.15

1.80±0.10

1.30±0.07

5.04±0.35

3.86±0.21

2.67±0.24

1.97±0.27

6.26±0.69

4.90±0.42

3.48±0.48

2.64±0.56

Marill 2014 223

4.30±0.27

3.14±0.20

2.04±0.13

1.45±0.09

5.37±0.49

4.30±0.30

3.15±0.34

2.45±0.42

4.56±0.12

3.38±0.07

2.23±0.09

1.60±0.09

6.21±0.18

4.89±0.11

3.50±0.13

2.67±0.15

4.48±0.18

3.62±0.11

2.70±0.13

2.13±0.16

4.31±0.32

3.37±0.19

2.39±0.22

1.81±0.26

Ferrandon et al. 2015 ,
Taghian et al. 1992 224,
Gursoy-Yuzugullu et al.
2017225
Franken et al. 2013 226,
Williams et al. 2007 227
Castro Kreder et. al. 2004 228,
Lawrence et. al. 2001 229,
Shewach et. al 1994 230,
Williams et al. 2007 227,
Leith et al. 1991 231
Castro Kreder et. al. 2004 228,
Lawrence et. al. 2001 229,
Leith et al. 1991 231
Williams et al. 2007 227,
Leith et al. 1991 231
Williams et al. 2007 227,
Leith et al. 1991 231
Leith et al. 1991 231
Leith et al. 1991 231,
Warenius et al. 1994 216
Leith et al. 1991 231
Leith et al. 1991 231
Leith et al. 1991 231
Leith et al. 1991 231
222

Colon adenocarcinoma
Colon adenocarcinoma
Colon adenocarcinoma
Colon adenocarcinoma
Colon adenocarcinoma
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5.36±0.30

4.20±0.18

2.98±0.21

2.26±0.24

3.92±0.48

3.10±0.40

2.23±0.32

1.71±0.27

3.44±0.06

2.73±0.04

1.98±0.04

1.53±0.05

5.70±1.19
4.65±0.79
4.94±1.72
2.85±0.25

4.14±0.85
3.63±0.63
3.71±1.24
2.09±0.18

2.68±0.55
2.57±0.47
2.49±0.81
1.37±0.12

1.89±0.40
1.94±0.38
1.80±0.59
0.98±0.09

MCF7
MDA-MB231
SNU-449
SK-HEP1
G-361
RPMI7951
SK-MEL28

Hepatocellular carcinoma

Castro Kreder et. al. 2004 228,
McGinn et al. 1996 232,
El-Awady et al. 2003 233
Trainor et. al 2012 234,
Rezakhani et al. 2020 235
Choi et al. 2019 236

Hepatocellular carcinoma

Choi et al. 2019 236

Breast ductal carcinoma
Breast adenocarcinoma

Melanoma
Melanoma
Melanoma

2.90±0.06

5.66±0.16

4.48±0.10

3.23±0.11

2.49±0.14

4.35±0.27

3.37±0.16

2.35±0.19

1.76±0.21

7.49±0.21

6.05±0.13

4.51±0.14

3.57±0.18

Hojo et al. 2017 237

5.72±0.49

4.70±0.42

3.61±0.34

2.94±0.30

Hojo et al. 2017 237

9.33±2.06

7.60±1.64

5.73±1.20

4.58±0.94

Ando and Woodhead 2016 ,
Warenius et al. 1994 216
Rofstad 1986, Warenius et al.
1994 216
Rofstad 1986, Marshall et al.
1994 216
68

Vulvar leiomyosarcoma

Warenius et al. 1994 216

RT-112

Bladder Carcinoma

LNCaP

Prostate carcinoma
Pancreatic
adenocarcinoma
Pancreatic
adenocarcinoma
Pancreatic
adenocarcinoma
Pancreatic
adenocarcinoma
Pancreatic
adenocarcinoma
Pancreatic
adenocarcinoma
Pancreatic
adenocarcinoma

PK1
HS766T
HPAC

2.04±0.24
3.87±0.45

Leiomyosarcoma

Capan1

2.68±0.20
3.48±0.07

Ovarian carcinoma

AsPC1

3.76±0.18

4.81±0.53

SK-UT-1
SK-LMS1

L3.3

4.78±0.29

4.42±0.09

A2780

MiaPaca2

2.32±0.10

6.31±0.65

OAW42

FaDu

2.88±0.08

7.70±0.77

Todorovic et al. 2019 238,
Wozny et al. 2017 239
Warenius et al. 1994 216
Franken et al. 2013 226,
Warenius et al. 1994 216
Warenius et al. 1994 216

KYSE450

3.78±0.07

5.28±0.10

Esophageal squamous
cell carcinoma
Esophageal squamous
cell carcinoma
Hypoharayngeal
squamous cell carcinoma
Ovarian carcinoma

OE21

4.61±0.11

El-Awady et al. 2003 233,
Warenius et al. 1994 216
El-Awady et al. 2003 233

4.47±0.11

3.32±0.07

2.20±0.08

1.59±0.08

3.01±0.28

2.15±0.20

1.37±0.13

0.96±0.09

3.20±0.20

2.31±0.12

1.48±0.14

1.04±0.13

3.68±0.23

2.91±0.20

2.10±0.17

1.61±0.15

6.28±0.81

4.99±0.65

3.62±0.49

2.79±0.40

6.60±0.08

5.12±0.05

3.58±0.06

2.68±0.06

2.54±0.18

1.80±0.12

1.13±0.08

0.79±0.05

Our data

4.55±0.11

3.47±0.15

2.38±0.17

1.75±0.17

Our data

8.91±0.28

7.17±0.20

5.32±0.21

4.18±0.25

Our data

5.38±0.08

4.34±0.08

3.23±0.11

2.54±0.12

Our data

5.84±0.12

4.88±0.14

3.85±0.17

3.20±0.20

Our data

6.41±0.23

5.01±0.28

3.55±0.32

2.68±0.32

Our data

4.26±0.07

3.31±0.07

2.33±0.08

1.75±0.08

Our data

4.81±0.14

3.82±0.17

2.78±0.21

2.14±0.23
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Appendix 1 – Cell culture equipment, media and reagents
I.

Cell lines and details on culturing conditions
The technical details of the cell culture media and additives are given in Supplemental

Table 41. Frozen cells (either in liquid N2 or in a -80°C freezer) were thawed and cultured in T25 and T-75 flasks for 2-3 weeks prior to irradiation. 24 h prior to irradiation, they were seeded
into either 6-well plates or T-12.5 flasks to perform the clonogenic assays. To transfer the cells
from the culture flasks to the colongenic vessels, the cells were washed with phosphate
buffered saline (PBS), and treated with trypsin. For the exposures at the HIMAC’s horizontal
beamline, 2 hours prior to irradiation the 6-well plates filled with ~15 ml of media and sealed
with aluminum sealers to ensure complete filling of media in each well. The sealers were
perforated immediately after irradiation to restore airflow. Details of these reagents and
equipment are given in Supplemental Table 40. Details of the media and additives used to
culture cells are given in Supplemental Table 41. All cell lines were maintained in a humidified
atmosphere at 37°C, with 5% CO2 in the air.

Supplemental Table 40. Reagents and supplies used to culture and process the cells.
Reagent/Supply
T-25 flask
T-75 flask
T-12.5 flask
6-well plates
PBS
Trypsin
Aluminum Sealer
Crystal Violet
DMSO
DAPI
Goat serum
Non-fat dry milk

Manufacturer (Cat. #)
Thermo Scientific (156367)
Thermo Scientific (156499)
Cell Treat (229321)
Corning Costar (3506)
Hyclone (SH30256.01)
Corning (25-053-CL)
Bio Rad (MSF1001)
Sigma (C0775-25G)
Tocris (3716)
Thermo-Fisher (622842)
Abcam (AB7481)
Bio-Rad (170-6404)
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Supplemental Table 41. Cell culture media and additives.
Cell Line
M059K
M059J
H1299
H460
BxPC-3
AsPC-1
PANC1
PANC1-XBP1-KO
Panc 10.05
MiaPaca-2
L3.3
HS766T
PK1
Capan-1
HPAC
MDA-MB-231
MDA-MB-231XBP1-KO
HT1080
HT1080-shDNAPKcs
HT1080shRAD51IND
HCC1937
HCC1937+BRCA1

Culture Medium; Details – Manufacturer
(Cat. #)
1:1 DMEM/F-12 Ham; with L-glutamine,
NaHCO3, without HEPES – Sigma
(D8062)

Media Additives – Manufacturer
(Cat. #)
10% FBS – Sigma (F0926)
1% PS – Hyclone (SV30010)
15 mM HEPES – Sigma (H0887)

RPMI 1640; with L-glutamine, NaHCO3 –
Sigma (R8758)

10% FBS – Sigma (F0926)
1% PS – Hyclone (SV30010)

DMEM: high glucose; with 4500 mg/L
glucose, L-glutamine, sodium pyruvate,
NaHCO3 – Sigma (D6429)

10% FBS – Sigma (F0926)
1% PS – Hyclone (SV30010)

MEM Alpha Modification; with LGlutamine, with Ribonucleusides and
Deoxyribonucleuosides – Hyclone
(SH30265.01)

10% FBS – Sigma (F0926)
1% PS – Hyclone (SV30010)

RPMI 1640; with L-glutamine, NaHCO3 –
Sigma (R8758)

10% FBS – Sigma (F0926)
1% PS – Hyclone (SV30010)
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Appendix 2 – Quantifying cell survival to photons, protons,
helium ions and carbon ions by clonogenic assay
I.

Introduction

A substantial number of the conclusions drawn from this work rely on interpretations of in vitro
radiation survival data derived from clonogenic survival assays. In general, this assay consists
of seeding known numbers of cells from single cell suspensions into growth dishes, irradiating
the cells, and then allowing them to grow and form colonies240. Cells that are not inactivated by
the radiation will divide indefinitely after irradiation and go on to form colonies which can then
be counted at the termination of the assay to determine how many cells survived the radiation
exposure. With the knowledge of how many cells were seeded, the surviving fraction can then
be calculated. By estimating the surviving fraction over a range of radiation doses, one can fit
these data to a survival model (such as the linear quadratic model) to obtain the cells’ survival
curve from which any desired biological endpoint can be estimated.
Performing the assay is not a technically challenging task, but it does consist of a large
number of steps, frequently leaving researchers with several options with regards to how to
proceed to the next step – both in terms of preparing and scoring the samples, as well as
analyzing the resulting data collected. In this appendix, we summarize the manner in which the
clonogenic survival data presented in this work were prepared, collected and analyzed, and
offer rationales for the methods employed wherever appropriate.

II.

Preparing the samples before or after irradiation
With respect to preparing the dishes for clonogenic assay, there are two general

approaches. In the first method, flasks containing cells are irradiated, and then immediately
following the irradiation, cells are seeded from the flasks into dishes to grow for the duration of
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the clonogenic assay. In the second, cells are seeded into the clonogenic assay dishes prior to
irradiation, and then the clonogenic assay dishes are irradiated. While there are a number of
advantages and disadvantages to both methods, the approach we used was to seed the cells
into clonongenic assay dishes prior to irradiation. The primary reason for this choice was the
throughput to be gained from preparing the samples in this manner.
When seeding before irradiation, to produce a single clonogenic survival curve, an
experimenter needs only a single flask of cells from which dishes corresponding to every dose
level in the survival curve can be produced. Accordingly, the concentration of cells in this flask
must only be measured a single time, and in principle, all of the dishes can be seeded from the
same diluted cell stock. This is extremely efficient in terms of supplies, but more importantly, in
terms of labor, as most of the time spent in preparing samples for clonogenic assay is
consumed in creating the single cell suspension, measuring the concentration of cells in it,
diluting it the appropriate amount to allow for seeding, and calculating how much volume of the
suspension to seed. Since there is only one flask needed to seed all the samples beforehand, a
large number of dishes can be produced with relatively little labor.
By contrast, when seeding after irradiation, the technician must create and quantify
single cell suspensions for each dose point in the assay, which is a substantial amount of extra
labor given that typically 4-6 dose points are used. But beyond the direct additional labor cost,
the fact that so much additional manpower is needed to process the samples for a single
survival curve greatly limits the throughput of the radiation exposures. This is because, in
general it is unwise to allow the cells to rest for a long period of time after irradiation, since the
combined effects of the cellular response to the radiation damage and the stress induced when
preparing of the dishes (which involves treating the cells with digestive enzymes such as
trypsin to bring them off the surface of the dish to form single cell suspensions) might result in
differences in overall survival240. Consequently, when seeding after irradiation, one is generally
limited more by how many samples one can reasonably process immediately after irradiation
than by how much total labor one is willing to expend.
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But seeding prior to irradiation introduces a few challenges. One such challenge is that
the cells often take some time to fall out of suspension and adhere to the surface of the dish. If
the cells are still in suspension when the dish is irradiated, then they will not be at the expected
depth, and receive a different radiation dose, especially for ions at the end of their range. Thus
it is important that all of the cells have adhered to the bottom of the dish prior to irradiation to
ensure robust dosimetry, and so it is undesirable to seed the cells immediately prior to
irradiation. But if the cells are seeded too far in advance, since they will grow and divide in the
period of time between seeding and irradiating, the number of cells in the dish at the time of
irradiation may be significantly higher than the number of cells seeded, resulting in
overestimated survival fractions.
In principle, both these issues can be solved by seeding the cells at the optimal time
prior to irradiation that will allow them just enough time to adhere to the dish, but not enough
time to grow significantly. This is aided by the fact that in many cases, adherent cells cannot
progress through the cell cycle, and thus do not proliferate, without being adhered241-246. But in
general this is difficult to do in a consistent manner across a variety of different cell lines, since
the optimal time before irradiation to seed the dishes will depend on the doubling time of the
cells and also their adhesion time, both of which can vary substantially between cell lines.
Instead, we have found it preferable simply to seed the cells 24 h prior to irradiation,
which allows ample time for the cells to adhere to the dishes, and afterwards, to correct for any
increased multiplicity in fast-growing cell lines as needed. In general, however, we have not
noticed any significant increases in multiplicity using this 24 h pre-irradiation incubation time,
likely in part due to the lack of proliferation while the cells are in suspension, but also in part
due to lesser proliferation once they are adhered as a result of less direct contact between
cells247. This likely occurs since the cells are seeded at very low densities into the dishes and
any factors contributing to growth from cell-cell signaling are removed from the media as part of
the seeding process and take some time to be restored.
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III.

Irradiating the dishes
Wherever possible, it is desirable to irradiate the cells through the bottom of the dish,

such that the radiation must only pass through a constant and small thickness of plastic before
impinging on the cells. This is in contrast to irradiating from the top, such that the beam passes
through the media before impinging on the cells. Irradiating from the bottom is desirable since it
is much easier to perform the dosimetry, since the media contributes only a very small amount
of scattered radiation to the dose received by the cells, and the small thickness of plastic
between the cells and the beam can be accounted by when doing the dosimetry, either
performing the dosimetry using the dish itself as part of the setup, or by cutting out the bottom
of the dish, and placing it immediately in front of the detector used to measure radiation dose. If
the radiation passes through the medium before reaching the cells, it is much more difficult to
perform the dosimetry precisely, since the volume of media used between experiments is not
constant, and the media’s meniscus results in different portions of the dish being at different
depths, and thus receiving different doses.
As we generally use clinical radiation therapy units to perform our irradiations, our
general approach to irradiating from the bottom is to place the dishes on the patient treatment
couch, rotate the gantry to 180° degrees, such that the beam would pass through the couch,
add any additional buildup material we elect to use, and then place the dishes atop this buildup
material. This then allows us to perform our dosimetry measurements in the same setup, with
our detectors set up on the top of the treatment couch and build-up material, with the gantry at
180°. Specific details of the irradiation setups we used for 6 MV x-rays, protons, He ions and C
ions are described below.
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III.1

Irradiation conditions for 6 MV x-rays

All photon irradiations in this work were
performed were performed at the University of Texas
MD Anderson Cancer Center, Houston, TX using
clinical 6 MV x-ray therapy units (Varian 2100 and
Varian TrueBeam series linear accelerators). In our
setup, we placed the gantry at 180° and irradiated the
samples through the treatment couch, placing our
samples on top of water equivalent plastic blocks such
that they were at a water equivalent depth of 10 cm,
and with water equivalent plastic positioned on top of
the samples to provide 10 cm of backscatter material
(Figure 37, Figure 38). The cells are exposed in 6-well
plates which were positioned within a custom acrylic
insert that can be seen in Supplemental Figure 13. The

Figure 37: Setup used for photon beam
irradiations. The gantry is placed at 180°
beneath the treatment couch (black slab).
Upon the couch, water equivalent plastic
(brown blocks) are placed, with cells residing
in 6-well plates placed in a custom acrylic
insert (clear plastic in the middle), with tissue
paper separating the plates inside the insert
(white).

insert closely conforms to the exterior of the
plates, providing material to ensure that
lateral charged particle equilibrium conditions
are satisfied at the sample position. We
irradiate the samples using a 40 x 40 cm2
field size, which allows four 6-well plates to
be irradiated simultaneously. The dosimetry
for this setup was performed using optically
stimulated luminescence (OSL) dosimeters
and is described in Supplemental Note 9.

Figure 38: Percent dose versus depth (black curve) for
the Truebeam 6 MV x-ray unit used to perform our x-ray
exposures at MD Anderson Cancer Center. The sample
position is denoted by the vertical blue dashed line.
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III.2

Irradiation conditions for protons

All proton irradiations in this work were performed at the University of Texas MD
Anderson Cancer Center Proton Therapy Center, in Houston, Texas. We used un-modulated
pristine beams of nominal energy 100 MeV (4.3 cm
range in water), which were achieved by parking the
range modulator wheel (RMW) at the shallowest step
during irradiation. Similar to our photon irradiations,
we placed the gantry at 180° and irradiated cells
through the treatment couch as can be seen in Figure
39. Water equivalent plastic blocks were then placed
atop the treatment couch, and the dishes to be
irradiated were placed on top of them, such that the
cells were at the desired depth in water. The
irradiations were performed using an 18 x 18 cm2 field
size delivered using the medium snout with an 18 x
18 cm2 aperture which permitted two 6-well plates to
be irradiated simultaneously. No additional

Figure 39: Setup used for proton irradiations.
The gantry is placed at 180° beneath the
treatment couch (black slab). Dishes
containing cells are placed on the treatment
couch on top of additional water equivalent
plastic as needed to achieve the desired
depth.

backscatter material was used as
backscatter does not contribute
significantly to the dose deposited by
protons.
Three depths in water were used
for this work, which were nominally 1.1
cm, 3.8 cm, and 4.3 cm. The two
shallower depths are proximal to the
Bragg peak, while the 4.3 cm depth is
distal to the Bragg peak as can be seen in

Figure 40: Percent dose (black curve, black axis) or doseweighted LET in water (blue curve, blue axis) versus depth for
the 100 MeV proton beam exposures performed at MD
Anderson Cancer Center. The sample positions used are
denoted by the vertical blue dashed lines.
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Figure 40. Although there is greater setup uncertainty when using the position that is distal to
the Bragg peak due to the high dose and LET gradients in this region, it was necessary to
make measurements in the distal portion of the Bragg peak to achieve relatively high LETs for
protons which are comparable to the LETs of He ions and lower LET C-ions. The dosimetry for
these conditions were performed using a parallel plate ionization chamber as described in
Supplemental Note 10. The dose weighted LETs at these three positions were 1.2 keV/µm, 2.6
keV/µm and 9.9 keV/µm, respectively, which were determined by Monte Carlo simulation.
Details of these simulations can be found in Supplemental Note 11.

III.3

Irradiation conditions for helium and carbon ion irradiations

Helium and Carbon ion irradiations in this work were performed at the Heavy Ion
Medical Accelerator (HIMAC) in Chiba, Japan with pristine beams of nominal energy 150
MeV/nucleon (He-ions) and 290 MeV/nucleon (C-ions). This beamline is a horizontal beamline
that uses water-equivalent energy degraders to achieve the specified dose-weighted LETs at
the sample position (Figure 41). The LET values in this beamline are determined as
summarized in Kanai et al., 1997 208 by use of a tissue-equivalent proportional counter.

Figure 41: (A) Horizontal beamline setup at HIMAC used to perform He- and C-ion exposures. Samples are placed
on a conveyor belt which transports them to the beam aperture, whereupon they are exposed with the desired dose
and radiation quality. Note that biological samples must be sealed to prevent media leakage when stood vertically in
the beamline. (B) Energy degraders upstream of the sample position are controlled remotely and inserted into the
beam path to give the desired LET (depth) at the sample position.

The LETs chosen in this work were 2.20, 6.97 and 14.0 keV/µm for the He-ions, and
13.5, 27.9 and 60.5 keV/µm for the C-ions. All of these depths correspond to depths in water
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that are proximal to the Bragg peak for each beam, as can be seen in Figure 42. These
conditions were selected so as to avoid the extremely high dose and LET gradients that are
present in the Bragg peak, which cause extremely large dosimetric uncertainties associated
with sample alignment.

Figure 42: Irradiation conditions for the He- and C-ion irradiations performed at HIMAC.
Percentage depth dose for He- (A) and C-ions (B). Dose weighted LET in water for He- (C)
and C-ions (D). The dashed lines indicate the depths at which our cell lines were exposed.

IV.

Terminating the assay (cell fixation)
After the cells have been irradiated, they must be incubated for sufficient time for them

to form colonies. Typically, this incubation period is on the order of 7-14 days, however the
precise time depends on the growth characteristics of the cell line used. There are a few factors
to consider when choosing when to terminate the assay. Most importantly, as we typically
define viable colonies as containing at least 50 cells240, this incubation period must be at least
5-6 doubling times to ensure that cells have had sufficient time to actually reach the threshold
size. But in practice, it is better to choose a time that significantly exceeds this minimum time
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because some cells whose DNA is damaged by the radiation will undergo temporary cell cycle
arrest while repairing the lesions in order to allow them more time to complete the repair248.
Thus, there may be a lag between irradiating the cells and the resumption of cell proliferation in
the dish. Also, it is generally preferable to allow the colonies to grow significantly larger than the
minimum threshold size in order to facilitate scoring them unambiguously.
But a secondary consideration must be made with regards to how the colony density
within a dish will impact our ability to score the colonies. If a very long post-irradiation
incubation period is chosen, the viable colonies will grow to cover a substantial area of the dish,
and for a sufficiently long growth period, there will be a significant amount of overlap between
adjacent colonies. Overlapping colonies makes scoring them much more challenging, and so
care must be taken to select a time that does not result in a significant amount of colony
overlap. The colony fixation times used in this work were arrived at by monitoring cell growth
within the dishes for a few days to weeks after irradiation, and terminating the assay when
colonies were relatively large, but before they had begun overlapping. The fixation times used
for the cell lines measured in this work are given in Table 8.
When it comes time to actually terminating the assay, there are two main results we
wish to achieve: that the cells in the dishes die but remain adhered to the dish, and that they
become stained with a dye so that they can be easily counted. These two objectives can be
achieved simultaneously by creating a mixture of 0.5% crystal violet dissolved in pure ethanol
and using it to fix and stain the dishes. The ethanol acts as the chemical fixative, while the
crystal violet acts to dye the cells a bright violet color, greatly enhancing their contrast against
the transparent dish. Since the only thing we wish to achieve in fixing the cells is for them to
remain adhered to the dish and to die, ethanol is the ideal choice of fixative since it will quickly
kill all the cells, can be disposed of easily down the conventional sink, and happens to also
readily dissolve crystal violet, so it can stain the cells simultaneously. Thus, in this work, all the
cells were fixed and stained with a mixture of 0.5% crystal violet in ethanol.
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Table 8: Cell lines used in this work, their histology, and clonogenic incubation period. GBM: Glioblastoma
Multiforme. NSCLC: Non-small cell lung carcinoma. PAAD: Pancreatic adenocarcinoma. FSA: Fibrosarcoma. DCIS:
Breast Ductal Carcinoma In Situ

Cell Line
M059K
M059J
H1299
H460
BxPC-3
AsPC-1
PANC-1
Panc 10.05
MiaPaca-2
L3.3
HS766T
PK1
Capan-1
HPAC
HT1080
HCC1937

V.

Cancer Histology
GBM
GBM
NSCLC
NSCLC
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
PAAD
FSA
DCIS

Clonogenic Incubation Time
9-10 days
9-10 days
8 days
10 days
14 days
14 days
14 days
14 days
10 days
21 days
14 days
14 days
14 days
14 days
8 days
18-20 days

Scoring viable colonies
A colony is generally defined as a grouping containing 50 or more cells240. Historically,

the colonies formed in these assays were counted manually, which is to say that dishes would
be visually inspected, and the number of colonies in them would be counted by visual
inspection. This would generally include an unaided visual survey to identify large colonies,
followed by a detailed survey of the smaller groupings with the aid of a microscope to
determine whether they met the colony threshold criteria. In this work, we automated the
counting of colonies through the creation of ImageJ macros designed to score the colonies in
scanned images of the dishes, which were individually calibrated to score colonies of each of
the cell lines used in this work. These methods are discussed in detail in Appendix III.

VI.

Analyzing survival data from one experiment

Generally, the process of analyzing data from clonogenic assay consists of determining the
survival fraction over a range of doses, fitting the data to a model to produce a survival curve,
and then using the survival curve to extract whatever biological endpoints are desired.
Descriptions of these calculations are described in the sections below.
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VI.1

Determining the survival fraction

The survival fraction for each dose, SFD, is determined by dividing the number of
colonies formed, Nc, by the number of viable cells seeded, nv.:

𝑆𝑆𝑆𝑆𝐷𝐷 =

𝑁𝑁𝑐𝑐
𝑛𝑛𝑣𝑣

However, when the dishes are prepared, we know only the total number of cells
seeded, ns, though not all of the seeded cells are necessarily viable and will go on to form a
colony independent the of radiation dose. While there are methods to count only the viable
population of cells within a suspension (e.g. by trypan blue exclusion249-251) we are still limited in
our ability to count any population of cells in suspension accurately and quickly. And so in
practice, when accounting for this viable cell subpopulation, we estimate the plating efficiency,
PE, (as detailed in VI.3) which is the proportion of viable cells in the population, and normalize
the data using this factor, calculating the survival fraction as:

𝑆𝑆𝑆𝑆𝐷𝐷 =

𝑁𝑁𝑐𝑐
𝑛𝑛𝑠𝑠 ∙ 𝑃𝑃𝑃𝑃

An additional benefit of employing this normalization factor is that it removes any added
systematic errors arising from the dilution process that would perturb the relationship between
the volume of the cell suspension added to a dish and the actual number of cells that that
volume is expected to contain.

VI.2

Uncertainties in the survival fraction

When cells are seeded into dishes for clonogenic assay, it is very difficult to know the
true number of cells seeded. Generally, the concentration of cells in a suspension is known,
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and a volume of that suspension is administered to the well so that the expected number of
cells seeded, ���,
𝑛𝑛𝑠𝑠 is equal to the desired number ns. So the survival fraction we measure at each

dose is truly:

𝑆𝑆𝑆𝑆𝐷𝐷 =

𝑁𝑁𝑐𝑐
���𝑠𝑠 ∙ 𝑃𝑃𝑃𝑃
𝑛𝑛

Under the assumption that the uncertainties in these quantities are not correlated, the
uncertaintiy in SFD, can be written in terms of the error propagation formula252 as:

𝜎𝜎𝑆𝑆𝑆𝑆𝐷𝐷 = ��

𝜕𝜕𝑆𝑆𝑆𝑆𝐷𝐷 2 2
𝜕𝜕𝑆𝑆𝑆𝑆𝐷𝐷 2 2
𝜕𝜕𝑆𝑆𝑆𝑆𝐷𝐷 2 2
� 𝜎𝜎𝑁𝑁𝑐𝑐 + �
� 𝜎𝜎𝑛𝑛���𝑠𝑠 + �
� 𝜎𝜎𝑃𝑃𝑃𝑃
𝜕𝜕𝑁𝑁𝑐𝑐
𝜕𝜕𝑛𝑛
���𝑠𝑠
𝜕𝜕𝜕𝜕𝜕𝜕

Since Nc and ���
𝑛𝑛𝑠𝑠 are Poisson distributed, their uncertainty can be taken to be �𝑁𝑁𝑐𝑐 and

���𝑠𝑠 respectively, while the uncertainty on the PE can be determined as described in VI.4.
�𝑛𝑛
Thus, we can calculate the uncertainty on the SFD’s as:

𝜎𝜎𝑆𝑆𝑆𝑆𝐷𝐷 = ��

2

2
2
1
𝑁𝑁𝑐𝑐
𝑁𝑁𝑐𝑐
2
� 𝑁𝑁𝑐𝑐 + �
𝑛𝑛𝑠𝑠 + �
���
�
𝜎𝜎𝑃𝑃𝑃𝑃
�
2
2
���
���
𝑛𝑛
���
∗
𝑃𝑃𝐸𝐸
𝑛𝑛𝑠𝑠 ∗ 𝑃𝑃𝑃𝑃
𝑛𝑛𝑠𝑠 ∗ 𝑃𝑃𝑃𝑃
𝑠𝑠

Which can be reduced to:

𝜎𝜎𝑆𝑆𝑆𝑆𝐷𝐷 =

𝑁𝑁𝑐𝑐
1
1
𝜎𝜎𝑃𝑃𝑃𝑃 2
� + +�
�
𝑛𝑛𝑠𝑠 ∗ 𝑃𝑃𝑃𝑃 𝑁𝑁𝑐𝑐 𝑛𝑛
���
���𝑠𝑠
𝑃𝑃𝑃𝑃
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Or in terms of SFD:

1
1
𝜎𝜎𝑃𝑃𝑃𝑃 2
𝜎𝜎𝑆𝑆𝑆𝑆𝐷𝐷 = 𝑆𝑆𝑆𝑆𝐷𝐷 � + + �
�
���𝑠𝑠
𝑃𝑃𝑃𝑃
𝑁𝑁𝑐𝑐 𝑛𝑛
From this form, it is evident that the uncertainties can be minimized when large
numbers of cells are seeded and large numbers of colonies are counted, however the
uncertainties are always bounded by our ability to estimate the plating efficiency.

VI.3

Combining the surviving fractions from multiple replicates

Typically, when samples are prepared for clonogenic assay, a number of replicates are
prepared for a single experiment, usually using a variety of numbers of cells seeded for the
same doses. This serves to increase the statistical power of the experiment, decrease the
likelihood that none of the dishes for a given dose will have a suitable number of colonies to
count, as well as to allow for the exclusion of outlying data, which is a common occurrence in
clonongenic assays. In particular, it is common to see that for larger numbers of cells seeded,
smaller surviving fractions are estimated due to systematic undercounting of colonies due to
colony overlap253.
A statistical approach to combining these data and excluding outlying data is described
by Gupta et al.253, whereby the z-tests are performed between the different estimates of the
SFs across seeding numbers, and exclusion criteria are set to decide upon the exclusion of
outliers. In our work, we used this approach to exclude data whose Z score exceeded 1.65 (i.e.
p<0.05 that the variation occurred from random chance). Then, to combine the data from
different replicates, as recommended by Gupta et al.253, rather than simply average the
measured SFs between replicates, we account for our improved confidence in the dishes with
larger seeding numbers by summing the number of colonies counted, Nc,i, across all included
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replicates, i, and dividing by the sum across all replicates of the expected number of cells
seeded, ����
𝑛𝑛𝑠𝑠,𝚤𝚤 :

𝑆𝑆𝑆𝑆𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =

1 ∑𝑖𝑖 𝑁𝑁𝑐𝑐,𝑖𝑖
𝑛𝑛𝑠𝑠,𝚤𝚤
𝑃𝑃𝑃𝑃 ∑𝑖𝑖 ����

This expression is mathematically equivalent to considering all included replicates as
one large replicate, with the number of cells seeded to be ∑𝑖𝑖 ����
𝑛𝑛𝑠𝑠,𝚤𝚤 and the number of colonies
counted to be ∑𝑖𝑖 𝑁𝑁𝑐𝑐,𝑖𝑖 . Thus the uncertainty on the SF estimated from the combination of the
replicates is simply:

1
1
𝜎𝜎𝑃𝑃𝑃𝑃 2
+
+�
�
𝜎𝜎𝑆𝑆𝑆𝑆𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝑆𝑆𝑆𝑆𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 �
∑𝑖𝑖 𝑁𝑁𝑐𝑐,𝑖𝑖 ∑𝑖𝑖 ����
𝑛𝑛𝑠𝑠,𝚤𝚤
𝑃𝑃𝑃𝑃
VI.4

Determining the plating efficiency

Commonly, the plating efficiency is estimated from the survival fraction measured at 0
Gy, since this is simply the fraction of viable cells that will form colonies in the absence of
radiation240. However, there are a number of reasons why this method may be undesirable.
First, if the control dish fails to form colonies, or cannot be accurately counted due to significant
colony overlap or contamination, then the whole experiment is lost because the plating
efficiency cannot be calculated. Second, if the control dishes happen to be outliers, there is no
way of knowing, and this error will be propagated across the whole experiment, creating an
outlying result for the whole experiment. Third, the control dish is actually the least precisely
measured dish of the whole assay. This is because generally, we increase the number of cells
seeded as the dose is increased to ensure that a statistically powerful number of colonies can
be measured for lower survival levels, and thus the number of colonies measured tends to be
approximately the same across all survival levels. But for lower survival levels, significantly
more cells need to be seeded to observe the same number of colonies, so the relative
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uncertainty on the number of cells seeded at lower survival levels is far lower. Thus, when the
number of colonies counted across doses is kept relatively invariant, the relative uncertainty in
the control dish tends to be the highest of all the dishes in the experiment.
This is aggravated by the fact that in the control dish, except in cases where cells form
very densely packed colonies, we must err towards seeding for lower colony densities to
prevent overlap, since the colonies tend to be larger in the controls than in the irradiated plates
due to there being no growth delay post-irradiation. So for an experiment performed in
triplicate, we will typically seed on the order of a few hundred cells, and count on the order of
an hundred colonies in all of the wells of the control combined. However, the uncertainty in both
of these quantities, which are Poisson distributed, is relatively large – for example, if we count
100 colonies across all controls the standard error is ±10, which means that our overall
uncertainty in the plating efficiency estimated this way will typically exceed 10%. We would
then propagate this >10% uncertainty into all of our data, greatly limiting the precision of the
whole assay.
But these problems with regards to estimating the plating efficiency can be mitigated by
instead using the whole dataset to estimate it. This both removes the dependence of the whole
experiment on the integrity of a single condition, while also leveraging the statistical power of all
of the data when estimating the plating efficiency instead of simply a subset of it, which in turn
allows for it to be estimated more precisely. This can be achieved by calculating the survival
quotient for each dose, SQD, which is simply the survival fraction without accounting for the
plating efficiency:

𝑆𝑆𝑆𝑆𝐷𝐷 =

𝑁𝑁𝑐𝑐
𝑛𝑛𝑠𝑠

Or after combining the results from all the included replicates:
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Then, since

𝑆𝑆𝑆𝑆𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =

∑𝑖𝑖 𝑁𝑁𝑐𝑐,𝑖𝑖
∑𝑖𝑖 ����
𝑛𝑛𝑠𝑠,𝚤𝚤

𝑆𝑆𝑆𝑆𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝑃𝑃𝑃𝑃 ∙ 𝑆𝑆𝑆𝑆𝐷𝐷,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
If we plot all the SQD,combined values versus dose, we can fit them to a modified version of
the linear quadratic model of the form:

𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝐷𝐷) = 𝑃𝑃𝑃𝑃 ∙ 𝑒𝑒 −𝛼𝛼∙𝐷𝐷− 𝛽𝛽∙𝐷𝐷

2

This expression contains the plating efficiency, PE, and so this fit will give us an
estimate of the PE that leverages the statistical power of our whole dataset when estimating it,
thus giving us a more precise estimate. Proof that this technique is more precise than using the
SQD,combined value at 0 Gy is given via Monte Carlo calculation as described in Supplemental
Note 12. In this work, all of the PEs were estimated by fitting all the SQD,combined values for a
given experiment to the above function, via variance-weighted least squares minimization in
Graph Pad Prism 7 (Graph Pad, San Diego, CA). This weighting is necessary both to ensure
that the differing uncertainties in the measurements are accounted for in the fit, but also
because the survival levels general span several orders of magnitude, and thus the absolute
deviation of the fit from the data at low survival level gives a negligible contribution to the sum
of square errors if not weighted. This in turn would mean that if unweighted, the fit would be
allowed to err by orders of magnitude from the data at low survival levels without consequence.
The uncertainties in the survival quotient needed for this fitting can be estimated by analogy
from the expression for the uncertainty on the surviving fraction, but disregarding the PE and
σPE terms:
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1
1
𝜎𝜎𝑆𝑆𝑆𝑆𝐷𝐷 = 𝑆𝑆𝑆𝑆𝐷𝐷 � +
���𝑠𝑠
𝑁𝑁𝑐𝑐 𝑛𝑛

In this work, the uncertainty in the plating efficiency, σPE, was obtained from the
uncertainty on the fit parameters, as reported by Graph Pad Prism, which correspond to the
square roots of the diagonal elements of the covariance matrix associated with the fit.

VII.

Combining data from multiple experiments and obtaining the survival curve
parameters for the linear quadratic model
From a single experiment, we can estimate the parameters of the survival curve by

fitting the survival fractions to a survival model, such as the linear quadratic model:

𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝐷𝐷) = 𝑒𝑒 −𝛼𝛼∙𝐷𝐷− 𝛽𝛽∙𝐷𝐷

2

But generally, since there is inherently a large amount of variability between
independent experiments in clonogenic assay254, it is necessary to perform multiple
independent experiments for the same conditions to assess the cells’ response without greatly
underestimating the assay’s precision. To combine the data from several experiments, one can
simply take the collection of all SFD,combined values measured across independent experiments, j,
and fit them simultaneously to the linear quadratic model:

𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑗𝑗 (𝐷𝐷) = 𝑒𝑒 −𝛼𝛼∙𝐷𝐷− 𝛽𝛽∙𝐷𝐷

2

This ensures that the uncertainties reported from the final fit parameters incorporate
both the inter- and intra-experimental variability present in the data while also properly
accounting for the statistical power of the data set as a whole. In this work, to obtain the
survival parameters for a given cell line’s response to a particular radiation quality, we fit the
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collection of all SFD,combined,j measured to the linear quadratic model via variance-weighted leastsquares minimization in Graph Pad Prism 7 (Graph Pad, San Diego, CA). This weighting
ensures that the different confidences we have in the measured responses from different
experiments are accounted for in the fit, while also ensuring, as before, that our final fits are not
insensitive to the data at lower survival levels. The uncertainties in the fit parameters provided,
as well as their covariance, were obtained using Graph Pad Prism 7, and correspond to the
elements of the covariance matrix associated with the fit.
In cases where the normality of the data cannot be assumed, bootstrapping techniques
may instead be employed to fit the model to the collection of measured survival data and
estimate the best-fit parameters and their uncertainties255. However, we believe that it is fair to
assume these data are normally distributed, since the number of colonies formed and number
of cells seeded follow Poisson distributions with relatively large expectation values, λ, and the
Poisson distribution tends to the Gaussian distribution for large λ values.

VIII.

Calculation of important biological endpoints from the linear quadratic
survival curve

There are a few values of importance that are frequently extracted from the survival
curves, namely the doses required to achieve a given survival level, e.g. the dose for 10%
survival (D10%), the surviving fraction at a specified dose, e.g. the surviving fraction for a dose of
� ), which is the integral of the survival curve.
2 Gy (SF2Gy), and the mean inactivation dose (𝐷𝐷
Ultimately, these quantities are best estimated by interpolating (or integrating) the survival

curve obtained from fitting all of the survival data for a given condition. In the sections below,
we give expressions for how these quantities and their uncertainties were calculated in this
work, which are based upon the best-fit survival curve parameters and their uncertainties
obtained with Graph Pad Prism 7.
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VIII.1 Calculating the dose required to achieve a given survival level, e.g.
D10%
The dose required to achieve a given survival fraction endpoint, Dendpoint, can be
obtained evaluating the linear quadratic equation, for the case where the dose, Dendpoint, results
in the desired endpoint, SFendpoint:

2

𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑖𝑖𝑖𝑖𝑖𝑖 = 𝑒𝑒 −𝛼𝛼𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 −𝛽𝛽𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

And then rearranging this expression to give Dendpoint in terms of SFendpoint:

𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =

−𝛼𝛼 ± �𝛼𝛼 2 − 4 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 �
2 𝛽𝛽

Note that this is simply the quadratic formula as applied to the linear quadratic equation
after having linearized it by taking the logarithm of both sides. In some cases, particularly for
higher LETs, the value of β is nearly 0, rending this expression hard to evaluate due to the β in
the denominator. In these cases, where the value of β can be considered null, Dendpoint was
estimated as:

𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒,𝛽𝛽=0 = −
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ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 �
𝛼𝛼

VIII.2 Calculating the uncertainty on dose required to achieve a given
survival level, e.g. σD10%
As before, the uncertainty on the dose required to achieve a particular endpoint,
Dendpoint, can be written in terms of the error propagation formula. But in this case, since we can
estimate the covariance of the survival curve parameters from the covariance matrix associated
with the fit, we do not need to assume that they are not correlated:

𝜎𝜎𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

= ��

𝜕𝜕𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝜕𝜕𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
𝜕𝜕𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 2 2
𝜕𝜕𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 2 2
𝑐𝑐𝑐𝑐𝑐𝑐(𝜎𝜎𝛼𝛼 , 𝜎𝜎𝛽𝛽 )
� 𝜎𝜎𝛼𝛼 + �
� 𝜎𝜎𝛽𝛽 + 2
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕

The partial derivatives of the expression for Dendpoint with respect to α and β are given
by:

𝜕𝜕𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
1
𝛼𝛼
⎛
=
− 1⎞ ; 𝑎𝑎𝑎𝑎𝑎𝑎
𝜕𝜕𝜕𝜕
2 𝛽𝛽
�𝛼𝛼 2 − 4 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 �
⎝
⎠
𝜕𝜕𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
2 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 � − 𝛼𝛼 2
1
⎛𝛼𝛼 +
⎞
=
𝜕𝜕𝜕𝜕
2 𝛽𝛽 2
2
�𝛼𝛼 − 4 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 �
⎝
⎠
Thus, the final expression by which the uncertainty on the dose required to achieve a
specified endpoint was calculated in this work is given by:
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𝜎𝜎𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

�
2
2
⃓
⃓
2
⃓
�
−
𝛼𝛼
2
𝛽𝛽
∙
ln�𝑆𝑆𝑆𝑆
1
𝛼𝛼
𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
⃓ ⎛
⎞ 𝜎𝜎 2 + ⋯
− 1⎞ 𝜎𝜎𝛼𝛼2 + 2 ⎛𝛼𝛼 +
⃓
𝛽𝛽
⃓
𝛽𝛽
⃓ �𝛼𝛼 2 − 4 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆
2 − 4 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆
�𝛼𝛼
�
�
⃓
𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
1 ⃓ ⎝
⎝
⎠
⎠
⃓
=
2 𝛽𝛽 ⃓
⃓
⃓ 2
2 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 � − 𝛼𝛼 2
𝛼𝛼
⃓
⎞ ∙ 𝑐𝑐𝑐𝑐𝑐𝑐(𝜎𝜎𝛼𝛼 , 𝜎𝜎𝛽𝛽 )
⃓… ⎛
− 1⎞ ∙ ⎛𝛼𝛼 +
⃓ 𝛽𝛽
⃓
�𝛼𝛼 2 − 4 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 �
�𝛼𝛼 2 − 4 𝛽𝛽 ∙ ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 �
⎠
⎝
⎠ ⎝
⎷

In the case where β is zero, this has the much simpler form:

𝜎𝜎𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 ,𝛽𝛽=0 = − ln�𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 � ∙

𝜎𝜎𝛼𝛼
𝛼𝛼 2

VIII.3 Calculating the surviving fraction for a given dose, e.g. SF2Gy
The surviving fraction for a given dose was calculated simply by evaluating the linear
quadratic equation, at that dose, Dendpoint:

2

𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 = 𝑒𝑒 −𝛼𝛼𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 −𝛽𝛽𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
VIII.4 Calculating the surviving fraction for a given dose, e.g. σSF2Gy
Once again, the uncertainty of the surviving fraction for a given dose can be calculated
by the error propagation formula:

𝜎𝜎𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

= ��

𝜕𝜕𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝜕𝜕𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
𝜕𝜕𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 2 2
𝜕𝜕𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 2 2
𝑐𝑐𝑐𝑐𝑐𝑐(𝜎𝜎𝛼𝛼 , 𝜎𝜎𝛽𝛽 )
� 𝜎𝜎𝛼𝛼 + �
� 𝜎𝜎𝛽𝛽 + 2
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕

The partial derivatives of the expression for SFendpoint with respect to α and β are:
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𝜕𝜕𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
2
2
𝜕𝜕𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
2
= −𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 ∙ 𝑒𝑒 −𝛼𝛼𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 −𝛽𝛽𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 ; 𝑎𝑎𝑎𝑎𝑎𝑎
= −𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
∙ 𝑒𝑒 −𝛼𝛼𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 −𝛽𝛽𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕

Thus, the expression by which the uncertainty on the surviving fraction for a given dose
is given by:

𝜎𝜎𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 = �

2
∙ 𝑒𝑒
𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

2
−2∙�𝛼𝛼𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 −𝛽𝛽𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
�

4
∙ 𝜎𝜎𝛼𝛼2 + 𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
∙ 𝑒𝑒
2

2
−2∙�𝛼𝛼𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 −𝛽𝛽𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
�

3
… 2 𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
∙ 𝑒𝑒 −2∙(𝛼𝛼𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑡𝑡−𝛽𝛽𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒) ∙ 𝑐𝑐𝑐𝑐𝑐𝑐(𝜎𝜎𝛼𝛼 , 𝜎𝜎𝛽𝛽 )

∙ 𝜎𝜎𝛽𝛽2 + ⋯

Which can be simplified to:

2
𝜎𝜎𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 = 𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 ∙ 𝑆𝑆𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 �𝜎𝜎𝛼𝛼2 + 𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒
∙ 𝜎𝜎𝛽𝛽2 + 2 𝐷𝐷𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 ∙ 𝑐𝑐𝑐𝑐𝑐𝑐(𝜎𝜎𝛼𝛼 , 𝜎𝜎𝛽𝛽 )

�)
VIII.5 Calculating the mean inactivation dose (𝑫𝑫

The mean inactivation dose can be calculated by integrating the survival curve as follows:

∞

∞

� = � 𝑆𝑆𝑆𝑆(𝐷𝐷)𝑑𝑑𝑑𝑑 = � 𝑒𝑒 −𝛼𝛼∙𝐷𝐷− 𝛽𝛽∙𝐷𝐷2 𝑑𝑑𝑑𝑑
𝐷𝐷
0

0

The integral of such a function has the area256:
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∞

2

� 𝑒𝑒 −𝛼𝛼∙𝐷𝐷− 𝛽𝛽∙𝐷𝐷 𝑑𝑑𝑑𝑑 =
0

√𝜋𝜋

𝛼𝛼 2
4
𝑒𝑒 𝛽𝛽

𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 �
2 �𝛽𝛽

𝑎𝑎
�
2 �𝛽𝛽

Where erfc is the complementary error function. However, it is frequently impractical to
evaluate this expression, because its exponential term tends to infinity while the
complementary error function tends to zero when their arguments are large. And this happens
frequently, because the exponential’s argument is α2/β while the complementary error
function’s argument contains a α/√β term, and the values of α generally tend to be much larger
than β, sometimes by many orders of magnitude. So it is a frequent occurrence that when this
expression is evaluated, when the very large exponential function and very small
complementary error function are multiplied together, there is not enough precision in the
floating point number representation to actually perform the calculation without inducing serious
� used in this work were instead obtained by
rounding errors. As a result of this, the values of 𝐷𝐷
numerical integration using MATLAB 2017 (Mathworks, Natick, MA).

VIII.6 Calculating the uncertainty on the mean inactivation dose (𝝈𝝈𝑫𝑫� )

� values by numerical integration, because we have an
Although we calculated the 𝐷𝐷

� . As before, we can
expression for this integral, we can use it to calculate the uncertainty on 𝐷𝐷
� in terms of the error propagation formula:
write the expression for the uncertainty on of 𝐷𝐷

�2
�2
� 𝜕𝜕𝐷𝐷
�
𝜕𝜕𝐷𝐷
𝜕𝜕𝐷𝐷
𝜕𝜕𝐷𝐷
2
𝑐𝑐𝑐𝑐𝑐𝑐(𝜎𝜎𝛼𝛼 , 𝜎𝜎𝛽𝛽 )
𝜎𝜎𝐷𝐷� = �� � 𝜎𝜎𝛼𝛼 + � � 𝜎𝜎𝛽𝛽2 + 2
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕 𝜕𝜕𝜕𝜕
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Fortunately, the complementary error function has closed-form derivatives257 whose
� with respect to α
symmetry will greatly facilitate taking the derivatives of the expression for 𝐷𝐷
and β:
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This is because if the partial derivative of the expression for 𝐷𝐷

written by the derivative product rule as:
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When we evaluate the derivative of the exponential term, we will retain the exponential
term, and when we evaluate the derivative of the complementary error function, we will get a
negative exponential term that negates the term in front of it:
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This will then allow us to reorganize the derivative in a way that we can express it in
�:
terms of 𝐷𝐷
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Which in turn lets us simplify this expression to:
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� with respect to β,
Analogously, if we take the partial derivative of the expression for 𝐷𝐷

by the product rule, we can write:
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And as before, the derivative of the exponential function retains the exponential
function, the derivative of the complementary error functions creates a negative exponential
term that negates the term in front of it, while the derivative of the 1/√β leaves its term in a
relatively similar form:
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Then, as before, this will allow us to reorganize the derivative in a way that we can
�:
express it in terms of 𝐷𝐷
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� is given by:
Thus, the expression used to calculate the uncertainty on 𝐷𝐷
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� is calculated by numerical
Which can be evaluated without issue if the value of 𝐷𝐷

integration.

In the event that β is zero, the expression for the mean inactivation dose is simply:
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The uncertainty in this case, is then simply:

𝜎𝜎𝐷𝐷�,𝛽𝛽=0 =
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IX.

Supplemental Information

Supplemental Note 9: Photon beam dosimetry with optically stimulated luminescence
dosimeters
*Note: a substantial portion of this note is written or based on the supplemental
information contained in the following publication of which I am an author:
Bright, Scott J., David B. Flint, Sharmistha Chakraborty, Conor H. McFadden, David S. Yoon,
Lawrence Bronk, Uwe Titt et al. "Nonhomologous end joining is more important than proton
linear energy transfer in dictating cell death." International Journal of Radiation Oncology*
Biology* Physics 105, no. 5 (2019): 1119-1125.

To perform dosimetry measurements for our photon beam setups, we used Al2O3:C
optically stimulated luminescence dosimeters (OSLDs) cut
from Luxel tape (Landauer Inc., Stillwater, OK), bleached
using a custom bleaching unit258, and packed in black
electrical tape (Supplemental Figure 12 and Supplemental
Figure 13). The OSLDs were read out on an in-house built
OSLD reader as described elsewhere259-261. To calibrate the
OSLDs, we placed them at a depth of 1.5 cm in water
equivalent plastic along the beam’s central axis with 10 cm of
backscatter, using a 100 cm source-to-surface distance (SSD)
setup (Supplemental Figure 12). The OSLDs cells were then
exposed using a 10 x 10 cm2 field to a range of doses from
0.3 to 0.5 Gy. Later, the detectors were read out to create a
calibration curve relating the OSL signal intensity to absorbed
dose, which is linear in this range of doses.

193

Supplemental Figure 12: OSLDs
packaged in black electrical tape
were placed atop 10 cm of water
equivalent plastic, before placing an
additional 1.5 cm of water equivalent
plastic atop them (omitted for clarity),
resulting in the detectors being
placed at a depth of 1.5 cm in water
equivalent plastic with 10 cm of
backscatter. They were then
irradiated using a 100 cm SSD setup.

OSLDs from the same batch as the calibration
detectors were then placed in the wells of empty 6-well plates
which had been inserted into a custom acrylic insert
(Supplemental Figure 13) that was built to minimize air gaps,
provide material to induce lateral scatter, and provide support
for the additional backscatter material used in the cell
irradiations that can be seen in Figure 37. The OSLDs were
then exposed to 50 monitor units (MU) in the same conditions
as the cell irradiations – at a depth of 10 cm in water
equivalent plastic with 10 cm of backscatter material as can
be seen in Figure 37. After reading out the detectors

Supplemental Figure 13: OSLDs
packaged in black electrical tape
were placed in the wells of 6-well
plates that had been inserted into a
custom acrylic insert.

irradiated at the cells’ position, they were compared to the calibration detectors to determine
the absorbed dose they received from 50 MU of machine output. This was then used to
calculate a dose/MU calibration factor, fDose/MU, for cells irradiated under the same conditions.
We then calculated the dose the cells received in terms of the number of MU they were
exposed to as follows:

𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 = 𝑀𝑀𝑀𝑀 ∙ 𝑓𝑓𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷/𝑀𝑀𝑀𝑀
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Supplemental Note 10: Proton beam dosimetry using ionization chambers
*Note: a substantial portion of this note is written or based on the supplemental
information contained in the following publication of which I am an author:
Bright, Scott J., David B. Flint, Sharmistha Chakraborty, Conor H. McFadden, David S. Yoon,
Lawrence Bronk, Uwe Titt et al. "Nonhomologous end joining is more important than proton
linear energy transfer in dictating cell death." International Journal of Radiation Oncology*
Biology* Physics 105, no. 5 (2019): 1119-1125.

Proton beam dosimetry was performed using a parallel plate ionization chamber, water
equivalent plastic blocks, and cutouts of the bottom of the dishes we used to irradiate cells. The
exposure measurements were performed using a calibrated Advanced Markus ionization
chamber (PTW, TN34045, S/N 0300) after having removed its cap to ensure that the water
equivalent thicknesses (WETs) were as close as possible to the conditions in which the cells
where exposed. The chamber was then placed in a chamber holder (Supplemental Figure 14A)
and measurements were made over a range of WETs, which were obtained using water
equivalent plastic (457-CTI, Gammex, Inc., Middleton, WI, USA) (Supplemental Figure 14B).
Measurements were performed for WETs of 1.1 cm (which is the WET of the treatment couch)
and WETs ranging from 3.5 cm to 4.5 cm in 1 mm increments (Supplemental Figure 14C).

Supplemental Figure 14: (A-B) Irradiation setup used to determine dose output factors for the clonogenic cell
survival irradiations. (A) The chamber was secured in a water equivalent chamber holder, and the cutout of a dish
was placed in front of the chamber. (B) The chamber holder, chamber and dish cutout were placed atop water
equivalent plastic slabs that were placed on the patient couch. Note that in this setup, the beam traverses the couch,
so the couch, water equivalent plastic and dish cutout determine the water equivalent depth. (C) Ionization chamber
measurements as a function of water equivalent depth, with the green circles representing the output measured with
the dish cutouts in front of the ionization chamber at water equivalent depths of 3.8 and 4.3 cm.

Since, for clonogenic cell survival experiments, cells are placed in dishes upon the
couch (or atop water equivalent blocks), the cells’ irradiation conditions include the beam
having also passed through the bottom of the dish. Although this small thickness of polystyrene

195

is inconsequential for low LET protons, in the vicinity of the Bragg peak, it perturbs the beam
enough to need to be accounted for. Thus, to determine the dose output at the depth of the
adhered cell layer, we cut out the bottom of a number of dishes used when irradiating cells – 6well plates, T12.5, T25 and T75 flasks – and included them as additional layers of material in
front of the ionization chamber (Supplemental Figure 14A). Model numbers of the plates and
flasks for which the WET was measured are in Supplemental Table 42 and the results of the
dose output for the different conditions, as well as the WETs of the plates and flasks are in
Supplemental Table 43 and Supplemental Table 44.
However, throughout this work, we only used 6-well plates when performing clonogenic
assays using protons. Thus, the total water equivalent depth for the conditions we used were
1.21, 3.91 and 4.42 cm (Supplemental Table 44). We did not measure the WET of the dishes
for the 1.1 cm condition, instead assuming them to have the same WET as for the 3.8 cm
condition. All the experiments performed in this work were done in gantry 2 at the MD
Anderson Proton Therapy Center, and because the beam traversed the couch, we used the
same couch top and the same couch position to minimize any variability due to heterogeneities
in couch density.

Supplemental Table 42: Product information of the dishes used in the irradiations.

Material

Manufacturer

Model

Part number

6-well plate

Polystyrene

Corning Inc

Costar

3506

T12.5

Polystyrene

Celltreat

12.5 cm2 Tissue Culture Flask

229321

T25

Polystyrene

Thermo Scientific

Nunc EasYFlask 25 cm2

156367

T75

Polystyrene

Thermo Scientific

Nunc EasYFlask 75 cm2

156499

196

Supplemental Table 43: Dose output factors and WETs associated with the bottom of the dishes used in the clonogenic
cell survival experiments performed in this work. 1.1, 3.8 and 4.3 cm are the nominal water equivalent depths used,
including slabs of water equivalent plastic and the couch thickness, on top of which the ionization chamber with the
dish cutout were placed. WET (mm) corresponds to the measured WET of the dish material placed in front of the
chamber at the specified water equivalent depths.

D, Gy/MU

WET, mm

1.1 cm

3.8 cm

4.3 cm

3.8 cm

4.3 cm

None

0.00790 ± 0.00002

0.014762 ± 0.000040

0.026062 ± 0.000014

—

—

6 well

—

0.016426 ± 0.000018

0.018424 ± 0.000055

1.075

1.206

T12.5

—

0.016737 ± 0.000014

0.016658 ± 0.000021

1.245

1.359

T25

—

0.016604 ± 0.000013

0.017498 ± 0.000040

1.175

1.286

T75

—

0.017061 ± 0.000036

0.014576 ± 0.000033

1.420

1.540

Supplemental Table 44: Total water equivalent depth at the sample positions used in this work, accounting for the
WET of the bottom of the dishes for each condition.

Water equivalent depth (cm)

None

6 well

T12.5

T25

T75

1.1

1.21

1.22

1.22

1.24

3.8

3.91

3.92

3.92

3.93

4.3

4.42

4.44

4.43

4.45
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Supplemental Note 11: Monte Carlo calculations of proton LETs

*Note: a substantial portion of this note is written or based on the supplemental
information contained in the following publication of which I am an author:
Bright, Scott J., David B. Flint, Sharmistha Chakraborty, Conor H. McFadden, David S. Yoon,
Lawrence Bronk, Uwe Titt et al. "Nonhomologous end joining is more important than proton
linear energy transfer in dictating cell death." International Journal of Radiation Oncology*
Biology* Physics 105, no. 5 (2019): 1119-1125.

**Note: this author did not contribute to the simulations performed in this section, and
are the results from them are provided here only for completeness. These simulations
were performed by Dr. Uwe Titt.

Monte Carlo (MC) simulations were performed to obtain the LETs corresponding to the
depths at which the cells were exposed with protons. The simulations were performed using
MCNPX version 2.7 262 using a validated MC model263 of the double scattering proton beam line
at MD Anderson Cancer Center Proton Therapy Center in Houston, Texas. A water phantom
was modelled with the upstream surface located at isocenter, 273 cm from the particle source.
The snout of the beam line was at a distance of 45 cm from the surface of the phantom. In the
water phantom, a series of 50 disks, each 1 mm in thickness and with a diameter of 0.5 cm
served as tallies for the proton fluence. The MC tallies were shifted by 0.2 mm to match the
experimental dosimetry data. The fluence through each disk was scored with an energy
resolution of 100 keV. Additionally, the energy deposition was scored with a circular mesh tally
of similar radius, but with a depth resolution of 0.1 mm. The transport of the protons was
terminated at a cutoff threshold of 1 keV, and a total of 2×108 source particles were transported
to ensure statistical uncertainties of less than 2% at depths where doses were larger than 5%
of the maximum dose.
The fluence-weighted, LETΦ, and dose-weighted, LETd, were calculated as follows 48-50:
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and

𝐿𝐿𝐿𝐿𝐿𝐿𝛷𝛷 =

𝐿𝐿𝐿𝐿𝐿𝐿d =

∞

∫0 𝑆𝑆el (𝐸𝐸)𝛷𝛷(𝐸𝐸, 𝑧𝑧)d𝐸𝐸
∞

∫0 𝛷𝛷(𝐸𝐸, 𝑧𝑧)d𝐸𝐸

∞

2
(𝐸𝐸) 𝛷𝛷(𝐸𝐸, 𝑧𝑧)d𝐸𝐸
∫0 𝑆𝑆el
∞

∫0 𝛷𝛷(𝐸𝐸, 𝑧𝑧) S(E)d𝐸𝐸

where Sel(E) is the electronic stopping power of the protons with energy E, and Φ(E,z)
denotes the fluence of protons with energy, E, at the location, z. To define the radiation quality
of the protons, we used the dose-weighted LETd in order to facilitate comparisons with our
heavy ion data, where LETd had been measured. However, because LETΦ has been shown to
be less dependent on parameters of the simulation, and therefore more robust than LETd 50, we
present the results for LETΦ here as well for completeness (Supplemental Figure 15).

Supplemental Figure 15: Monte Carlo simulations of the setup used in the experiments. (A) Normalized depth dose
distribution to demonstrate that the simulated dose (black line) agrees with measured dose (black circles) using
multi-layer ionization chamber device (Zebra, IBA Dosimetry GmbH, Germany). The blue curve shows the simulated
depth LETΦ distribution for completeness (B) Electronic stopping power Sel spectra at the positions in which cells
were exposed. The value of the electronic stopping power is approximately equal to the value of the LET for the
energy range under investigation. The values of the fluence- (LETΦ) and dose-weighted LET (LETd) are shown.
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Supplemental Note 12: The plating efficiency is more precisely estimated by fitting the
whole dataset rather than using the control’s survival fraction
To verify that calculating the plating efficiency by fitting the unnormalized data was
superior to using the survival quotient for a dose of 0 Gy, we sought to show that the variance
in the analyses were less when the plating efficiencies were estimated via fitting. We first
analyzed survival data for a condition that we had a large number of repeats, HT1080 cells
exposed to protons with an LET of 1.2 keV/µm (n = 10, with 5 identical dose levels), in two
different ways. First, by calculating the plating efficiency using the survival quotient of the
control, and second by fitting the unnormalized survival curve and taking the value of the fit at 0
Gy dose. Then we compared the variance of the data in two ways, first by calculating the zscore of each measured surviving fraction relative to the mean for that dose level
(Supplemental Figure 16A), and second by calculating the relative deviation of each measured
survival fraction to the mean for that dose level (Supplemental Figure 16B). These
normalizations were necessary in order to increase the statistical power of the dataset, since
comparing variances requires very large datasets to find statistically significant results, and this
would allow the data across all dose levels to be combined. Nevertheless, while the variances
observed for both normalizations were smaller when using the fitting method, we could not

Supplemental Figure 16: Comparison of variances observed in the survival of HT1080 cells exposed to 1.2 keV/µm
protons. The variances were quantified in terms of (A) the z-score of each measured surviving fraction with respect
to the mean for that dose level, and (B) the relative deviation of each surviving fraction from the mean of that dose
level. For each variance metric, the plating efficiency was calculated by two different methods: fitting the
unnormalized survival data, or by using the survival quotient at 0 Gy; with F-tests being performed to compare the
variances between methods.
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prove this with high statistical significance (p = 0.6427 and p = 0.3184 by F-tests of the zscores and relative deviations, respectively) because of the low statistical power of the F-test.
Thus, since in order to confirm these differences experimentally, we would need to
perform a large number of redundant experiments which were not feasible, we instead created
a Monte Carlo simulation in MATLAB 2017 (Mathworks, Natick, MA) to simulate the raw data
generated in clonogenic survival experiments and analyze these data by the two methods to
asses which method induced less variance. In these simulations, and over a number of dose
levels (0, 2, 3.5, 5 and 6 Gy), we simulated the process of seeding cells into the dishes,
accounting for the inherent variability in the equipment used to prepare the samples, and with
the expectation of achieving 50 colonies per dish across all doses (similar to our in vitro
workflow), based upon known survival curve parameters of the HT1080 cells. We then
simulated the doses the dishes would actually receive based upon the expected variability in
machine output, and in turn determined what number of cells survived this radiation exposure
and went on to form colonies by assuming that the probability of a cell surviving and being
counted followed a Poisson distribution whose expectation value is determined from the known
cell survival curve parameters. The details of these sources of variability and the statistical
distributions we assumed they follow are summarized in Supplemental Table 45.
Then, with these simulated data of how many cells were seeded and how many
colonies were counted in each dish, we could create survival curves. To verify that these
simulated data were consistent with the measured data, we simulated 10 survival curves for
HT1080 cells exposed to 1.2 keV/µm protons which we compared against our 10 measured
experiments for these conditions (Supplemental Figure 17A and Supplemental Figure 17B).
Qualitatively, the variability in the survival curves appeared comparable, and so from each
experiment, we calculated the z-score normalized survival fractions relative to the mean for
each dose level, and the relative deviation of each surviving fraction relative to the mean of
each dose level using both methods to calculate the plating efficiency (Supplemental Figure
17C and Supplemental Figure 17D). These distributions were very similar to those calculated
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from the in vitro data (Supplemental Figure 16A and Supplemental Figure 16B) and could not
be distinguished via F-test (P values ranging from 0.1469 – 0.8330).

Supplemental Table 45: Sources of variability included in the Monte Carlo simulation, the statistical distribution they
follow, the uncertainty they were assumed to have, and rationales for those assumptions

Source of
variability

Statistical
distribution

Uncertainty
Assumed

Dose Precision

Normal

0.3%

Micropipette
accuracy
Micropipette
precision
Pipette accuracy
Pipette precision
Cells seeded

Normal

3%

Output factors of clinical radiation therapy units are
checked daily, and must differ by less than 3%
from the last calibration264.
Based upon repeated OSLD measurements we
performed when making dosimetry measurements
Technical specifications265

Normal

0.6%

Technical specifications265

Normal
Normal
Poisson

3%
1.5%
�𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 #𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

Colonies formed
and counted

Poisson

Additional
biological
variability

Normal

�𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 #𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

Technical specifications266
Technical specifications266
When the volume of media pipetted into the dish is
extracted from the suspension, this samples a
finite number of cells from the suspended
population. This sampling is Poisson distributed.
Radiation interactions follow a Poisson distribution,
and thus so too does the process by which cells
are killed by radiation267.
The radiosensitivity of cells measured by
clonongenic assay is known to vary greatly
between experiments254. Across 79 independent
experiments, the D10% and D50% for A549 cells
had COVs of 22% and 31% respectively254. So we
expect that the total uncertainty from all sources is
~25%, of which perhaps ~10% can be accounted
for when considering the dosimetric and other
experimental uncertainties. This extra uncertainty
was added by varying the true survival curve
parameters for each replicate.

Dose Accuracy

Normal

2%

15%
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Rationale

Supplemental Figure 17: In vitro (A) and simulated (B) survival curves for HT1080 cells exposed to 1.2 keV/µm
protons. The variance in the simulated data are quantified data in terms of (C) the z-score of each measured
surviving fraction with respect to the mean for that dose level, and (D) the relative deviation of each surviving fraction
from the mean of that dose level. For each variance metric, the plating efficiencies were determined either by the
fitting method or by using the survival quotient for a dose of 0 Gy, with F-tests being performed to compare the
variances between methods.

Confident that our simulations produced results that followed a similar distribution to our
in vitro survival data, we then re-ran the simulations for 1000 replicates, and compared the
variance in the data across the two methods of determining the plating efficiency. Comparing
the variance in both the z-score of the surviving fraction relative to the mean of each survival
level and the relative deviation of the surviving fraction from the mean at each survival level,
our simulations show that variance in the fitting method is about 36% less when considering the
deviations in the z-scores from the mean surviving fraction at each dose level (p < 0.0001)
(Supplemental Figure 18A) and about 13% less (p < 0.0001) when considering the relative
deviations from the mean surviving fraction at each dose level (Supplemental Figure 18B).
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Supplemental Figure 18: Comparison of variances observed in simulated survival data (1000 replicates) of HT1080 cells
exposed to 1.2 keV/µm protons. The variances are quantified in terms of (A) the z-score of each measured surviving
fraction with respect to the mean for that dose level, and (B) the relative deviation of each surviving fraction from the
mean of that dose level. For each variance metric, the plating efficiencies were determined by two different methods: by
fitting the unnormalized survival data, or by using the survival quotient (SQ) at 0 Gy, with F-tests being performed to
compare the variances between methods.
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Appendix 3 – Automated scoring of viable colonies in
clonogenic assays using a high-resolution scanner and an
automated ImageJ analysis pipeline

I.

Introduction
Since their first description by Markus and Puck 268, the clonogenic assay has been

used ubiquitously in the field of radiation biology to assess cellular viability after radiation
exposure 1,122,186,190,214,216,231,269, and despite the emergence of newer techniques that seek to
assess cell viability in much less time consuming manners270-272, clonogenic assay
nevertheless remain the gold standard for assessing radiosensitivity of cells in vitro. The assay
consists of seeding known numbers of cells from single cell suspensions into growth dishes
before or immediately after irradiation and incubating the cells for several days or weeks after
irradiation to allow them to grow and form colonies 240. Cells that become inactivated by the
radiation will either die, become senescent, or divide a few times before becoming senescent,
while cells that are not inactivated by the radiation will divide indefinitely after irradiation and go
on to form colonies. Thus, when the assay is terminated, viable cells are scored by counting
the number of colonies that are present in the dish, and the surviving fraction for a given
radiation dose is calculated by dividing the number of colonies observed by the number of cells
seeded after accounting for the cells’ plating efficiency (the fraction of cells forming colonies in
the absence of radiation) 240. In this way, the surviving fraction over a range of radiation doses
can be estimated, and the data fit to a survival model (typically the linear quadratic model) to
obtain a survival curve.
The analysis of clonongenic survival data depend greatly on how a colony of cells is
defined. In practice, colonies are typically defined as groupings of cells containing 50 or more
cells 240. This definition for the smallest colony forming unit (CFU) is chosen because some
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cells may carry lethal damage for several cell divisions before finally becoming senescent, but
a grouping of 50 cells ensures that the progenitor cell has undergone 5-6 divisions, for which it
is extremely improbable that the cell still carries lethal damage. Colonies defined in this manner
are often counted by eye, first by fixing the cells at the termination of the assay, and then
staining them with a dye to make the cells (and colonies) easier to assess visually.
But, scoring the colonies in a clonogenic assay in this way presents a number of
logistical issues. First, this technique is extremely time-consuming due the difficulty of
assessing the clonogenicity of small colonies by the unaided eye. Often, colonies are too small
to visually confirm that the number of cells that form them greatly exceeds 50 cells, requiring
the scorer to assess the smaller colonies under a microscope to verify which groups of cells
contain at least 50 cells. This process requires the person not only to manually count all the
colonies formed in a dish, which takes on the order of a minute, but in many cases, manually
count all of the cells within a colony after having located it under the microscope, which takes
on the order of a minute per colony, so it can often take hours to score all the dishes required
to produce a single survival curve.
Second, this technique is extremely biased to the individual that scores the colonies,
both with regards to the scorer’s ability to locate small colonies, and the scorer’s intuition with
regards to colony morphology, density, and separating colonies that have grown together. It is
often assumed that since normalizing the data by the plating efficiency removes many
systematic biases in the experiment, these biases will be accounted for in that normalization.
However, the size, morphology and density of colonies often varies with dose, which in turn
means that the impact of these biases on the controls and irradiated dishes are not the same,
and so the plating efficiency cannot account for them. Thus, we often see different survival
curves calculated for the same raw data when analyzed by different people 273.
But both of these limitations can be overcome by automating the counting process
which greatly increases the throughput as well as the reproducibility of the analyses. In general
terms, this can be achieved by creating a digital image of the dishes containing the stained
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colonies, which can then be processed using a variety of image processing techniques to score
the colonies, and a number of groups have published on these techniques to score colonies in
this manner 273-280. Many of these methods are tailored towards detecting colonies that are
bright, high density, and have sharp edges, similar to those of bacterial colonies, thus allowing
for an area-based threshold to consistently score colonies with greater than 50 cells 274.
However, many human cancer cell lines do not form dense groupings with sharp edges, which
makes it challenging to calibrate the cell line specific parameters used in these image
processing techniques. Furthermore, area-based thresholds are not always appropriate for
human cancer cell lines since colony morphology can vary dramatically between cell lines, but
also even within the same cell line.
The primary issue that arises from these differing colony morphologies is related to
differences in the cell densities within colonies. If a cell line forms colonies that are sometimes
dense, but sometimes loose, then a colony area threshold cannot be defined without having a
large number of false positive or false negatives. Even when a cell line only forms loose
colonies, it is not uncommon to have a range in cell densities within the loose colonies which
makes it difficult to define a colony area threshold. This issue is compounded by the fact that
colony morphology and size often varies with dose, with colonies generally becoming looser
with increasing dose 276. Thus, colony area-based thresholding may result in loose colonies
with fewer than 50 cells being erroneously counted at higher doses.
Thus, in order for our image processing techniques to be robust to the wide range of
colony morphologies observed in human cancer cell lines, they need to quantify the number of
cells within a colony without relying on the colony area if the colonies are not dense. In this
work, we present such a methodology that involves scanning the dishes using a film scanner
capable of resolving individual cells, and counting colonies using open-source ImageJ macros
that allow for consistent colony scoring in spite of changing colony morphologies, areas and
densities. Further, we present a method to calibrate the image processing software to a given
cell line’s typical colony morphology using a simple light microscope that can be applied over a
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wide range of colony phenotypes. Our methodology represents a simple and consistent way to
dramatically increase the accuracy, reproducibility and throughput of clonogenic assays using
only equipment readily available to most scientific laboratories where cells are irradiated – a
film scanner, a light microscope, and a computer capable of running ImageJ.

II.

Materials and methods
II.1

Staining of dishes

Prior to counting the colonies, a stain must be used to increase the contrast between
the adhered cells and background of the dish as they are otherwise barely visible. For the
purposes of the macros described herein, we assumed that the dishes were stained using a
solution of 0.5% crystal violet in ethanol, as this is the stain that was used to calibrate the
macro parameters. In principle, any stain may be used as the image processing software can
calibrated to detect features of any hue, but one should avoid dyes of pure red, blue or green,
as this may result is poor contrast in one of the detection channels of the scanner. As we
describe later, by ensuring that there is contrast between the stained cells and the background
in each color channel of the scanner, a number of artifacts that have the same brightness as
the stained cells, but do not have the same hue, are more easily excluded. This further permits
us to calibrate the expected background levels and feature brightnesses in the red, green and
blue channels independently, in order to optimize the detection of image features whose hue
matches that of the stained colonies, which in our case is violet.

II.2

Creating a digital image of the dishes with a film scanner

After the dishes are stained, we desire a digital image of them to process and score the
colonies. We found that a conventional film scanner is sufficient in terms of sharpness,
contrast, and resolution to produce an image which can easily be used to score the colonies,
whether visually, using automated counting macros. Although it may be technically feasible to
use a conventional reflective scanning system (such as one might use to scan paper
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documents) to produce such images, a film scanner provides a number advantages over a
conventional scanner. First, this type of scanner can produce images at much higher resolution
than conventional scanners, which allows individual cells of low-density colonies to be
resolved. Second, and more importantly to our methodology, using a film scanner allows for the
plates to be scanned in film-scanning mode, where rather than measuring the brightness of
light reflected off the dishes, the intensity of the light transmitted through the dish is measured.
This produces superior contrast between the cells and the background of the dish, since the
dye renders the cells nearly opaque but leaves the dishes transparent, though still slightly
reflective. This also removes a number of artifacts that appear in reflective scans such as
shadows in the background caused by reflected light off the vertical surfaces of the dishes, and
highly reflective regions bottom surface of the dish appearing white and hiding all cell
information beneath them. Since, in the transmission scan, there is inherently more contrast,
the analogues of these types of artifacts are substantially less detrimental to image quality: the
projection of the vertical portion of the well attenuating transmission slightly, and reflections off
the bottom of the dish leaving some regions of the background slightly darker.
While film scanners are certainly less readily available across institutions than
conventional reflective scanners, since film scanners are used to evaluate film for film
dosimetry, such scanners should be readily available at any institution where film dosimetry is
performed. Thus, when used to evaluate clonogenic assays after radiation exposure, such
scanners should be readily available, but even if one’s institution does not possess one, they
are relatively inexpensive to purchase used (under $1000). In this work we used an Epson
XL10000 film scanner to scan our dishes, scanning the dishes in film scanning mode at a
resolution of 2400 DPI (10.6 μm pixel size). This resolution was chosen as it generally allows
for single cells to be resolved, and because higher resolutions were found to not substantially
increase image quality, likely due diffraction of light through the dish limiting the resolving
power of the scanner’s optics.
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II.3

Image processing software

Once digital images of the dishes are produced, we wish to automate the scoring of
colonies using image processing software. In this work, we selected Fiji ImageJ v 1.6 to
process the images, as it is an open-source java-based image processing suite that is widely
used and free to download. ImageJ is an ideal environment to develop image processing
macros that can be run on images and image sets, as it contains a number of built-in functions
to perform various image processing operations (thresholding, convolution, Fourier transform,
etc.), and allows for scripting of these built-in functions using java 281-283 . Accordingly, our
image processing pipeline is a java-based macro that runs with ImageJ. A description of the
methods used in our macros is given below.

III.

Conceptual workflow of our colony counting macros
The overall workflow of our macros consists of: defining the region in which to count

colonies, subtracting the background and other dim noise, creating a binary mask of the
stained cells in the dish, blurring the groupings of cells together to create solid masses
corresponding to colonies, segmenting and counting the colonies, and finally rejecting false
positives.

III.1

Defining the region of interest in which to count

At the beginning of the image processing workflow, the dish must be segmented to
select the area in which to the search for colonies will be performed, corresponding to the cell
growth area of the dish. In our macros, we often assume a circular growth area as most of our
clonogenic assays are performed in 6-well plates with circular wells. However, in principle any
shape of growth area can be segmented with the proper definition of the region of interest
(ROI). Below we detail methods for segmenting circular dishes and noncircular cell culture
flasks.
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III.1.a Circular dish segmentation
To define the location of
a circular growth area, our
macros require the user to
define a square region of
interest (ROI) which inscribes
the circular growth area (Figure
43). This is done in favor of
simply having the user specify
the circular ROI directly because

Figure 43: User-defined square ROI inscribing a circular well (left). The
macro creates a circle inscribed by the square to use as the working area
(right). A small projection of the well’s wall can be seen in the bottom of
the circular ROI.

it is much easier in terms of sizing and alignment for the user to resize and translate a square
ROI that circumscribes the growth area using ImageJ’s rectangle tool than it is for the user to
draw an oval that completely aligns over the growth area. From this square, the code calculates
the circle the square circumscribes and then subtracts a small buffer diameter from the circular
ROI to ensure that small variations in the user’s positioning of the square does not allow the lip
of dish to be considered in the working ROI. The well lip (and to a lesser extent any projection
of the well’s wall) can create artifacts due to appearing bright in all channels, and so this buffer
helps ensure that it remains outside the working ROI.

III.1.b Noncircular well segmentation
While one could ask the user to manually draw an ROI in a non-circular vessel, this
process is very imprecise and tedious for complex shapes. Instead, if the relative dimensions of
the vessel are predefined in the code, the user can be tasked with specifying the size and
location of the ROI to be scored instead, which is much more reproducible. But when using this
approach, the user must also specify the rotation of the vessel in the scanned image to ensure
that the encoded ROI shape is properly aligned with respect to the vessel’s orientation in the
image. Both of these constraints can be met by requiring the user to draw a line on the image
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using ImageJ’s line tool to identify two predefined vertices in the ROI. Then, by measuring the
line’s length and using it to scale the area of the ROI, and by measuring the angle the line
makes with respect to the coordinate axes of the image, the rotation of the ROI in the image’s
coordinate system can be calculated, and the ROI can be rescaled and rotated accordingly. We
successfully implemented this method to segment T-12.5, T-25 and T-75 flasks by asking the
user to draw a line starting at the bottom left corner of the flask’s growth area and extending up
to the flask’s top right corner. We then scale pre-calculated ROI dimensions according to the
length of the line and apply a rotation matrix to the vertices using the angle the line is rotated in
the image’s coordinate system. An example of this can be seen in Figure 44.

Figure 44: User-defined line drawn between specified corners of T-12.5 flask (left image, magenta line) is used to
calculate the size, position and rotational orientation of a complex ROI (right image, magenta polygon) whose
relative dimensions are encoded in the macros.

III.2

Thresholding the image to exclude the background and noise

After staining and rinsing the dishes, there will often be a low level uniform background
signal from residual stain in the growth area. While this background signal is generally much
dimmer than the colonies, it can sometimes disrupt the macro’s ability to accurately determine
the size and shape of colonies so it is best to exclude it. An example of such noise can be seen
in the top panel of Figure 45. To exclude this background noise, we select a threshold intensity,
Tnoise, between the background level and the stained cell brightness to create a binary image
containing cells in white and background in black (Figure 45, bottom). This also eliminates any
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other low-intensity noise in the image and maximizes the
contrast of the cells relative to the background.
In our macros, we define this threshold
individually for each color channel in the scanned image,
before recombining the thresholded images with a binary
AND operation. This ensures that only features for which
there is sufficient contrast in all three channels are
retained. This drastically reduces artifacts caused by
dirt or dust or other foreign objects on the dishes that
have different hues than the stained cells. Calibration of
these thresholds is described in §IV.7.

III.3

Agglomerating cells into colonies

Once the noise and background have been
excluded and we have an image containing bright cells
and black background, we wish to segment and contour
the colonies in order to count them. However, we cannot
draw these contours until we have solid objects

Figure 45: Example of well showing
residual crystal violet stain (top), which is
removed after thresholding the image by
Tnoise (bottom).

representing the colonies, since at this point contouring round objects may instead contour
single cells. Thus, we must first agglomerate the groupings of cells for the purpose of
identifying the locations and extents of the colonies. In this case, we are interested in
identifying the clusters of cells that are sufficiently dense to be considered colonies based upon
the typical morphology of the colonies of a given cell line. This is achieved through a
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combination of blurring and masking. First, we use
ImageJ’s Gaussian Blur function to blur the image
using a blur radius, rρ, equal to the average radial
pixel distance between cells in a colony of typical
cell density. This convolves the image with a
Gaussian kernel of standard deviation rρ and
causes cells whose proximity is consistent with
that of cells in a colony to be blurred together.
Estimation of radial distance between cells in a
colony, rρ, for a given cell line is described in
AP3§IV.3.
We then mask the image, making white all
pixel values above a threshold, Tcell, (Figure 46).
This threshold is selected to ensure that all cells
and points surrounding them within rρ will also be
mapped to white. Accordingly, within a high cell
density region of such a colony, the whole area
will become a solid white mass, while single

Figure 46: Example colony showing cells after
blurring by radius rρ and applying threshold Tcell.
Groupings of cells whose density are consistent with
that of the colony are blurred together.

senescent cells will simply be left as outliers with a radius rρ. We can then use the ImageJ
method Remove Outliers to remove outliers smaller than radius routliers which will remove any
remaining specks of noise as well as small groupings of senescent cells smaller than the
smallest CFU. Estimation of Tcell and routliers is given in AP3§IV.8 and AP3§IV.4 respectively.

III.4

Filling in the holes in the colonies and smoothing the colony borders

At this point, we have an image with a black background containing large white masses
corresponding to the colonies. However, the colonies often contain holes due to local variations
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in cell density or brightness as in Figure 46. As eventually, we will
wish to watershed the image to separate colonies which form close
together and merge into single objects (see §III.5), we must fill
these holes to prevent the individual colonies with incomplete filling
from being erroneously watershed. While it is often possible to fill
the holes using ImageJ’s built in Fill Holes method, this is
undesirable in cases of high colony density because it can
agglomerate several colonies into a single mass which will be
scored as one large colony. A better way to fill the holes is to run a
second Gaussian Blur this time with a blur radius, rcolony, which
corresponds to the pixel radius of the smallest colony forming unit
(CFU). This blurs together features that are smaller than the
smallest CFU and thus smooths over any holes in the colony
(Figure 47B). It also smooths the borders of the colony, allowing it
to be easily contoured. Estimation of rcolony is given in §IV.2.

III.5

Contouring the colonies

Once the sub-colony features have been blurred out, we can
contour the colonies. We do this by first masking the image by
selecting a threshold brightness above which to map the pixels to
white, and mapping the darker pixels to black. This threshold should
be selected both to ensure an accurate contour of the colonies, but
also to ensure that any holes in the colonies are successfully filled
(Figure 47C). Estimation of the contour threshold, Tcolony is given in
§IV.9.
Once the image is masked, we watershed it using ImageJ’s
Watershed method. This separates colonies that formed close
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Figure 47: Example colony (A),
cells after blurring by radius rcolony
(B), thresholding by Tcolony (C)
and watershedding (D). This
process fills in the holes in the
colony, smooths the colony
border to allow contouring of cells
whose density are consistent with
that of the colony, and separates
merged colonies.

together and were blurred into single objects (Figure 47D). Finally, we use ImageJ’s Analyze
Particles method to contour all bright objects with an area greater than the area of the smallest
CFU, ACFU . This creates ROIs contouring each solid object whose radius is greater than that of
the smallest colony forming unit and so all of the colonies will be contoured. We will refer to
these ROIs below as colony ROIs.

III.6

Checking the validity of contoured colonies

After we have contoured all of the colony ROIs, it is good practice to screen them to
eliminate false positives. There are a few common causes of false positives, but using our
method, the most common are: bright artifacts caused by residual stain in the dish, which tend
to have the same hue and comparable brightness to the dimmer true colonies; and groupings
of individual cells with non-uniform density, which are sometimes recorded as colonies despite
not containing the 50 cells necessary to meet the colony criteria. The methods below describe
methods to screen out these artifacts.

III.6.a Verifying the number of cells in a contoured colony
To eliminate false positives arising from colony ROIs containing fewer than 50 cells, we
perform a check in each ROI to ensure that at least 50 cells are present. To accomplish this,
we return to the thresholded binary image generated in §III.2 which shows white cells on a
black background (Figure 48A) and select the region corresponding to each colony ROI. Within
each region, we watershed it to separate groupings of multiple cells (Figure 48B), and run the
Analyze Particles method to contour solid objects with an area greater than the pixel area of a
single cell, Acell. This will produce ROIs contouring of all of the cells or groupings of cells within
a colony (Figure 48C), which we will refer to as cell ROIs. Colony ROIs containing more than
50 cell ROIs are retained, while colony ROIs with fewer than 50 cell ROIs are processed
further. Estimation Acells of is given in §IV.5.

216

Colony ROIs containing fewer than 50 cell ROIs
do not necessarily contain too few cells to be
considered colonies. In some cases, and particularly for
denser colonies, multiple cells are too close together to
be successfully resolved, and so are scored as single
objects (Figure 48C). To account for this, for colony
ROIs containing fewer than 50 cell ROIs, we compute
the total pixel area of the cell ROIs and compare it to a
calibrated pixel area corresponding to 50 contoured
cells, A50cells . If the total area of the cell ROIs is less
than A50cells, the colony is rejected, and otherwise it is
retained. Estimation A50cells of is given in §IV.6.
However, in the case of very dense colonies, the area
threshold ACFU is often sufficient to identify colonies
since groupings of loose cells are never mistakenly
counted as colonies.

III.6.b Verifying the hue of the
contoured colonies
Despite employing a size buffer when
segmenting the growth area of the dish as described in
§II.4a, occasionally the lip of the well will still be present
in the segmented image, as can be seen in the bottom
edge of the well in Figure 43. The well lip will present
good contrast in all of the color channels since the
background corresponds to the opacity of the dish’s
growth surface, and light travelling through lip is
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Figure 48: (A) Cells in example colony after
thresholding by Tnoise. (B) Watershedding of
cells to separate individual or groupings of
cells within the colony’s contour (magenta).
(C) Contoured cells or groupings of cells
(magenta) within the colony (cyan) to assess
how many cells are present in the colony
and their total area.

attenuated much more than light travelling through the growth surface due to the much larger
distance travelled through the dish material. If the colonies to be scored are not particularly
bright, and a sufficiently large region of the well lip is present in the image it can be scored as a
colony as its area can exceed A50cells. To eliminate such features, we can remove the colonies
whose hues are inconsistent with the dye used to stain the cells, since the well lip is not stained
by the dye and will simply appear gray. Filtering with respect to the hue also helps eliminate
noise in the image caused by dirt, dust or hair on the bottom of the dish, as well as solid
precipitates left in the well after washing and drying the dishes which will be gray as they also
do not become stained by the dye.

III.6.c Verifying the texture contoured colonies
Occasionally, after rinsing the dye out of the dishes, incomplete rinsing can result some
small remnants of the dye remaining when the plates are set to dry. These remnants are
deposited onto the dish as it dries, and it appears in the images as a relatively uniform haze in
the background, which can be seen in Figure 43 as the halo-like band in the middle of the well.
These will have the same hue as the dye, are relatively bright, and are generally quite large in
area, so it is possible that brighter, more granular regions within it will inadvertently be scored
as colonies. To avoid scoring these artifacts, we can filter the colonies based upon their
texture, as this noise tends to be very smooth compared to the colonies due to the presence
the individual bright cells in the colonies.
We have found two parameterizations of the texture that can be used towards filtering
the colonies which depend on whether the colonies formed are bright and dense or dim and
diffuse. For diffuse colonies, the coefficient of variation can be used to filter out these artifacts
as the standard deviation of pixel values within a colony is much larger relative its mean than
for to the stain artifacts due to the bright cells and dark background within a colony. For dense,
bright colonies, using the coefficient of variation can cause false negatives by excluding
particularly bright colonies despite large absolute standard deviations in their pixel intensities.
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To work around this, we can instead weigh the coefficient of variation by the square of the
mean pixel value, i.e. compute the mean times the standard deviation. This allows us to
separate bright, highly granular objects from dimmer, smoothly varying objects and exclude this
type of artifact.
However, we have noted that these artifacts can occasionally appear granular and thus
be difficult to exclude based upon these simple parameterizations of their texture.
Consequently, calibrating the parameters used to exclude this type of noise is very challenging
due the variability in its appearance as well as due to the its relatively infrequent occurrence.
Thus, given this type of noise is infrequent and can be avoided by thoroughly rinsing the dishes
after staining, it may be preferable to simply ensure that the dishes are washed thoroughly after
staining and to avoid these types artifacts, and manually remove any such artifacts upon visual
inspection.

IV.

Calibration of macro parameters
For each cell line to be analysed a number of general and cell-line specific parameters

must be calculated to ensure that the macros detect colonies corresponding to 50 cells of that
cell line. Among the cell-line specific parameters are a number of geometric parameters that
describe the size and density of the colonies: the pixel radius of the smallest CFU, rcolony, the
radial pixel distance between cells in a colony, rρ, the outlier radius, routlier, pixel area
corresponding to cells within the smallest CFU, A50cells, and the minimum cell pixel area, Acell.
But in our formalism, all of these parameters can be derived from the pixel area of the smallest
CFU, ACFU, after having calibrated it, which means that only a single geometric parameter
needs to be calibrated. Only one brightness threshold per channel, Tnoise, which corresponds to
the threshold below which background noise is excluded, must be estimated by the user, as in
our formalism the brightness thresholds to define the contours of individual cells, Tcell, and to
define the colony contours, Tcolony, are independent of cell line, and thus the calculated values
shown below are hard-coded into our macros.
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IV.1

Calibration of the area of the smallest CFU, ACFU

For each cell line, the smallest CFU will occupy a given physical area. When the dish is
scanned, this physical area will translate to a pixel area, ACFU, which in turn will depend on the
resolution of the scan. We can calculate this area by first manually contouring a small test
colony and calculating its pixel area, Atest colony. We can then take dish to a light microscope
locate the contoured colony in the dish, and count the number of cells in the test colony, Ncells.
Under the assumption that the density of cells within colonies does not vary with colony area,
then ACFU is given by:

𝐴𝐴𝐶𝐶𝐶𝐶𝐶𝐶 = 𝐴𝐴𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∙

50
𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

Wherever possible, it is best to select colonies close in size to the smallest CFU, as this
will minimize any discrepancies caused by differences in the penumbral fraction of the
contoured colony’s area. Accordingly, after setting this baseline value of ACFU and using it to
establish baseline values for the other parameters, it is best to recalibrate ACFU at the end,
allowing the macro to contour the colonies automatically so as to more consistently account for
the penumbra of small colonies. This measurement can then be repeated several times for
different colonies to determine an average ACFU so as to not bias the threshold to a particular
colony’s cell density. In cases where multiple colony morphologies of varying cell density are
common, since ACFU defines the lower bound in colony area, it should be calibrated to the
densest morphology so as to not exclude small dense colonies.

IV.2

Calculation of rcolony in terms of ACFU

Under the assumption that small colonies are circular, rcolony is simply the radius of the
circle with area ACFU:
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𝐴𝐴𝐶𝐶𝐶𝐶𝐶𝐶
𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑜𝑜𝑛𝑛𝑛𝑛 = �
𝜋𝜋
IV.3

Calculation of rρ in terms of ACFU

To calculate the radial distance between cells in a colony, rρ , we must remember that it
measures the average radial distance between the centers of adjacent cells within a colony
including any empty space between cells. Thus, we must consider how the cells are packed
within a colony. The relationship between the colony area, Acolony, and the number of cells, Ncell,
of area Acell that can be packed into that area is given in terms of the packing density, η, as
follows:

𝜂𝜂 =

𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∙ 𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

Thus, if we assume that the cells occupy a circular area, Acell, that correspond to their
physical area plus a buffer region of empty space between them and adjacent cells, then we
can rewrite Acell as πrρ2, and rearrange the above equation to yield:

𝜂𝜂 ∙ 𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑟𝑟𝜌𝜌 = �
𝜋𝜋 ∙ 𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
For circular objects, it was shown by Lagrange that the most efficient packing
arrangement is hexagonal packing, which has a density of 284:

𝜂𝜂 =

𝜋𝜋

√12
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So for such a packing of cells, we find rρ to be:

𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑟𝑟𝜌𝜌 = �
√12 ∙ 𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
So for our theoretical smallest CFU with an area of ACFU and containing 50 cells, we can
calculate rρ as:

𝐴𝐴𝐶𝐶𝐶𝐶𝐶𝐶
𝑟𝑟𝜌𝜌 = �
√12 ∙ 50
IV.4

Calculation of routliers in terms of ACFU
We employ ImageJ’s Remove Outliers method to remove
small debris from the well before blurring the cells into
colonies. Remove Outliers applies a median filter of radius
routliers. Here, we are interested in removing debris that is
smaller than cells, as well as low density groupings of single
senescent cells that might contribute to scoring false positive

Figure 49: Small grouping of cells
(black) overlaid with the median filter
(red)

colonies. To remove these artifacts, we wish our filter to
remove all objects smaller than those with radius rρ, but we

will need a slightly larger filter to also remove the single senescent cells.
To ensure that we retain groupings of multiple cells, we consider the case of a small
number of cells Ncells of radius rρ clustered together as is depicted in Figure 49. Since the image
is binary, a median filter will remove clusters of cells only if the area of the circle defined by
routliers is greater than twice the combined area of the cells defined by rρ. Thus to retain
groupings of Ncells cells, our filter radius routliers must satisfy:
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2
< 2 ∙ 𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∙ 𝜋𝜋𝑟𝑟𝜌𝜌2
𝜋𝜋𝑟𝑟𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜

Which simplifies to

𝑟𝑟𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 < �2 ∙ 𝑁𝑁𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∙ 𝑟𝑟𝜌𝜌
So to retain groupings of 2 or more cells, we find:

𝑟𝑟𝑜𝑜𝑜𝑜𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 = 2 𝑟𝑟𝜌𝜌
IV.5

Calibration of the minimum pixel area for single cells, Acell

In order to verify the number of cells present in a colony exceeds 50, we must identify
individual cells within a colony using the area threshold parameter Acell which is defined as the
minimum area required for a region to be deemed to be at least one cell. The optimal size to
use for of Acell depends on the physical diameter of the cells and the resolution of the image but
the relationship is not straightforward, as it depends on several factors which arise due to the
fact that the image has been thresholded into a binary image. Importantly, it depends on the
orientation of the cell with respect to the pixel grid, and the degree to which refraction of light
through the dish alters the point spread function of the scanner, since these will affect the
intensity of the pixels in the cell’s penumbra which may be thresholded out due to partial
volume averaging. While in principle, we might try to calculate the absolute minimum number of
pixels which are free from penumbral effects across all orientations, this is in fact a special
case of the smallest-circle problem 285 for which there is no analytical solution, and even if a
numerical approach is employed, it may not accurately account for the PSF blurring. Instead,
we have found the following approximation to be useful:
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Consider a circular cell of radius rcell
superimposed upon image pixels of size of dpixel
(Figure 50, green). We assume that pixels which
are covered marjoritarily by the cell are likely to
appear bright in the image since they are likely to
be retained through the binary thresholding.
However, the minimum number of bright pixels
observed for an arbitrary cell will depend strongly
on its orientation with respect to the grid due the

Figure 50: Example of a circular cell (green) imposed
on a square grid of pixels (black lines). The pixels
filled in in red are completely covered by the cell and
should appear bright in the image. The pixels filled in
in pink are partially covered majoritarily by the cell,
and may appear bright in the image. The pixels filled
in in gray are very minimally covered by the cell, and
are unlikely to appear bright in the image.

cell’s penumbra. But if we consider now a square
cell of area 2 rcell2 defined by the square
circumscribed by the circular cell (Figure 50,
blue), this square corresponds a region in the

circular cell for which there are minimal penumbral effects, independent of the orientation of the
cell with respect to the pixel grid. The number of pixels covered majoritarily by the square cell,
Psquare cell, is generally greater than the ratio of Asquare cell, to that of the pixel are, Apixel:

𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑒𝑒 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 >

𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝐴𝐴𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

But since the circular cell circumscribes the square cell, the number of pixels covered
majoritarily by the circular cell, Pcircular cell, is always at least as large as Psquare cell :

𝑃𝑃𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ≥ 𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
So then since Pcircular cell ≥ Psquare cell and Psquare cell > (A square cell / Apixel), we find that:
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𝑃𝑃𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 >

2
𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
2 𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
= 2
𝐴𝐴𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

And so we have a lower bound for Pcircular cell, which is the minimum number of bright
pixels we might observe for a circular cell. We can therefore use this lower bound as Acell :

𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ~

2
2 𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
2
𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

The inequality governing the number of pixels that will be covered majoritarily by the
square cell fails only in the case where a cell is aligned with the grid and is slightly larger than a
matrix of pixels. The worst possible case of this occurs for a square cell of area roughly twice
that of the pixel area:

2
𝐴𝐴𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ~ 2 𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

For a cell of that size, while we may be inclined to select 2 pixels as our threshold,
some possible alignments of the cell with respect to the pixel grid result in much of the area of
Asquare cell covering only small regions of the 8 adjacent pixels. But in this case, the
corresponding circular cell would have diameter of 2 dpixel and so its true extent is to the
midpoint of the adjacent pixels along the grid axes. In such a case, it can be shown that for the
adjacent pixels along the grid axes, the circular cell covers a fraction of these pixels’ area equal
to:

𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
2 𝜋𝜋 + 3√3 − 6
=
~0.457
𝐴𝐴𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
12
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Given that the true extent of the circular cell covers nearly 46% of the area of 4
additional pixels, it is exceedingly unlikely that a cell will be aligned in such a way as to not
marjoritarily cover at least one pixel, and even more so when we consider effect of focal spot
blurring, and the ellipticity of real cells. Thus, we are exceedingly unlikely to exclude real cells
when calculating Acell as 2 r2cell / d2pixel.
As a practical note, in our case, we scan at 2400 DPI, which corresponds to a pixel size
of 10.6 μm. In most cases, the cell diameter is approximately 20-30 µm, and so we tend to
use a value of Acell between 2 and 4 pixels.

IV.6

Calibration of the area of 50 cells within a colony, A50cells

For colonies with higher cell density, the cells often cannot be individually resolved, and thus it
is not possible to contour the cells in a colony and count them individually. Instead, we can
contour all the groupings of cells, calculate their area, and compare it to the area typically
occupied by 50 cells, A50cells. To determine A50cells, we use the macro to create an ROI
contouring a small colony near the CFU threshold. Then, we apply this ROI to the binary image
containing white cells on a black background created in §III.2 (Figure 48B). Within this region,
we watershed the cells, and use Analyze Particles to contour the groupings of cells and
compute the total area of the contoured cells (Figure 48C). We can then count the number of
cells in this colony using a light microscope, and determine A50cells as follows:

𝐴𝐴50 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =

𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑜𝑜𝑜𝑜 𝑁𝑁 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
∙ 50
𝑁𝑁 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

When calibrating this parameter, it is important to consider the degree to which the cells
will present as giant senescent cells following irradiation. This will impact the accuracy of A50Cells
in filtering small colonies as the giant senescent cells may occupy the same area as many
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normal cells. It may be necessary to adjust the radius of the Remove Outliers method used in
§IV.4 to ensure that the single senescent cells are not counted.

IV.7

Calibration of noise threshold, Tnoise

For each color channel, i, we calibrate a noise threshold,
Tnoise,i , that excludes the background as well as other low-intensity
noise in the image. In general, the selection of Tnoise,i is somewhat
arbitrary and very cell-line and stain dependent, as it depends on the
brightness of the stained cells relative to the background, how bright
any additional noise to be excluded is, and also the hues of the
colonies and the noise. To calibrate Tnoise,i we first define the
background level for each channel, Bi , as its median pixel value
since the area of the images are primarily background. Then, for
each channel, we define Tnoise, i as:

𝑇𝑇𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛,𝑖𝑖 = 𝐵𝐵𝑖𝑖 + 𝑎𝑎𝑖𝑖 �𝐵𝐵𝑖𝑖
Where αi is a cell-line specific parameter for the ith color
channel. The selection of αi should be based on the histogram in

Figure 51: Intensity
histogram (frequency vs
pixel value) in the red
channel of the image. The
gray distribution is the
logarithm of the black
frequency distribution. The
red line on the histogram
indicates the threshold
selected

pixel intensities. In general, the histogram should have a shape resembling that of Figure 51,
where there is a large distribution of low-intensity noise, and relatively flat distribution of higher
intensities corresponding to the stained cells. To select αi, we should choose αi such that the
whole distribution of low-intensity noise is excluded as is indicated by the red line in Figure 51.
In this parameterization we are tacitly assuming that the pixel intensities of the
background noise are Poisson distributed, and we set our threshold some number of standard
deviations αi above the mean noise level. The advantage of this parameterization is that it
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scales with the staining efficiency, since Bi is proportional to the staining efficiency, but it does
not scale with the number of colonies in the well (in the limit where the background is the
majority of the image area), and so it will separate the background from the colonies for a wide
range of cell densities and overall image brightness.

IV.8

Selection of cell brightness threshold, Tcell

The cell brightness threshold, Tcell is applied after having applied ImageJ’s Gaussian
Blur method, which convolves the image with a Gaussian kernel and blurs together the cells
within a colony. The purpose of this threshold is to select the brightness level along the blurred
edges of the cells (or groupings of cells) above which our macro will consider there to be cells
present. Accordingly, this threshold corresponds to the brightness at which a single cell in a low
density region will be contoured with radius rρ, since groupings of cells with higher density will
be blurred together and appear brighter than Tcell. So we wish to know the intensity at a radius
rρ of a cell blurred via Gaussian Blur and thus we must first determine the intensity profile of a
blurred cell, Iblur,cell. It can be shown (§VII.1) that for a circular cell with radius rmax, and
brightness h, described by a circ function, the intensity profile in polar coordinates (r,θ )
following convolution with a Gaussian kernel of variance σ2 takes the form:

𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜃𝜃)� =

𝑟𝑟 2
−
𝑒𝑒 𝜎𝜎2

∞

𝑘𝑘

𝑘𝑘=0

𝑙𝑙=0

2𝑙𝑙
𝑟𝑟 2
h
𝑟𝑟 2𝑘𝑘
𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚
− 𝑚𝑚𝑚𝑚𝑚𝑚
∙ ∙ � 2𝑘𝑘
∙ �1 − 𝑒𝑒 𝜎𝜎2 ∙ � 2𝑙𝑙 �
𝜎𝜎 ∙ 𝑘𝑘!
𝜎𝜎 ∙ 𝑙𝑙!
2

So to determine our threshold Tcell, we wish to investigate the intensity profile near a
single cell of radius rp. The cell’s intensity profile, Icell, should have a brightness equal to the bit
depth, B = (2Nbits-1 ), and under the assumption that there is little additional empty space that
can be resolved between the cells, rmax will be approximately equal the radial size of a cell, rρ:

228

1,
𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃) = 𝐵𝐵 ∙ �
0,

𝑟𝑟 < 𝑟𝑟𝜌𝜌
𝑟𝑟 ≥ 𝑟𝑟𝜌𝜌

And since we blur this cell with a Gaussian kernel of radius σ = rρ, the cell’s intensity profile is:

𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃) = 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 �𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝑟𝑟𝜌𝜌 (𝑟𝑟, 𝜃𝜃)� = 𝑒𝑒

−

𝑟𝑟 2
𝑟𝑟𝜌𝜌 2

∞

𝑘𝑘

𝑘𝑘=0

𝑙𝑙=0

𝐵𝐵
𝑟𝑟 2𝑘𝑘
1
∙ ∙ � 2𝑘𝑘
∙ �1 − 𝑒𝑒 −1 ∙ � �
𝑟𝑟𝜌𝜌 ∙ 𝑘𝑘!
2
𝑙𝑙!

Then since

𝑘𝑘

�
𝑙𝑙=0

1
𝛤𝛤(𝑘𝑘 + 1,1)
= 𝑒𝑒 1 ∙
𝛤𝛤 (𝑘𝑘 + 1)
𝑙𝑙!

We find:

𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑙𝑙 (𝑟𝑟, 𝜃𝜃) = 𝑒𝑒

−

𝑟𝑟 2
𝑟𝑟𝜌𝜌 2

∞

𝐵𝐵
𝑟𝑟 2𝑘𝑘
𝛤𝛤(𝑘𝑘 + 1,1)
∙ ∙ � 2𝑘𝑘
∙ �1 −
�
𝛤𝛤 (𝑘𝑘 + 1)
𝑟𝑟𝜌𝜌 ∙ 𝑘𝑘!
2
𝑘𝑘=0

Finally, to determine Tcell, we desire the intensity of the blurred cell at r = rρ, so we must
evaluate Icell at r = rρ, yielding:

𝑇𝑇𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 �𝑟𝑟 = 𝑟𝑟𝜌𝜌 , 𝜃𝜃� = 𝑒𝑒

−1

∞

𝐵𝐵
1
𝛤𝛤(𝑘𝑘 + 1,1)
∙ ∙ � ∙ �1 −
�
𝛤𝛤 (𝑘𝑘 + 1)
2
𝑘𝑘!
𝑘𝑘=0

This series converges to a value of 0.939835. Thus, we find:

𝑇𝑇𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 0.172873 ∙ 𝐵𝐵
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IV.9

Selection of colony contour brightness threshold, Tcolony

The colony brightness threshold, Tcolony is applied after having applied ImageJ’s
Gaussian Blur method to blur together the cells within a colony, and we wish to pick a threshold
brightness that will allow us to contour the colonies in the image. Here, we can use similar
reasoning in the determination of Tcell but substituting rρ with rcolony since the spatial intensities of
the colonies before being blurred can be described by a circ function of radius rcolony. So by
analogy we find:

𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 (𝑟𝑟, 𝜃𝜃) = 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 �𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃)�
= 𝑒𝑒

−

𝑟𝑟 2
𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 2

∞

𝐵𝐵
𝑟𝑟 2𝑘𝑘
𝛤𝛤(𝑘𝑘 + 1,1)
∙ ∙�
∙ �1 −
�
2𝑘𝑘
𝛤𝛤 (𝑘𝑘 + 1)
𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∙ 𝑘𝑘!
2
𝑘𝑘=0

However, for Tcolony we do not desire the intensity for which r = rcolony since this value will result
in distinct colonies being blurred together. As the purpose of this threshold is to fill the holes in
colonies and to smooth and closely contour colonies’ borders, we once again select the
intensity for which r = rρ since this will ensure that colonies will be contoured with a margin of
the radial size of one cell, and fill all the holes in a colony. Accordingly, we find:

𝑇𝑇𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 �𝑟𝑟 = 𝑟𝑟𝜌𝜌 , 𝜃𝜃� = 𝑒𝑒

−

𝑟𝑟𝜌𝜌 2
𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 2

∞

𝑟𝑟𝜌𝜌 2𝑘𝑘
𝐵𝐵
𝛤𝛤(𝑘𝑘 + 1,1)
∙ ∙�
∙ �1 −
�
2𝑘𝑘
𝛤𝛤 (𝑘𝑘 + 1)
𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∙ 𝑘𝑘!
2
𝑘𝑘=0

Then since we know that:

𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑟𝑟𝜌𝜌 = �
√12 ∙ 50

𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑎𝑎𝑎𝑎𝑎𝑎 𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = �
𝜋𝜋
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Therefore,
𝑟𝑟𝜌𝜌

𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐

𝜋𝜋
=�
√12 ∙ 50

We can rewrite Tcell to be independent of rcolony and rρ:

𝑇𝑇𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 =

𝜋𝜋
−�
𝑒𝑒 √12 ∙ 50

𝑘𝑘
𝜋𝜋
�
𝐵𝐵
𝛤𝛤(𝑘𝑘 + 1,1)
∙ 50
∙ ∙ � √12
∙ �1 −
�
𝛤𝛤 (𝑘𝑘 + 1)
𝑘𝑘!
2
∞

𝑘𝑘=0

�

This series sums to 0.636927, thus we find:

𝑇𝑇𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 �𝑟𝑟 = 𝑟𝑟𝜌𝜌 , 𝜃𝜃� = 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 �𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃)� |𝑟𝑟=𝑟𝑟𝜌𝜌 = 0.278336 ∙ 𝐵𝐵
Here we can see that both Tcolony and Tcell are both independent of cell-line dependent
parameters such as rρ and r. A major advantage of this formalism is that by choosing rp and
rcolony as our blur radii, our selection of brightness thresholds is no longer arbitrary and does not
depend on any cell-line dependent parameters. Consequently, these brightness thresholds can
be applied to any cell line.

V.

The application of our workflow to cancer cell liens of varying colony
morphology
Using our workflow, we successfully automated the counting of colonies in clonogenic

assays across 20 distinct cancer cell lines with cell densities varying from 39 – 6656 cells/mm2
within the colonies. We characterized the colony morphologies we observed into three types
based upon whether individual cells within a colony could be resolved in a 2400 DPI scan as
follows: (i) dense – cell density was so high that individual cells within the colonies could not be
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resolved; (ii) intermediate – cell density was moderate within the colonies, allowing some of the
cells to be resolved individually; (iii) loose – cell density was low within the colonies and the
vast majority of individual cells could be resolved. These cell lines are summarized in Table 9.
Table 9: Cell lines for which we have automated the scoring of colonies using the methods described in this work,
the cell densities within their colonies, and the observed colony morphologies as characterized by the resolvability of
single cells within the colonies after a 2400 DPI scan.

Cell Line

4T1
AsPC1
BxPC3
Capan1
ECC1
H460
H1299

Tumor Type

Mouse metastatic breast
cancer
Human pancreatic
adenocarcinoma
Human pancreatic
adenocarcinoma
Human pancreatic
adenocarcinoma
Human endometrial
adenocarcinoma
Human large cell lung
carcinoma
Human non-small cell lung
carconima

HCC1937

Human ductal breast
carcinoma

HCC1937+BRCA

Human ductal breast
carcinoma

HPAC

Human pancreatic
adenocarcinoma
Human pancreatic
adenocarcinoma
Human fibrosarcoma

Hs766T
HT1080
L3.3

Human pancreatic
adenocarcinoma

M059J
M059K
MiaPaca2

Human glioblastoma
Human glioblastoma
Human pancreatic
adenocarcinoma

Panc1

Human pancreatic
adenocarcinoma

Panc1005

Human pancreatic
adenocarcinoma
Human prostate
carcinoma
Human pancreatic
adenocarcinoma
Human glioblastoma

PC3
PK1
T98G

Cell density in
colonies
(cells/mm2)
382
230 - 282
1559
2076
2266
1690
186 - 485
39 - 238
139 - 306
242
492
264 - 592

1623
71 - 90
133 - 162
152 - 606
122 - 458
800
609
6556
609
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Colony morphology

Intermediate
Intermediate
Dense
Dense
Dense
Dense
Both dense and loose
colony morphologies
present
Both dense and loose
colony morphologies
present
Both dense and loose
colony morphologies
present
Intermediate colony
density
Intermediate colony
density
Both dense and loose
colony morphologies
present
Dense, but with substantial
vertical growth, so the cell
density number is likely
significantly higher that we
report here
Loose
Loose
Both dense and loose
colony morphologies
present
Both dense and loose
colony morphologies
present
Dense
Intermediate
Dense
Intermediate

V.1

Cell lines with dense colonies

In general, dense colonies are the easiest to score using
our methodology. For such colonies, individual cells within the
colonies are generally incapable of being resolved, even with a
high resolution scan, and consequently, the colonies will appear
relatively bright and uniform but with a sharp edge between the
cells and background. This morphology is ideal for contouring as
the large contrast at the edge of a colony between cells and
background lessens the impact of the choice of the background
noise threshold, Tnoise, which is somewhat arbitrary. In turn, this
means that for such colonies, our workflow relies primarily on the
colony area threshold, ACFU, which is easy to estimate and provides
a very consistent metric to discriminate dense colonies based on
their area since the cell density within colonies does not vary
greatly for dense colonies.

Figure 52: (A) Example of
BxPC3 colony with sharp edges
and internal cavities. (B)
Erroneous watershedding of
colony across the two opposing
regions of concavity

However, a few issues can arise when scoring very dense colonies. First, while the
sharp edges of colonies generally facilitate watershedding colonies that have merged together,
these sharp edges can also occasionally cause the watershedding methods in ImageJ to
subdivide single colonies if their surfaces are not strictly convex. A prime example of this the
cell line BxPC3 which forms colonies with extremely sharp edges, but that are also quite jagged
with many small concave regions, in addition to commonly forming distinct internal cavities
(Figure 52A). ImageJ’s watershedding method will identify these concave regions on opposite
sides of a colony (or from the edge to a cavity if it is too large to be blurred out) and watershed
them, erroneously subdividing the colony into multiple smaller colonies (Figure 52B). For
colony morphologies where this is the case, it is often preferable to disable watershedding (as
we did with BxPC3), since with the colonies being very dense, it is not necessary for the
colonies to cover a large area to possess significantly more than 50 cells, and so the assay can
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be appropriately seeded and terminated such that the spacing between colonies is very large
and the colonies are very unlikely to overlap geometrically.
A second issue is that very dense colonies have a tendency to grow somewhat
vertically instead of purely horizontally in vitro. This makes the calibration of ACFU extremely
difficult, both because the pixel area of a colony does not correspond in a linear fashion to the
number of cells in it, but also because it is nearly impossible to count the number of cells in a
colony under a light microscope due to their vertical overlap. While it is possible to try to
characterize a nonlinear relationship between colony area, intensity, and the number of cells in
the colony 280, we have found that this is generally unnecessary in favor of simply terminating
the assay after a longer incubation period to ensure that the true colonies have grown well past
50 cells, and selecting an area threshold based upon the area that a monolayer of 50 cells
would occupy. Such techniques were applied to L3.3 and PK1 cells.

V.2

Cell lines with loose colonies

An advantage of our methodology is that it is capable of
accurately counting loose-forming colonies (Figure 53) as it is not
reliant on the colony area based threshold, ACFU, to determine
whether a grouping of cells contains at least 50 cells. Rather, our
methodology allows us to identify individual cells within a grouping
and count them to determine whether there are at least 50 cells in
it. Thus, for loose forming colonies our method is fairly robust to
the variable cell densities that can often be seen in loose colonies.
However, in cases where the cell densities are very low and
also where the cell staining is not very bright, a number of
challenges arise in employing our methodology to score the
colonies. The first is that in such circumstances it can be difficult to
select a background noise threshold, Tnoise, that can precisely
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Figure 53: (A) Example of loose
M059K colony for which
individual cells can be resolved
and counted (B) to determine
whether it meets the colony
criteria.

separate the background from the cells without removing much of the dim penumbra of the
cells themselves. Consequently, when we calculate our second threshold, Tcell, which sets the
brightness level above which we assume that cells are present in the image, the assumption
that there is little empty space that can be resolved between the cells will not be rigidly adhered
to since much of the cells’ penumbra may be thresholded out. Consequently, the blurring and
thresholding steps performed may fail to completely fill in all the holes in a colony, which in
turn, may result in some dimmer colonies being erroneously watershed. To work around this,
where needed, one can decrease the value of Tcell to account for this.

V.3

Cell lines with intermediate density colonies

When scoring colonies of intermediate density, we calculate the total area of all the cells
within a colony to determine if it meets the threshold area, ACFU, since by definition we can’t
resolve all the individual cells in the colony to individually count them (Figure 48). This is better
than simply calculating the total area of the colony and comparing it to ACFU since it will more
accurately reflect how many cells are in colonies of varying cell density.
However, for intermediate density colonies, issues can arise when it comes to the
presence of large senescent cells in the dish. Noted as early as in Markus and Puck’s
description of the clonogenic assay 268, following radiation exposure, a small fraction of cells
can grow much larger than normal, becoming abnormal “giant” cells. These giant cells are
senescent and thus are not proliferative286, and though they have not been killed by the
radiation, are not viable insofar as they are no longer dividing indefinitely. Thus, when counting
colonies in a clonogenic assay, we do not wish to include senescent cells when assessing
whether a grouping of cells meets the criteria of a colony, since senescent cells are not viable.
But since giant cells have the same physical area as many normal cells, it is possible that a
small grouping of senescent cells along with some giant cells have sufficient cell area to meet
the area threshold ACFU despite not containing 50 viable cells.

235

Unfortunately, we cannot exclude these contoured structures for having too few cells,
since we generally cannot resolve all the cells in viable colonies of intermediate density, and so
the number of cells that can be counted is not a reliable indicator of how many cells are actually
present in the colony. And also, since the induction of these giant cells is more common for
higher radiation doses, this error cannot be normalized out when accounting for the plating
efficiency. Thus, if the induction of giant cells is common for a given cell line, one must be
careful to avoid scoring a large number of false positives, whether by applying a texture-based
filter to remove them from the count or by performing manual quality assurance on the output.

V.4

Cell lines with highly variable colony density, exhibiting both loose and

dense colony morphologies

Figure 54: Example of H1299 cells forming dense colonies (28 and 29), Intermediate colonies (15, 30 and 31) and
loose colonies (16, 17 and 27).

In general, when a cell line presents multiple common colony morphologies (such as in
Figure 54), it is much more difficult to automate the scoring. In the context of our workflow, this
is because if a colony is dense, we rely primarily on an area threshold, ACFU, to identify
colonies, but if a colony is loose, we can simply count the number of cells in the colony.
Applying either of these methods to the whole well will result in a large number of false
positives or false negatives, so no matter our selection, we will need to perform some sort of
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quality assurance afterwards to properly assess the output of our macros. But whatever
method to identify colonies is selected, it must err towards producing false positives rather than
false negatives so that no information is lost and the false positives can later be excluded.
To address this issue, we have implemented a hybrid selection method that somewhat
alleviates this problem. In this case, we define the blurring radii differently in the blurring and
thresholding steps that identify the location of individual cells versus individual colonies. When
first identifying the cells, we blur the image with a blurring radius rρ corresponding to cells in
loose colonies before thresholding by Tcell. This correctly identifies the location of cells in loose
colonies, while slightly enlarging the cells in dense colonies. However, since the cells in dense
colonies cannot be resolved to begin with, this manifests itself by only very slightly enlarging
the cells at the perimeter. Then, when identifying the colonies, we blur the image with a radius
rcolony corresponding to a dense colony before thresholding by Tcolony. This creates an accurate
contour for the dense colonies, where we rely upon the area threshold to identify colonies,
while providing a fairly accurate contour of the loose colonies where we can count the number
of cells to identify colonies. However, since the blur radius is a little smaller than what would be
ideal for the loose colonies, some of them may not be completely filled in by the blurring and
tresholding procedure, resulting in some erroneously watershed colonies. But these false
positives are rare and can be excluded manually during the quality assurance check.

VI.

General discussions of our methodology
Automating the scoring of clonogenic assay dishes represents an important

improvement to the technique as it greatly reduces the labor required to analyze the data
collected, and greatly improves the reproducibility of the assay by minimizing user-dependent
biases related to colony scoring. And as clonogenic assay are ubiquitous in radiation biology,
integrating this automation widely into the methods employed across the field allows for
substantial increases in throughput and consistency between different experimenters.
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Many groups have published methods to achieve this automation, but they rely on
different types of analyses, using different software packages and using different types
equipment to acquire images of the dishes and perform analyses 273-280. Some of these
techniques are built on open-source platforms, such as ImageJ, which are ideal for widespread
use insofar as any experimenter can freely obtain and modify the software to meet the
constraints of their cell lines and imaging systems. However, since all of these methods
involve some sort of blurring and brightness and area thresholding, the constraints imposed by
their imaging systems cannot easily be decoupled from the constraints imposed by the cell
lines’ physical appearance. This is because the brightness threshold selected defines the
extent to which cells in a colony’s penumbra are retained, and so the area threshold selected
must account for the constraints imposed by brightness threshold in order to ensure that the
contoured area in fact corresponds to at least 50 cells. Consequently, calibrating these image
processing methods in a robust way for a new experimenter with a different imaging system
can be extremely challenging due to the interdependence of these thresholding parameters.
Our formalism seeks to address this issue by decoupling the relationship between the
brightness and area thresholds. We achieved this by selecting blurring radii that correspond
directly to the physical arrangement of cells in a colony, which in turn means that many of the
brightness thresholds can be calculated directly from the area threshold, ACFU, and thus can be
hard-coded into the workflow. The only arbitrary brightness threshold the user has to input is
the background noise threshold which, due to our choice of film scanner over a conventional
scanner, is not very sensitive to the user’s selection due to the excellent contrast present in the
scan.
Thus, an important advantage of our formalism is the relatively few cell-line specific
parameters that need to be calibrated in order to automate our colony-counting workflow, and
the relative ease with which they are calibrated. With respect to the geometric parameters used
in our formalism, all of them can be described in terms of the quantity ACFU and thus these
relationships are hard-coded in relation to this lone user-specified geometric parameter. The
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calibration of ACFU is equivalent to any area threshold one would need to calibrate in a typical
automated colony-counting workflow, where the user must essentially quantify the relationship
between cell area and pixel area in order to identify colonies by their area. This can be
accomplished by light microscope when individual cells cannot be resolved, or in the case of
loose, resolvable colonies, by directly measuring the images with ImageJ, and so this process
is no more burdensome than the analogous process for other image processing workflows.
But where our methodology is particularly advantageous is when it comes to the userdefined brightness thresholds. Unlike the area thresholds, brightness thresholds are often
defined in a much more arbitrary way, where user bias has a much greater impact on the
threshold selected. In our formalism, the only brightness threshold that needs to be specified by
the user is the background noise threshold, Tnoise, which can be defined in a much less arbitrary
way than brightness thresholds relating to the boundaries of objects in the image, simply by
using the median pixel value as an estimate for the middle of the background level. And for the
other brightness thresholds in our formalism – Tcell, which describes the brightness at the
boundary of a cell, and Tcolony, which describes the brightness at the boundary of a colony – we
can take advantage of mathematical symmetries in our formalism to calculate and hard-code
these values in a manner that is independent of cell line specific geometric parameters. Thus,
in our formalism, the only brightness and area thresholds defined by the user are largely
independent of one another.
An additional benefit of this formalism is that it is not completely reliant on an area
threshold to make determinations about whether or not a grouping of cells is a colony. Since
we pair our image-processing workflow with a scanner that can acquire images with a
resolution of ~20 μm, we can resolve individual cells in loose-forming, and sometimes
intermediate colonies allowing us to simply count the number of cells present to identify a
colony. This is extremely advantageous versus a colony area threshold considering that looseforming colonies usually display a range of cell densities that makes it hard to define a

239

consistent area threshold, and because cell density within colonies can often decrease with
radiation dose.
A major limitation of our workflow is that it requires a high resolution film scanner to
produce the desired images. While this type equipment is not available in every laboratory,
such equipment should be available to laboratories performing film dosimetry, and is relatively
inexpensive to purchase used. And thus, if a group has access to a radiation source to perform
clonogenic assay to quantify radiation survival, it is likely that their institution will have an
appropriate scanner to analyze radiochromic film for dosimetry purposes, and if not, be able to
purchase one at a relatively low cost (in fact we purchased our scanner on eBay for $800).
A final limitation to our workflow is that a number of colony morphologies cannot be
consistently scored without producing a significant number of false positives. This is of
particular importance for colonies of intermediate density as well as colonies that have highly
variable density, due to the presence of giant senescent cells that are difficult to exclude from
the analyses. However, that we are able to resolve individual cells across many cell
morphologies makes excluding them from the analysis much easier than for techniques
employing lower resolution scans and that rely on a colony area threshold to identify colonies.
Whether this exclusion is performed visually or by incorporating a texture based filter into the
analysis pipeline, the choice of a sufficiently high contrast, high resolution scanner to make this
technically feasible is important to improving the accuracy of these automated colony counting
workflows.
In our workflow, we elected to have the user exclude such false positives manually by
visual inspection. While this does add some additional time and user-dependence to their
output, it is generally quite small since these types of false positives are relatively rare, and the
implementation and calibration of texture-based filters to remove them automatically is difficult
to achieve without introducing a fair number of false negatives. At the same time, leaving it up
to the user allows the user to double-check the output to make sure that no other imaging
artifacts have also been included in the analyses.
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Our philosophy when it comes to these image-processing pipelines is that no matter
what, there will always be some small number of false positives and false negatives, and while
one might desire to try to have the two equal one another so that no corrections need to be
made, this is extremely difficult to achieve. Accordingly, we prefer them to err towards false
positives, since then they will still identify everything that could conceivably be a colony in
terms of its cell area or number of cells, and let the user exclude those which are in fact false
positives. The rationale for this is that it is very difficult for a user to confidently reintroduce false
negatives when the colonies are dense, because they cannot quantify how many cells are in
the colonies without taking them to a microscope and counting them, the tediousness of which
is part of the problem we are trying to solve in the first place. Thus, we see these pipelines less
as tools that count the number of colonies in dishes, and more tools that help the user quickly
and reproducibly identify which groupings of cells are likely to be colonies without the need of a
microscope to manually count the number of cells within them.

VII.

Supplemental Information
VII.1

Convolution of Gaussian and circ:

Before blurring the cells, they have a spatial intensity profile, Icirc(r,θ) that is essentially a
circ function of height, h, and radius rmax:

1,
𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃) = ℎ ∙ �
0,

𝑟𝑟 < 𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚
𝑟𝑟 ≥ 𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

ImageJ’s Gaussian Blur method convolves the image with the Gaussian kernel, Gσ(x,y) of the
form:

2

𝑥𝑥 +𝑦𝑦
1
−
𝜎𝜎 2
𝑒𝑒
𝐺𝐺𝜎𝜎 (𝑥𝑥, 𝑦𝑦) =
2 𝜋𝜋 𝜎𝜎 2
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2

So Iblur,cell will resemble the general form of a Icirc convolved with Gσ, Icirc,blur:

𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐,𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 (𝑥𝑥, 𝑦𝑦) = 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑥𝑥, 𝑦𝑦), 𝐺𝐺𝜎𝜎 (𝑥𝑥, 𝑦𝑦)� =

𝑣𝑣=−∞,𝑢𝑢=−∞

�

𝑣𝑣=−∞,𝑢𝑢=−∞

𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑢𝑢, v) ∙ 𝐺𝐺𝜎𝜎 (𝑥𝑥 − 𝑢𝑢, 𝑦𝑦 − v) ∙ 𝑑𝑑𝑑𝑑 ∙ 𝑑𝑑v

Since Icirc is best defined in polar coordinates due to its radial symmetry, we are better off
performing our convolution in polar coordinates. Accordingly, we must rewrite our convolution
in polar coordinates, but to do so, we must first rewrite the Gaussian kernel, Gσ (x-u,y-v), which
is shifted in x and y by the convolution variables u and v into polar coordinates r and θ, shifted
by the convolution variables ρ and φ. Applying the shift by u and v, we note that the Gaussian
kernel in Cartesian coordinates becomes:

2

𝑥𝑥 +𝑦𝑦
1
−
𝜎𝜎 2
𝑒𝑒
𝐺𝐺𝜎𝜎 (𝑥𝑥, 𝑦𝑦) =
2 𝜋𝜋 𝜎𝜎 2

2

2

(𝑥𝑥−𝑢𝑢) +(𝑦𝑦−𝑣𝑣)
1
−
𝜎𝜎 2
→ 𝐺𝐺𝜎𝜎 (𝑥𝑥 − 𝑢𝑢, 𝑦𝑦 − 𝑣𝑣) =
𝑒𝑒
2 𝜋𝜋 𝜎𝜎 2

2

So when we introduce radial coordinates r and θ, with corresponding convolution
variables ρ and φ, we can relate them to the corresponding Cartesian coordinates as follows:

𝑥𝑥 = 𝑟𝑟 cos(𝜃𝜃) → 𝑢𝑢 = 𝜌𝜌 cos (𝜑𝜑)
𝑦𝑦 = 𝑟𝑟 sin(𝜃𝜃) → 𝑣𝑣 = 𝜌𝜌 sin(𝜑𝜑)

Accordingly, our Gaussian kernel shifted by the convolution variables, Gσ (x-u,y-v), can be
written in polar coordinates as:

𝐺𝐺𝜎𝜎 (𝑟𝑟 cos(𝜃𝜃) − 𝜌𝜌 cos (𝜑𝜑), 𝑟𝑟 sin(𝜃𝜃) − 𝜌𝜌 sin(𝜑𝜑))
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Note that this is not equivalent to Gσ(r-ρ,θ-φ). Accordingly, we will denote the Gaussian kernel
shifted by the convolution variables as Gσ(r,ρ,θ,φ):

2

(𝑟𝑟 cos(𝜃𝜃)−𝜌𝜌 cos (𝜑𝜑)) +(𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟(𝜃𝜃)−𝜌𝜌 sin(𝜑𝜑))
1
−
𝜎𝜎 2
𝑒𝑒
𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜌𝜌, 𝜃𝜃, 𝜑𝜑) =
2 𝜋𝜋 𝜎𝜎 2

2

Which can be expanded to:

𝑟𝑟
1
−
𝑒𝑒
𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜌𝜌, 𝜃𝜃, 𝜑𝜑) =
2 𝜋𝜋 𝜎𝜎 2

2 +𝜌𝜌2 −2∙𝑟𝑟∙𝜌𝜌(cos(𝜃𝜃) cos(𝜑𝜑)+sin(𝜃𝜃) sin(𝜑𝜑))

𝜎𝜎2

Whereupon we can recall the identities:

cos(𝜃𝜃) cos(𝜑𝜑) =

cos(𝜃𝜃 − 𝜑𝜑) + cos(𝜃𝜃 + 𝜑𝜑)
2

𝑎𝑎𝑎𝑎𝑎𝑎

sin(𝜃𝜃) sin(𝜑𝜑) =

cos(𝜃𝜃 − 𝜑𝜑) − cos(𝜃𝜃 + 𝜑𝜑)
2

To simplify the Gaussian kernel to:

𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜌𝜌, 𝜃𝜃, 𝜑𝜑) =

𝑟𝑟
1
−
∙
𝑒𝑒
2 𝜋𝜋 𝜎𝜎 2

2 +𝜌𝜌2 −2∙𝑟𝑟∙𝜌𝜌 ∙cos(𝜃𝜃−𝜑𝜑)

𝜎𝜎 2

Now, when we convolve the Gaussian kernel with our cell in polar coordinates, the convolution
will have the form:

𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜃𝜃)� =

𝜌𝜌=∞,𝜑𝜑=2𝜋𝜋

�

𝜌𝜌=0,𝜑𝜑=0

𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝜌𝜌, φ) ∙ 𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜌𝜌, 𝜃𝜃, 𝜑𝜑) ∙ 𝜌𝜌 ∙ 𝑑𝑑𝑑𝑑 ∙ 𝑑𝑑φ

So we can then apply the functional form of our Gaussian kernel:

243

𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜃𝜃)� =

𝜌𝜌=∞,𝜑𝜑=2𝜋𝜋

�

𝜌𝜌=0,𝜑𝜑=0

𝑟𝑟
1
−
𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝜌𝜌, φ) ∙=
∙
𝑒𝑒
2 𝜋𝜋 𝜎𝜎 2

2 +𝜌𝜌2 −2∙𝑟𝑟∙𝜌𝜌 ∙cos(𝜃𝜃−𝜑𝜑)

𝜎𝜎 2

∙ 𝜌𝜌 ∙ 𝑑𝑑𝑑𝑑 ∙ 𝑑𝑑φ

And since our convolution variables are ρ and φ, and Icirc does not depend on φ, we can
separate the convolution integrals as follows:

𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜃𝜃)�

𝜌𝜌=∞

𝜑𝜑=2𝜋𝜋

𝑟𝑟 2
𝜌𝜌2
2∙𝑟𝑟∙𝜌𝜌 ∙cos(𝜃𝜃−𝜑𝜑)
1
− 2
− 2
𝜎𝜎 2
𝜎𝜎 ∙ � 𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝜌𝜌, φ) ∙ 𝑒𝑒 𝜎𝜎 ∙ 𝜌𝜌 ∙ � � 𝑒𝑒
=
∙
𝑒𝑒
∙ 𝑑𝑑φ� ∙ 𝑑𝑑ρ
2 𝜋𝜋 𝜎𝜎 2
𝜌𝜌=0

𝜑𝜑=0

The integral over φ defines a modified Bessel function of the first kind, I(z), as follows:

𝜑𝜑=2𝜋𝜋

� 𝑒𝑒

𝜑𝜑=0

2∙𝑟𝑟∙𝜌𝜌 ∙cos(𝜃𝜃−𝜑𝜑)
𝜎𝜎 2

∙ 𝑑𝑑φ = 2 𝜋𝜋 𝑰𝑰𝟎𝟎 �

2 ∙ 𝑟𝑟
∙ 𝜌𝜌�
𝜎𝜎 2

Thus,

𝜌𝜌=∞

𝑟𝑟 2
𝜌𝜌2
1
2 ∙ 𝑟𝑟
− 2
− 2
𝜎𝜎
𝜎𝜎
∙ � 𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝜌𝜌, φ) ∙ 𝑒𝑒
∙ 𝜌𝜌 ∙ 𝑰𝑰𝟎𝟎 � 2 ∙ 𝜌𝜌� ∙ 𝑑𝑑ρ
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜃𝜃)� = 2 ∙ 𝑒𝑒
𝜎𝜎
𝜎𝜎
𝜌𝜌=0

Then since Icirc is zero unless 0 < ρ < rmax , and is otherwise equal to h, we can rewrite this
expression as:

244

𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

𝑟𝑟 2
1
−
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜃𝜃)� = 2 ∙ 𝑒𝑒 𝜎𝜎2 ∙ ℎ ∙ �
𝜎𝜎

𝜌𝜌=0

𝑒𝑒

𝜌𝜌2
− 2
𝜎𝜎

∙ 𝜌𝜌 ∙ 𝑰𝑰𝟎𝟎 �

2 ∙ 𝑟𝑟
∙ 𝜌𝜌� ∙ 𝑑𝑑ρ
𝜎𝜎 2

Then we can recall the series expansion for modified Bessel function of the first kind, I(z):

1 2 𝑘𝑘
𝑧𝑧 �
�
1
4
𝐼𝐼𝜂𝜂 (𝑧𝑧) = � 𝑧𝑧� �
𝑘𝑘! Γ (𝜂𝜂 + 𝑧𝑧 + 1)
2
𝜂𝜂 ∞

𝑘𝑘=0

Where Γ is the gamma function, and where for our case 𝜂𝜂 = 0 and z = 2 r ρ / σ2, so:
∞

2
1 2 ∙ 𝑟𝑟
�4 � 2 ∙ 𝜌𝜌� �
𝜎𝜎

𝑘𝑘

∞

0
2 ∙ 𝑟𝑟
1 2 ∙ 𝑟𝑟
𝑟𝑟 2𝑘𝑘 ∙ 𝜌𝜌2𝑘𝑘
𝐼𝐼0 � 2 ∙ 𝜌𝜌� = �
∙
𝜌𝜌�
�
=
�
𝑘𝑘! Γ (0 + 𝑘𝑘 + 1)
𝜎𝜎 4𝑘𝑘 ∙ (𝑘𝑘!)2
𝜎𝜎
2 𝜎𝜎 2
𝑘𝑘=0

𝑘𝑘=0

Thus, our integral over ρ becomes:

𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

�

𝜌𝜌=0

𝜌𝜌2
−
𝑒𝑒 𝜎𝜎2

2 ∙ 𝑟𝑟
∙ 𝜌𝜌 ∙ 𝑰𝑰𝟎𝟎 � 2 ∙ 𝜌𝜌� ∙ 𝑑𝑑ρ =
𝜎𝜎

𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

�

𝜌𝜌=0

𝜌𝜌2
−
𝑒𝑒 𝜎𝜎2

∞

∙ 𝜌𝜌 ∙ �

𝑘𝑘=0

𝑟𝑟 2𝑘𝑘 ∙ 𝜌𝜌2𝑘𝑘
∙ 𝑑𝑑ρ
𝜎𝜎 4𝑘𝑘 ∙ (𝑘𝑘!)2

But an integral of sums is equivalent to a sum of integrals, so:

𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

�

𝜌𝜌=0

𝜌𝜌2
− 2
𝑒𝑒 𝜎𝜎

∞ 𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

2 ∙ 𝑟𝑟
∙ 𝜌𝜌 ∙ 𝑰𝑰𝟎𝟎 � 2 ∙ 𝜌𝜌� ∙ 𝑑𝑑ρ = � �
𝜎𝜎

𝑘𝑘=0 𝜌𝜌=0

𝜌𝜌2
− 2
𝜎𝜎
𝑒𝑒

∙ 𝜌𝜌 ∙

𝑟𝑟 2𝑘𝑘 ∙ 𝜌𝜌2𝑘𝑘
∙ 𝑑𝑑ρ
𝜎𝜎 4𝑘𝑘 ∙ (𝑘𝑘!)2

Many of these terms do not depend on the integration variable, ρ, so we can simplify this to:
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𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

�

𝜌𝜌=0

𝜌𝜌2
−
𝑒𝑒 𝜎𝜎2

2 𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

∞

2 ∙ 𝑟𝑟
𝑟𝑟 𝑘𝑘
∙ 𝜌𝜌 ∙ 𝑰𝑰𝟎𝟎 � 2 ∙ 𝜌𝜌� ∙ 𝑑𝑑ρ = � � 2𝑘𝑘
� ∙ �
𝜎𝜎 ∙ 𝑘𝑘!
𝜎𝜎
𝑘𝑘=0

𝜌𝜌=0

𝑒𝑒

𝜌𝜌2
− 2
𝜎𝜎

∙ 𝜌𝜌2𝑘𝑘+1 ∙ 𝑑𝑑ρ

Then, we can evaluate the right integral:

𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

�

𝜌𝜌=0

𝜌𝜌2
− 2
𝜎𝜎
𝑒𝑒

∙ 𝜌𝜌2𝑘𝑘+1 ∙ 𝑑𝑑ρ =

2
1 2(𝑘𝑘+1)
𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚
∙ 𝜎𝜎
∙ �Γ(𝑘𝑘 + 1) − 𝜞𝜞 �𝑘𝑘 + 1, 2 ��
𝜎𝜎
2

Where Γ(a,x) is the incomplete gamma function. We can then use the relationships below
which hold for integers s > 0:

𝛤𝛤(𝑠𝑠 + 1) = 𝑠𝑠!

𝑎𝑎𝑎𝑎𝑎𝑎

𝛤𝛤(𝑠𝑠 + 1, 𝑥𝑥) = 𝑠𝑠! 𝑒𝑒

−𝑥𝑥

𝑠𝑠

�
𝑙𝑙=0

𝑥𝑥 𝑙𝑙
𝑙𝑙!

To rewrite the above integral as:

𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

�

𝜌𝜌=0

𝜌𝜌2
−
𝑒𝑒 𝜎𝜎2

∙ 𝜌𝜌2𝑘𝑘+1 ∙ 𝑑𝑑ρ =

1 2(𝑘𝑘+1) ⎛
∙ 𝜎𝜎
∙ ⎜𝑘𝑘! − 𝑘𝑘! ∙
2
⎝

𝑟𝑟 2
− 𝑚𝑚𝑚𝑚𝑚𝑚
𝑒𝑒 𝜎𝜎2
𝑘𝑘

𝑙𝑙

2
𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚
�
𝜎𝜎 2 ⎞
∙�
𝑙𝑙! ⎟
𝑘𝑘

𝑙𝑙=0

2𝑙𝑙
𝑟𝑟 2
1
𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚
− 𝑚𝑚𝑚𝑚𝑚𝑚
= ∙ 𝜎𝜎 2(𝑘𝑘+1) ∙ 𝑘𝑘! ∙ �1 − 𝑒𝑒 𝜎𝜎2 ∙ � 2𝑙𝑙 �
𝜎𝜎 ∙ 𝑙𝑙!
2

�

⎠

𝑙𝑙=0

So then our convolution integral over ρ is given by:

𝜌𝜌=𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚

�

𝜌𝜌=0

𝜌𝜌2
− 2
𝜎𝜎
𝑒𝑒

∞

2

𝑘𝑘

2𝑙𝑙
𝑟𝑟 2
2 ∙ 𝑟𝑟
𝑟𝑟 𝑘𝑘
𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚
1 2(𝑘𝑘+1)
− 𝑚𝑚𝑚𝑚𝑚𝑚
∙ 𝜌𝜌 ∙ 𝑰𝑰𝟎𝟎 � 2 ∙ 𝜌𝜌� ∙ 𝑑𝑑ρ = � � 2𝑘𝑘
∙ 𝑘𝑘! ∙ �1 − 𝑒𝑒 𝜎𝜎2 ∙ � 2𝑙𝑙 �
� ∙ ∙ 𝜎𝜎
𝜎𝜎 ∙ 𝑘𝑘!
𝜎𝜎 ∙ 𝑙𝑙!
𝜎𝜎
2
𝑘𝑘=0

𝑙𝑙=0
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Which simplifies to:

𝜌𝜌=𝑟𝑟𝜌𝜌

�

𝜌𝜌=0

𝜌𝜌2
−
𝑒𝑒 𝜎𝜎2

∞

𝑘𝑘

𝑘𝑘=0

𝑙𝑙=0

2𝑙𝑙
𝑟𝑟 2
2 ∙ 𝑟𝑟
𝜎𝜎 2
𝑟𝑟 2𝑘𝑘
𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚
− 𝑚𝑚𝑚𝑚𝑚𝑚
∙ 𝜌𝜌 ∙ 𝑰𝑰𝟎𝟎 � 2 ∙ 𝜌𝜌� ∙ 𝑑𝑑ρ =
∙ � 2𝑘𝑘
∙ �1 − 𝑒𝑒 𝜎𝜎2 ∙ � 2𝑙𝑙 �
2
𝜎𝜎 ∙ 𝑘𝑘!
𝜎𝜎 ∙ 𝑙𝑙!
𝜎𝜎

Thus, our convolution is given by:

∞

𝑘𝑘

𝑘𝑘=0

𝑙𝑙=0

2𝑙𝑙
𝑟𝑟 2
𝑟𝑟 2
1
𝜎𝜎 2
𝑟𝑟 2𝑘𝑘
𝑟𝑟𝑚𝑚𝑚𝑚𝑚𝑚
− 2
− 𝑚𝑚𝑚𝑚𝑚𝑚
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 (𝑟𝑟, 𝜃𝜃), 𝐺𝐺𝜎𝜎 (𝑟𝑟, 𝜃𝜃)� = 2 ∙ 𝑒𝑒 𝜎𝜎 ∙ 𝐵𝐵 ∙
∙ � 2𝑘𝑘
∙ �1 − 𝑒𝑒 𝜎𝜎2 ∙ � 2𝑙𝑙 �
𝜎𝜎
2
𝜎𝜎 ∙ 𝑘𝑘!
𝜎𝜎 ∙ 𝑙𝑙!

Which can be simplified:

𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄�𝑰𝑰𝒄𝒄𝒄𝒄𝒄𝒄𝒄𝒄 (𝒓𝒓, 𝜽𝜽), 𝑮𝑮𝝈𝝈 (𝒓𝒓, 𝜽𝜽)� =

VII.2

𝒓𝒓𝟐𝟐
− 𝟐𝟐
𝝈𝝈
𝒆𝒆

∞

𝟐𝟐

𝒌𝒌

𝒓𝒓
𝒉𝒉
𝒓𝒓𝟐𝟐𝟐𝟐
𝒓𝒓𝟐𝟐𝟐𝟐
− 𝒎𝒎𝒎𝒎𝒎𝒎
𝒎𝒎𝒎𝒎𝒎𝒎
∙ ∙ � 𝟐𝟐𝟐𝟐
∙ �𝟏𝟏 − 𝒆𝒆 𝝈𝝈𝟐𝟐 ∙ � 𝟐𝟐𝟐𝟐 �
𝟐𝟐
𝝈𝝈 ∙ 𝒌𝒌!
𝝈𝝈 ∙ 𝒍𝒍!
𝒌𝒌=𝟎𝟎

𝒍𝒍=𝟎𝟎

Example of ImageJ macro code used to automatically score colonies for

H460 cells in 6-well plates
*Note that // indicate comments in the code
//Displays prompt for cell line, well number and seeding number
Dialog.create("Cell Line, well number and seeding ")
Dialog.addNumber("Dose", 0);
Dialog.addNumber("Seeding Number", 0);
Dialog.addChoice("Well Number", newArray("1", "2","3","4","5","6"));
Dialog.show();
dose = Dialog.getNumber();
seedingNumber = Dialog.getNumber();
wellNumber = Dialog.getChoice();
ImageName = getTitle();
dotIndex = lastIndexOf(ImageName,".");
StringLength = lengthOf(ImageName);
ImageExtension = substring(ImageName,dotIndex,StringLength);
ImageTitle = substring(ImageName,0,dotIndex);
ImageDir = getDirectory("image");
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dir = getDirectory("choose where to save");
getSelectionCoordinates(xpoints, ypoints); //This gets essentially reads in the user's input ROI
setBatchMode(1); //Suppresses all but the final output
run("Duplicate...", " "); //Create copies of the well to work with
rename("WellOverlay");
run("Duplicate...", " ");
rename("WorkingImage");
width = getWidth(); //Figure out dimensions of ROI based on user input
height = getHeight();
buffer = floor(width/120); //Create buffer region
ovalWidth = width - 2*buffer;
ovalHeight = height - 2*buffer;
xCorner = buffer;
yCorner = buffer;
///////////// MACRO PARAMETERS /////////////
ColonyThreshold1 = floor(height*width/39731.55)+1; //dense
ColonyThreshold2 = floor(height*width/39731.55)+1; //loose
ColonyRadius = sqrt(ColonyThreshold1/PI);
CellDensityRadius = sqrt(ColonyThreshold2/50/PI/sqrt(12));
OutlierRadius = 2*CellDensityRadius;

//if there is only one density, make these the same

CellAreaRadius = sqrt(ColonyThreshold1/50/PI/sqrt(12));
Acell = round(2*(CellAreaRadius*CellAreaRadius)); //Approximates the cell radius using the dense colony threshold
if (Acell==0){
Acell = 1;
}
Tcell = floor(0.172873 * 255)+1; //Brightness thresholds
Tcolony = floor(0.278336 * 255)+1;
RThresh = 19; //Noise thresholds
GThresh = 19; // exclude pixels with intensities < median + XThresh*sqrt(median)
BThresh = 7;
UniformityThresh = 100; // exclude colonies where mean*stdev < UniformityThresh
HueThresh = 30; // exclude colonies where red+green-2*blue < HueTresh
CellFractionOfColonyArea = 1; // Exclude colones where (area of cells) < fraction * min colony
// This is used for intermediate colonies when we need the area of all the cells
////////// END OF MACRO PARAMETERS //////////
makeOval(xCorner,yCorner,ovalWidth,ovalHeight); //Select ROI
run("Clear Outside");
//Split the image into RGB channels
ContrastThreshold = newArray(3);
min=newArray(3);
max=newArray(3);
filter=newArray(3);
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a=getTitle();
selectWindow("WorkingImage");
run("RGB Stack");
selectWindow("WorkingImage");
run("Convert Stack to Images");
run("Set Measurements...", "area mean standard min median redirect=None decimal=1");
//Rename RGB windows for later use
selectWindow("Red");
rename("0");
selectWindow("Green");
rename("1");
selectWindow("Blue");
rename("2");
for (i=0;i<3;i++){ //for each channel
selectWindow(""+i);
run("Duplicate...", " ");
selectWindow(""+i);
makeOval(xCorner,yCorner,ovalWidth,ovalHeight);
List.setMeasurements();
Mean = List.getValue("Median"); //This estimates the background noise level in each channel.
StdDev = sqrt(Mean);
//These apply that threshold to each channel
if(i==0){
ContrastThreshold[i] = floor(Mean+RThresh*StdDev)+1;
setThreshold(ContrastThreshold[i], 255);
}
if(i==1){
ContrastThreshold[i] = floor(Mean+GThresh*StdDev)+1;
setThreshold(ContrastThreshold[i], 255);
}
if (i==2){
ContrastThreshold[i] = floor(Mean+BThresh*StdDev)+1;
setThreshold(ContrastThreshold[i], 255);
}
run("Convert to Mask");
run("Duplicate...", " ");
rename("ContrastAdjusted_"+i);
selectWindow(""+i);
//This blurs and thresholds to identify the cells
run("Gaussian Blur...", "sigma=CellDensityRadius");
setThreshold(Tcell, 255);
run("Convert to Mask");
}
//Combine the results from each channel by logical AND
imageCalculator("AND create", "0","1");
imageCalculator("AND create", "2","Result of 0");
selectWindow("Result of 0");
run("Close");
imageCalculator("AND create", "ContrastAdjusted_0","ContrastAdjusted_1");
imageCalculator("AND create", "ContrastAdjusted_2","Result of ContrastAdjusted_0");
selectWindow("Result of ContrastAdjusted_0");
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run("Close");
for (i=0;i<3;i++){ // clean up some windows
selectWindow(""+i);
close();
selectWindow("ContrastAdjusted_"+i);
close();
}
selectWindow("Result of 2"); //Take combined result
run("Remove Outliers...", "radius=OutlierRadius threshold=1 which=Bright"); //RemoveOutliers
run("Gaussian Blur...", "sigma=ColonyRadius"); //Blur by colony radius
setThreshold(Tcolony, 255); //Threshold the image to create colonies
run("Convert to Mask");
run("Watershed"); //Watershed to separate merged colonies
run("Analyze Particles...", "size="+ColonyThreshold1+"-Infinity circularity=0.0-1.00 color=Magenta add");
//Contour the colonies
colonyNumber = roiManager("count");
selectWindow("WellOverlay"); //Create some additional windows to work in
run("Duplicate...", " ");
rename("WellOverlay_2");
selectWindow("WellOverlay_2");
//Uniformity Filtering
for (i=(colonyNumber-1);i>=0;i--){
roiManager("Select", i);
List.setMeasurements();
Mean = List.getValue("Mean");
StdDev = List.getValue("StdDev");
Uniformity = Mean*StdDev; //Calculate COV as uniformity parameter
if (Uniformity < UniformityThresh){ //If less uniform, exclude
roiManager("Select", i);
roiManager("Delete");
colonyNumber--;
}
}
selectWindow("WellOverlay_2");
run("Close");
//Hue Filtering
reds=newArray(colonyNumber); //initialize variables
greens=newArray(colonyNumber);
blues=newArray(colonyNumber);
for (i=0;i<3;i++){ //for each channel
selectWindow(""+i+"-1");
for (j=(colonyNumber-1);j>=0;j--){ //for each colony
roiManager("Select", j);
getStatistics(area,mean); //get mean pixel intensity
if (i==0){
reds[j] = mean; //define mean red, blue and green for each colony
}
if (i==1){
greens[j] = mean;
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}
if (i==2){
blues[j] = mean;
}
}
}
//This can be used to output the hue values for QAing and calibrating
//for (i=0;i<colonyNumber;i++){
//print(reds[i],greens[i],blues[i]);
//}
for (i=(colonyNumber-1);i>=0;i--){ //for each colony

}

if((reds[i]+greens[i]-2*blues[i])<HueThresh){//if it is bluer than it should be, exclude
roiManager("Select", i);
roiManager("Delete");
colonyNumber--;
}

for (i=0;i<3;i++){ //clean up the windows
selectWindow(""+i+"-1");
close();
}
//Checking for Area/Number of cells in colony
selectWindow("Result of ContrastAdjusted_2");
run("Watershed"); //watershed the cells to separate them
roiManager("Show All");
for (i=(colonyNumber-1);i>=0;i--){ //for each colony
roiManager("Select", i); //select colony
run("Analyze Particles...", "size=Acell-infinity circularity=0.1-1.00 color=Magenta add"); //contour cells
nCells = roiManager("count")-colonyNumber; //count how many cells are present
if(nCells<50){
ColonyArea = 0; //initialise variable
if(nCells > 0){ //if there's at least one object
for (j=(colonyNumber+nCells-1);j>=colonyNumber;j--){ //for each object
roiManager("Select", j);
getStatistics(area); //get its area
ColonyArea += area; //add it to the tally of the colony's cell area
roiManager("Delete");
}
}
if (ColonyArea < CellFractionOfColonyArea*ColonyThreshold2){
//This condition represents the area occupied by 50 cells
roiManager("Select", i); //If the sum of areas of the cells are less than the threshold, exclude
roiManager("Delete");
colonyNumber--;
}
}else{ //if there's more than 50 cells
for (j=(colonyNumber+nCells-1);j>=colonyNumber;j--){ //for all cell ROIs
roiManager("Select", j); //just delete the cell ROIs found, but keep the colony
roiManager("Delete");
}
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}

}

if(nCells > 0){ //clean the up results
run("Clear Results");
}

run("Close");
//Place the colony contours over the image
selectWindow("WellOverlay");
roiManager("Show All");
//Measure statistics about the colonies if desired
for (i=0;i<colonyNumber;i++){
roiManager("Select", i);
run("Measure");
}
if (colonyNumber>0){ //create an output file with the colony statistics
saveAs("Results",
dir+ImageTitle+"_Dose_"+dose+"_Gy_"+"_Well_"+wellNumber+"_Seeded_"+seedingNumber+"_Colonies_"+colony
Number+".csv");
selectWindow("Results");
run("Close");
}
run("Flatten"); //superimpose the colony outlines over the image
selectWindow("WellOverlay");
close();
selectWindow("WellOverlay-1");
setFont("Arial", 128, "bold");
drawString(colonyNumber, buffer, 10*buffer, "gray"); //Place the number of colonies found on the image
//name and save the file
rename(ImageTitle+"_Dose_"+dose+"_Gy_"+"_Well_"+wellNumber+"_Seeded_"+seedingNumber+"_Colonies_"+col
onyNumber+ImageExtension);
saveAs(ImageExtension,dir+ImageTitle+"_Dose_"+dose+"_Gy_"+"_Well_"+wellNumber+"_Seeded_"+seedingNumb
er+"_Colonies_"+colonyNumber);
setBatchMode(0);
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